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ABSTRACT 
There is a pressing need for the discovery of new antimicrobials to fight antibiotic resistant 
bacteria. The aim of this thesis was the discovery and characterisation of new bacteriocins 
from two sources, fermented foods and human faeces, testing the hypothesis that bacteria 
from the same niche will produce antimicrobials uniquely suited to act in this niche. Isolates 
from culture collections and new isolates from food and faecal samples were screened 
against a panel of pathogens responsible for food spoilage and human disease. Promising 
candidates were selected for genome sequencing, antimicrobial characterisation and 
biological study. The genome of Lactobacillus gasseri LM19 showed the presence of 
antimicrobial genes encoding, among others, a new bacteriocin, gassericin M. L. gasseri 
LM19 could survive and express its bacteriocin genes under colonic conditions. Its 
administration modulated the effects of Clostridium perfringens on the gut microbiota 
composition.  Streptococcus agalactiae DPC7040 was previously shown to produce the 
natural variant nisin P. MALDI-ToF analysis confirmed that nisin P is three amino acids 
shorter than nisin A and that two lanthionine rings were absent in 50% of molecules. This 
structure impacted on its antimicrobial activity, which was weaker than that of nisin A and 
nisin H in faecal fermentations. Staphylococcus epidermidis strains isolated from faecal 
samples were compared with skin isolates with respect to genomic and phenotypic traits. 
It was concluded that S. epidermidis has no specific genomic features to colonise different 
body sites but is likely to adapt its metabolism to the different conditions. Potential novel 
antimicrobials were found in Lactobacillus amylovorus and Lactobacillus crispatus isolates, 
which showed probiotic properties and interesting phenotypic differences between strains. 
Together, this work further demonstrates that fermented food and gut environments are 
valuable sources of new isolates, the study of which can yield new antimicrobials and give 
insights into bacterial ecology and evolution.  
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1.1. The antimicrobial resistance problem 
Antimicrobials are substances that have the ability to kill or inhibit the growth of 
microorganisms. They have been used as preservatives and as a way of managing infections 
over centuries. The presence of tetracyclines has been reported in histological studies in 
ancient bones in Egypt and traditional knowledge relating to the use of antimicrobials has 
been transmitted over generations in Chinese medicine, Greco-Roman and Hindu cultures 
[1]. However, in the pre-antibiotic era, events involving a microbial infection had 
considerable potential to have fatal consequences and it was not until the discovery of 
penicillin, the first natural antibiotic in 1928, that humankind experienced a significant 
antimicrobial-mediated improvement in life quality, reflected in an increase in life 
expectancy and the absence or minimisation of sequelae after infectious processes. 
Unfortunately, prescription policies are not always adhered to and there are many 
examples of antibiotic misuse by humans [2, 3]. Some antibiotics can be used as 
prophylactics, and they were provided to animals in farms in order to avoid epidemics and 
accelerate growth until 2006. [3]. Agricultural production is another big market for 
antibiotic use [3]. All of these factors have increased the appearance of antibiotic 
resistance. Resistance is manifested by an antibiotic not being effective against a certain 
pathogen at a certain dose. This is brought about by the fact that bacteria have developed 
different ways to avoid the effect of antibiotics, including modifications that decrease the 
ability of the antibiotic to penetrate through the cell envelope, efflux pumps that take the 
antibiotic out of the cell, targeted modification and enzymatic inactivation of the antibiotic, 
among others [4]. These resistance traits can be products of an innate resistance or occur 
by acquisition of resistance. This acquisition might be by spontaneous mutation (especially 
in membrane receptors and targets) or by incorporation of foreign DNA (plasmid exchange, 
transformation or transposons). Pathogens frequently exchange genetic material in order 
to gain ecological fitness, but these resistance genes do not necessarily come from other 
pathogenic bacteria, they can also be in a reservoir of commensal cells, forming what is 
known as the ‘resistome’ [5, 6]. The use of broad-spectrum antibiotics instead of more 
target specific antibiotics is one of the causes of the antibiotic resistance problem [7, 8]. 
Multidrug resistant (MDR) [9], extensively drug resistant (XDR), and pandrug-resistant 
(PDR) organisms [10, 11] are a product of this situation. Some of them are also known as 
‘ESKAPE’ organisms (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, 
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Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). Right 
now, the treatment approach in these situations is the use of a combination of different 
drugs, but effectiveness of this solution is also becoming more limited. Unfortunately, the 
dearth of new antibiotics is further exacerbating the situation. Since the 1980’s, very few 
classes of new antibiotics have been discovered and, as a general rule, the new 
antimicrobials on the market are modifications of the pre-existing ones [12]. Challenges 
with the development of new antibiotics include the need of sourcing new compounds, 
identifying novel antibiotic targets (ribosome, cell wall synthesis and DNA gyrase or 
topoisomerase are the current ones) and the challenge of breaking through the bacterial 
envelope, especially in Gram-negatives [9]. Persisters are also another important challenge. 
Antibiotics can only work in the presence of active targets, but persisters are dormant cells 
produced stochastically during bacterial growth that are not active, and therefore 
antibiotics cannot be effective on these cells. All pathogens studied have shown the ability 
to form persisters and the pathways for their formation are highly redundant [13, 14]. 
Similarly, spore formation is another challenge since spores are more resistant to 
antibiotics than the corresponding vegetative cells. Some spore-forming organisms are 
pathogenic and also cause food spoilage [15]. Biofilms can be considered another challenge 
in antibiotic resistance. It is more common to find bacteria in biofilm communities rather 
than as isolated cells. These biofilms provide advantages to bacteria because cells share 
molecules like enzymes, siderophores and extracellular polymers. Biofilms offer bacteria 
advantages against dehydration, predators and antibiotics, and are a major problem in 
healthcare, contributing to persistent infections [16, 17]. 
It is necessary to develop platforms that allow a systematic strategy to have an efficient 
search for new antibiotics. The combination of old and new strategies and the 
incorporation of new tools could be the key to identify and develop prodrugs, biologically 
inactive compounds that require metabolisation to activate, and/or species-specific 
compounds and overcome previous challenges, like the ‘great plate count anomaly’, that 
states that only 1% of microorganisms present in natural samples are able to be cultured, 
limiting antibiotic discovery. Screening of natural sources in combination with genomics 
and transcriptomics could help with silent operons and could enable drug discovery from 
microorganisms that have previously gone uncultured [4, 12, 18]. 
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Antibiotic resistance is a serious problem. The World Health Organisation (WHO) has 
predicted a huge rise in deaths by infections due to resistant microorganisms, reaching 10 
million deaths per year by 2050 [3]. Given the time necessary to develop an effective drug, 
including the associated clinical trials, considerable efforts in novel antibiotic 
discovery/development is needed in the coming years.  
1.2. Microbial ecology 
Most of the antibiotic compounds found during the ‘golden era’ of antibiotics discovery 
(1940-1960) came from natural sources, specifically, soil-derived actinomycetes [9]. 
Natural environments continue to be reliable sources for new compounds of interest [9, 
12]. Natural environments can be considered as balanced ecosystems, and within them, 
living organisms establish different relationships that can be positive, negative or neutral. 
An example of positive relationship is ‘mutualism’, where both parties are benefiting from 
the interaction. The opposite end is ‘competition’ and usually happens when two parties 
share the same resources in the same niche, experiencing a decrease in their ecological 
fitness because the access to resources is limited. Competition can be interspecies 
(between different species) and intraspecies (between individuals of the same species). 
Among microorganisms, competition for resources can very intense and antimicrobials 
producers can gain a considerable advantage. Other hypotheses contend that 
antimicrobials might have an additional social purpose, serving as signals or even 
promoting biodiversity [19, 20]. Like many compounds, the production of antimicrobials is 
likely to be linked to a phenomenon known as ‘quorum sensing’, related to population 
density. Bacteria are very likely to live in communities and this quorum sensing is how they 
regulate their gene expression in response to biotic or abiotic stress [21, 22].  
1.3. Bioactive potential of the human gastrointestinal tract (GIT) 
The human body hosts a rich microbiome consisting of many different microbial 
ecosystems. Trillions of microorganisms have co-evolved with us over time and the richest 
microbial communities are found in the gastrointestinal tract, skin and urogenitalia, 
although microbial communities are also present in lungs, placenta, breast milk and eyes 
[23]. Additionally, some of these communities may be related. For example, the 
transference that occurs between the oral and gut microbiota has been linked to the 
development of a number of conditions [24, 25]. The presence of an entero-mammary 
pathway has also been suggested [26], the existence of which could be critical for the early 
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colonisation of the human gut and for future systemic development [27]. Because of this 
microbial vastness, there remains much to be learned about the human microbiome. 
However, it is clearly a potentially significant source of metabolites, including broad and 
highly specific antimicrobials [28]. At the moment, this metabolite variety includes 
production of lipids and glycolipids, oligosaccharides, terpenoids, polyketides, amino acids, 
nonribosomally synthesised peptides and ribosomally synthesised post-translationally 
modified peptides (RiPPs). Although relatively unexplored, the studied compounds showed 
different functions, such as immunomodulation, cytotoxicity, antioxidant activity and, of 
course, antimicrobial capacity [29]. For these reasons, the human microbiome, more 
specifically, the human GIT, constitutes a promising source of new antimicrobials.  
1.3.1. Conditions and microbiota composition in the human GIT 
The diversity of microbial species in the human GIT can be linked to the variety of 
environmental conditions present therein. Several factors influence the abundance and 
diversity of microorganisms in the gut:  
1.3.1.1. Geography. The GIT is not uniform. There is a small and a large intestine with 
different functions and special structures. The small intestine is composed of the 
duodenum, jejunum and ileum and its main function is absorption of nutrients and 
chemical digestion. The large intestine is mainly represented by the colon, but has other 
structures i.e. the caecum, appendix and rectum. Its functions include the final absorption 
of water and salts and the fermentation and breakdown of the previously undigested 
products. The caecum and appendix have been described as reservoirs of microorganisms 
that might have an immunomodulatory function. The interior of the GIT is also varied, the 
surface of the epithelium presents crypts in the small intestine and the colon, where 
microorganisms are more protected than in the lumen from the flow of nutrients [30]. Both 
have a mucus layer composed of mucins, glycoproteins of high molecular mass, that 
obstruct the access of the microbial cells to the host cells, but also can be a nutrient source 
to certain bacteria. 
1.3.1.2. Temperature. Temperature is one of the most important factors regulating gut 
microbial composition and growth. It affects important aspects like pH, water activity, ion 
activity, viscosity, hydration and aggregation of macromolecules, toxic action of 
metabolites and solubility of gases (especially oxygen and carbon dioxide). The small and 
large human intestine have an average temperature of 37°C. This is essential for the 
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optimal performance of enzymes and the breakdown of indigestible fibres. This 
temperature will select mesothermic microorganisms to live within the gut.  
1.3.1.3. Gas composition. The gas mixture in the GIT has a microbial origin, with the 
exception of N2 and O2 that originate from swallowed air. This swallowed air has an 
influence on the upper regions of the intestinal tract. There is a decreasing gradient of 
oxygenation from the proximal to the distal part of the small intestine that ultimately will 
determine the distribution of aerobic and anaerobic bacteria. Oxygen tolerant bacteria and 
facultative anaerobes will be present in small intestine [30]. In the colon, fermentation 
processes make it a hypoxic environment and the gases such as H2, CO2, H2S and CH4 are 
present, as a result of the different processes carried out by fermentative bacteria and 
hydrogenotrophs, their symbiotic counterparts. Archaea are responsible for methane 
production [31].  
1.3.1.4. pH. pH is not constant across the gastrointestinal tract. The proximal part of the 
small intestine is more acidic due to its proximity to the stomach and the presence of bile 
acids, while the pH increases progressively through the rest of the GIT, being highest at the 
descending part of the colon and the rectum, where it reaches over 6.5. In regions of the 
gut where the presence of microorganisms is higher, products of microbial fermentation 
also influence the pH.  
1.3.1.5. Osmotic effects. Osmolarity depends on the type of food eaten and the region of 
the gut. Osmotic pressure is one of the main factors that control emptying of the stomach 
and the outcome is a mixture with the isotonic gastric secretions [32]. 
1.3.1.6. Surface tension. Surface tension is one of the parameters that affect the physiology 
of bacteria [32] and is variable across the different regions in the gut, mainly because of 
the effects of fat digestion and bile secretions at the proximal end of the small intestine. It 
has an influence over other parameters, like the redox potential. Food and additives also 
play a major role over this parameter. 
1.3.1.7. Nutrients. Food ingested will be the main source of nutrients for the 
microorganisms that inhabit the gut [33]. Nutrients that arrive to the gut might be 
digestible or indigestible, and the proportions of which will influence the composition of 
the microbiota. Primary ingested foods will be used by certain species to obtain nutrients, 
and the products generated by this metabolism will serve as substrates for other species. 
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Bacteria also synthesise compounds that are beneficial for the host, in the case of humans 
for example, B complex vitamins. 
1.3.1.8. Liquid flow. Flow rates are not constant across the gut, being controlled by the 
chemical and physical nature of the food, drink, secretions in the gut and absorption that 
removes products. Liquid flow influences the degree to which certain microbes are washed 
out of the gut. Organisms that are better able to adhere to the epithelium and mucus layer 
will be more protected and more likely to be successful in the colonisation of the small 
intestine [30, 32].  
As a result of the variation of all of these parameters, the gut microbiota is heterogeneous 
across the GIT, but it is also heterogeneous through time. From the moment of delivery, 
the GIT begins to be colonised and changes until it stabilises at the third year of life [34, 
35]. After this, the composition remains constant and tends to recover after acute changes, 
like use of antibiotics [30] but the influence of long-term habits, such as consumption of a 
specific type of diet, are more difficult to overcome if trying to modulate microbe 
composition and proportion [34]. Because of the considerable variability in microbial 
composition across individuals, defining what exactly constitutes a healthy GIT microbiome 
is a difficult challenge [23]. However, a functional approach has provided more promising 
results in this area. This is rooted in the ability of many components of the microbiota to 
present redundant functionality beyond the specifics of species composition [35]. 
Regardless, both approaches, i.e., determining taxonomies and identification of functional 
patterns, continue to undergo further development [36]. Cultivability problems might 
improve by culturomics approach, pointed as a solution to fill gaps left by traditional 
cultures and culture-independent techniques [37-39]. There are other strategies that do 
not rely on microbial cultures, such as metagenomic profiling [35, 40, 41], that allow an 
accurate compositional characterisation from stool samples and can help to identify 
microbial groups and functions related to healthy and dysbiotic metagenomic profiles and 
specific diseases and syndromes. However, non-abundant groups can be under 
represented [39] suggesting that a combination of techniques might be the best approach 
for a reliable characterisation of the human microbiota. Also, most of the studies carried 
out regarding microbiological composition of the gut have been performed using stool 
samples, and that might imply a misrepresentation of gut mucosal microbiota [30, 42].  
Chapter I. General introduction 
 
8 
 
In terms of composition, the most abundant bacterial phyla in the gut are Bacteroidetes, 
Firmicutes, Actinobacteria, Proteobacteria and Verrucomicrobia [30]. There are also 
Archaea and Eukarya representatives and viruses [36]. In general, colonisation of the small 
intestine is led by groups of facultative anaerobes able to grow fast and tolerate the effects 
of bile acids, like Firmicutes (Lactobacillaceae) and Proteobacteria (Enterobacteriaceae), 
favoured by lower pH and higher oxygen levels and antimicrobial compounds (both of host 
and bacterial origin). Once in the colon, when pH increases, and oxygen levels and 
antimicrobials decrease, the transit time is slower and with the presence of easily digestible 
nutrients there is a proliferation of fermentative organisms able to degrade more complex 
compounds, like polysaccharides and fibre. Bacteroidetes group (Bacteroidaceae, 
Prevotellaceae and Rikenellaceae) in the lumen and Firmicutes (Lachnospiraceae and 
Ruminococcaceae) in the inter-fold regions are the most common organisms. 
1.3.2. Antimicrobial activity in the gut  
Microbes in the gut employ a range of different strategies to compete for the resources in 
the environment. Some of them are direct, such as competitive removal of essential 
substrates, accumulation of D-amino acids, and lowering of the oxidation-reduction 
potential. Other strategies involve the production of metabolites with the ability to limit 
the growth of surrounding bacteria. This activity can be classified as specific, such as the 
case for some bacteriocins, or non-specific, if the regulatory agent does not address a 
specific target. In the latter case, activity might have other impacts, beneficial or 
undesirable, in the host. Some of the compounds that possess non-specific antimicrobial 
properties are summarised below. 
1.3.2.1. Unspecific antimicrobial activity 
1.3.2.1.1. Hydrogen peroxide 
Hydrogen peroxide consists of two atoms of hydrogen and two atoms of oxygen. It is an 
example of a ‘reactive oxygen species’, and although these are by-products of oxidative cell 
metabolism, it has been suggested that its production might have a biological purpose itself 
[43]. Hydrogen peroxide can be produced by pathogens and opportunistic species, species 
with probiotic properties and commensal microbiota. Usually, microbial species that 
accumulate hydrogen peroxide are able to adapt their energy metabolism to anaerobic 
environments, but in the presence of molecular oxygen, hydrogen peroxide and other 
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partially reduced oxygen species can be produced, when this molecular oxygen captures 
electrons from the enzymes involved in electron-transfer, mainly flavoenzymes [44]. 
Hydrogen peroxide is the result of central carbon and energy metabolism, oxidases are a 
pivotal part of its production: pyruvate oxidase (Pox), lactate oxidase (Lox) and NADH 
oxidases (Nox), but depending on the producing species, the importance of each specific 
oxidase in the production will vary [43]. However, specific reactions and enzymes that 
catalyse hydrogen peroxide formation are still being characterised [43, 44]. The absence of 
enzymes that scavenge hydrogen peroxide, such as catalase and NADH peroxidase, is also 
an important disseminated characteristic of these producers.  
Traditionally, hydrogen peroxide is well known for its antimicrobial properties. This activity 
is based on the oxidising effects that hydrogen peroxide has over the bacterial cells and 
their molecular structures. Therefore, DNA and protein repair system are used by cells to 
minimise its effect. Those systems were reviewed by Imlay [44]. Hydrogen peroxide 
regulation is not very well characterised in gut environments and it has been suggested 
that it contributes to maintaining a homeostatic microbiota. It is known, though, that some 
lactobacilli, streptococci and enterococci can produce relative high amounts of hydrogen 
peroxide and that these amounts can be similar to those released by phagocytic cells [45]. 
Production of hydrogen peroxide can be an asset in certain environments, but that does 
not mean that it is beneficial at all times as its activity is not only toxic for bacteria, but also 
for human cells [46]. Strus et al [45] reported differences in gut microbiota composition 
and abundance in chronic inflammatory lesions in colons of people affected by Crohn’s 
disease and ulcerative colitis, with aerobic streptococci and lactobacilli, respectively, being 
more abundant. These might lead to an increase of hydrogen peroxide concentration, 
exacerbating harm of the epithelium [45]. Despite the fact that the gut is mainly an 
anaerobic environment, the presence of oxygen gradients close to the mucosal surface has 
been proven [47], which contributes to harm the epithelium.  
It has also been noted that the antimicrobial activity of hydrogen peroxide seems to work 
synergistically with other compounds produced by bacteria available in the environment, 
such as lactic acid. This may be explained by an ability of lactic acid to induce sensitivity or 
permeabilise bacterial membranes, thus facilitating hydrogen peroxide diffusion [48].  
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1.3.2.1.2. Organic acids 
An organic acid has carboxyl groups, sulfonyl groups and sometimes alcohols that promote 
their acidic properties. Short-chain fatty acids (SCFAs) are saturated aliphatic organic acids 
with less than six carbon atoms, such as formate, acetate, propionate, lactic acid and 
butyrate. Their activity is highly influenced by the conditions in the environment that 
surrounds them. One of the factors is pH, since they are mainly weak acids and both 
dissociated and undissociated forms are common. Their antimicrobial mode of action is not 
fully understood, but it is believed that the undissociated form of the organic acid crosses 
the lipid membrane with dissociation occurring once inside in the neutral pH, producing 
ions that affect the homeostasis of the cell, causing stress. Another level of action for 
organic acids is at the cell membrane, where they interfere in the regulation of transport 
at the membrane and cell wall function. These activities of organic acids have resulted in 
their use in food conservation against foodborne pathogens [49].   
SCFA origin in the gut is through fermentation of resistant carbohydrates that have not 
been digested in the small intestine. This fermentation takes place mainly in the colon using 
substrates such as starches, dietary fibre, sugars and alcohols among others [50], including 
protein and amino acid fermentation. The type of starch is very likely to have an influence 
in the production and proportion of SCFAs [51]. This process provides extra energy to the 
host. SCFAs are produced in millimolar concentrations in anaerobic conditions. It has been 
reported that acetate production is common among gut bacteria, but propionate and 
butyrate production is not as extended.  
SCFAs are considered to be very important as regulators of different functions in the human 
gut. They impact inflammatory processes and are an important part of glucose 
homeostasis. Immune processes, along with lipid metabolism and appetite regulation, are 
also influenced by SCFAs [52]. Lactic acid is produced by lactic acid bacteria and it is one of 
the most important products of their carbohydrate metabolism, either following a 
homofermentative or heterofermentative pathway. Lactic acid bacteria include a variety of 
groups: lactobacilli, carnobacteria, streptococci, lactococci, enterococci, leuconostoc, 
pediococci, aerococci and tetragenococci. Lactic acid has an inhibitory activity against a 
wide range of bacteria, including Gram-positive and Gram-negative targets. Recent studies 
[53, 54] proved that low concentrations, 0.5% (v/v), were enough to have an inhibitory 
effect on Salmonella, E. coli and L. monocytogenes over a two hour exposure period. SDS-
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PAGE confirmed that there was a leakage of proteins from the target cells, meaning that 
cell membrane damage is the main physiological effect. 
1.3.2.1.3. Other non-specific inhibitory compounds 
Many of these inhibitory compounds have a fermentative origin and are products of the 
degradation of other compounds, like lactic acid or ethanol, that ultimately become SCFAs, 
CO2 and H2. Carbon dioxide exhibits antimicrobial activity by lowering intra- and 
extracellular pH and its disrupting effect on the cell membrane, and by replacing the 
molecular oxygen leading to a transformation of the surrounding atmosphere into an 
anaerobic environment. 
Another fermentation product is diacetyl or 2, 3-butadione. It is produced by some species 
of Lactobacillus and Pediococcus, among others. The antimicrobial ability of diacetyl has 
been described previously [55]. Gram-negative bacteria and fungi seem to be the most 
affected by diacetyl activity, followed by yeast and Gram-positive non-lactic acid bacteria. 
Lactic acid bacteria have shown the less susceptibility to its action, at any pH. This effect 
over Gram-negative organisms might be explained because diacetyl interferes with 
arginine-binding proteins of Gram-negative bacteria. The activity of diacetyl is influenced 
by pH, requiring different optimums to act against different organisms [55]. Its use in 
combination with other compounds, such as reuterin, makes it act synergistically [56]. 
Diacetyl has been studied mostly as a food preservative.  
Protein and amino acid fermentation can lead to the production of ammonia and amines. 
Ammonia can be formed by oxidative or reductive deamination of amino acids while 
amines are the result of decarboxylation and in an acidic environment can form nitrogen 
(N-nitroso) compounds. There are amino acids that are of special interest, like cysteine and 
methionine, whose degradation derives in the generation of H2S. This compound is also 
generated by sulphate-reducing bacteria (SRB) using lactate, ethanol, succinate and H2. 
Aromatic amino acids also produce phenols and indoles.  
1.3.2.2. Specific antimicrobial activity 
1.3.2.2.1. Peptidic antimicrobial activity 
Bacteria can produce target-specific antimicrobial peptides. Antimicrobial peptides are 
classified based on their biosynthesis, which can be ribosomal or non-ribosomal. Typically, 
antimicrobial peptides are 10–50 amino acids in length and their ability to kill bacteria 
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depends on their interaction with bacterial membranes and cell walls, and so does their 
selectivity. The identification and direct isolation of those compounds is difficult. Recently, 
a bioinformatics tool, ClusterFinder, has been able to identify thousands of biosynthetic 
gene clusters from human metagenomic samples encoding antimicrobial peptides, among 
other compounds. This highlights the potentially underexploited therapeutics that can be 
sourced from within the human microbiome. 
1.3.2.2.1.1. Non-ribosomal peptides (NRPs) 
NRPs are synthesized by multienzyme complexes of multifunctional peptide synthetases 
and constitute secondary metabolites. NRPs are a large class of bacterial products and they 
are present in several environments. Their study has provided many of the antibacterial 
compounds currently in use, such as vancomycin or polymyxin, that are considered as 
peptide derived. However, there are very few NRPs characterised from the human 
microbiota. The peptides cereulide and zwittermicin, both produced by pathogenic Bacillus 
cereus, and tilivalline, produced by pathogenic Klebsiella oxytoca, were isolated initially 
from bacteria isolated from the human gut, although they are not common human gut 
microbiome representatives [28]. Their activity has been described as cytotoxic [28]. 
Zwittermicin activity has been reported as antimicrobial but resistance genes for it have 
also been identified [28]. Therefore, the use of NRPs as therapeutics would be limited. 
1.3.2.2.1.2. Ribosomally synthesised peptides (bacteriocins) 
Bacteriocins are ribosomally synthesised antimicrobial peptides. Although they are not 
referred to as traditional antibiotics, they do have antibiotic activity and they have been 
proven to provide an ecological advantage to the producing strains in order to survive in 
highly competitive environments [57]. Bacteriocins are important in bacterial population 
dynamics. They are found to be very effective and specific against competitors from the 
same environment as their producers and many of them have been discovered by 
screening a variety of natural environments [58-66]. 
1.4. Bacteriocins 
Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria. They 
constitute a heterogeneous group that include many different subgroups. The first 
bacteriocin was discovered by Andre Gratia in 1925 and was named a ‘colicin’ because they 
were active against Escherichia coli. Perhaps the best known bacteriocin is nisin, produced 
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by Lactococcus lactis and is most frequently used as a food preservative [67]. Bacteriocins 
have low toxicity and that makes them suitable for being used as food and beverage 
preservatives, since traditional antibiotics are prohibited for use in foods. These low toxicity 
effects have been proven for a number of bacteriocins in different studies [68, 69]. 
However, some bacteriocins have shown some cytotoxic activity [70]. Bacteriocins can 
exhibit broad-spectrum antimicrobial activity, giving them the possibility of being used as 
a traditional antibiotic, and some exhibit narrow-spectrum, which makes them suitable for 
targeting specific harmful microorganisms without negatively impacting on other microbes. 
Bacteriocins activity has been shown in vitro and in vivo [70, 71]. As a general rule, 
bacteriocins produced by Gram-positive bacteria show better activity against Gram-
positive pathogens and bacteriocins produced by Gram-negative bacteria work more 
effectively against Gram-negative pathogens. However, the use of bioengineered 
derivatives has made it possible to cross this barrier somewhat [72]. As bacteriocins have 
a ribosomal origin, they offer the possibility of being bioengineered, either by gene 
manipulation or partial/complete chemical synthesis, enhancing their features [73, 74]. 
Additionally, bacteriocins can have synergistic activity when combined with other 
substances, such as lactic acid, that allows the permeabilization of the bacterial membrane. 
Bioactivity is in a nano- to micromolar range and the absence of taste, colour or odour, 
makes them also suitable for industrial and clinical purposes [75]. 
Bacteriocins are produced by bacteria in natural environments, and this property can be 
exploited in order to produce the antimicrobial in situ [76]. Probiotic strains could be 
considered for this purpose and there are several studies that report beneficial outcomes 
of different strains controlling pathogens or infection-associated microorganisms [76, 77]. 
A very important advantage of bacteriocins over traditional antibiotics is that resistance is 
not easily developed against them.  
1.4.1. Classification 
Because bacteriocins are a heterogeneous group, different criteria have been used for their 
classification, such as primary structure, molecular weight, mode of action, heat stability 
or genetic properties. Currently the most accepted classification is based on their structure. 
Here, we follow the classification proposed by Cotter et al, 2013 [70].  
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1.4.1.1. Class I 
This class contains different groups of small heat-stable peptides (<10 KDa), all having in 
common the presence of modified amino acids that are introduced through enzymatic 
modification during their biosynthesis. These modifications influence their function 
through the formation of characteristic amino acids and structures. Representatives of 
lantibiotics, sactibiotics, microcins, linear azole or azoline-containing peptides or lasso 
peptides have been described in strains of gut origin and are being increasingly studied 
(Table 1.1). Other class I groups that do not yet have representatives isolated from gut 
bacteria are linaridins, proteusins, patellamide-like cyanobactins, anacyclamide-like 
cyanobactins, thiopeptides and bottromycins [70]. 
 
Table 1.1.  Class I bacteriocins produced by bacteria originally isolated from the human 
gut.  
 
Class I (modified) 
Group Distinctive 
feature 
Bacteriocin 
from human 
gut isolate 
Gut Producer 
first isolated 
from human  
Activity against Reference 
Microcins  Microcin L E. coli LR05 Shigella sonnei  
E. coli  
Pseudomonas 
aeruginosa  
[150] 
Microcin M E. coli Nissle 
1917 
E. coli 
Salmonella 
[151] 
Microcin V 
(ColicinV) 
E. coli E. coli  [49] 
Microcin H47 
(MccH47) 
E. coli H47 E. coli, 
Salmonella, 
Enterobacter, 
Shigella, 
Klebsiella, 
Proteus spp. 
[152] 
 
Microcin E492 Klebsiella 
pneumoniae 
RYC492 
Escherichia, 
Klebsiella, 
Salmonella, 
Citrobacter, 
Enterobacter 
[153]  
Lasso peptide Lasso knot 
structure 
Microcin J25 E. coli AY25 E. coli   
Salmonella sp, 
Shigella flexneri 
[96] 
Sactibiotics Sulphur-α-
carbon 
linkages 
Thuricin CD Bacillus 
thuringiensis 
DPC 6431 
Clostridium 
difficile, Bacillus 
cereus, 
Bifidobacterium 
firmus, Listeria 
monocytogenes 
[154] 
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Lantibiotics
  
Lanthionine 
bridges  
Ruminococcin 
A 
Ruminococcus 
gnavus 
 
Bacteroides sp, 
Clostridium sp, 
Bifidobacterium 
sp, B. cereus 
[116] 
Nisin O Blautia obeum 
A2-162 
Clostridium 
perfringens, C. 
difficile, 
Lactococcus 
lactis 
[118] 
Cytolysin ClyLl 
and ClyLs 
Enterococcus 
faecalis 
Gram-positive 
bacteria 
[114] 
BLD 1648 Bifidobacterium 
longum 
(strain DJO10A) 
 [117] 
Linear azole-
or azoline-
containing 
peptides 
Heterocycles 
but no other 
modifications 
Microcin B17  E. coli Nissle 
1917 
E. coli, 
Salmonella, 
Shigella 
[151] 
 
1.4.1.1.1. Lantibiotics  
Lantibiotics are the most studied group of bacteriocins. The ‘lantibiotic’ term comes from 
‘lan-thionine containing antibiotic’. Lantibiotics are part of the group of lanthipeptides. 
However, not all exhibit antimicrobial activity, and the ones that do are referred to as 
lantibiotics. They are small peptides (<5 kDa) that include modified amino acids known as 
dehydroalanine (Dha) and dehydrobutyrine (Dhb) that are the result of the dehydration of 
Ser and Thr residues respectively, forming 2,3-didehydroalanine and (Z)2,3-
didehydrobutyrine. There is a stereospecific intramolecular addition of a cysteine residue 
to form a lanthionine (Lan) or methyllanthionine (MeLan) bridges [78]. There are described 
up to 17 uncommon amino acids [79]. The function of these amino acids in unknown, but 
it is suspected to be related to the interaction with free sulfhydryl groups on cell envelopes 
of target organisms.  
Lantibiotic genes are organised in highly conserved clusters that usually encode proteins 
with similar functions. A typical lantibiotic cluster presents genes for a precursor peptide 
(LanA), modification enzymes (LanB and LanC or LanM), usually a protease to remove the 
leader peptide (LanP); LanT encodes a family of transport proteins, ABC, that translocate 
the peptide and sometimes encodes the protease activity too; LanR and LanK constitute a 
two-component regulatory system, and LanI and LanFEG are responsible for self-immunity 
(Figure 1.1).  
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Figure 1.1. Examples of bacteriocin cluster organisation among the different bacteriocin 
classes. Genes are coloured according to the function of their products: red, precursor 
peptides; green, post-translational modifications; blue, export; yellow, immunity; pink, 
regulation; purple, export and immunity; orange, lysis; grey, unknown function. Class I: 
microcin J25 [80]; nisin A [81]; microcin E-492 [80]; thuricin CD [82]; microcin B17 [80]; class 
IIa bacteriocin 43 [83]; class IIb ABP-118 [84]; class IIc AS-48 [85]; class IId microcin S [86]; 
class III colicin [87]. 
There are differentiated steps that have been described in the production and maturation 
of lantibiotics: synthesis of the prelantibiotic, dehydration and linkage reactions, removal 
of the leader sequence and secretion. There are four groups that are differentiated based 
on the enzymes present during the maturation process: class I, LanBC-modified, class II, 
LanM-modified. Class III uses LanKC and class IV uses LanL, but they do not show 
antimicrobial activity. Lipid II binding is the most common mechanism of action of 
lantibiotics, a target in the cell-wall formation process. There are two ways of disrupting 
the cell wall, either by inhibiting its synthesis or by pore formation. Nisin A, first isolated 
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from Lactococcus lactis and the most studied lantibiotic (Figure 1.2), has both functions, 
but not all lantibiotics do. However, this activity on the cell wall is the reason for lantibiotics 
to not be very effective against Gram negative bacteria, since they are protected by a 
lipopolysaccharide membrane that shields the cytoplasmic membrane [88]. It has been a 
common belief that lantibiotics are only produced by Gram positive bacteria. Despite this, 
the identification of pinensins, a lantibiotic type bacteriocin produced by Gram-negative 
bacteria that exhibits antifungal activity [89], refutes this idea and highlights the vastness 
of metabolic diversity. Currently, the transference of the in vitro efficacy to the in vivo tests 
is one of the main focuses in lantibiotic research [90]. There are lantibiotics tested in vivo 
for a variety of health applications, especially targeting bacteria of clinical relevance, and 
currently in pre-clinical development.  
Other lantibiotics include ruminococcin A, produced by Ruminococcus gnavus, isolated 
from human faeces. It was the first characterised bacteriocin from a strict anaerobe 
isolated from a human faecal sample and its activity was shown to be induced by  trypsin 
[91]. Genomic analysis of B. longum DJO10A identified the presence of a novel lantibiotic, 
BLD1648. This is important because bifidobacteria are classified as beneficial commensal 
bacteria, but the isolation and characterisation of antimicrobial compounds of ribosomal 
origin has been very difficult. Activity against bifidobacteria suggests competition 
functionality. Another lantibiotic recently described from human gut origin is nisin O, 
produced by Blautia obeum A2-162 [92, 93]. Butyrivibriocin [94], Butyrivibriocin OR79 [95] 
and Butyrivibriocin AR10 [94] were bacteriocins produced by bacteria isolated from 
gastrointestinal tracts (rumens) of animals. Nisin H has also been identified produced by a 
porcine gut isolate, Streptococcus hyointestinalis DPC6484 [61].  
Human pathogens can synthesise lantibiotics too. The two-component cytolysin, isolated 
from E. faecalis is an example, contributing causes to bacterial virulence and antibiotic 
resistant infections and being highly efficient against other Gram-positive bacteria. 
Cylolysin has two subnunits, large (L) and small (S) whose post-translational modification is 
controlled by the gene cylM. They are transported outside the cell by the ABC transport 
system and activated by cylA. Its activity is regulated by quorum-sensing autoinduction. 
The process starts with two genes, cylR1 and cylR2, whose products prevent the 
transcription of the bacteriocin components. The small subunit of the cytolysin induces the 
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expression and when it reaches a certain concentration, derepression from the two 
inhibitory genes takes place [96].  
 
Figure 1.2. Nisin A structure [97]. 
1.4.1.1.2. Microcins 
Microcins are peptides of less than 10 kDa produced by Enterobacteriaceae that are 
differentiated from colicins, also produced by Enterobacteriaceae and are bigger than 20 
kDa, by their molecular mass. Microcin clusters typically involve a precursor, secretion 
proteins and elements for self-immunity. There are two groups of microcins, a class I of 
peptides smaller than 5 kDa with post-translational modifications, and a class II (between 
5-10 kDa) that can be divided into class IIa, encoded on plasmids, and class IIb, encoded on 
the chromosome. They are described as hydrophobic and heat-, pH- and protease-stable 
[80]. Microcins have a precursor peptide that is cleaved at the transport stage [98]. 
Although 16 microcins have been identified, only eight are structurally characterised [98]. 
Microcins are believed to mimic essential nutrients to act like a ‘Trojan horse’, like iron-
siderophore complexes, that the target bacterial cell detects and incorporates and once 
inside the cell, microcins act on the enzymes or inner membrane [99]. Microcins are 
involved in in vivo interspecies and intraspecies competition among Enterobacteriaceae in 
the gut during inflammation and they are able to inhibit cell growth [100, 101]. The 
structure of microcin E-492 is shown in Figure 1.3. 
 
Figure 1.3. Microcin E-492 structure [102]. 
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1.4.1.1.3. Lasso peptides 
Lasso peptides have bacterial origin and named by their distinctive structure as a knot, 
including a macrolactam ring crossed through by the C-terminal tail (Figure 1.4). The 
structure is stable and sustained by steric interactions and disulphide bridges. Three classes 
of lasso peptides are described at the moment, based on the number of disulphide bridges. 
Class I has two disulphide bonds, class II does not have any and class III possesses just one 
disulphide bond [103, 104]. They have enzymes with inhibitory activity, receptor 
antagonistic behaviour and some of them also exhibit antimicrobial activity. Genome 
mining has increased the discovery of biosynthetic gene clusters encoding lasso peptides. 
In addition to activity-based discovery, 38 lasso peptides were known in 2015 [105]. Most 
of the described lasso peptides have been reported from soil, sludge and water bacteria, 
with the exception of zucinodin, isolated from an intracellular bacterium of 
erythroleukemia cell line origin, and microcin J25, from a bacterium of human origin. Their 
stability has also made them attractive to be used as new chemical scaffolds.  
Microcin J25 is considered the paradigm of lasso peptide and has been extensively studied. 
It is made up of 21 amino acids and produced by E. coli AY25, isolated from the faeces of a 
newborn. Typically, it forms a ring by a lactam linkage between the first glycocin and the 
eighth glutamate [106]. The tail is formed by the thirteen residues left, with the 
phenylalanine in position 19 and the tyrosine in position 20 acting as plugs [107]. There are 
four genes in the biosynthetic cluster: a precursor (mcjA), cleavage of leader peptide 
(mcjB), a macrolactam ring formation gene (mcjC) and a gene that encodes the ATP-binding 
cassette transporter (mcjD) (Figure 1.1). The biosynthesis of lasso peptides is not fully 
understood at the moment [108]. The microcin J25 antimicrobial target is the Gram-
negative RNA polymerase, which it inhibits, but also the depolarization of cell membranes 
in Salmonella and E. coli species [105]. 
 
Figure 1.4. Microcin J25 structure [109]. 
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1.4.1.1.4. Sactibiotics 
Sactipeptides are a general denomination for peptides that are characterised by having an 
intramolecular bridge between a cysteine sulphur and an α-carbon (Figure 1.5). 
Sactipeptides do not always exhibit inhibitory activity, and those who do are known as 
sactibiotics. They have been mainly identified by genome mining [110]. Currently there are 
four sactibiotics described, although not all of them have been deeply characterised: 
Subtilosin A, Propionicin F, Thuricin H and Thuricin CD [111]. Thuricin CD is one of the most 
studied. It was isolated from Bacillus thurigiensis DPC6431, a representative of the human 
gut. It is particularly important because it has been  shown to have very specific activity 
against important pathogens: Clostridium difficile, Bacillus cereus, Bacillus firmus and 
Listeria monocytogenes [112]. It consists of two subunits, Trnα and Trnβ (Figure 1.4). Its 
genomic cluster presents structural genes, transport, immunity and post translational 
modification genes (Figure 1.1). The presence of genes encoding for the radical S-
adenosylmethionine (SAM) is also characteristic. Research on thuricin CD mode of action is 
still ongoing. Both subunits act on the cell membrane, collapsing the membrane potential 
irreversibly. More specifically, results suggest that the peptides get inserted in the 
membrane of the cell, forming a pore that leaks ions and ultimately lyses the cell [113]. 
Thuricin CD effects were similar to the ones exhibited by vancomycin and metronidazole, 
both used to treat C. difficile infections. 
 
 
Figure 1.5. Structure of thuricin CD subunits [114]. 
1.4.1.1.5. Linear azole-or azoline-containing peptides (LAPs) 
These peptides are also known as LAPs and their main feature is that they present different 
combinations of heterocyclic rings of thi-azole and (methyl)oxazole, produced by a 
cyclodehydration of cysteine, serine and threonine, and a dehydrogenation depending on 
flavin mononucleotide. Their antimicrobial activity is not fully understood yet. Microcin B17 
is a LAP produced by E. coli isolated from baby faeces [115] (Figure 1.6). Its antimicrobial 
activity targets the gyrase [116] and it is extensively studied to connect the effect between 
its structure and its function, in order to obtain information to design new antimicrobials 
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that mimic its function [117], especially since the inhibition of topoisomerases and gyrases 
constitute new targets for designing antimicrobials [118, 119]. Its applications have been 
studied by conducting in vivo studies to address its ability to control infections in infants 
[120] and cattle [121], proving its beneficial action.  
 
Figure 1.6. Microcin B17 structure [122]. 
1.4.1.2. Bacteriocins class II 
Class II is the largest group of bacteriocins. They are unmodified small heat stable peptides 
(<10 kDa). There are four subgroups, according to Cotter et al, based on their structure-
function relationships [123].  
Table 1.2. Class II bacteriocins produced by bacteria originally isolated from the human 
gut. 
 
Class II (unmodified or cyclic) 
Group Distinctive 
feature 
Bacteriocin 
from 
human gut 
isolate 
Gut 
Producer 
first isolated 
from human  
Activity against Reference 
IIa peptides 
(pediocin 
PA-1-like 
bacteriocins) 
Conserved 
YGNGV 
motif (N 
represents 
any amino 
acid) 
Bac43 Enterococcus 
faecium 
VRE82 
E. faecalis, E. faecium, 
Enterococcus hirae, 
Enterococcus durans, and L. 
monocytogenes 
[122] 
 Bacteriocin 
RC714 
E. faecium 
strain RC714 
E. faecalis, E. faecium, L. 
monocytogenes, Listeria 
innocua, Listeria murrayi, 
Listeria grayi, Lactobacillus 
paracasei, Lactobacillus 
plantarum, Leuconostoc sp., 
and Pediococcus pentosaceus 
[124] 
 Bacteriocin 
31 
E. faecalis 
YI717 
E. hirae 9790, E. faecium, and L. 
monocytogenes 
[155] 
IIb peptides Two 
unmodified 
peptides 
ABP-118 
  
Lactobacillus 
salivarius 
UCC-118 
L. monocytogenes  [127] 
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are required 
for activity 
Acidocin 
J1132 
Lactobacillus 
acidophilus 
JCM1132 
Lactobacillus sp [126] 
Gassericin 
T 
Lactobacillus 
gasseri SBT 
2055 
Lactobacillus delbrueckii subsp. 
bulgaricus 
[130] 
Lactacin F Lactobacillus 
johnsonii 
Lactobacillus sp,  
E. faecalis 
[156]  
IIc peptides Cyclic 
peptides 
Gassericin 
A 
L. gasseri 
LA39 
Bacillus, Clostridium, 
Lactobacillus spp, Lactococcus 
lactis, Leuconostoc 
mesenteroides, Listeria spp, 
Pediococcus cerevisiae, S. 
aureus, Streptococcus 
agalactiae 
[157] 
Reutericin 
6 
Lactobacillus 
reuteri LA 6 
L. acidophilus, L. delbrueckii 
subsp. bulgaricus and L. 
delbrueckii subsp. lactis  
[158] 
AS-48 E. faecalis 
AS-48 
Gram-positive and Gram-
negative 
[159] 
IId peptides Unmodified, 
linear, non-
pediocin-
like, single-
peptide 
bacteriocins 
Microcin S E. coli G3/10  E. coli G3/10  [136] 
Rhamnosin 
A 
Lactobacillus 
rhamnosus 
strain 68 
Micrococcus lysodeikticus ATCC 
4698 
[138] 
Bac 32 vancomycin-
resistant E. 
faecium 
(VRE) 200 
E. faecium, E. hirae, and E. 
durans 
[139] 
 
1.4.1.2.1. Class IIa  
Also known as pediocin-like bacteriocins, they are characterised by a highly conserved N-
terminal consensus sequence YGNGVXaaCXaaK/NXaaXaaC, including the ‘pediocin box’ 
(YGNGV). They also have two cysteines in the conserved region forming a disulfide bond, 
required for the antimicrobial activity (Figure 1.7). Their specificity is based in the C-
terminus and they act by permeabilising the cell wall. The target receptor is the sugar 
transporter mannose phosphotransferase system (Man-PTS), present in Gram-positive and 
Gram-negative bacteria. They are known for having strong activity against Listeria spp. 
Typically, biosynthesis requires at least four genes, a structural gene encoding a precursor, 
and three others encoding an immunity protein, ATP-binding cassette transporter and a 
protein for extracellular translocation (Figure 1.1). The cluster is regulated by quorum 
sensing by a three component system: an inducer peptide, a membrane associated 
histidine protein kinase, and a cytoplasmic response regulator [124] . 
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A typical class IIa bacteriocins of human gut origin is bacteriocin 43, isolated and 
characterised from a clinical isolate vancomycin-resistant E. faecium (VRE). Its sequence 
showed high homology with bacteriocin 31 from E. faecalis YI717 and bacteriocin RC714 
from a similar origin [125, 126].  
 
Figure 1.7. Structure of bacteriocin class IIa enterocin NKR-5-3C [127]. 
1.4.1.2.2. Class IIb 
Bacteriocins that belong to this subclass require two peptides acting synergistically to 
exhibit their antimicrobial activity (Figure 1.8). Usually, the structural genes are in the same 
operon and are expressed simultaneously. The killing mechanism involves membrane 
permeabilization, that leads to the leakage of small cytoplasmic molecules and monovalent 
cations (Na+, K+, Li+, Cs+, Rb+ and choline), but not divalent cations or anions. Some also 
include H+. The peptides that constitute the bacteriocin are typically of 30 to 50 amino acids 
in length and have similar characteristics to one peptide bacteriocins, being usually 
cationic, hydrophobic or amphiphilic. There is a typical double-glycine leader type 
sequence in the N terminus that it is cleaved off during transport. It is commonly accepted 
that individual peptides do not have individual antimicrobial activity by themselves, but 
there are exceptions [128].  
Examples of  this class of bacteriocins produced by human gut representatives include 
acidocin J1132, isolated from L. acidophilus JMC 1132 [129]. It was found that its production 
is limited by pH of the medium not being above 7.0, having its maximum production at pH 
5.0. Its mode of action is bactericidal instead of bacteriolytic [129]. ABP-118 is produced by 
the probiotic L. salivarius UCC118 [84]. L. salivarius UCC118 produces ABP-118 in vivo and 
it has able to control L. monocytogenes infection in mice [130]. It can act also as a gut 
microbiota regulator, increasing Bacteroidetes and Proteobacteria and decreasing 
Actinobacteria [131]. Gassericin T and Lactacin F also belong to this class. Gassericin T is 
produced by a L. gasseri isolated from human faeces and it is part of the Lactacin F family, 
sharing a 60% similarity [132]. Lactacin F requires two hydrophobic peptides LafA and LafX 
for its antimicrobial activity and it has been shown to act synergistically in combination with 
nisin [125]. 
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Figure 1.8. Structure of bacteriocin class IIb lactococcin Q [127]. 
1.4.1.2.3. Class IIc 
Class IIc bacteriocins are generally cationic peptides that present a covalent bond between 
C and N termini and are cyclic peptides (Figure 1.9). They have some degree of 
hydrophobicity. Traditionally, their mode of action was attributed to disruption and 
permeation of the bacterial cell membrane to small molecules, leading to cell death. 
However, new modes of action have been identified, such as inhibition of nucleic acid, 
protein and cell wall synthesis and enzyme activity [133]. Their three-dimensional structure 
is considered to have a role in their stability, making them more resistant to proteolysis 
[134].  
The most studied circular bacteriocin is AS-48, an α-helical and cationic peptide, first 
isolated from E. faecalis but produced by different Enterococcus species isolated from 
clinical and food samples. It is very broadly distributed among Enterococcus, and also 
presents different derivatives, both engineered and natural (e.g. AS-48J, isolated from goat 
cheese [135]). It has shown stability and solubility through a broad range of pH and 
temperature, and the most attractive feature is its spectrum of action, having activity over 
Gram-positive and Gram-negative bacteria. Its applications include being a well-proven 
food preservative, but with new strategies like lipome-encapsulation, its functionality 
might be increased. The successful treatment against S. aureus from cow mastitis opens 
the possibility to veterinarian applications. Other applications are being investigated at the 
moment, like its use as a leishmanicidal agent [136], for Propionibacterium acnes control 
[137] or against bacterial biofilms [138-141]. Gassericin A is another example of a class IIc 
bacteriocin produced by the human gut isolate L. gasseri LA39, presenting the same 
primary amino acid sequence as reutericin 6 produced by L. reuteri La6, both isolated from 
Chapter I. General introduction 
 
25 
 
faeces of the same baby with a difference of two months’ time between sample collection 
[133]. However, they differ in one D-alanine residue that confers on gassericin A a broader 
spectrum of activity. In fact, gassericin A can inhibit the growth of L. reuteri La6, but not the 
other way around. 
 
Figure 1.9. Structure of bacteriocin class IIc lactocyclicin Q [127]. 
1.4.1.2.4. Class IId  
This group has been proposed as a miscellanea group for different bacteriocins of class II 
that did not fit elsewhere.  It comprises unmodified, linear, non-pediocin like, single 
bacteriocins (Figure 1.10). Some examples of this class are microcin S, a bacteriocin 
produced by an E.coli strain that is part of the probiotic Symbioflor, constituted of six 
different E. coli genotypes [142]; rhamnosin A, bac 43 and bac 32 were also assigned to this 
subclass of bacteriocins. Microcin S is capable of inhibiting the adhesion of the 
enteropathogenic E. coli E238/6 to intestinal epithelial cells. Bac 43 and bac 32 have a 
clinical origin. There are other class II bacteriocins produced from bacteria isolated from 
the gastrointestinal tract of animals: bovicin 255 [143], coagulin A [144], enterocin 1071 
[145], lacticin Z [146] and lichenin [147].  
 
Figure 1.10. Structure of bacteriocin class IId lacticin Q [127]. 
1.4.1.3. Bacteriocins class III 
Class III are large, heat-labile proteins (>30 kDa). Their mode of action and structure differ 
from other bacteriocins and it is common that they present different domains. In general, 
bacteriocins from class III are not very well characterised. Their mode of action consists of 
promoting lysis of the cell wall by a conserved endopeptidase-like domain in the N-terminal 
region. The C-terminal region is responsible for recognition of the target (Figure 1.11). They 
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are classified in two groups, class IIIa, formerly known as bacteriolysins, an example being 
helveticin J [148]. Class IIIb disrupt membrane potential but are known for being non-lytic 
bacteriocins.  
Colicin V was the first colicin described, originally isolated from E. coli and initially it was 
classified as a microcin. Since then, many colicins have been isolated from other enteric 
bacteria. They are described as a narrow spectrum bacteriocins and their antimicrobial 
activity is conducted in different ways, such as inhibiting macromolecular synthesis, causing 
DNA breakdown and stopping protein synthesis  [87]. Colicins can be divided into two 
subgroups. The criteria is based on their encoding plasmids: group A are on small plasmids 
and excreted and group B are encoded by large plasmids and are not excreted, although 
some of them have mixed characteristics. Typically, colicin operons are formed by a 
structural gene, an immunity gene and a lysis protein gene (Figure 1.1). Other bacteriocins 
are bacteriocin 28b, from Serratia marescens clinical isolates and helveticin J, identified 
from the genome of L. acidophilus NCFM, a probiotic strain that is widely commercialized 
and helveticin-M from L. crispatus isolated from chicken gut [149]. Other class III 
bacteriocins with animal gastrointestinal tract origin are alveicins A and B [150], albusin B 
[151], bacteriocin 28b linocin M18 [152]. 
 
Figure 1.11. Structure of bacteriocin class III colicin A [87]. 
Table 3.  Class III bacteriocins produced by bacteria originally isolated from the human 
gut.  
 
Class III 
Group Distinctive 
feature 
Bacteriocin 
from 
human gut 
isolate 
Gut 
Producer 
first isolated 
from human  
Activity 
against 
Reference 
Bacteriolysins  Colicins  E. coli Enterobacteria [49] 
Bacteriocin 
28b 
Serratia 
marcescens 
E. coli [141]  
Non-lytic 
bacteriocins 
 Bacteriocin 
helveticin J  
L. 
acidophilus 
NCFM  
 [142] 
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1.4.1.4. Class IV 
Although some researchers do not consider class IV to be bacteriocins and they are not 
listed in the classification of Cotter et al [70], they will be briefly mentioned. They are 
complex bacteriocins that require carbohydrate or lipid moieties to be functional. Leucocin 
S is an example of a bacteriocin with a glucidic moiety and lactostrepcins produced by L. 
lactis [153] are examples of bacteriocins with lipidic moieties. Lactocin 27 needs both 
groups [154].  
1.4.2. Regulation of bacteriocin biosynthesis 
The production and excretion of bacteriocins is subject to different kinds of regulation. 
Some require quorum sensing which, as stated previously, is a cell-density-dependent 
mechanism of regulation [155]. Production of antimicrobial peptides usually happens at 
the end of the bacterial growth phase and the beginning of the stationary phase. There is 
a characteristic signal molecule production during growth and at a certain concentration it 
triggers rapid production of the antimicrobial peptide. The objective is very likely to kill the 
targets without giving them time to defend themselves. This is very common in lantibiotics 
and their own products can act as triggers in order to autoregulate their own synthesis, for 
example, nisin and subtilin and their two-component regulatory systems (RK) [156]. 
Mersacidin is another lantibiotic produced by Bacillus sp., in stationary phase, and is 
regulated by itself in an exponentially growing culture [157].  
Some bacteriocins do not require a specific regulator and their promoters respond to pH 
at the transcriptional level. Promoters P1 and P3 in lacticin 481 produced by L. lactis [158] 
depend on the intra and extracellular acidification. This acidic sensitivity might have an 
ecological response related to quorum sensing, since lactic acid is released in media during 
fermentation, meaning that a very acidic environment is due to a dense population and the 
secretion of the bacteriocin is necessary for survival. This pH regulatory system has also 
been observed in lactocin S and nisin production [159]. 
Trypsin can also act as a regulator in production of bacteriocins. Ruminococcin A is an 
example of such, a lantibiotic produced by Ruminococcus gnavus E1. Trypsin is responsible 
for processing an inactive precursor peptide that, once turned into an active form and over 
a certain threshold, induces biosynthesis pathway. This proteolytic interaction is exclusive 
for trypsin, with other proteases not being able to generate the same effect [160]. 
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There are also examples of general regulators involved in bacteriocin production, like 
diacyl-glycerol kinase in mutacin II or the galactose inducing nisin promoter [161]. 
1.4.3. Identification, production and characterisation of bacteriocins 
Traditionally, bacteriocins have been identified by antagonistic activity using bioassays such 
as overlays, cross-streaks, drop test, filter discs or well-diffusion (Figure 1.12).  
 
Figure 1.12. Examples of assays performed to identify antimicrobial activity. (A) spot test; 
(B) overlay; (C) well diffusion. 
This is a very limited strategy as the first challenge that presents is known as the ‘plate 
count anomaly’, where just a small percentage of the bacterial species are able to grow in 
culture media. Among the ones that grow, they do not necessarily find the appropriate 
conditions to induce the production of bacteriocins, as all bacterial products depend also 
on the environmental conditions, including diet [126, 162, 163]. Some of the bacteriocin-
like compounds identified required the presence of a specific trigger to release its activity, 
like for example, presence of trypsin [58], proven to be effective as an antimicrobial 
inductor in human gut isolates. This reinforces the idea of the important role that 
environment plays in the production of these compounds. Other problems may arise, like 
false positives due to other antimicrobial compounds, like organic acids or hydrogen 
peroxide activity. Bacteriophages are another source of false positives. To test that, zones 
of clearing are excised and tested by plaque assay [164].  
Overcoming these limitations requires the understanding of the factors and interactions 
that take place in the environment of the producing bacteria, and the development and 
implementation of strategies to mimic these interactions. Current limited knowledge on 
microbial ecology makes this task highly difficult. However, there are new strategies, like 
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peptidogenomics, that attempt to integrate genomic and phenotypic information with a 
mass spectral molecular networking of microbes grown in a plate [165]. Other approaches 
are increasing the success in the identification of new bacteriocins too. Currently, the 
development and implementation of molecular tools with genomic information has 
allowed the identification of putative bacteriocin clusters that might be not expressed in 
genomes, both in culturable and unculturable species [166]. There are public software and 
databases to identify putative bacteriocin clusters in sequenced genomes and access to 
bacteriocin peptide sequences. BAGEL with 482 sequences [167] and BACTIBASE with 345 
sequences [168] are the most commonly used. Other databases are available to identify 
potential new bacteriocin clusters in the gut, like the Human Microbiome Project’s 
reference genome database [169]. Furthermore, other genome mining strategies, like 
Hidden Markov Model, have been proved useful for bacteriocin identification. Database 
combinations are available too, like BUR (‘Bacteriocins of the URMITE database’), where 
BAGEL, BACTIBASE and NCBI databases for bacteriocin published sequences are combined.  
The next challenging stage is the bacteriocin purification. In general, since bacteriocins are 
a heterogeneous group, it is difficult to identify a standardised protocol [170]. Different 
methods for purification can be performed depending on biochemical structures. Some of 
the commonly used ones consist of different phases, such as ammonium sulphate 
precipitation, ion exchange, hydrophobic interaction, gel filtration and reversed-phase high 
pressure liquid chromatography. Another one extensively used is a protocol with three 
steps: ammonium sulphate precipitation, chloroform/methanol extraction/precipitation 
and reversed-phase high pressure liquid chromatography. Mass spectroscopy and nuclear 
magnetic resonance (NMR) spectroscopy are other techniques used to characterised 
bacteriocins further [77].  
Regarding bacteriocins, use of these –omics tools and bioinformatics can help to 
understand some of the problems that their research presents, for example instability in 
their production, or loss of activity, either because they are encoded by plasmids or 
because they have complex regulatory mechanisms [126, 171].  
1.4.4. Bioengineering of bacteriocins 
Rational design might be the key to have more potent bacteriocins, based on the structure-
function relationship [171]. The objective is to achieve a higher stability for application in 
industry. For example, four analogues of lactocin S have been generated using solid-phase 
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peptide chemistry to enhance the oxidative stability to atmospheric oxygen by removing 
sulphur atoms [172]. Mersacidin has undergone modifications that have enhanced its 
activity against methicillin resistant Staphylococcus aureus (MRSA) and vancomycin 
resistant enterococci (VRE) [73]. Nisin has been one of the most modified bacteriocins in 
order to enhance its ability to have more pathogen targets and treat biofilms [17, 74], but 
it has not been the only one [173]. The generation of nisin derivatives can be achieved by 
different strategies, the non-targeted approach, using random mutagenesis to create 
derivatives that are analysed further or site-directed mutagenesis and mutagenesis by 
saturation. The enhanced activity is tested against a wide range of targets, both Gram-
positives and Gram-negatives, and food settings in complex matrices. [174]. The analysis of 
these mutants has contributed to elucidating the mechanisms that control activity and 
regulation, by knowing which residues are key for activity and which residues modify 
activity in different bacteriocins, allowing the possibility of further improving the desired 
features. 
1.4.5. Prospective applications of bacteriocins 
1.4.5.1. Industrial applications 
Bacteriocin could be considered as a serious solution for food industry and veterinary 
purposes [175]. However, the use of bacteriocin-producing strains is still questioned due 
to their doubtful functionality under industrial food processing conditions, and the 
development of bacteriocin preparations for commercial use is not fully developed due to 
the difficulties in bacteriocin production and in the food use approval. Nonetheless, this 
situation is starting to change, and countries like Japan are expanding bacteriocin use as 
preservatives in food industry and veterinary [127]. 
Despite these problems, bacteriocins have proved to be able to solve preservative 
problems in bakery industry, alcoholic beverages, to avoid spoilage bacteria, meat 
products, brined shrimp industry, protection of fresh fruits, vegetables and sauces, baby 
foods [176]. One of the most extended uses of bacteriocins is in dairy industry, especially 
with the use of nisin, that has been used as a preservative in different types of cheese to 
control Bacillus sp spore germination, and also has been tested against bacterial 
contamination in chilled desserts, flavoured mil and canned evaporated milks [177]. Nisin 
is licensed as a food preservative (known as E324) and is considered as safe by the WHO.  
Other bacteriocins used in dairy industry are class IIa bacteriocins that go under the 
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commercial name Alta 2341™ of Microgard™, able to control L. monocytogenes, S. aureus, 
Pseudomonas and E. coli [177]. Lacticins and enterocins, especially AS-48 and KP are other 
bacteriocins that have been proved to be useful in dairy industry for food preservation 
[177].  
Bacteriocins applications in food industry not only involved the addition of the bacteriocin 
or the production in situ by the responsible bacteria. Thus, another application is the 
production of edible films or coatings with bacteriocins for food preservation in raw food 
or food without further cooking, that has proved effective to reduced pathogens such as L. 
monocytogenes and S. aureus [177]. 
Other industrial applications involve their use as disinfectants or their use in aquaculture, 
especially as probiotics and encapsulated bacteriocins, livestock and in agriculture [176].  
Potential applications involve the pharmaceutical industry, since they have been suggested 
as potential anti-tumoral drug candidates [178]. This is the case of pore-forming colicin A 
and E1, able to inhibit the growth of human tumor-cell lines.  Colicins D, E2, E3 and A were 
also capable of inhibiting murine leukaemia cells [178]. However, these applications still 
need to be further developed.  
1.4.5.2. Clinical applications 
The regulatory properties attributed to natural antimicrobials, and especially the ones 
produced by human GIT bacteria and the ones produced by bacteria with probiotic 
characteristics from fermented foods, are considered desirable traits towards controlling 
potential gut dysbiosis, and therefore, are considered for clinical applications. Research 
conducted to establish microbiota alterations in certain pathologies has shown dysbiotic 
relationships in the gut microbiota in certain pathologies. Dysbiosis in the gut has been 
associated not only with metabolic syndrome, type 2 diabetes, colorectal cancer or IBD, 
but also with psychological problems, like anxiety and depression, via the gut-brain axis 
[179]. Rational application of bacteriocins, either directly or produced by bacteria in situ as 
probiotics, have been started to be studied as a method to modulate the structure and 
function of gut microbiota in these acute and chronic host etiologies [180-184] . In general 
terms, the analysis of potential activity inferred from structure and amino acid composition 
of bacteriocins [185] suggests two strategies. One is the production of many of low activity 
and the other, the production of highly effective specific-target bacteriocins. The aim would 
be maintaining homeostasis with a functional focus and developing defensive strategies 
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against elements that could cause dysbiosis. Despite the increasing research in this area, 
the complexity of GIT microbial ecology makes it a difficult task at the moment, with further 
understanding required. For example, despite the fact that administration of probiotics is 
taken often as a beneficial approach, it has been suggested that the abrupt interruption of 
a probiotic administration can cause gut dysbiosis by increasing pathogen susceptibility and 
other alterations in the intestinal epithelium and metabolites, according to research 
conducted in a tilapia model [186]. Further research is required to elucidate whether these 
results can be extended to humans or to all the probiotic bacteria.  
The lack of a stablished a paradigm of a healthy gut microbiota makes the identification of 
specific targets difficult [34]. However, general features can be highlighted, like the ratio of 
Firmicutes / Bacteroidetes. A correlation between this altered ratio and the development 
of metabolic syndrome and diabetes type 2 has been established and reviewed previously 
[33, 34, 187]. Besides that, some species have been identified as enriched in mice models 
with induced metabolic syndrome, like Enterobacter cloacae B29 and Clostridium 
ramnosum. Bacteriocin producer L. salivarius UCC118 was tested in obese mice showing 
temporary reductions in weight gain. The most promising effect was the modification of 
this ratio, by the increase of Bacteriodetes and Proteobacteria and the lower number of 
Actinobacteria.  
Another example of the regulatory potential of bacteriocins in gut microbial populations is 
bactofencin A, produced from a L. salivarius isolated from porcine intestine. Despite the 
fact that it did not have a direct inhibition activity against Clostridium, Bacteroides, 
Bifidobacterium and Fusobacterium, when tested in a distal colon model, populations 
showed modifications in a positive way [188]. More recently, in an experiment where 
probiotic bacteriocin producers were supplemented to water given to mice, initial 
metataxonomic data suggested that gut microbiota populations were not affected. 
However, a deeper analysis at lower taxonomic levels showed that potentially problematic 
bacteria, like Clostridium or Staphylococcus, were inhibited [189]. Analysing these results 
show us that, although we cannot expect big changes in in vivo experiments at higher 
taxonomy level in microbiota, there are subtle changes that are favourable for the host 
without major disturbances in the gut. In addition, these studies highlight the importance 
of the analysis scale.  
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Bacteriocin production in situ by a probiotic is one of the desirable, yet challenging tasks 
for developing treatments. To be effective, the probiotic cells need to survive and colonise 
the human gut. Additionally, the antimicrobial needs to be produced and be active in the 
gut environment. Thuricin CD is an example of this challenge. Despite its efficacy against C. 
difficile, when delivering B. thuringiensis DPC6431 through the intestinal tract of mice, 
results showed the inefficiency of this approach. However, alternative supplementation 
routes were found to be effective, like rectal administration [190]. Also, other possibilities 
can be explored, like synbiotics and delivery systems to help and protect the producer 
strain or the compound. Tablets of nisin with a pectin / HPMC polymer mixture are an 
example of this delivery strategy that is gaining interest [191].  
But not only target-specific bacteriocin producers help to control infections in the gut. As 
mentioned before, the acetate-producing bifidobacteria protects  epithelial cells in mice 
infected with E. coli O157 from damage [192]. A common trend that colorectal cancer 
presents with T2D is the lower levels of butyrate producing microorganisms and SCFA have 
been highlighted for inducing transcriptional changes in C. albicans, being the butyric acid 
responsible for the inhibition of yeast-hyphal transition [193]. Despite that, nonspecific 
action against pathogens can lead to undesirable and uncontrolled effects. Thus, acetate 
has been suggested as a promoter of metabolic syndrome and obesity [194].   
1.4.6. Challenges and future developments in bacteriocin research 
Antibiotic resistance has transformed the search for new antimicrobials into one of the 
most important tasks in the following decades. By understanding the natural environment 
where problematic bacteria grow, we may be able to find solutions to address this problem. 
Bacteriocins are antimicrobials that can develop an important role against antibiotic 
resistance. There are limitations in the identification and isolation of bacteriocins that may 
be overcome by new techniques like genomic and bioinformatics tools, genome mining and 
metagenomics. However, ultimately, this genomic information has to be translated into the 
laboratory, and then to achieve efficacy in vivo. The combination with other disciplines and 
the bioengineering process are offering the possibility to improve the technology necessary 
to make bacteriocins a serious and efficient alternative to antibiotics, including production 
improvement and the scale-up process. Besides the bioengineering opportunities, there is 
also improvement in delivery. Nanotechnology offers opportunities to get bacteriocins to 
the location where they have to exert their action, avoiding possible modifications due to 
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environment and conditions that might reduce or destroy their function. For example, the 
use of liposomal nanovesicles containing bacteriocins has been reported against Listeria 
monocytogenes in goat milk [195]. There is more research to conduct in the food area in 
order to assess any impact on taste, flavour or sensorial analysis regarding nanovesicles. 
Another possibility that is being explored is the combination of bacteriocins and traditional 
antibiotics. Bacteriocins and antibiotics have different mechanisms of action and 
resistance, therefore a synergistic effect would be desirable, improving and enhancing the 
effects of both of them individually [17, 196]. Bacteriocins delivery by probiotics to be 
produced at the site of infection [70, 76] also offer huge possibilities. Complex health 
alterations, like IBD, colon cancer, anxiety, depression and irritable bowel syndrome have 
been linked to gut microbiota [197-200]. Ultimately, further understanding of the microbial 
relationships and ecology will help to the development of more effective treatments, both 
for targeted intervention and to maintain gut and host homeostasis.  
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1.5. Aims and objectives of the thesis  
This project aims to identify new antimicrobials produced by isolates from gut and food 
origin, with a special focus on the identification of bacteriocins, ribosomally synthesised 
peptides and proteins that will be effective against gut pathogens and food spoilage 
bacteria. Our hypothesis is that mining bacteria from the same niche as the pathogen will 
identify novel antimicrobials which are uniquely suited to act in this niche.  
This thesis has four main objectives. 
Objective 1:  Identify bacterial isolates with antimicrobial activity against gut and food              
pathogens 
Strains from the culture collections of both QIB and Teagasc were tested. Those isolates 
had previously shown antimicrobial activity but not characterised. The use of neutralising 
agents, heat- and protease-resistance tests helped to identify which of those strains were 
likely to be bacteriocin producers rather than producers of organic acids. The selected 
strains were phylogenetically identified by 16S rDNA sequencing and screened against a 
selected panel of gut and food pathogens to test the host range of the bacteriocins. Isolates 
showing good antimicrobial activity against relevant pathogens were further characterised. 
Objective 2:  Purify and sequence bacteriocins by MS and identify biosynthetic gene clusters 
Antimicrobials of proteinaceous origin were purified with the most suitable method and 
MS protocols and NMR methods were used for structure characterisation.  The relevant 
biosynthetic gene clusters were identified by combining genomic information obtained in 
the previous objective.  
Objective 3:  Examine mechanisms of synthesis, biological activity and host range  
The purified peptides were used to determine the full relevant host range of the 
antimicrobials and the calculations of their minimum inhibitory concentrations (MICs). 
Gene expression was tested using RT-qPCR as response to changes in environmental 
conditions to obtain information on how the antimicrobials are produced in the native 
environment and how their production might be controlled or improved. Regulatory 
activity was also examined.  
Objective 4:  Test stability and activity of selected bacteriocins in complex environments 
(colon model and Micro-Matrix) and assess their effects on the native microbiota 
The stability and activity of the peptides was tested within complex environments in vitro 
in a human colon model and a Micro-Matrix fermenter, with a mixed microbiota, both 
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spiked or not with the pathogen of interest. Effects on pathogens and the native microbiota 
was assessed by next generation sequencing. 
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2.1. Microbiology 
This compilation of materials and methods were used throughout the PhD project. 
Chemicals and consumables were purchased from Sigma Aldrich/Merck (UK) unless stated 
otherwise. 
2.1.1. Culture media 
Table 2.1 summarises the media used for microbiology work. For solid media preparation 
15 g/l agar (Difco, UK) were added before autoclaving. For overlay assays, sloppy agar 
containing 7 g/l was prepared.  
Table 2.1. List of media used in this study. 
Media Details State 
MRS medium 
(de Man-Rogosa-
Sharpe) (Oxoid, 
UK) 
Prepared from ready-prepared commercial powder. Liquid, 
solid 
MRS in-house 
preparation 
10 g/l trypticase peptone, 2.5 g/l yeast extract, 3 g/l trypticase 
peptone, 3 g/l K2HPO4, 3 g/l KH2PO4, 2 g/l tri-ammonium citrate, 
0.2 g/l pyruvic acid, 0.3 g/l cysteine . HCl, 0.575 g/l MgSO4 . 7H2O, 
0.12 g/l MnSO4 . 7H2O, 0.034 g/l FeSO4. 7H2O and 1 ml Tween 80, 
supplemented with 2% glucose after autoclaving 
Liquid, 
solid 
BHI (brain heart 
infusion) 
Prepared from ready prepared commercial powder. Liquid, 
solid 
BHI + 
complements 
media 
BHI media (Oxoid), 5 g/l yeast extract, 0.1 g cysteine, 0.02 g/l 
haemin and 200 µl of 10 mM vitamin K1 solution 
Liquid 
media 
Robertson’s 
cooked meat 
medium 
Purchased from Southern Group Laboratories Ltd, UK. Liquid 
M17 (Oxoid) Prepared from ready prepared commercial powder Liquid 
media 
GM17 5 g/l glucose to M17 media added to after autoclaving Liquid, 
solid 
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Batch model and 
Micro-matrix 
media  
2g/l peptone water, 2g/l yeast extract, 0.1 g/l NaCl, 0.04 g/l 
K2HPO4, 0.04 g/l KH2PO4, 0.01 g/l MgSO4 . 7H2O, 0.01 g/l CaCl2 . 
2H2O, 2 g/l NaHCO3, 0.5 g/l cysteine . HCl, 0.5 g/l bile salts, 2 ml 
Tween 80, 0.02 g/l hemin (pre-dissolved in 1M NaOH) and 10 µl 
vitamin K1 
Liquid 
Carbon Free 
Basal Medium 
CFBM 
2 g/l peptone water, 2 g/l yeast extract, 0.1 g/l NaCl, 0.04 g/l 
KH2P04, 0.04 g/l K2HP04, 0.01 g/l MgS04·7H20, 
0.01 g/l CaCl2·6H20, 2 g/l NaHC03, 2 ml Tween-80, 
0.05 g/l haemin solution, 10 μl Vitamin K1, 0.5 g/L L-cysteine HCl 
and 0.5 g/l bile salts. 
Liquid 
Minimal media 
M9 
64 g/l Na2HPO4 x 7H2O, 15 g/l KH2PO4, 2.5 g NaCl, 5 g NH4Cl, 20% 
v/v of M9 salts, 0.2% v/v of 1M MgSO4, 2% v/v of 20% glucose, 
0.001% v/v of 1M CaCl2 
Liquid 
LB (Luria Bertani) 
medium 
Prepared from ready prepared commercial powder. Liquid, 
solid 
L medium 10 g/l tryptone (Difco, UK), 5 g/l yeast extract (Difco, UK), 5 g/l 
NaCl and 1 g/l D-glucose  
Liquid, 
solid 
ROGOSA (Oxoid) Prepared from ready prepared commercial powder Solid 
 
2.1.2. Bacterial strains and their growth conditions 
Typically, strains were stored at -80 oC in 1 ml working aliquots of multiple use in 40% 
glycerol and grown in conditions listed in tables 2.2 and 2.3. Antibiotics used during the 
project are listed in table 2.4. Stocks of Clostridium species were made using Robertson’s 
cooked meat medium (Southern Group Laboratory, UK). Microbial cultures were set up by 
adding 100 µl of the stock to the appropriate media. Anaerobic conditions were set up by 
pre-reducing media overnight in anaerobic chamber (Don Whitley, UK) in an atmosphere 
of 5% CO2, 10% H2 and 85% N2 or, alternatively, by using Anaerocult ®A (Merck, UK) to 
maintain anaerobic conditions in an anaerobic jar. 
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Table 2.2. List of bacterial strains used in this project. 
Strain name Isolate 
code 
Media Growth conditions Source 
INDICATOR STRAINS 
S. enterica serovar 
Typhimurium 
LT2 (QIB) LB or L 37 °C, 250 rpm 
aerobic or 
anaerobic 
QIB culture collection 
E. coli ATCC 
25922 
LB or L 37 °C, 250 rpm 
Aerobic or 
anaerobic 
QIB culture collection 
American Type Culture 
Collection 
E. coli LMG 2092 LB or L 37 °C, static, 
aerobic or 
anaerobic 
Instituto de Productos 
Lacteos (IPLA) 
Cronobacter 
sakazakii 
DSMZ 
4485 
NCTC 
11467 
BHI 37 °C, static, 
aerobic 
Deutsche Sammlung von 
Mikroorganismen und 
Zellkulturen (DSMZ) 
C. sakazakii LMG 5740 BHI 37 °C, static, 
aerobic 
IPLA 
Clostridium 
perfringens 
NCTC 3110 BHI + 
complements 
37 °C, static, 
anaerobic 
QIB culture collection 
Clostridium difficile NCTC 
11209 
BHI + 
complements 
37 °C, static, 
anaerobic 
QIB culture collection 
Listeria innocua NCTC 
11288 
BHI 37 °C, static, 
aerobic or 
anaerobic 
QIB culture collection 
Campylobacter 
jejuni 
NCTC 
11168 
Brucella agar 37 °C, static, 
microaerophilic, 5% 
O2 
QIB culture collection 
Micrococcus luteus MC8166 MRS 37 °C, static, 
aerobic 
QIB culture collection 
Lactobacillus 
bulgaricus 
5538 MRS 37 °C, static, 
anaerobic 
Teagasc culture collection 
L. bulgaricus LMG 6901 MRS 37 °C, static, 
anaerobic 
Teagasc culture collection 
QIB ISOLATESa 
Lactobacillus 
amylovorus 
Lac 20 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
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Lactobacillus 
gallinarum 
Lac 24 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
mucosae 
Lac 25 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. mucosae Lac 28 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
saerimneri 
Lac 29 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. mucosae  Lac 30 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
crispatus 
Lac 32 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 34 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
taiwanensis 
Lac 37 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus reuteri Lac 40 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gallinarum Lac 43 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 44 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 45 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. reuteri Lac 46 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gallinarum Lac 47 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 50 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 51 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. crispatus Lac 52 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
frumenti 
Lac 53 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. reuteri Lac 54 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
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L. reuteri Lac 55 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. reuteri Lac 56 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
paracasei 
R1 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. paracasei R2 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. paracasei R3 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium sp FI10480  BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium sp FI10481 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium 
longum 
FI10917a BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Enterococcus 
faecalis 
LM1 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis LM4 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis LM14a MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis LM18 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis LM31 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM4 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM5 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis M12 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis M22 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis SC1 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis SC8 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
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E. faecalis VM6 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri PM9 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri PM19 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Staphylococcus 
epidermis 
LM10 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Klebsiella milletis LM11 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Klebsiella 
pneumoniae 
LM12 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobadillus 
gasseri 
LM19 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri LM21 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis LM24 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
K. milletis LM26 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri HM8 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM3 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM6 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM7 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM9 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM10 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM11 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM12 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM13 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
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K. milletis HLM14 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM15 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri HLM17 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
E. faecalis HLM20 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
K. milletis HLM21 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri HLM23 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. gasseri HLM24 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. paracasei Lac1 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
plantarum 
Lac2 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. plantarum Lac3 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
pentosus 
Lac4 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. pentosus Lac5 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. plantarum Lac6 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Lactobacillus 
rhamnosus 
Lac17 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. plantarum Lac18 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. plantarum Lac20 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac21 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac22 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac23 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
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L. rhamnosus Lac24 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac25 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac26 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac27 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. rhamnosus Lac28 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
L. plantarum Lac29 MRS 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium 
adolescentis 
Bif1 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium 
animalis 
Bif3 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. animalis Bif4 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. animalis Bif5 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. animalis Bif8 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif9 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif10 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif12 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif14 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium 
catenulatum 
Bif15 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif16 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif17 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif18 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
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B. adolescentis Bif19 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. adolescentis Bif20 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. longum Bif21 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. catenulatum Bif22 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium sp Bif25 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
B. longum Bif27 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
Bifidobacterium sp Bif30 BHI 37 °C, static, 
anaerobic 
QIB culture collection 
TEAGASC ISOLATES 
Pediococcus 
acidilactici 
Li3 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Enterococcus spp 133 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Streptococcus 
salivarius 
107 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Streptococcus 
mutans 
130 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Enterococcus spp 106 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Streptococcus spp 134 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Streptococcus 
agalactiae 
Sagal BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
S. salivarius 130.3 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Enterococcus 
faecium 
111 Li BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
S. mutans 110 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
S. salivarius  DPC 6988 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
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E. faecalis 102 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
S. epidermidis 104 Lb BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides 
intestinalis  
DSM 
17393 
BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
B. fragilis  LMG10263 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides 
vulgatus  
LMG 
11767 
BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides 
thetaiotaomicran  
LMG 
11262 
BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides dorei  DSM 
17855 
BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides spp  9 -1-42FAA BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Bacteroides 
uniformis  
DSM 6597 BHI  37 °C, static, 
anaerobic 
Teagasc culture collection 
Coprobacillus sp  29_1/D6 BHI + 
complements 
37 °C, static, 
anaerobic 
Teagasc culture collection 
FAECAL AND FOOD ISOLATES FROM THIS STUDY 
-- Strain 12c LB 37 °C, static, 
anaerobic 
This work 
S. epidermidis 9c BHI + 
complements 
37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI01 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI02 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum  
GI03 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI04 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI06 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI07 MRS 37 °C, static, 
anaerobic 
This work 
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L. plantarum /L. 
paraplantarum 
GI08 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI09 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI11 MRS 37 °C, static, 
anaerobic 
This work 
L. plantarum /L. 
paraplantarum 
GI13 MRS 37 °C, static, 
anaerobic 
This work 
S. salivarius GI14 GM17 37 °C, static, 
anaerobic 
This work 
S. salivarius GI16 GM17 37 °C, static, 
anaerobic 
This work 
S. epidermidis YI03 BHI 37 °C, static, 
anaerobic 
This work 
S. epidermidis YI04 BHI 37 °C, static, 
anaerobic 
This work 
S. epidermidis 99 BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F505G GM17 37 °C, static, 
anaerobic 
This work 
Blautia sp. F501B BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F505B BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F508B BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F514B BHI 37 °C, static, 
anaerobic 
This work 
Roseburia sp. F516B BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F521B BHI 37 °C, static, 
anaerobic 
This work 
Ruminococcus sp. K-
1 
F522B BHI 37 °C, static, 
anaerobic 
This work 
Blautia sp. F523B BHI 37 °C, static, 
anaerobic 
This work 
Ruminococcus sp. K-
1 
F524B BHI 37 °C, static, 
anaerobic 
This work 
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Blautia sp. F525B BHI 37 °C, static, 
anaerobic 
This work 
S. epidermidis F530B BHI 37 °C, static, 
anaerobic 
This work 
B. bifidum F501M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F503M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F505M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F510M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F511M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F512M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F513M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F515M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F516M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F519M M17 37 °C, static, 
anaerobic 
This work 
B. adolescentis F520M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F523M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F524M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F525M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F526M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F527M M17 37 °C, static, 
anaerobic 
This work 
B. bifidum F528M M17 37 °C, static, 
anaerobic 
This work 
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CONTROL STRAINS 
S. epidermidis  DSM 
20042 
BHI 37 °C, static, 
anaerobic 
DSMZ 
S. epidermidis DSM 
28764 
BHI 37 °C, static, 
anaerobic 
DSMZ 
S. epidermidis DPC 6293 BHI 37 °C, agitation, 
anaerobic 
Teagasc culture collection 
S. epidermidis DPC 6010 BHI 37 °C, agitation, 
anaerobic 
Teagasc culture collection 
L. rhamnosus GG  
ATCC 
53103 
MRS 37 °C, static, 
anaerobic 
IPLA  
VECTOR STRAINS 
E. coli pUK200 FI10474 L + Cm 37 °C, static, 
aerobic 
QIB culture collection 
- No match in Ribosomal Database project. a, strains from the QIB culture collection 
were previously isolated from human faecal material by Carmen Nueno Palop, 
Daniela Musolino, Valeria Rizello and Diane Hatziioanou. 
Table 2.3. List of genetically modified organisms made and growth conditions used in this 
project 
Strain name Plasmid Media Growth 
conditions 
Antibiotic 
resistance 
L. gasseri LM19 pUK200b MRS  37°C, static, 
anaerobic 
Chloramphenicol 
(Cm) 
L. amylovorus 
Lac 20 
pUK200 MRS 37°C, static, 
anaerobic 
Cm 
L. crispatus Lac 
50 
pUK200 MRS 37°C, static, 
anaerobic 
Cm 
L. crispatus Lac 
51 
pUK200 MRS 37°C, static, 
anaerobic 
Cm 
E. coli ATCC 
25922 
pUK200 MRS 37°C, static, 
anaerobic 
Cm 
b [201] 
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Table 2.4. Antibiotics used for general genetic modifications and selection studies. 
Antibiotic Solvent used for preparation Final concentration 
Chloramphenicol  Ethanol 7.5 µg/ml 
Erythromycin Ethanol 400 ng/ml 
Gentamycin dH2O 10 and 50 µg/ml 
Streptomycin dH2O 50 µg/ml 
Penicillin dH2O 50 I.U./ml 
Amphotericin DMSO 1.25 µg/ml 
Kanamycin dH2O 50 µg/ml 
2.1.3. Measurement of cell growth  
Bacterial cell growth was calculated in broth and plates using different methods. For 
growth measurements in broth growth, Jenway spectrophotometer (UK) and Synergy HT 
Microplate reader (Biotek, UK) were used measuring optical density at 600 nm (OD600). 
Additionally, growth curves were measured using Bioscreen C (Growth Curves USA, USA). 
Omnilog ®Phenotype Microarray™ (Biolog Inc, USA) was used for phenotypic 
characterisation based on bacterial growth. 
Bacterial enumeration in colony forming units (CFU) was conducted by plating 10 µl in 
triplicates for each 10-fold dilution on the appropriate solid media.  
2.1.4. Microscopy  
2.1.4.1. Gram stain and light microscopy 
Typically, Gram staining was conducted using a kit from Invitrogen (UK) by transferring a 
loopful of liquid culture to a clean glass slide, this was spread and dried by flaming briefly 
using a Bunsen burner on the underneath of the slide. The slide was flooded with crystal 
violet solution for one min, washed off briefly with tap water to remove stain and drained. 
The slide was flooded again with Gram’s Iodine solution for one min and washed off with 
tap water and drained again carefully before flooding again using 95% alcohol for 10 s for 
decolorization and washed with tap water. The slide was drained again and flooded with 
safranin solution for 30 s before washing off again using tap water and dried with blotting 
paper. For examination under light microscope (Leica, UK), immersion oil was used.  
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2.1.4.2. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy 
(TEM) 
Bacterial strains were grown overnight following specific growth conditions. 1 ml of culture 
was centrifuged at 4000 g for 5 min at RT. SEM and TEM was performed by Kathryn Cross 
and Catherine Booth (QIB) following protocols described previously [202].  
2.1.5. Bioassays to measure antimicrobial activity 
2.1.5.1. Antimicrobial overlay assay 
5 µl aliquots of an overnight culture of the test strain were spotted onto agar plates 
(containing 2% v/v of NaHCO3 if lactic acid production was expected) and incubated for 1-
2 d. Grown bacterial colonies were exposed to UV light (302 nm) for 15 minutes and then 
covered with 5 ml of soft agar cooled to <50oC inoculated with 100 µl of the indicator strain 
overnight culture (with the exception of E. coli and S. enterica, where the inoculum was 
200 µl). Overlay plates were incubated overnight in aerobic or anaerobic conditions 
depending on the indicator strain growth requirements. Antimicrobial activity was 
considered positive if an inhibition zone in the growth of the indicator strain was observed 
[203].  
2.1.5.2. Cross streak assay 
The test strain was streaked onto an agar plate (containing 2% v/v of NaHCO3 if lactic acid 
production was expected) and incubated to allow growth. These streaks were exposed to 
UV light for 15 minutes and cross-streaked with different indicator strains. Plates were 
incubated overnight in different conditions depending on the indicator strains. 
Antimicrobial activity was considered positive if an inhibition zone in the growth of the 
indicator strain was seen [203]. 
2.1.5.3. Drop test 
Indicator strains were cultured overnight depending on their growth conditions and diluted 
1:100 in phosphate buffered saline (PBS). 100 µl was plated onto agar plates using an L-
shaped loop to produce a lawn. 10 µl of cell free supernatants (centrifuged at 3220 g for 
10-15 min and filtered through a 0.22 µm filter (Millipore) to remove bacteria), from 
overnight cultures of the test strain, were spotted onto the lawn. Plates were incubated as 
appropriate and antimicrobial activity was considered positive if an inhibition zone in the 
growth of the indicator strain was seen. 
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2.1.5.4. Filter disc 
The method was followed as above (drop test) but supernatants were spotted onto a 5 mm 
filter disc (3 mm, Whatman) that was placed onto the bacterial lawn and plates were kept 
at 4oC for 2 hours to allow diffusion through the agar and then incubated at different 
conditions depending on the indicator strain. Antimicrobial activity was considered positive 
if an inhibition zone in the growth of the indicator strain was seen [203]. 
2.1.5.5. Well-diffusion assays 
The aim of this method is to assess the antimicrobial activity of a liquid supernatant, placed 
in a well in the agar, by the inhibition in the growth of an indicator strain inoculated in that 
agar. For this purpose, L. bulgaricus 5583 was used as an indicator strain and cultured 
overnight in MRS broth, anaerobically at 37oC. 1 mL of this culture was inoculated in 200 
mL of molten MRS agar (normal strength) and poured in plates where wells were 
performed. To obtain the cell-free supernatants, 1.5 mL of culture of the strain to be tested 
were centrifuged at 16,000 g for 2 min. After this, 50 µL were placed inside the 
corresponding well and the plate was left for overnight anaerobic incubation at 37oC. The 
expected result is the presence of an inhibition zone of growth of the indicator strain 
around the well. For a positive control L. salivarius 6502 was used, and for negative control, 
MRS broth without inoculation was used.  
2.1.5.6. Campylobacter assays 
Skirrow plates (Oxoid) were inoculated with 50 μl of a ‘one-shot’ C. jejuni glycerol stock and 
incubated overnight at 37oC in a microaerobic cabinet. The following day, cells grown on 
the Skirrow plate were resuspended in 2 ml of PBS and the OD600 was measured. A dilution 
of final A600 = 1 was prepared in 1 ml of PBS. 5 ml of Brucella/agar mix (1.5 g agar in 100 
ml of Brucella broth with 0.01% of triphenyl tetrazolium chloride (TTC)) were added and 
quickly mixed and poured into a fresh Brucella plate. Filter discs were placed onto the agar 
and spotted with 10 µl of the previously filtered supernatant of the cultured strain of 
interest. A positive control of 10% hydrogen peroxide was used. Plates were placed faced 
up in a bag and incubated overnight in microaerobic conditions (85% N2, 5% O2, 10% CO2) 
in a MACS-MG-1000 controlled atmosphere cabinet (Don Whitley Scientific, UK). Presence 
of antimicrobial activity was considered positive if an inhibition zone in the growth of C. 
jejuni was seen. 
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2.1.5.7. Modification of growth conditions and inducers 
In order to induce antimicrobial production, growth conditions of antimicrobial-producing 
bacteria were modified. They were grown in 20 ml of different media (GM17, L, BHI, BHI+C, 
M17, MRS without glucose, MRS + 0.05M cysteine HCl + 0.5M sucrose, M17 Broth + 0.5 M 
sucrose, M17 + 2.5% glycine or M9 minimal media), with different period of incubation (24, 
48 and 72 h), and under aerobic and anaerobic conditions and tested for antimicrobial 
activity by drop test method.  
2.1.5.8. Co-culture assays 
In order to induce the release of antimicrobials in the media, strains that showed 
antimicrobial activity were co-cultured in different combinations, by inoculating first the 
strain of interest and at 24 h the pathogen or by inoculating both of them at the same time. 
After that, drop tests were performed as described previously. 
2.1.5.9. Minimum inhibitory concentration (MIC) assays 
96-well plates (Sarstedt) were pre-treated with bovine serum albumin (BSA). For this 
purpose, 0.5 g of BSA (Sigma) was mixed with 2.5 ml of 20X PBS. Water was added to the 
mix for a total volume of 50 mL. 200 µL were added to each well and the plate was 
incubated for 30 to 45 mins at 37oC. After this time, BSA was removed and the wells washed 
with 1X PBS and air dried in a sterile hood. This pre-treatment must be prepared the day of 
assay. For MICs, peptide concentrations of 4X the highest test concentration were prepared 
in 350 µL of the growth media required for the target strain to grow, and 100 µL of this mix 
was added to the first well of each row. 100 µL of the same media were added to each well 
and 2-fold serial dilution was performed alongside the row. After this, 100 µL of culture 
inoculated with the target strain was added to each well. To prepare this inoculum, an 
overnight culture was sub-cultured the day of the assay and incubated until an OD600 of 0.5 
was reached. The culture was diluted 1:10 and 20 µL of this added to 980 µL of media. 150 
µL of this new mix was added to 14.85 mL of growth media, from where the 100 µL per well 
were added. The objective is to standardise the final inoculum to 105 cfu/mL in 200 µL. The 
plate was incubated under the requirements of the target strain, and MIC determined as 
the lowest peptide concentration where there was no growth of the target strain.  
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2.1.6. Assessment of characteristics of probiotic activity 
2.1.6.1. Autoaggregation  
Autoaggregation assays were carried out following the protocol described by Tuo et al 
[204], with some modifications. Bacterial cultures were grown with the requirements of 
each strain for 24 h and their OD 600 was corrected to 1.2 ± 0.05. 1 ml of each corrected 
culture was measured after 2, 4 and 24 h for autoaggregation using a Ultrospec 10 
spectrophotometer (Amersham Biosciences). Incubation was performed on the bench at 
room temperature. Percentage of autoaggregation was calculated by (At / Ao-1) x 100 
where At is absorbance at time = 24 hours and Ao represents absorbance at time = 0 h.  
2.1.6.2. Antioxidant activity 
In order to evaluate the antioxidant activity of the tested strains, a protocol described by 
Gil-Rodriguez et al was used [205]. This method was based on measuring the percentage 
of reduction of the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical. Bacterial cells were 
harvested by centrifuging 1 ml of a 24 h cell culture, at 17000 x g during 5 min. The pellet 
was washed twice with 0.9% NaCl sterile solution and resuspended in 1 mL of the same 
saline solution to maintain the viability of the cells. 800 µL were transferred to a new tube 
and 1 mL of the DPPH solution prepared at a concentration of 0.2 mM in methanol was 
added, vortexed and incubated in darkness for 30 min at room temperature. After that, 
tubes were centrifuged at 17000 g for 5 min, and 300 µL transferred to a 96 well plate. 
Absorbance was measured at 517 nm in a Synergy HT plate reader from BioTek and Gen5 
software version 2.00.17. Percentage of reduction of DPPH was calculated by (1-A517 sample 
/ A517 blank) * 100.  
2.1.6.3. Bile salt hydrolase (BSH) activity 
To test BSH activity, an adaptation of Sedlackova et al was followed [206]. Strains were 
grown in their appropriate conditions for 24 h. After that, 5 µL of the culture were spotted 
onto a soft agar (0.7%) plate containing calcium chloride 0.375 g/L and 0.3% Sodium 
taurodeoxycholate hydrate. Plates were incubated for 3 d. BSH activity was characterised 
by the presence of a bright white precipitate.  
2.1.7. Preparation of a faecal inoculum for faecal fermentations 
The samples of healthy donors, with no antibiotic treatment during the last six months, 
were collected and maintained at 4oC during 1-2 h before processing. 200 g of faeces in 
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total were placed in a Circulator 400 stomacher bag (Seward, UK) alongside an equal 
volume of 50 mM phosphate buffer with 0.05% (w/v) cysteine hydrochloride. After filtering 
and homogenising in a Stomacher 400 circulator (Seward), the faecal slurry was centrifuged 
(4000 x g) and resuspended in 50 mM phosphate buffer.  
2.1.8. Biofilm formation 
2.1.8.1. Biofilm formation on abiotic surfaces 
To measure biofilm formation of the strains of interest, three abiotic surfaces were tested: 
gold (16-well E-plates), glass and polystyrene (PE). Bacterial cultures were standardised for 
a couple of days. To do that, a colony of each bacteria was selected and cultured in 10 ml 
of the appropriate liquid medium. After 24 h, it was subcultured in 10 ml of fresh medium 
at 1% and another subculture was performed after another 24 h. Bacterial counts were 
performed at this point at -6 to -8 dilutions. An appropriate volume of bacterial culture was 
added to each well of the 16-well E-plate (ACEA Biosciences Inc), 96-well PE plate (200 l 
in each case) and 12-well plate (BD Falcon) (1ml) where a sterilised glass cover was added 
previously. Bacterial adhesion was monitored by xCelligence RTCA-DP (ACEA Biosciences 
Inc., USA) for 24 h and biofilm formation was confirmed by crystal violet staining assay.  
2.1.8.2. Crystal violet staining 
Supernatants were removed from the wells where the biofilms were grown, and these 
were washed with PBS in equivalent volumes to the previously removed from the wells. 
One volume of 0.1% crystal violet solution equivalent to the volume added to each well 
was added and incubated at room temperature for 15 min. Crystal violet was removed from 
the wells and an equivalent volume of 33% acetic acid was added. The mixture was 
transferred immediately to a 96-well plate and OD read at λ=595 nm, used to measure 
crystal violet.  
2.1.8.3. Adhesion on biotic surface 
The HT29 cell line (human colon adenocarcinoma, ECACC 91072201, European Collection 
of Cell Cultures, Salisbury, UK) was used as a model to test adhesion of the tested strain to 
a biotic surface [207]. Cells were grown until confluency in a 12-well plate (BD Falcon). 
Bacterial cultures were standardised for two d in 10 ml of the appropriate medium and an 
overnight culture was centrifuged (17,000 x g, 10 min) and washed twice with PBS. The 
pellet was resuspended in 10 ml of PBS and 2.5 ml were taken, pelleted and resuspended 
Chapter II. General material and methods 
 
57 
 
in 2.5 ml of McCoy’s medium (MM) without antibiotics. Bacterial counts were performed 
at this stage in dilutions -6 to -8. HT29 cells were washed twice with 1 ml of Dubelco’s PBS. 
1 ml of the bacterial suspensions were added to each well. The plate was incubated for 1 h 
at 37C in microaerophilic conditions and after that wells were washed twice with 1 ml 
Dubelco’s PBS. 1 ml of Trypsin-EDTA solution 0.25% was added to each well and incubated 
for 5-10 min at 37C in microaerophilic conditions. The reaction was stopped by adding 1 
ml of the HT29 culture medium MM, and the suspensions were homogenised and serial 
dilutions (-3 to -7) performed in PBS. L. rhamnosus GG that showed previously adhesion 
levels of 1-5% was used as a positive control. Percentage of adhered bacteria was 
calculated by (adhered bacteria/added bacteria) x 100.  
2.1.8.4. Exclusion of pathogens 
2.1.8.4.1. Exclusion of pathogens using live strains 
To identify possible ability of the Lactobacilli and S. epidermidis isolates to prevent and/or 
impede pathogen attachment to a biotic surface such as the HT29 cell line, a fluorescence 
dye (SYTO-9) that targets DNA was used. The HT29 cell line was grown to confluence in a 
48 well plate. Tested bacteria and pathogenic bacteria were grown separately overnight 
after being standardised over 2 d. 1.5 ml of those overnight cultures were washed with PBS 
and OD600 readings were standardised to approximately 1x109 cfu/ml. The pellets were 
resuspended in 1.5 ml McCoy’s medium with antibiotics (gentamycin, streptomycin, 
penicillin and amphotericin)[207]. In the pathogen suspensions, 4.5 l of SYTO9 
(Invitrogen) were added, to a final concentration of 15 M and the mix was incubated in 
darkness for 2 h at room temperature. The unbound dye was removed by centrifugation at 
3,200 x g for 10 minutes and the pellet was resuspended in 1.5 ml of MM with antibiotics, 
and the suspension kept in darkness. 100 l of labelled pathogen and 100 l of probiotic 
suspension to test were mixed and added to the HT29 cell plate. Tested lactobacilli bacteria 
were combined in equal proportion in 100 l and added to 100 l of each pathogen. Before 
the addition of the 200 l, HT29 cell wells were washed at least once with PBS. A control of 
labelled pathogen was set, consisting of 100 l of labelled pathogen and 100 l MM with 
antibiotics. The plate was incubated in darkness for an hour at 37C in microaerophilic 
conditions. The supernatant of each well was removed and the well washed with PBS. 100 
l trypsin-EDTA solution was added to each well and incubated for 5-10 min at 37C in 
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darkness and microaerophilic conditions. To stop the reaction, 100 l MM with antibiotics 
were added and the 200 l of each well transferred to an appropriate fluorometer-
validated 96-well plate. Fluorescence was measured in a Cary Eclipse Fluorescence 
Spectrophotometer (Agilent) at excitation wavelength of 470 nm and emission wavelength 
of 512 nm. Percentage of adhesion was measured by (fluorescence emitted by bacteria 
adhered / fluorescence emitted by bacteria add) x 100. 
2.1.8.4.2. Exclusion of pathogens using dead strains 
To test if the possible influence of the tested bacteria on the adhesion of the pathogens to 
the HT29 cell line required the viability of the tested strains, a treatment to supress their 
viability was added. HT29 cells of approximately 150 passages were grown in a 48-well plate 
and the tested bacteria were standardised for 2 d and grown overnight. After this, tested 
bacteria were harvested by centrifugation, washed with PBS and recentrifuged at 3000 x g 
for 10 min, and resuspended in PBS. Suspensions were treated with UV light in a UV 
chamber (15 W, Selecta, Spain) in three cycles of 30 min each, resuspending for a few 
minutes after each one. 100 l of each tested bacteria was plated in the appropriate agar 
media to confirm that no viable cells were present in those suspensions. Non-viable 
bacterial suspensions were stored at 4C. 1.5 ml of those suspensions were washed with 
PBS and resuspended in 1.5 ml McCoy’s medium with antibiotics. Pathogens were grown 
overnight after being standardised for two days and 4.5 l of SYTO9 were added to the 
viable pathogen suspensions to a final concentration of 15 M. The mix was incubated in 
darkness for 2 h at room temperature and the unbound dye removed by centrifuging at 
3200 g for 10 min. The pellet was resuspended in 1.5 ml of MM with antibiotics, and the 
suspension kept in darkness. The protocol used for live bacteria (2.3.1) was then followed. 
2.1.9. Phenotypic studies using BIOLOG system 
BIOLOG studies were conducted using an OmniLog® Phenotype MicroArray™ following 
manufacturer’s instructions for panels PM1, PM2, PM3, PM11, PM12, PM13, PM16, PM18 
and PM19. 
2.2. Molecular biology 
Protocols were performed following methods described in Sambrook et al. [208]. Kits and 
conditions were followed according to manufacturer’s instructions.   
Chapter II. General material and methods 
 
59 
 
2.2.1. PCR primers 
Primers used during this project are summarised in Table 2.5. 
Table 2.5. List of primers used in this project.  
Name Target Sequence Product 
(bp) 
Reference 
AMP_F 16S  5’-GAG AGT TTG ATY CTG 
GCT CAG 
1500  
 
[209] 
AMP_R 16S  5’-AAG GAG GTG ATC 
CAR CCG CA 
[209] 
Bif_F Bifid 16S 5’-GAA CGG GTG AGT 
AAT GCG TG 
700 Designed by C. 
Nueno-Palop 
Bif_R Bifid 16S 5’-TGT TCT TCC CGA TAT 
CTA CAC 
plnC_F Plantaricin C 5’-AGC AGA TGA AAT 
TCG GCA G 
109  [210] 
plnC_R Plantaricin C 5’-ATA ATC CAA CGG 
TGC AAT CC 
[210] 
plnG_F Plantaricin G 5’-TGC GGT TAT CAG TAT 
GTC AAA G 
454  [210] 
plnG_R Plantaricin G 5’-CCT CGA AAC AAT TTC 
CCC C 
[210] 
CO1 16S Teagasc 5′-AGT TTG ATC CTG GCT 
CAG 
1500  [211] 
CO2 16S Teagasc 5′-TAC CTT GTT ACG ACT [211] 
P181 pUK200 
comprobation 
5’-GCG AAG ATA ACA 
GTG ACT CTA 
140  [212] 
P54 pUK200 
comprobation 
5’-CGG CTC TGA TTA AAT 
TCT GAA G 
LGgyrAF Gyrase A L. gasseri 
LM19 
5’-TTG ATT GCC TTA ACC 
CTT CG 
136 This work 
LGgyrAR 5’-TTC CCAT TGA ACG 
AAC ATCA 
Cluster 1.1F LM19 C.1.1 
 
5’-TAT TGG TGC ATG 
GAG AGG TG 
124 This work 
Cluster1.1R 5’-CCA GCC CAC ACA TTG 
TAC TG 
Cluster1.2F LM19 C.1.2 
 
5’-TTG GGG TAG TGT 
TGC AGG AT 
97 This work 
Cluster1.2R 5’-TGA TGT TGC AGC TCC 
GTT AG 
Cluster2F Helveticin J-like 5’-CTT GGG TAC AAA 
GCG GAG AA 
176 This work 
Cluster2R 5’-GCC TGC TCG GTT 
AAG ATA AG 
Cluster3.1F GamA  
(=Gassericin T) 
5’-CTG GAT GGG CTC 
TTG GAA AT 
112 This work 
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Cluster3.1R 5’-TTT CCG AAT CCA CCA 
GTA GC 
Cluster3.2F GamX 
(=Gassericin X) 
5’-TGG GGG AAT GCT 
GTA ATA GG 
100 This work 
Cluster3.2R 5’-CTC CTA AGC CAC 
AGG CAG TC 
GamYF Gassericin Y 5’-ACT CAA ATC GTA 
GGA GGA AAA GG 
150 This work 
GamY R 5’-AAA GCA TGC ACC 
TGA ACCA 
GasM F Gassericin M 5’-AGC AGG AGG AGC 
ATT TTC AA 
90 This work 
GasM R 5’-CCT GCT GCA CCA CCT 
AAA AT 
Cluster 3.3 
F 
Immunity gene 
gamI3 
5’-CAG ATG AAG AAG 
CAT TAC TTG AAA A 
102 This work 
Cluster 3.3 
R 
5’-TTC CAG GCC AAG TAT 
TAG TTG TA 
s-Clper-F C. perfringens  5’-GGG GGT TTC AAC 
ACC TCC 
170 [213] 
ClPER-R 5’-GCA AGG GAT GTC 
AAG TGT 
515F Region V4 5’-GTG CCA GCM GCC 
GCG GTA A 
292 [214] 
806R 5’-GGA CTA CHV GGG 
TWT CTA AT 
 
2.2.2. General PCR methods 
Thermal cycling was typically performed using a Veriti 96 well Thermal Cycler (Applied 
Biosystems, USA) and PCR Sprint (Thermo Scientific, UK). Primers were designed with 
annealing temperature of 55-60oC and were purchased from Sigma Genosys. GoTaq 
(Promega) and Platinum PCR SuperMix (Thermo Fisher) were used for general PCR testing 
and Phusion polymerase (Finnzymes) was used for cloning purposes because of its high 
fidelity. dNTPs were purchased from Bioline. 
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Table 2.6. PCR reaction mix composition for the three polymerases used during the 
project. 
GoTaq polymerase Phusion polymerase Platinum PCR SuperMix 
Component Quantity Component Quantity Component  Quantity 
DNA 
template 
1 µl DNA 
template 
1 µl (˜ 5 or 
50 ng) 
DNA 
template 
1 µl 
5 x GoTaq 
Reaction 
Buffer  
10 µl 5 x Phusion 
Reaction 
Buffer  
10 µl Reaction 
buffer 
45 µl 
dNTPs (0.2 
mM of each 
one)  
0.4 µl dNTPs (0.2 
mM of each 
one)  
0.4 µl dNTPs (0.2 
mM of each 
one) 
Included in 
buffer 
Forward 
primer 20 
µM  
1 µl Forward 
primer 20 
µM  
1.25 µl Forward 
primer 20 
µM  
2 µl 
Reverse 
primer 20 
µM  
1 µl Reverse 
primer 20 
µM  
1.25 µl Reverse 
primer 20 
µM  
2 µl 
UPH2O 36.35µl UPH2O 35.7 µl UPH2O Included in 
buffer 
1.25 U/µl 
GoTaq DNA 
polymerase  
0.25 µl 1 U/µl 
Phusion 
Polymerase 
0.4 µl 22 U/ml Taq 
Polymerase 
Included in 
buffer 
Total volume 50 µl Total volume 50 µl Total volume 50 µl 
 
Table 2.7. PCR conditions for the three polymerases used during the project. 
GoTaq polymerase Phusion polymerase Platinum PCR SuperMix 
Temperature and 
time 
Cycles Temperature and 
time 
Cycles Temperature and 
time 
Cycles 
95oC 2 min x 1 98oC 30 s x 1 94oC 30 s x 1 
95oC 30 s } 
}x 25-30 
} 
98oC 10 s } 
}x 25-30 
} 
94oC 30 s } 
}x 25-35 
} 
55-60oC 30 s TAoC 30 s 55oC 30 s 
72oC 1 
min/kb 
72oC 15-30 
s/kb 
72oC 1 
min/kb 
72oC 5 min x 1 72oC 5 min x 1 72oC 5 min x 1 
 
2.2.2.1. PCR from liquid cultures 
150 µl of overnight bacterial culture were centrifuged at 13,000 x g for 1 min. Supernatant 
was removed and 150 µl of UPH2O added. In the case of lactic acid bacteria, colony wash 
buffer (100 mM NaCl, 10 mM Tris pH 7 and 1 mM EDTA) was used instead of UPH2O. The 
pellet was resuspended by vortexing then the suspension was centrifuged again, 
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supernatant was removed, and the pellet was resuspended in 15 µl of UPH2O. The sample 
was boiled at 95 oC for 5 min and 1 µl was used as a DNA template for PCR reaction.  
2.2.2.2. PCR from bacterial colonies 
A colony was sampled using a toothpick and resuspended in 10 µl of UPH2O. The sample 
was boiled at 95oC for 5 min and 1 µl was used as a DNA template for PCR reaction. 
2.2.2.3. 16S identification 
Identification of strains was determined using PCR amplification of the 16S ribosomal DNA 
gene following primers and conditions summarised in tables 2.6 and 2.7. PCR cycles were 
limited to 25 to avoid errors. If a high G+C content was expected, 5% DMSO was added.  
2.2.3. Agarose gel electrophoresis 
Agarose gels were produced by adding agarose powder at 1% w/v (2% for small fragments, 
0.7% for genomic (g)DNA to 0.5 x TBE buffer (Fisher Scientific). 1 kb Hyperladder (Bioline) 
was used as a DNA size marker. 5 µl of DNA marker and a mix of 9 µl of DNA sample plus 1 
µl of loading buffer were typically loaded in the gel wells. 0.5 x TBE buffer was used to 
conduct electrophoresis. To visualise DNA, gels were stained for 30 min in ethidium 
bromide 1 μg/ml and washed in water afterwards. DNA bands were visualised with UV 
using an AlphaImager (Alpha Innotech).   
2.2.4. DNA purification  
PCR products were purified (to remove buffers, dNTPs, short DNA fragments and enzymes) 
using Sure Clean (Bioline), following manufacturer’s instructions with small variations. 
Briefly, 5 µl of a pink co-precipitant were added to the PCR mix. An equal volume of Sure 
Clean was added, vortexed and left to incubate for 30 min at room temperature. After this, 
the mixture was centrifuged at 16,000 x g for 30 min and the supernatant was removed. 
The pink pellet was washed in a volume of 70% ethanol of twice the original sample volume 
and centrifuged again for 5 min. All the ethanol was removed, and the sample was left to 
air dry on the bench. Once dried, sample was resuspended in 20 µl of EB buffer (10 mM 
Tris-HCl pH 8.5). 
2.2.5. 16S rDNA sequencing 
DNA concentration was measured using a Nanodrop 2000 (Thermo Scientific, UK) and 
sequencing was performed by Eurofins Genomics (Germany). 300 ng of DNA were required 
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in a volume of 15 µl. Additionally, 1 µl of a primer at a concentration of 20 µM and UPH2O 
to a final volume of 17 µl. Data provided by Eurofins was analysed using Finch TV sequence 
viewer software and SeqMan and Seqmatch II (DNAStar, Lasergene). Species were 
identified using the Ribosomal Database Project [215]. 
2.2.6. Extraction of genomic DNA (gDNA) 
2.2.6.1. From single bacterial culture 
Genomic DNA extraction was carried out using the GenElute TM Bacterial Genomic DNA Kit 
from Sigma Aldrich. The protocol provided in the kit was followed and the concentration of 
gDNA was measured by Qubit 3 (Invitrogen, UK) and Nanodrop 2000 (Thermo Scientific, 
UK), with agarose gel electrophoresis to confirm the integrity of the gDNA. The gDNA was 
eluted in EB buffer (10 mM Tris-HCl pH 8.5). 
2.2.6.2. From faecal fermentation samples 
Genomic DNA extraction was carried out using the FastDNA Spin Kit for Soil (MP 
Biomedicals, USA) and and AllPrep DNA/RNA Mini Kit (Qiagen, UK), following 
manufacturer’s guidelines.  
2.2.7. RNA work 
2.2.7.1. RNA isolation 
Each fermentation sample was mixed with two volumes of RNAlater (Sigma-Aldrich, UK) 
and centrifuged for 10 min at 18,000 x g and 4oC. Supernatant was discarded, and pellets 
stored at -80 oC until extraction which was performed using the Qiagen RNeasy extraction 
kit with minor modifications. Pellets were resuspended in 1 ml RLT buffer provided in the 
kit, complemented with 10 µl of β-mercaptoethanol (Millipore) and transferred to lysing 
matrix E tubes (MP biomedicals LLC, France). Samples were lysed in a FastPrep-24 
homogeniser (MP biomedicals) by applying 2 pulses of 30 s and intensity 6.0 with an 
interval of 1 minute on ice between each pulse. After this, samples were centrifuged for 10 
min at 17,000 x g and the supernatant transferred to clean 15 ml tubes and mixed with an 
equal volume of 70% ethanol. The mixture, including any precipitate, was transferred to 
spin tubes and centrifuged at 8,000 x g for 1 min. The flow-through was discarded and 700 
µl buffer RW1 added to the RNeasy spin column and centrifuged again at 8,000 x g. 500 µl 
buffer RPE were added to the spin column and centrifuged for 1 min at 8,000 x g and the 
flow- through discarded. The last step was repeated, but this time centrifuged for 2 min. 
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The RNA was eluted in 100 µl RNase-free water and quantified by Nanodrop 2000 (Thermo 
Scientific, UK).  
2.2.7.2. RNA cleaning  
DNase treatment was performed using the Turbo DNA-freeTM kit (Invitrogen, UK). Isolated 
RNA was adjusted to a concentration of at most 100 ng/µl. 87 µl of the RNA sample was 
mixed with 10 µl 10X Turbo DNase buffer and 3 µl of TurboTM DNase (2 U / µl). The reaction 
was incubated at 37 oC for 30 min. After the incubation, 10 µl of resuspended DNase 
Inactivation Reagent were added, mixed and incubated at room temperature for 5 min. 
Samples were centrifuged at 17,000 g for 2 min, the supernatant transferred to a RNase 
free tube, and concentration and RNA quality measured by Nanodrop.  
2.2.7.3. cDNA synthesis 
cDNA synthesis was carried out using the QuantiTect® Reverse Transcription Kit (Qiagen) 
using 100 ng RNA per reaction in 12 µl RNAse-free water. 2 µl of gDNA Wipeout buffer 7x 
were added to a total reaction volume of 14 µl and incubated for 2 min at 42oC before being 
placed on ice. Reverse-transcription master mix was prepared according to manufacturer’s 
recommendations and a control reaction replacing the reverse transcriptase with water 
was set up at the same time. The mixture was incubated for 15 min at 42oC then 3 min at 
95oC to inactivate the transcriptase. cDNA was stored at -20oC. 
2.2.8. qPCR and RT-qPCR 
2.2.8.1. qPCR primer design 
qPCR primers were designed using Primer 3 (v. 0.4.0) free software. Primer size were 
designed for a maximum of 20 bases and the product size between 50-200 bp, with 
preference around 100 bp. Melting temperature was established between 60-62oC for all 
of them. The presence of secondary structures and dimers were tested with Netprimer 
(Premier Biosoft) and primers were tested on 10-fold dilutions of gDNA of test strains to 
confirm their specificity and their efficiency (> 90%, slope -3,1 and Rsq >0.985). Oligos were 
also tested to check that they do not form primer dimers by a control test where the DNA 
template was substituted by UPH2O.  
2.2.8.2. qPCR 
Aliquots were taken from fermenters and DNA extraction was performed using QIAmp Fast 
DNA Stool Mini Kit (Qiagen, UK), following the manufacturer’s instructions. Absolute 
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quantification by qPCR was performed using the Roche LightCycler 480 II platform (Roche, 
UK). To quantify 16S bacterial counts, a standard curve was created using 1000 to 100 
copies of 16S rDNA/μl and KAPA Lightcycler 480 mix (KAPA Biosystems Ltd., UK) according 
to manufacturer’s instructions summarised in table 2.8. All samples were run in triplicate 
and controls for no DNA template were set up in each run. qPCR conditions are summarised 
in table 2.9.  
2.2.8.3. RT-qPCR  
qPCR was performed using 384-well plates (4titude) in the ViiA™ 7 System (Applied 
Biosystems) and the SensiFAST™ SYBR® No-ROX Kit (Bioline, USA). Reaction mix 
composition and conditions are summarised in tables 2.8 and 2.9. Reactions were set up in 
duplicate and controls for primers and no transcriptase samples were set in each run.  
Table 2.8. Reaction mix composition for the two polymerase mixes used during the 
project for qPCR and RT-qPCR. 
SensiFAST™ SYBR® No-ROX KAPA SYBR® FAST 
Component Quantity Component Quantity 
DNA 
template 
0.6 µl DNA 
template 
1 µl 
SensiFAST™ 
master mix 
3 µl KAPA master 
mix 
5 µl 
Forward 
primer 20 
µM  
0.24 µl Forward 
primer 20 
µM  
0.5 µl 
Reverse 
primer 20 
µM  
0.24 µl Reverse 
primer 20 
µM  
0.5 µl 
UPH2O 1.92 µl UPH2O 3 µl 
Total volume 6 µl Total volume 9 µl 
 
Table 2.9. PCR conditions for the two polymerases used for qPCR and RT-qPCR. 
 SensiFAST™ SYBR® No-ROX KAPA SYBR® FAST 
 Temperature and time Cycles Temperature and time Cycles 
Preincubation 95oC 5 min x 1 95oC 5 min x 1 
Amplification 95oC 20 s } 
}x 40 
95oC 20 s } 
60oC 1 s 55oC 20 s }x 45 
- - 72oC 20 s } 
Melting curve 95oC 15 s x 1 95oC 5 s x 1 
55oC 10 s x 1 47oC 1 min x 1 
- -  97oC 1 min x 1 
Cooling 40oC 10 min x 1 40oC 5 min x 1 
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2.2.9. Bioinformatics analysis 
2.2.9.1. Whole genome sequencing (WGS), trimming, assembly and annotation by 
MicrobesNG 
Microbes NG performed the WGS. Briefly, DNA was quantified in triplicates with the 
Quantit dsDNA HS assay in an Eppendorf AF2200 plate reader. Genomic DNA libraries were 
prepared using Nextera XT Library Prep Kit (Illumina, San Diego, USA) following the 
manufacturer’s protocol with the following modifications: two nanograms of DNA instead 
of one were used as input, and PCR elongation time was increased to 1 min from 30 
seconds. DNA quantification and library preparation were carried out on a Hamilton 
Microlab STAR automated liquid handling system. Pooled libraries were quantified using 
the Kapa Biosystems Library Quantification Kit for Illumina on a Roche light cycler 96 qPCR 
machine. Libraries were sequenced on the Illumina HiSeq using a 250 bp paired end 
protocol. The reads were trimmed using Trimmomatic 0.30 with a sliding window quality 
cutoff of Q15 [216] and the quality was assessed using in-house scripts combined with the 
software Samtools [217], BedTools [218] and bwa-mem [219]. All the sequenced genomes 
had a minimum coverage of 30x. De novo assembly was performed on samples using 
SPAdes version 3.7 [2], and contigs were annotated using Prokka 1.11.  
2.2.9.2. Genome mining for bacteriocin genes 
Genomes were analysed with different software to identify putative bacteriocin clusters. 
BAGEL 3 and BAGEL 4 [220] to target bacteriocin clusters and antiSMASH to target 
secondary metabolites [221]. The assembly was also annotated with RAST (Rapid 
Annotation using Subsystem Technology) and visualised with SEED [222]. Genome data was 
visualised using Artemis [223] and Integrative Genomics Viewer (IGV) version 2.4 [224]. 
DNA and amino acid sequences identified as putative bacteriocin genes and proteins were 
analysed using BLAST [225] to assess their relationships with other peptides using default 
parameters. Genedoc was used for sequence alignments and Clone manager (Sci-Ed 
software) for cluster construction.  
2.2.9.3. 16S-based metataxonomics analysis 
Total gDNA concentration was measured by Qubit 3 (Invitrogen, UK) and normalised. The 
V4 region of the 16S rRNA gene was used for high throughput sequencing using the Illumina 
MiSeq platform. Data analysis was conducted using the Quantitative Insights into Microbial 
Ecology (QIIME2 version 2018.11) [226]. 
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2.2.9.4. Identification of biogenic amines 
Presence of genes related to biogenic amines metabolism was assessed by screening 
manually the RAST annotation of the sequenced genomes.  
2.2.10. Transformation of Lactobacilli 
2.2.10.1. Plasmid preparation 
10 ml of an o/n culture of the E. coli strain containing the plasmid of interest were 
centrifuged for 10 min at 13,000 x g and 4oC. Plasmids were extracted using the E.Z.N.A. 
Plasmid DNA Mini Kit (VWR, UK) following manufacturer’s instructions.  
2.2.10.2. Preparation of competent lactobacilli  
The method used for the generation of electro-competent lactobacilli was based on the 
use of glycine [227]. Three subcultures were done at 37°C: first day, inoculating 10 ml of 
medium (MRS [Oxoid], 0.5 M sucrose, 3% glycine). Second day, 5 ml of that culture were 
used to inoculate 50 ml of pre-warmed medium, and the third day, 25 ml of the culture 
were used to inoculate 200 ml of prewarmed medium and this was incubated until OD600 
0.2-0.3. After that, cells were harvested by centrifuging 10 min at 5000 x g. A first wash of 
225 ml of ice cold 10% glycerol/0.5 M sucrose was performed. The second wash was done 
using 55 ml of 10% glycerol/ 0.5 M sucrose/ 50 mM EDTA and incubated on ice for 15 min. 
The third wash was with 55 ml of 10% glycerol/0.5 M sucrose. Cells were resuspended in 
2.25 ml of 10% glycerol/ 0.5 M sucrose, aliquoted in volumes of 40 µL and flash frozen on 
dry ice.  
2.2.10.3. Electroporation of electrocompetent Lactobacilli cells 
Plasmid pUK200 [228] was added to 40 µL of electro-competent cells. The mixture was 
incubated for 1 min on ice and transferred to a pre-chilled electroporation cuvette 
(Geneflow Limited Paul Fisher House). A pulse of 1500 V, 800 Ω and 25 µF was applied using 
a BioRad electroporator. 450 µL of pre-chilled MRS+glucose/ 20 mM MgCl2/ 2mM CaCl2 
were added to the cuvette and the mixture transferred to a chilled 2ml screwcap tube and 
incubated for 2 h at 37oC. 100 µL of the cells were plated in MRS plates with 
chloramphenicol 7.5 µg/ml and incubated overnight at 37oC. 6 colonies of each were 
selected and grown in MRS medium with chloramphenicol 2.42 µg/ml and the inserted 
plasmid confirmed by PCR using primers p181 and p54 [229] using GoTaq DNA Polymerase 
according to manufacturer’s instructions (Promega). Transformation efficiency was 
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calculated using “Bacteria Transformation Efficiency Calculator” 
(https://www.sciencegateway.org/tools/transform.htm).  
2.3. Protein work 
2.3.1. Assays to assess the nature of the antimicrobial  
2.3.1.1. Heat stability test 
30 µl of the cell-free supernatant from the test strain was heated to 60˚C for 10 min, 30 
min and 1 h, at 90˚C for 10 min and 30 min, and 121˚C for 15 min. Samples were cooled on 
ice before being tested by drop test or filter disc test.  
2.3.1.2. Protease resistance test 
Cell-free supernatant from the test strain was incubated with 1 and 0.1 mg/ml of different 
proteases, trypsin (Sigma T1426), proteinase K (Melford MB2005), pancreatin (Sigma 
P3292) and protease (Sigma P6911), using sodium phosphate buffer 20 mM, pH 6, for 1 
hour at 37˚C. Samples were cooled on ice and tested for antimicrobial activity by drop test 
or filter disc test.  
2.3.2. Antimicrobial analysis of supernatant proteins separated by SDS-Polyacrylamide 
gel electrophoresis (PAGE) 
To prepare the samples to be electrophoresed to test the activity of the separated 
peptides, cultures of the strains of interest were grown overnight according to their specific 
requirements. Cultures were centrifuged at 8,000 x g for 20 min and up to 12 ml of the 
supernatant were transferred to a Millipore concentration column of 3,000 or 10,000 MW 
cut-offs (or others as appropriate), that was centrifuged again at 1700 g for 20 min. The 
resulting fractions, both the eluted and the concentrated ones, were tested by well-
diffusion assay. The following day, after identifying the fractions with activity, 75 µL of the 
sample and 25 µL of LDS 4x sample buffer (Sigma Aldrich, Co. Wicklow, Ireland) were mixed 
and heated at 70oC for 10 minutes then cooled on ice for 2 min.  
TruPage TM Precast gels of 4-20% SDS for peptides (Sigma Aldrich, UK) were used. The gel 
was rinsed with RNAse free water after being removed from the packaging and placed into 
the gel unit with wells facing inwards. 1X MOPS SDS buffer (Sigma) diluted from 20x stock 
with Milli Q water was added to the chamber. After washing the wells with buffer, 10 µL of 
protein marker and 25 µL of sample were added to the wells using a Hamilton syringe. 
BioRad Precision Plus protein Dual Extra Standards was used as a reference for protein 
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mass. Gels were run at 30 Amps until the dye left the gel, removed from the case and 
washed for 2-3 minutes with water first and left shaking at room temperature for 45 
minutes in 1% tween 80. Gels were run in duplicate. The gel was stained by being washed 
with water once and added to Coomassie stain (Sigma), with shaking for an hour. After that, 
it was washed with water 2-3 times for 10 min and photographed. The duplicate gel was 
washed with water three times, overlaid with the indicator strain in molten agar (L. 
bulgaricus 5583) and incubated at 37oC overnight.  
2.3.3. Protein extraction by bead beating 
Bacterial cells were pelleted by centrifuging the culture at 17,000 x g for 5 min. 500 µl of 
extraction buffer (TN 20mM Tris-HCl pH8, 50mM NaCl or NP 20 mM sodium phosphate 
pH6) was added to the cell pellet. It was vortexed to resuspend the pellet and transferred 
to a 2 ml screw cap tube with 100 µl of sterile acid washed glass beads (0.1 mm) and 
maintained on ice. Bead beating was performed using a FastPrep FR120 cell disrupter (MP 
Biomedical, UK) by applying 4 pulses of 30 s at speed 6 with 5-10 minutes on ice in between 
pulses. Samples were centrifuged at 13,000 x g for 20-30 min at 4oC. Supernatant and cell 
pellets were assayed for antimicrobial activity by drop test. 
2.3.4. Soluble and insoluble cell protein extracts by sonication 
Bacterial cells were pelleted by centrifuging the culture at 17,000 x g for 5 min. Cells were 
resuspended in 500 µl of extraction buffer (TN 20mM Tris-HCl pH8, 50mM NaCl or NP 20 
mM sodium phosphate pH6) by vortexing. Samples were sonicated using a Soniprep 150 
(MSE (UK) Ltd, UK) machine by applying 7 pulses of 15 s and cooling the samples during 30 
s on ice in between pulses. Debris was pelleted by centrifuging 25 min at 13,000 x g and 
4oC. Supernatant was transferred to a new tube and pellet resuspended in 500 µl of 
extraction buffer.  
2.3.5. Ethanol precipitation of proteins 
100 ml of culture supernatant and an equal volume of 100% ethanol previously cooled at -
80oC o/n were placed in a 250 ml centrifuge tube. The mixture was incubated for 5 min 
shaking continuously and centrifuged at 10,000 x g for 30 min at 4oC. After this, it was air 
dried for 15 min and then resuspended in the appropriate buffer into 1/1000 of the original 
volume.  
Chapter II. General material and methods 
 
70 
 
2.3.6. Acid treatment for protein extraction 
1 ml of o/n cultures were treated by adding 35 µl of 50% HCl before being centrifuged to 
pellet cells at 13,000 x g for 2 min. pH was restored with NaOH 1M and supernatants were 
tested by well diffusion assay using negative controls of acidified and non-acidified media.  
2.3.7. Colony mass spectrometry 
Strains were grown in normal media plates and after that, a few colonies were picked to be 
analysed. The process consisted of spinning down the cells and mixing them with 50 ul 70% 
propan-2-ol, 0.1% TFA, vortexed a few times and centrifuged down again. Samples were 
analysed using mass spectrometry (MS) by Paula O’Connor (Teagasc). 
2.3.8. Ammonium sulphate precipitation 
Ammonium sulphate was used to precipitate and concentrate peptides and proteins in 
culture. Ammonium sulphate was added to the culture in fractions of 10% w/v and left 
stirring for 2 hours at 4oC. After 2 hours, volumes were centrifuged at 10,000 x g and pellets 
were resuspended in 50 mM sodium acetate buffer at pH 6 and assayed by well-diffusion 
assay against indicator strain as stated before.  
2.3.9. Protein and peptide partial purification 
In order to purify the bacteriocins, as a general rule, tested isolates were grown in 500 ml 
of media. Cells were separated from the supernatant by centrifugation (8000 g, 20 min) 
and cells and supernatant were assayed independently. The cell pellet was resuspended in 
100 ml of 70% propan-2-ol, 0.1% TFA using a stirrer for 3 or 4 h at room temperature, 
centrifuged again and the supernatant retained to test its activity. The solvent stability of 
the antimicrobial was characterised by mixing of 300 µl with 700 µL of water, acetonitrile, 
0.1% TFA or acetonitrile with 0.1% TFA, incubating at room temperature for 4-5 h and 
plating on the indicator. Peptides were characterised by being stable at low pH and in the 
presence of acetonitrile. After that, a run in the mass spectrometer was conducted. The 
next step is the ability of the antimicrobial to bind to reversed phase and cation exchange 
columns. For reversed phase, 3 ml of the supernatant was incorporated on a 3ml, 200 mg 
Strata-E C18 SPE column (Phenomenex, Chesire, UK) pre-equilibrated with methanol and 
water (100%). After washes with 3 ml of 30% ethanol and 3 ml of 70% 2-propanol 0.1% TFA. 
The fractions needed to be tested for antimicrobial activity to check if the activity has been 
lost and were then analysed through MS. For the cation exchange column, 10 ml of 
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supernatant were added to an Econo column that contained 2 ml of SP sepharose (GE 
Healthcare, UK). The column was washed with 15 ml of 10 mM potassium phosphate, 25% 
acetonitrile pH 2.5 and 10 ml of 20 mM potassium phosphate, 25% acetonitrile pH 2.5 
containing 1M KCl. Different buffers were tested in order to find the most suitable one for 
the compound (generally sodium phosphate at different concentrations and salts). After 
eluting and identifying the different active fractions and analysis by MS, they were further 
analysed by analytical reversed phase HPLC column Proteo Jupiter C18 RP-HPLC 
(Phenomenex, UK) running a 35%-65% acetonitrile, 0.1% TFA gradient and buffer B is 90% 
acetonitrile 0.1% TFA. Each sample was aliquoted at 250 µl, monitored at 214 nm and 
fractions collected at intervals of 1 minute. Fractions were further analysed against the 
indicator strain and the mass spectrometer. Heat and protease tests were also performed. 
2.3.10. Preparation of gel slices for trypsin digestion 
To identify antimicrobial peptides in culture, bands of interest (inhibition of indicator strain 
previously shown) were cut from the protein gel and destained with 30% ethanol for 30 
min at 65°C, before being washed with triethylammonium bicarbonate buffer (TEAB) /50% 
acetonitrile (ACN). After that, it was incubated with 10 mM dithiothreitol (DTT), 30 min, 
55°C. DTT was removed and iodoacetamide (IAA) 30 mM in 50 mM TEAB was added and 
incubated for 30 min at room temperature in the dark. The IAA solution was removed and 
the sample washed with TEAB/50% ACN for 15 minutes at room temperature and washed 
with 50 mM TEAB afterwards. Buffer was removed, and the slices cut in 1x1mm pieces 
before being transferred to a low bind tube (Eppendorf) and being washed with TEAB/50% 
ACN for 15 minutes and 100% acetonitrile for another 15 minutes. After this, the slices 
were put in a speed vac and dried for 30 min followed by trypsin digestion and MS. 
2.3.11. Trypsinisation and MS 
Treated gel slices were given to Dr. Gerhard Saalbach (JIC) and he performed trypsinisation 
on them followed by MS [230]. Results were visualised using proteome software Scaffold 
TM version 4.8.4.  
2.3.12. Identification of peptides of interest 
To identify candidates for antimicrobial peptide, the proteins and peptides obtained by MS 
were analysed manually to look for cleavage sites and calculate the different size options 
for each one. The peptide sequences were correlated with their genes and Artemis [231] 
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was used for visualising the gene neighbourhood and identify genes that could be linked to 
the presence of a bacteriocin. 
2.4. General chemistry 
2.4.1. Organic acid quantification 
2.4.1.1. High Pressure Liquid Chromatography (HPLC) 
Fermented samples were defrosted and filter sterilised using 0.2 μm-pore-size syringe 
filters (Whatman International Ltd, UK) and 300 µl injected into Chromacol vials (Fisher 
Scientific, UK). Concentrations of formic, acetic, lactic, propionic, butyric acid and γ-
aminobutyric acid (GABA) were quantified by HPLC using a Perkin-Elmer Flexar HPLC system 
coupled with refractive index and photo diode array detectors for 210, 280 and 325 nm 
wavelengths (PerkinElmer Inc, USA). Analyses were conducted using an Aminex HPX-87H 
organic acid analysis column (Bio-Rad Laboratories Ltd, UK) and Chromera Manager version 
3.0, 2011 (PerkinElmer Inc, USA). Chromatographic conditions were as described previously 
[232]. A standard curve was constructed using reference concentrations at 100, 60, 40, 20, 
10, 5 and 1 mM of formic acid (eluted at 14.3 min), acetic acid (15.3 min), lactic acid (13.1 
min), propionic acid (17.6 min), butyric acid (18.9 min) and GABA (22.0 min) (all from Sigma 
Aldrich). Standards were run at the beginning and the end of each set of samples.  
2.4.1.2. Nuclear Magnetic Resonance (1H-NMR) 
SCFA were measured using Nuclear Magnetic Resonance (1H-NMR) by Dr Ian Colquhoun 
(QIB). NMR buffer was mixed with cell-free sample supernatant in a proportion 1:10. NMR 
buffer composition per 100 ml: D2O: 0.26 g NaH2PO4, 1.44 g K2HPO4, 17.1 mg sodium 3-
(Trimethylsilyl)-propionate-d4 (TSP), 56 mg NaN3. 500 µl were collected in 5 mm NMR 
Tubes (GPE Scientific Ltd, UK). High resolution 1H NMR spectra were recorded on a 600 MHz 
Bruker Avance III HD spectrometer fitted with a 5 mm TCI cryoprobe and a 60 slot 
autosampler (Bruker, Rheinstetten, Germany). Sample temperature was controlled at 
3000K and the D2O signal was used as lock. Each spectrum consisted of 512 scans of TD = 
65,536 data points with a spectral width of 20.49 ppm (acquisition time 2.67 s). The 
noesygppr1d presaturation sequence was used to suppress the residual water signal with 
low power selective irradiation at the water frequency during the recycle delay (D1 = 3 s) 
and mixing time (D8 = 0.01 s). A 900 pulse length of approximately 8.8 µs was used, with 
the exact pulse length determined automatically for each sample. Spectra were 
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transformed with 0.3 Hz line broadening and zero filling and were automatically phased 
and referenced (to TSP) using the TOPSPIN 3.2 software. The resulting Bruker 1r files were 
converted to Chenomx (.cnx) format using the ‘Batch Import’ tool in the Processor module 
of Chenomx NMR Suite v8.12 with the TSP concentration set to 0.1 mM. Concentrations 
were obtained using the Chenomx Profiler module (Chenomx Inc, Canada). 
2.5. Statistical analysis 
Significant differences between groups were established using a paired t-test, assuming 
normal distribution, equal variances. Both sides of the distribution were considered. 
Significance was considered when P value was <0.05. Calculations were performed using 
Excel 365.  
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3.1. Introduction 
There is a need for new antimicrobials to fight the global rise of antimicrobial resistance. 
Since the golden era of antibiotic discovery, new antibiotics have most frequently been 
derived through chemical modifications of pre-existing structures. Previously, 
antimicrobials originated from natural sources, and recently it has been proposed that 
researchers should turn again to that strategy for new antimicrobial discovery. This is 
partially rooted in the premise that the production of antimicrobials represents an 
expression of antagonistic ecological relationships among bacteria. Therefore, there are 
microbiology techniques to uncover these traits, like direct and deferred antagonism 
procedures. The main difference between these approaches is that for the direct 
procedure, test and indicator isolates are grown at the same time, while in the deferred 
procedure the test organism is grown and killed before the application of the indicator 
strain. Deferred antagonism has been established to be the more sensitive assay, and 
therefore is considered the better option for bacteriocin discovery, where it has been used 
extensively. It should be noted that, in some cases, antimicrobials may not be expressed in 
the absence of competitor strains, which may result in antimicrobial producers being 
overlooked if only this assay is used [233].  
More recently, classical approaches, such as the aforementioned deferred antagonism 
assay, can be coupled with new advanced techniques to provide a more comprehensive 
picture of the potential of each isolate. Thus, MS has been used to identify the presence of 
potential products of interest in bacterial cultures [234]. In the case of detecting 
antimicrobial peptides, MS is able to show the presence of products with masses within the 
range 3000-8000 Da associated with antimicrobial activity, narrowing the range of 
potential bacterial isolates to work with. Genomes can also be screened for antimicrobial-
encoding clusters using software designed for this purpose, such as BAGEL 3 (currently 
version 4) [220] and antiSMASH [221]. This is notable as the drop in sequencing costs has 
allowed a rapid increase in genomic analysis data to complement other data or to provide 
primary information directly. In summary, a combination of different strategies can 
increase the efficiency of the search for bioactive compounds and the identification of 
potential probiotic bacterial isolates.  
The aim of the work in this chapter was the identification of new antimicrobials active 
against pathogenic bacteria in the human GIT and food. For this reason, five faecal samples 
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and one sample of yoghurt, kefir, gherkins in brine and miso were screened to isolate 
bacteria that exhibited antimicrobial activity. 208 out of 1736 (11.98 %) isolates showed 
inhibitory activity by different bioassays. In addition, 130 faecal isolates from culture 
collections at QIB and Teagasc were tested for the same purpose. From these 338 strains, 
39 isolates that showed interesting antimicrobial activity were investigated further for 
additional probiotic activity and MS was performed on their cultures. From these, the 
genomes of 11 representative promising isolates were sequenced and analysed. For 
purification purposes, we were particularly interested in those isolates whose antimicrobial 
activity was present in the culture supernatant, and different attempts were conducted to 
release cell-associated activity. Only 4 of the QIB isolates (L. gasseri LM19, L. amylovorus 
Lac 20, L. crispatus Lac 50 and L. crispatus Lac 51) and 12 from the Teagasc isolates showed 
non-manipulated inhibitory activity in the supernatant. Some of the antimicrobials 
produced by these isolates are studied further in the following chapters.   
3.2 Methods 
3.2.1. Food and faecal screening 
Faecal inoculum was prepared as explained in section 2.1.7. Ten-fold dilutions of samples 
were prepared in 450 µl of pre-reduced PBS. 100 µl of dilutions 10-4, 10-5 and 10-6 were 
plated on pre-reduced and non-pre-reduced MRS, LB, ROGOSA and GM17 using a L-shaped 
loop. Plates were incubated in aerobic and anaerobic conditions at 37oC for 3-4 d in order 
to allow the growth of different microorganisms. Up to 50 colonies grown in each media 
were selected and streaked onto fresh media plates for testing antimicrobial activity by 
overlay assay as described in section 2.1.5.1. A master plate for each media was prepared 
for further stock preparation. Faecal samples were provided by different donors, from a 
study approved by the QIB Human Research Governance committee (IFR01/2015) 
registered at http://www.clinicaltrials.gov (NCT02653001). Food samples were processed 
in the same way as the faecal samples. Kefir samples were provided by Nourish Kefir (UK), 
yogurt by The Coconut Collaborative Ltd (UK), gherkins in brine by Morglel Fine and Organic 
Foods Ltd (UK) and organic miso by Source Foods (UK).  
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3.2.2. Isolates obtained from culture collections 
3.2.2.2. QIB culture collection  
Strains previously isolated from faecal samples and breast milk, and placed in the QIB 
collection, were screened. A total of 105 isolates showed antimicrobial activity. 27 of them 
were isolated by Carmen Nueno-Palop and Daniela Musolino from human faecal material. 
Strain FI10917 was isolated by Diane Hatziioanou from a human faecal sample. 37 breast 
milk isolates were provided by Complutense University of Madrid. Valeria Rizzello, from 
Messina University, provided 18 Lactobacillus sp. isolates and 20 Bifidobacterium sp.  
3.2.2.3. Teagasc isolates 
Strains previously isolated by James Hegarty and Calum J. Walsh from faecal samples were 
assayed for antimicrobial activity by overlay, cross-streak and well-diffusion assay.  
3.3. Results 
3.3.1. Isolation and screening  
3.3.1.1. Screening of faecal samples 
Screening of faecal samples from five different donors was conducted and a total of 900 
strains isolated using anaerobic conditions and 480 from aerobic conditions were analysed 
for antimicrobial activity. 32 strains (3.6%) showed antimicrobial activity to at least one 
indicator strain, when tested against C. perfringens, L. innocua, C. sakazakii, E. coli and S. 
enterica sv Typhimurium (Table 3.1). One isolate (strain 12c) lost the activity previously 
shown against S. enterica sv Typhimurium as soon as it was cultured in liquid media after 
the initial isolation. 16S rRNA sequencing was used to identify the bacterial isolates. 
3.3.1.2. Screening of food samples 
Kefir products were screened on two occasions after which 180 isolated strains were tested 
but none of them showed any antimicrobial activity. Screening of bacteria isolated from 
organic miso, gherkins in brine and yogurt was also performed and 176 colonies showed 
antimicrobial activity (Table 3.1). However, only 47 could be subcultured.  
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Table 3.1. Spectrum of action of cultured isolates from faecal and fermented food 
screenings. 
Isolate Identification by 16S rDNA  % similarity Activity against 
 C. p. L. i. C. s. S. e. E. c. 
Strain 12c nt nt      
GI01 Lactobacillus plantarum- 
Lactobacillus paraplantarum 
100      
GI02 nt nt      
GI03 L. plantarum - 
L. paraplantarum 
100      
GI04 L. plantarum - 
L. paraplantarum 
100      
GI06 L. plantarum - 
L. paraplantarum 
100      
GI07 L. plantarum - 
L. paraplantarum 
100      
GI08 L. plantarum - 
L. paraplantarum 
100      
GI09 L. plantarum - 
L. paraplantarum 
100      
GI11 L. plantarum - 
L. paraplantarum 
100      
GI12 nt nt      
GI13 L. plantarum - 
L. paraplantarum 
98.9      
GI14 Streptococcus salivarius 100      
GI16 S. salivarius 100      
YI03 S. epidermidis 100      
YI04 S. epidermidis 100      
99 S. epidermidis 100      
F505G Blautia sp. 92.7      
F501B Blautia sp. 94.9      
F505B Blautia sp. 100      
F508B Blautia sp. 100      
Chapter III. Screening for antimicrobial activity 
 
79 
 
F512B nt nt      
F514B Blautia sp. 97.2      
F516B Roseburia sp. 93.4      
F521B Blautia sp. 95.6      
F522B Ruminococcus sp. K-1 98.3      
F523B Blautia sp. 98.7      
F524B Ruminococcus sp. K-1 95.5      
F525B Blautia sp. 100      
F529B nt nt      
F530B S. epidermidis 100      
F501M Bifidobacterium bifidum 99.7      
F503M B. bifidum 93.9      
F505M B. bifidum 99.0      
F510M B. bifidum 93.5      
F511M B. bifidum 100      
F512M B. bifidum 100      
F513M B. bifidum 96.5      
F515M B. bifidum 99.8      
F516M B. bifidum 99.4      
F519M B. bifidum 100      
F520M B. adolescentis 93.5      
F523M B. bifidum 100      
F524M B. bifidum 99.5      
F525M B. bifidum 98.3      
F526M B. bifidum 98.0      
F527M B. bifidum 83.3      
F528M B. bifidum 99.5      
 
Green showed antimicrobial activity in overlay assays; red showed no antimicrobial 
activity.  C. p. C. perfringens NCTC 3110; L. i., L. innocua NCTC 11288; C. s., C. sakazakii 
NCTC 11467; S. e., S. enterica sv Typhimurium LT2; E. c., E. coli ATCC 25922, nt, not tested.  
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3.3.2. Isolate testing 
3.3.2.1. QIB culture collection 
A total of 105 isolates from different culture collections in QIB were tested against a panel 
of 8 indicator strains (C. perfringens, S. enterica sv Typhimurium, E. coli, L. innocua, C. 
sakazakii, M. luteus, C. jejuni and L. bulgaricus) and showed varying patterns of 
antimicrobial activity. Results are summarised in Table 3.2. In general, test strains showed 
stronger activity when they were directly in contact with the indicator strain, such as 
overlay and cross streak assays. Bifidobacterium spp and Lactobacillus spp isolated from 
faecal samples showed the strongest activity. Drop test and filter disc assays were all 
negative except against C. jejuni. 52 isolates were able to inhibit C. jejuni growth. However, 
these plates did not have sodium carbonate in their composition, therefore, this inhibitory 
activity might be non-specific and due to the effect of the lactic acid, instead to the 
production of a novel antimicrobial.  One interesting result of a cross streak assay showed 
that two strains, E. faecalis LM1 and E. faecalis LM4, exhibited antimicrobial activity against 
C. sakazakii only in the region between the two test producer streaks, indicating the 
antimicrobial production might be regulated by quorum sensing (Fig. 3.1). Well-diffusion 
assays that were carried out using L. bulgaricus DPC5583 as indicator strain identified four 
culture supernatants that displayed inhibitory activity: from L. gasseri LM19, L. amylovorus 
Lac 20 and L. crispatus Lac 50 and Lac 51.  
 
Figure 3.1.  Inhibition zone in combination of E. faecalis LM1 and LM4 against C. sakazakii 
indicating potential quorum sensing regulation. 
3.3.2.2. Teagasc isolates 
The most interesting Teagasc isolate was a S. agalactiae isolate, that was able to produce 
nisin P and was further investigated within this thesis (Chapter V). Coprobacillus sp. strain 
29_1/D6 was an isolate that had a gene for a new lantibiotic in its genome. However, it was 
not further studied due to the difficulties in detecting its antimicrobial activity. 
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Table 3.2. Summary of activity of QIB and Teagasc isolates against different indicator 
strains. 
   C j C p S e E c L i M l C s L b 
16S rDNA match Isolate 
code 
(%) 
similarity  
F O C O C O C O C O C O C W 
QIB ISOLATES 
L. amylovorus Lac 20 85.4 ++ - +++ - - - - + +++ - ++ +++ - ++ 
L. gallinarum Lac 24 100 - - + - + - + + + - ++ +++ - - 
L. mucosae Lac 25 100 - - + - + - ++ - +++ - - + - - 
L. mucosae Lac 28 90.1 ++ - - - +++ - +++ + ++ - - + - - 
L. saerimneri Lac 29 92.7 ++ - +++ - ++ - ++ + +++ - ++ +++ - - 
L. mucosae  Lac 30 100 +++ - + - + - + ++ + - + +++ - - 
L. crispatus Lac 32 100 - - +++ - +++ - +++ - ++ - ++ +++ +++ - 
L. crispatus Lac 34 100 +++ - - - ++ - ++ ++ ++ - ++ +++ - - 
L. taiwanensis Lac 37 96.9 - - + - + - + ++ - - - +++ - - 
L. reuteri Lac 40 97.1 - - - - + - + - - - - +++ - - 
L.gallinarum Lac 43 99.6 ++ - + - + - + - + - + +++ +++ - 
L. crispatus Lac 44 100 - - - - +++ - +++  ++ - - +++ +++ - 
L. crispatus Lac 45 98.0 - - - - + - + + + - + +++ - - 
L. reuteri Lac 46 93.4 ++ - + - + - + ++ + - + +++ + - 
L. gallinarum Lac 47 100 ++ - - - +++ - +++ + +++ - ++ +++ +++ - 
L. crispatus Lac 50 100 + - - - ++ - ++ - ++ - ++ +++ +++ +++ 
L. crispatus Lac 51 99.3 +++ - + - + - + - - - - +++ - +++ 
L. crispatus Lac 52 96.7 - - + - + - + - - - - +++ +++ - 
L. frumenti Lac 53 91.2 ++ - +++ - +++ - +++  +++ - + +++ - - 
L. reuteri Lac 54 84.6 +++ - +++ - ++ - ++ ++ ++ - ++ +++ - - 
L. reuteri Lac 55 83.7 - - - - +++ - +++ + +++ - - +++ - - 
L. reuteri Lac 56 83.4 + - - - +++ - +++ + +++ - - +++ - - 
L. paracasei R1 100 + - +++ - +++ - +++ + +++ - - +++ - - 
L. paracasei R2 100 - - +++ - +++ - +++ + +++ - - +++ +++ - 
L. paracasei R3 100 - - +++ - +++ - +++ + +++ - ++ +++ - - 
Bifidobacterium 
sp 
FI10480  100 +++ - ++ - + - + + ++ - + - - - 
Bifidobacterium 
sp 
FI10481 - + - ++ - ++ - + + ++ - + - +++ - 
B. longum FI10917a 100 + - +++ - +++ - +++ - + - ++ - +++ - 
E. faecalis LM1 100 - - - - - - - - - - ++ - +++ - 
E. faecalis LM4 100 + - - - - - - - - - + - +++ - 
E. faecalis LM14a 100 + - - - - - - - + -  - - nt 
E. faecalis LM18 100 - - - - - - - - - - - - - nt 
E. faecalis LM31 100 - - - - - - - - ++ - ++ - ++ nt 
E. faecalis HLM4 100 - - - - - - - - ++ - + - ++ nt 
E. faecalis HLM5 100 + - - - - - - - - - + - + nt 
E. faecalis M12 100 - - - - - - - - - - + - + nt 
E. faecalis M22 100 - - - - - - - - ++ - + - - nt 
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E. faecalis SC1 100 + - - - + - - - - - + - - nt 
E. faecalis SC8 100 + - - - - - - - - - + - - nt 
E. faecalis VM6 100 + - - - - - + - - - + - - nt 
L. gasseri PM9 100 - - - - - - + - ++ - + - - - 
L. gasseri PM19 100 - - - - - - + - - - - - - - 
S. epidermis LM10 100 + - - - - - - - + - + - - - 
K. milletis LM11 99.0 + - - - - - - - + - + - - - 
K. pneumoniae LM12 100 - + + - + - - - + - + - + - 
L. gasseri LM19 100 + + + - - - - - ++ - ++ - ++ +++ 
L. gasseri LM21 100 + - - - - - - - ++ - ++ - ++ - 
E. faecalis LM24 100 - - - - - - - - + -  - - - 
K. milletis LM26 99.0 - - - - - - + - - - - - + - 
L. gasseri HM8 100 - - - - - - - - + - + - - - 
E. faecalis HLM3 100 - - - - - - - - - - + - + - 
E. faecalis HLM6 100 + - - - - - - - - - + - ++ - 
E. faecalis HLM7 100 + - - - - - - - - - + - ++ - 
E. faecalis HLM9 100 + - - - + - - - - - + - - - 
E. faecalis HLM10 100 - - - - - - - - - - + - - - 
E. faecalis HLM11 100 - - - - - - - - - - + - - - 
E. faecalis HLM12 100 - - - - + - - - - - ++ - - - 
E. faecalis HLM13 100 + - - - + - + - - - ++ - - - 
K. milletis HLM14 99.0 + - - - + - + - - - + - - - 
E. faecalis HLM15 100 - - - - + - - - - - ++ - - - 
L. gasseri HLM17 100 - - - - - - - - - - + - - - 
E. faecalis HLM20 100 + - - - - - - - - - - - ++ - 
K. milletis HLM21 99.0 - - - - - - - - - - - - ++ - 
L. gasseri HLM23 100 + - - - - - - - - - + - - - 
L. gasseri HLM24 100 - - - - - - - - - - + - - - 
L. paracasei Lac1 100 ++ - - ++ +++ ++ +++ ++ - - - +++ +++ - 
L. plantarum Lac2 100 ++ - - ++ +++ ++ +++ ++ - - - +++ +++ - 
L. plantarum Lac3 100 ++ - - ++ +++ ++ +++ ++ - - ++ +++ - - 
L. pentosus Lac4 100 ++ - - ++ +++ ++ +++ ++ +++ - ++ +++ - - 
L. pentosus Lac5 100 ++ - - ++ +++ ++ +++ ++ +++ - ++ +++ ++ - 
L.plantarum Lac6 100 ++ - - ++ +++ ++ +++ ++ - - ++ +++ +++ - 
L. rhamnosus Lac17 100 ++ - - ++ +++ +++ +++ ++ - - ++ +++ +++ - 
L. plantarum Lac18 100 ++ - - ++ +++ ++ +++ ++ +++ - ++ +++ - - 
L. plantarum Lac20 100 ++ - - ++ +++ ++ +++ ++ +++ - ++ +++ +++ - 
L. rhamnosus Lac21 100 + - - ++ +++ ++ +++ + - - ++ +++ +++ - 
L. rhamnosus Lac22 100 ++ - +++ ++ +++ ++ +++ ++ +++ - ++ +++ +++ - 
L. rhamnosus Lac23 100 + - - ++ +++ ++ +++  - - ++ +++ +++ - 
L. rhamnosus Lac24 100 + - - ++ +++ ++ +++ ++ +++ - ++ +++ +++ - 
L. rhamnosus Lac25 100 + - - ++ +++ ++ +++ ++ +++ - ++ +++ + - 
L. rhamnosus Lac26 100 + - ++ ++ +++ ++ +++ + - - ++ +++ +++ - 
L. rhamnosus Lac27 100 + - - ++ +++ ++ +++ ++ +++ - ++ +++ +++ - 
L. rhamnosus Lac28 100 + - - ++ +++ ++ +++ ++ - - ++ +++ + - 
L. plantarum Lac29 100 ++ - ++ ++ +++ ++ +++ ++ +++ - ++ +++ +++ - 
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B. adolescentis Bif1 100 - - - - +++ ++ +++ - +++ - + ++ - - 
B. animalis Bif3 100 - ++ - - - - - +++ - - + ++ ++ - 
B. animalis Bif4 100 - ++ - - - - - +++ - - - ++ - - 
B. animalis Bif5 100 - + - - - - - +++ - - - ++ ++ nt 
B. animalis Bif8 83.5 - ++ - - - - - +++ - - - ++ - nt 
B. adolescentis Bif9 100 - - - - - - - - - - - - - nt 
B. adolescentis Bif10 100 - - - + +++ +++ +++ +++ +++ - - ++ +++ - 
B. adolescentis Bif12 100 - - - - - - - +++ +++ - - ++ - - 
B. adolescentis Bif14 100 - - - + +++ +++ +++ +++ +++ - + + +++ - 
B. catenulatum Bif15 100 - + - + +++ +++ +++ +++ +++ - + + +++ - 
B. adolescentis Bif16 100 - - - + - - +++ +++ +++ - - + +++ - 
B. adolescentis Bif17 100 - - - + - - - +++ - - - ++ - - 
B. adolescentis Bif18 100 - - - - - - - - - - - - - - 
B. adolescentis Bif19 100 - - - + - - - +++ - - - - - - 
B. adolescentis Bif20 100 - - - - - - - - - - - - - - 
B. longum Bif21 100 - ++ - + +++ +++ +++ +++ +++ - + ++ ++ - 
B. catenulatum Bif22 100 - + - + +++ - +++ +++ +++ - + ++ ++ - 
- Bif25 - - - - - - - - +++ - - - - - - 
B. longum Bif27 100 - ++ - + +++ - +++ +++ +++ - - ++ ++ - 
- Bif30 - - - - + +++ - +++ +++ +++ - + ++ ++ - 
S. epidermidis Strain 9c 94.8  - + - +++ - +++ + +++   - +++ - 
TEAGASC ISOLATES 
P. acidilactici Li3  nt - - - - - - -   - - - - - + 
Enterococcus sp 133 nt - - - - - - - - - - - - - + 
S. salivarius 107 nt - - - - - - - - - - - - - + 
S. mutans 130 nt - - - - - - - - - - - - - + 
Enterococcus sp 106 nt - - - - - - - - - - - - - + 
Streptococcus sp 134 nt - - - - - - - - - - - - - + 
S. agalactiae Sagal nt - - - - - - - - - - - - - + 
S. salivarius 130.3 nt - - - - - - - - - - - - - - 
E. faecium 111 Li nt - - - - - - - - - - - - - - 
S. mutans 110 nt - - - - - - - - - - - - - - 
S. salivarius  
DPC 6988  
E-999 nt - - - - - - - - - - - - - - 
E. faecalis 102 nt - - - - - - - - - - - - - - 
S. epidermidis 104 Lb nt - - - - - - - - - - - - - - 
Bacteroides 
intestinalis  
DSM 
17393 
nt - - - - - - - - - - - - - - 
B. fragilis  LMG 
10263 
nt - - - - - - - - - - - - - + 
Bacteroides 
vulgatus  
LMG 
11767 
nt - - - - - - - - - - - - - + 
Bacteroides 
thetaiotaomicran  
LMG 
11262 
nt - - - - - - - - - - - - - - 
Bacteroides dorei  DSM 
17855 
nt - - - - - - - - - - - - - - 
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Bacteroides sp 9-1-
42FAA 
nt - - - - - - - - - - - - - - 
Bacteroides 
uniformis  
DSM 
6597 
nt - - - - - - - - - - - - - - 
Coprobacillus sp  strain 
29_1/D6 
nt - - - + - - - - - - - - - + 
 
C j- C. jejuni NCTC 11168; C p – C. perfringens NCTC 3110; L i- L. innocua NCTC 11288; S e -
S. enterica LT2; E c-E. coli ATCC 25922; M l – M. luteus MC8166; C s-C. sakazakii DSMZ 4485 
; L b – L. bulgaricus DPC5538; F, filter disc assay; O, overlay assay; C, cross streak assay; W, 
well diffusion assay; nt- not tested. 
-, No activity; +, 1mm radius inhibition zone; ++, 1-5mm radius inhibition zone; +++, 
>5mm inhibition zone. 
3.3.3. Attempts to release antimicrobial activity in the supernatant 
As antimicrobial activity was more evident from direct contact assays, it was hypothesised 
that antimicrobials were remaining attached to the producer cells. Different methods were 
used in order to improve the release of possible antimicrobial peptides and proteins into 
the supernatant, such as through the use of acidic treatments with HCl or with isopropanol, 
but inhibition of the indicator strain with these supernatants was not increased relative to 
the negative controls. A second possibility was that the presence of a competing strain 
would induce or improve antimicrobial production. However, no antimicrobial activity was 
detected after test strains and indicator strains were co-cultured in media recommended 
for their growth or in minimal medium M9. Lastly, a range of culture conditions and 
potential inducers were used. Despite the multiple combinations of different conditions, 
no consistent inhibitory activity was apparent. The inhibitory activity that was observed 
sporadically was not clear and may have been due to the pH of the media. Attempted 
induction with trypsin, bile salts and Tween-80 did not produce any noticeable 
antimicrobial activity. Acetone precipitation also did not show any effect on the 
antimicrobial activity of the treated supernatants.  
3.3.4. Chemical production and characterisation 
3.3.4.1. Colony Mass Spectrometry (MS) 
This technique allowed a primary screening of the compounds produced by colonies of the 
isolates grown on agar. Isolates of S. epidermidis or the bifidobacteria did not present 
noticeable peaks. Chromatograms of E. faecalis isolates also did not show any remarkable 
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peaks. Some of the lactobacilli, i.e., L. gasseri LM19 and L. crispatus Lac 50 and Lac 51, 
whose antimicrobial activity in the cell-free supernatant was tested, presented peaks that, 
after further study, corresponded to bacteriocins (Chapters 4 and 7). However, L. 
amylovorus Lac 20, that also presented activity in the supernatant, did not produce a 
chromatogram with any possible masses, suggesting that its antimicrobial might be 
secreted, and it does not remain attach to the cell in a manner that would facilitate easy 
detection. Figure 3.2 shows the chromatograms resulting from the colony MS analysis of 
the sequenced isolates.   
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S. epidermidis F530B 
E. faecalis LM1 
 
E. faecalis LM4 
 
L. plantarum GI14 
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 L. crispatus Lac 51 
 
Figure 3.2. MS chromatograms of colonies from selected isolates 
3.3.4.2. Characterisation of antimicrobial peptides and proteins: temperature and 
protease tests 
Protease tests on active cell-free supernatants showed that the antimicrobials were 
proteinaceous in nature, i.e., antimicrobial activity was not detectable after protease 
treatment (Table 3.3). In the case of temperature tests, cell-free supernatants retained 
activity in the majority of the cases, suggesting the antimicrobials were peptides that were 
stabilised by modification, i.e. disulphide bridges or more considerable modifications. 
However, L. crispatus Lac 50 and Lac 51 cell-free supernatants lost their activity after 
incubation at/or above 90 oC, indicating that the antimicrobial activity could be due to a 
protein or unmodified peptide that, when denatured, loses the activity.  
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Table 3.3. Summary of antimicrobial activity shown by different supernatants after heat 
and protease treatment. 
 Heat treatment Protease treatment 
 60 
oC  
10 
min 
60 
oC  
30 
min 
60oC  
1 h 
90 
oC  
10 
min 
90 
oC  
30 
min 
121 
oC  
15 
min 
Proteinase 
K 
Protease Trypsin Pancreatin 
L. gasseri LM19 ++ ++ ++ ++ ++ ++ - - - - 
L. amylovorus 
Lac 20 
++ ++ ++ ++ ++ ++ - - - - 
L. crispatus  
Lac 50 
++ ++ ++ - - - - - - - 
L. crispatus  
Lac 51 
++ ++ ++ - - - - - - - 
P. acidilactici Li3 + + + + + + - - - - 
Enterococcus sp 133 + + + + + + - - - - 
S. salivarius 107 + + + + + + - - - - 
S. mutans 130 + + + + + + - - - - 
Enterococcus sp 106 + + + + + + - - - - 
Streptococcus sp 
134 
+ + + + + + - - - - 
S. agalactiae Sagal ++ ++ ++ ++ ++ ++ - - - - 
B. fragilis LMG 
10263 
+ + + + + + - - - - 
Bacteroides 
vulgatus LMG 
11767 
+ + + + + + - - - - 
 
-No activity; + :1mm radius inhibition zone; ++: 1-5mm radius inhibition zone; +++: >5mm inhibition zone.  
3.3.5. Identification of antimicrobial genomic traits  
The presence of potential antimicrobial and metabolic gene clusters in the genomes of 
antimicrobial-producing strains was investigated using specialist software tools antiSMASH 
and BAGEL3 and manually using searches following a general annotation (RAST) of the 
genome. AntiSMASH did not identify as many regions of interest as BAGEL3, which 
specifically targets regions similarity to bacteriocin-encoding clusters (Figure 3.3). More 
specifically 24 putative bacteriocin-encoding clusters were identified using BAGEL 3, while 
only two were identified by antiSMASH. AntiSMASH identified a number of microcins that 
BAGEL3 did not (Table 3.4). Further analysis showed that it was the same microcin 
structural gene and no additional genes for transport, immunity or regulatory functions 
were identified by the program. Thus, these microcins were not followed up. Also, 
antiSMASH identified a number of terpenoids and other products of secondary metabolism 
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that were also not followed up, due to our main interest in antimicrobial peptides. Manual 
identification of bacteriocins based on RAST results did not provide any additional 
information.  
Table 3.4. Potential bacteriocin hits using BAGEL 3 and antiSMASH. 
Sequenced isolate BAGEL 3 antiSMASH 
 B. longum FI0917 - - 
S. epidermidis 9C  Delta lysin 
Sactipeptide 
Microcin 
(Parvimonas micra) 
S. epidermidis F530B Delta lysin 
Sactipeptide 
Microcin (P. micra) 
E. faecalis LM1 Cytolysin ClyLl and 
ClyLs 
Glycocin 
Cytolysin ClyLl and 
ClyLs 
 
E. faecalis LM4 Cytolysin ClyLl and 
ClyLs 
Glycocin 
Cytolysin ClyLl and 
ClyLs 
 
L. plantarum GI14 Bovicin 255 peptide 
Plantaricins N and K 
Microcin (P.micra) 
 S. epidermidis 99 Delta lysin Microcin (P.micra) 
 L. gasseri LM19 LS2 chains a and b 
Helveticin J 
Acidocin LF221B 
(Gassericin 
K7B)Pediocin 
Gassericin T 
- 
L. amylovorus Lac 20 - - 
L. crispatus Lac 50 Enterolysin A (2) 
Helveticin J (2) 
Lactococcin 972 
- 
L. crispatus Lac 51 Enterolysin A (2) 
Helveticin J (2) 
Putative bacteriocin 
- 
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(A) S. epidermidis F530B and 9C 
• Sactipeptide 
 MSSRPLLCGVVIEFRCAGVGLDSFNLFSSPFRRGG 
 
• Delta lysin  
MAADIISTIGDLVKWIIDTVNKFKK 
 
(B) E. faecalis LM1 
• Cytolysins ClyLl and ClyLs 
MENLSVVPSFEELSVEEMEAIQGSGDVQAETTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHC 
VLNKENQENYYSNKLELVGPSFEELSLEEMEAIQGSGDVQAETTPACFTIGLGVGALFSAKFC 
 
• Glycocin 
MLNKKLLENGVVNAVTIDELDAQFGGMSKRDCNLMKACCAGQAVTYAIHSLLNRLGGDSSDPAGCNDIVRKY
CK 
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(C) E. faecalis LM4 
• Cytolysins ClyLl and ClyLs 
MENLSVVPSFEELSVEEMEAIQGSGDVQAETTPVCAVAATAAASSAACGWVGGGIFTGVTVVVSLKHC 
VLNKENQENYYSNKLELVGPSFEELSLEEMEAIQGSGDVQAETTPACFTIGLGVGALFSAKFC 
 
• Glycocin 
MLNKKLLENGVVNAVTIDELDAQFGGMSKRDCNLMKACCAGQAVTYAIHSLLNRLGGDSSDPAGCNDIVRKY
CK 
 
(D) L. plantarum GI14 
• Bovicin 255 peptide.   
MILTIPANSGLTTQQIQEAQRIVDQFNEQAINNNVILDGESNPQSSITSPKFGLMLAKQYRYYTANGYEYRDKKG
HWHYVVTKSPFEAAFGVALHGWEGALGGSWKSGHEK  
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• Plantaricins N and K 
MKIKLTVLNEFEELTADAEKNISGGRRSRKNGIGYAIGYAFGAVERAVLGGSRDYNK 
MKSLDKIAGLGIEMAEKDLTTVEGGKNYSKTWWYKSLTLLGKVAEGTSSAWHGLG 
LPQKKLAKISGGFNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR 
MAEKDLTTVEGGKNYSKTWWYKSLTLLGKVAEGTSSAWHGLG 
MKIQIKGMKQLSNKEMQKIVGGKSSAYSLQMGATAIKQVKKLFKKWGW 
MLQFEKLQYSRLPQKKLAKISGGFNRGGYNFGKSVRHVVDAIGSVAGIRGILKSIR 
MKKFLVLRDRELNAISGGVFHAYSARGVRNNYKSAVGPADWVISAVRGFIHG 
MTVNKMIKDLDVVDAFAPISNNKLNGVVGGGAWKNFWSSLRKGFYDGEAGRAIRR 
 
(E) S. epidermidis 99 
• Delta lysin.  
MAADIISTIGDLVKWIIDTVNKFKK 
 
(F) L. gasseri LM19 
• LS2 chains a and b 
MKVLNECQLQTVVGGKNWSVAKCGGTIGTNIAIGAWRGARAGSFFGQPVSVGAGALIGASAGAIGGSVQCV
GWLAGGGR 
MIEKVSKNELSRIYGGNNVNWGSVAGSCGKGAVMGIYFGNPILGCANGAATSLVLQTASGIYKNYQKKR 
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• Helveticin J 
MKKGFVQIMIGKETQLCLVNKLENIHHVVVQASAIDGNNVFALQLLHKQSDVIVYQTPNDSETVTFNEDRPILYL
KGPNSAGTAGGHTQTWVQSGENNKWFVGTKPKRHGNTYWTTQIARVAVSGYQTQTFTNNTELPRLSYLNRA
GSGYGDGSVAYPGKDLVRVEAAVSPNRQYFLIASIDINHTGHFAVYNLDEVNKKLDEAEEKAEDVNIQNLNCLG
AFNVPHFNDQKIISIQGYGIDDNKNIYISSQPSPHTTFLGFPKQGKPREIVKIPWGISDPSKWSVVNLDNSLKLDA
LNFCTEFEGIQVTSDCLYLTVAYHQRNSDLTTLMNRIYQVEKF 
 
 
• Acidocin LF221B (Gassericin K7B), Pediocin and Gassericin T 
MKNFNTLSFETLANIVGGRNNWAANIGGVGGATVAGWALGNAVCGPACGFVGAHYVPIAWAGVTAATGGF
GKIRK 
MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACGLGGAAIGGYLGYKSN 
MKNELKQVLNDFISLAKTHYDRKGNEYLLEQLEVALDKLEHNVQDEVDEARATYQNINTICFANHLHLETDEEAL
LEKIKEFSMSKGWLGGLNSWNTTNTWPGR 
 
(G) L. crispatus Lac 50 
• Enterolysin A 
MKKTESKFALLAALIAILAFASIPLWQNNLNSLRPQTHTVKKKKTAKKKKVVHVTWGYPFKKLYEKKIKFKSGQKF
GETDVIRRVYPSKSYFHDGYDFGFSEVGHSPVYAVHAGTVHRVKYAPGLGLYIWIISDDGYVEVYQEGFLSITDIY
VKKGQKVKLGQKIGKLTGSHIHLGVTKTDKDYIDKKHDNTPCKYYWKDNGTWLNPMKIIEDNLRAAGKDPVQ 
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• Enterolysin A 
MKFRKLIISLLGTALLTSSVGLSTTTASADTLDDSQNTTEVQPKNLKWAYPFKANKKNGVRPMYNAQTFGITNY
MRSTTPPSYFHDGWDFGFSEVGHSNVYAIHQGTVKKVAYGNGLGWFIWVISPDNYVEVYQEGFNKKKDIYVK
TGQKIKLGQKIGKLTGSHLHLGVTQTNKDYINKYGFPCKNWNVNNGTWLNPIEVIKSNLKK 
 
• Helveticin J 
MVKSITPHLVYRLNGMHHVVAQVGVVNGDHVFALQLLHSAHDVLVYRKHEGLTKNIDYTDPHLVMMGFGHT
QTWVAANDKDEYFVGAKPNSGNWTTQIARVKYPRLLPERYTSNTQLPRLSHLNHVTDVPYDGHDHLHRVEAS
VSPNGKYFMIASIWDDGSGHFGLLDLNEVNQKLNENGTKNTPITDLHCLSAFHIDNFDNPSVAPDEEMPQMID
SVQGYAIDDDKNIYISNQLSPKINHETGEVTTWSRKIVKFPWGETNSDNWQVAMVDGIDLPDRYSEMESIHVN
AANDIYLTVAYHQKYIKGGEYKLRTLENQIFHITDL 
 
• Helveticin J 
MVDISLKSRLYAPFARVVQKANIGHTYTYVLQMYKNNTYVSRAKNGASISSPTPGLTLVGRTGAEIKAGKNKYAA
GGHTQTWEYAGPTGDGSWFIGTKPNDDRWTTQIARVKYNSGRVSNNTQMARISNLVEITNGDWHGKHIKR
VEAAVSPNYKYLMIATVWTDNSGHFGLYELPKVNALLNGNPGGNVTVSELKQCQAGEVIDIDNFVGRIGSIQG
YDIDDDLNVYVSSQYDPTHADSNKRKIVKFSWEQPGALNTLDLTGDTRLNQNFAGYPTELEGIQVIGNNDLYLT
VAYHNKNGVGTIGNQIFRVKW 
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• Lactococcin 972 
MKKKNFTKAFTIAMVSASLLAVGPASAVLAKNVGGGDWNYGYSWNYGWSKYYHGTRKHSATVAYNSDEHR
DTRARGYTAYAEYHKIPPTGLSYWWNVY 
 
(H) L. crispatus Lac 51 
• Helveticin J 
MVKNITPELVYRLNGMHHVVAQVGAVIDKHVFALQLLHSAHDVLVYRKHEGLTKNVDYTEPHLVMTGFGHTQ
TWVPANDNDEYFVGVKPNSGNWTTQIARVKYPKLLPENYTSNTQLPRLSHLNRATDVPYDGHNHLHRVEASV
SPNGKYFMIAAIWDDDSGHFALYDLNEVNQKLDENGTTNTPITDLHCLSAFHIDNFDHPSVAPSEEAPQMIDSV
QGYAIDDDKNIYISNQLSPKINHETGEVTTWSRKIIKFPWGETNSDNWQVAMIDGIDLPDRYSEMESIHVKAPD
DIYLTVAYHQKYIKGGEYKLRTLENQIFHITDL 
 
• Putative bacteriocin 
MRKKKMKIFNKKNLLLSSAVVAGMLLVSDVNSATFTVYAAEQQSSVGQASQAVKAGNSLTQEQIQQANKYIKI
ENNQYMLDTSNKSCTLSPETIHKIQEVLTLFNKTVRENNVVLLSNEDVENNNLDQEVSPFITFVKGKKRKHRKSH
GYIVGYGSNGYCYKDSKGNFHYYVTKSPLQTVLDVNRQGLESALGGGWVQAPENAHWHGFEYHR 
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• Helveticin J 
MVDISLKSRLYAPFARVVQKANIGHTYTYVLQMYKNNTYVSRAKNGASISSPTPGLTLVGRTGAEIKAGKNKYAA
GGHTQTWEYAGPTGDGSWFIGTKPNDDRWTTQIARVKYNSGRVSNNTQMARISNLVEITNGDWHGKHIKR
VEAAVSPNYKYLMIATVWTDNSGHFGLYELPKVNALLNGNPGGNVTVSELKQCQAGEVIDIDNFVGRIGSIQG
YDIDDDLNVYVSSQYDPTHADSNKRKIVKFSWEQPGALNTLDLTGDTRLNQNFAGYPTELEGIQVIGNNDLYLT
VAYHNKNGVGTIGNQIFRVKW 
 
• Enterolysin A 
MKFRKLIISLLGTALLTSSVGLSTTTASADTLDDSQNTTEVQPKNLKWAYPFKANKKNGVRPMYNAQTFGITNY
MRSTTPPSYFHDGWDFGFSEVGHSNVYAIHQGTVKKVAYGNGLGWFIWVISPDNYVEVYQEGFNKKKDIYVK
TGQKIKLGQKIGKLTGSHLHLGVTQTNKDYINKYGFPCKNWNVNNGTWLNPIEVIKSNLKK 
 
• Enterolysin A 
MKKTESKFALLAALIAILAFASIPLWQNNLNSLRPQTHTVKKKKTAKKKKVVHVTWGYPFKKLYEKKIKFKSGQKF
GETDVIRRVYPSKSYFHDGYDFGFSEVGHSPVYAVHAGTVHRVKYAPGLGLYIWIISDDGYVEVYQEGFLSITDIY
VKKGQKVKLGQKIGKLTGSHIHLGVTKTDKDYIDKKHDNTPCKYYWKDNGTWLNPMKIIEDNLRAAGKDPVQ 
 
Figure 3.3. Bacteriocin cluster prediction from BAGEL3 in studied genomes with the 
sequence of the predicted bacteriocin operons. 
Table 3.5 summarises the results of the BLAST analysis of the putative peptide sequences 
identified by BAGEL3. L. gasseri LM19 contained a number of regions of potential interest, 
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but a more detailed analysis of the homologous sequences identified by BLAST, both DNA 
(Blastn) and amino acid (Blastp), showed that those of greatest interest were associated 
with production of the bacteriocin gassericin T. The presence of sequences with similarity 
to helveticin J in some genomes (L. gasseri LM19, L. crispatus Lac 50 and L. crispatus Lac 
51) was studied, and these analyses showed that the match was to a hypothetical protein 
that has been sequenced in another organism but does not have an associated function. 
This was also the case with glycocins identified in E. faecalis. L. plantarum GI14 was 
predicted to encode a bovicin 255-like protein where similarity is based on a partial match 
of the amino acid sequence. Lactococcin 972 from L. crispatus Lac 50 and the putative 
bacteriocin of L. crispatus Lac 51 present a similar situation.  However, there was no 
evidence of production of these peptides.  
Table 3.5. Summary of Blastn and Blastp analysis of putative bacteriocins identified by 
BAGEL3  
Isolate Bacteriocin Percentage 
identity 
nucleotide 
E-
value 
Top match Percentage 
identity 
amino acid 
E-
value 
Top match 
S. 
epidermidis 
9C and  
S. 
epidermidis 
F530B 
Delta lysin 100 2e-
10 
Delta 
hemolysin 
100 2.6e-
21 
Delta 
hemolysin 
Sactipeptide 100 6.6e-
29 
S. 
epidermidis 
CRISPR2 
repeat 
region 
58 2e-
10 
2-hydroxyacid 
dehydrogenase 
E. faecalis 
LM1 
Cytolysin 
Cly Ll 
100 2e-
06 
Cytolysin  
E. faecalis 
100 4e-
45 
Cytolysin  
E. faecalis 
Cytolysin 
Cly Ls 
100 1e-
42 
Cytolysin  
E. faecalis 
100 4e-
15 
Cytolysin  
E. faecalis 
Glycocin 94 9.9e-
05 
E. faecalis 
plasmid 
No hits No 
hits 
No hits 
E. faecalis 
LM4 
Cytolysin 
Cly Ll 
100 2e-
06 
Cytolysin  
E. faecalis 
100 4e-
45 
Cytolysin  
E. faecalis 
Cytolysin 
Cly Ls 
100 1e-
42 
Cytolysin  
E. faecalis 
100 4e-
15 
Cytolysin  
E. faecalis 
Glycocin 100 3.2e-
8 
E. faecalis 
complete 
genome 
100 3e-
52 
Hypothetical 
protein E. 
faecalis 
L. 
plantarum 
GI-14  
 
Bovicin 255 
peptide 
No hits No 
hits 
No hits 76 9e-
11 
Hypothetical 
protein L. 
plantarum 
Plantaricin 
N 
100 3e-
35 
Plantaricin 
N 
100 4.7e-
05 
Plantaricin N 
Plantaricin 
K 
100 2e-
37 
Plantaricin 
K 
100 2.5e-
05 
Plantaricin K 
S. 
epidermidis 
99 
Delta lysin 100 2e-
10 
Delta 
hemolysin 
100 3.2e-
21 
Delta 
hemolysin 
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L. gasseri 
LM19 
LS2 chain a 99 1e-
117 
Gassericin 
K7A 
100 1e-
45 
Hypothetical 
protein, 
Bacteriocin 
leader domain 
LS2 chain b 100 1e-
102 
Gassericin 
K7A 
Gassericin 
A 
100 9e-
42 
Hypothetical 
protein, 
Bacteriocin 
leader domain 
Helveticin J 97 0 L. gasseri 
complete 
genome 
98 0 Hypothetical 
protein 
Helveticin J 
Acidocin 
LF221B 
(Gassericin 
K7B) 
100 1e-
112 
Gassericin 
T cluster 
100 2e-
44 
Gassericin T 
Pediocin 100 4e-
96 
Gassericin 
T cluster 
100 2e-
38 
Gassericin T 
Gassericin T 100 4e-
133 
Gassericin 
T 
100 2e-
69 
Gassericin T 
L. crispatus 
Lac 50 
 
Enterolysin 
A 
99 0 L. crispatus 
ST1 
100 0 Peptidase M23 
Enterolysin 
A 
99 0 L. crispatus 
ST1 
100 0 Peptidase M23 
Helveticin J 99 0 L. 
helveticus  
99 0 Hypothetical 
protein 
Helveticin J 
Helveticin J No hits No 
hits 
No hits 100 7e-
19 
Hypothetical 
protein 
Helveticin J 
Lactococcin 
972 
No hits No 
hits 
No hits 46 0 Lactococcin A 
L. crispatus  
Lac 51 
 
Helveticin J 89 0 L. crispatus 
ST1 
92 0 Hypothetical 
protein 
Helveticin J 
Putative 
bacteriocin 
99 0 L. crispatus 
ST1 
99 7e-
151 
Hypothetical 
protein 
 L. crispatus 
Helveticin J No hits No 
hits 
No hits 100 6e-
163 
Hypothetical 
protein 
Helveticin J 
Enterolysin 
A 
99 0 L. crispatus 
ST1 
100 0 Peptidase M23 
Enterolysin 
A 
99 0 L. crispatus 
ST1 
100 3e-
156 
Peptidase M23 
 
3.3.6. Screening for probiotic traits 
Some typical probiotic traits were screened in order to have a deeper background of the 
potential of the different isolates, for future applications.  
3.3.6.1. Auto-aggregation  
In general, with the exception of L. plantarum Lac 3, L. paracasei R2 and L. reuteri Lac 46, 
tested strains showed some level of auto-aggregation capability. L. paracasei Lac 1, L. 
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reuteri Lac 54, L. gallinarum Lac 43 and L. rhamnosus Lac 26, only showed auto-aggregation 
in aerobic conditions (Figure 3.4). L. pentosus Lac 4 and L. frumenti Lac 53 showed different 
levels of auto-aggregation but only under anaerobic conditions. Many of the tested isolates 
showed a high variability. The isolates that showed more consistent activity, with less 
variation and high percentage aggregation, were L. crispatus Lac 50 and Lac 51, L. 
rhamnosus Lac 22, L. mucosae Lac 30 and the Bifidobacteria FI10480 and FI10481. All these 
strains exhibited similar levels of auto-aggregation under both aerobic and anaerobic 
conditions.  
 
Figure 3.4. Percentage of auto-aggregation capability of different food and faecal isolates 
when grown in aerobic and anaerobic conditions. Results are the mean of triplicate 
measurements +/- standard deviation. 
3.3.6.2. Antioxidant activity 
The antioxidant activity of tested isolates was, in general, low relative to that of other 
strains considered as probiotics, that usually present levels of DPPH reduction around 80%. 
The highest levels observed were associated with B. longum FI10917, which showed levels 
of around 70% DPPH reduction. However, none of the other bifidobacteria or lactobacilli 
showed similarly high levels of antioxidant activity. Indeed, of the strains tested, only S. 
epidermidis F530B displayed comparatively high levels of anti-oxidant activity.  
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Figure 3.5. Percentage of reduction of DPPH as a measurement of antioxidant capacity of 
different food and faecal isolates. Results are the mean of triplicate measurements +/- 
standard deviation. 
3.3.6.3. Bile salt hydrolase (BSH) activity 
BSH activity was also measured for some of the isolates. The activity was characterised by 
the presence of a bright white precipitate from the colonies growth on the plates 
supplemented with bile salts. Table 3.6 summarises the isolates that presented this BSH 
activity.  
Table 3.6. BSH activity of different isolates. 
Isolate BSH activity Isolate BSH activity 
L. mucosae Lac 30 √ Bifidobacterium sp FI10480 √ 
L. gasseri LM19 √ L. amylovorus Lac 20 √ 
L. reuteri Lac 56 √ L. plantarum GI13 √ 
L. crispatus Lac 50 √ L. crispatus Lac 51 √ 
L. mucosae Lac 28 √ L. paracasei R1 x 
L. gallinarum Lac 43 √ L. paracasei R2 x 
L. frumenti Lac 53 √ E. faecalis LM4 x 
L. reuteri Lac 54 √ L. rhamnosus Lac 26 x 
L. crispatus Lac 34 √ L. rhamnosus Lac 22 x 
L. reuteri Lac 46 √ S. epidermidis 99 x 
L. gallinarum Lac 47 √ L. pentosus Lac 4 x 
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S. salivarius GI16 √ E. faecalis LM1 x 
L. plantarum GI01 √   
 
 
Figure 3.6. White precipitate as product of the BSH activity of L. amylovorus Lac 20 and L. 
crispatus Lac 50 and Lac 51. Absence of white precipitate in negative control. 
3.4. Discussion 
The screening for antimicrobial activity from among 1803 strains from two new sources 
(fermented foods and faeces) in addition to existing strains in the QIB and Teagasc culture 
collections yielded a total of 313 isolates that showed antimicrobial activity against at least 
one indicator strain (c. 17 %). 32 isolates of faecal origin exhibited antimicrobial activity 
initially, but the majority of them were not able to be further subcultured. Kefir samples 
did not provide any isolates with antimicrobial activity based on the methods used, but 
screening of strains from other fermented foods such as organic miso, yogurt and gherkins, 
yielded 176 colonies that showed antimicrobial activity. 16S rRNA analysis established that 
the isolates from these sources were not very diverse.  
There are challenges in the implementation of culture-based techniques with a view to 
isolating antimicrobial-producing strains. The first relates to the culture media itself, since 
it is estimated that only a small percentage of bacteria are able to grow in conventional 
media [235]. In the case of fermented foods, the presence of a predominant species is 
common, especially if these fermented foods are commercially available and not naturally 
fermented [236]. In the case of screening from faecal samples, it is thought that growth 
factors are frequently retained on the agar surface during the initial screening, permitting 
initial growth but that, when subcultured, these factors are diluted or no longer present, 
and bacteria are not able to grow again or antimicrobial production can no longer be 
induced.  
The outcome of the analysis of QIB and Teagasc isolates was different to that for freshly 
isolated bacteria, most likely as these were bacteria that had previously shown both 
antimicrobial activity and the ability to be subcultured. The main difficulty with these 
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isolates was, in some instances, the loss of the antimicrobial-producing phenotype. With 
the exception of three isolates, these strains inhibited at least one indicator strain on the 
basis of at least one bioassay. It is important to note that not all bioassays indicated the 
presence of antimicrobial activity. The clearest differences was between the bioassays that 
required contact with the indicator strain, such as the overlay and cross-streak assays, and 
those that used cell-free supernatant, like the drop test, filter disc and well-diffusion assay. 
As presented in table 3.2, it is clear that the antimicrobial activity exhibited is most 
frequently observed in the contact bioassays. In fact, only four isolates from QIB and 12 
from Teagasc exhibited antimicrobial activity when assessed by well-diffusion assay. In 
these instances activity was against L. bulgaricus DPC 5583, a strain that has been typically 
used for antimicrobial discovery as a consequence of its extreme sensitivity to bacteriocin 
[61]. Similarly, C. jejuni was also very sensitive to the supernatants, but the lack of sodium 
carbonate in the plates composition suggests that this activity might be due to the lactic 
acid. It can be culture supernatants that showed antimicrobial activity by well-diffusion 
assay, did not show the same activity by drop test or filter disc. This situation can be due to 
a concentration factor or to the fact that drop tests and filter discs get dry at a relatively 
early stage during the incubation period of the assay, whereas the well-diffusion assay 
allows a longer exposure to a bigger volume of cell-free supernatant containing the 
potential antimicrobial compounds. Overall, this highlights the importance of using 
different bioassays when screening for new antimicrobials, since their potential activity 
might vary depending on its origin or mode of action. 
Despite the fact that there was evidence of the presence of antimicrobial activity in the 
studied isolates, the absence of this antimicrobial activity in the supernatant of most strains 
was a challenge when it came to the further characterisation of the antimicrobial 
compounds [62, 237, 238]. The use of a co-culture-based approach did not yield a 
qualitative increase in the production of antimicrobial in the supernatant when assessed 
using the drop test bioassay, despite the use of the minimal medium M9 to induce higher 
competition. Treatments performed to release the antimicrobial compound did not 
produce active supernatants. Methods for crude protein extraction and ethanol and 
acetone precipitation were performed to attempt the release and concentrate the activity 
in the supernatant. However, none of the strategies were successful on a regular basis. One 
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explanation might be that the compounds were not produced in sufficient amounts for 
concentration to provide a solution.  
Mass spectrometry (MS) has proved to be useful for identifying the presence of 
antimicrobial compounds of the cell surface of bacteria [239]. In particular, colony MS can 
be useful as a screening method if one is interested in identifying the presence of 
compounds within the range of bacteriocin masses. In this situation, although colony MS 
was useful to identify potential masses of interest, the information provided was not 
always definitive. For example, despite the fact that colony MS of L. gasseri LM19 and the 
two L. crispatus Lac 50 and Lac 51 revealed peaks consistent with the putative antimicrobial 
peptides encoded by these strains, L. amylovorus Lac 20, that displayed inhibitory activity 
in well-diffusion assays, did not. However, in the case of L. amylovorus Lac 20 it could be 
that the compound is released in the media rather than be attached to cell surface. It 
should be noted that the absence of peaks corresponding to putative antimicrobials 
encoded does not mean that these antimicrobials cannot be produced, but rather it can 
reflect the level of production, the nature of the compound, the degree to which it is 
attached to the cell surface or the absence of the factors required to trigger its production.  
We sequenced isolates that showed interesting features (such as E. faecalis LM1 and LM4 
that showed the inhibition zone in combination, indicating a potential quorum sensing 
regulation [240]) or that in previous work showed antimicrobial activity (such as B. longum 
FI10917). Additionally, we sequenced the QIB isolates that showed inhibitory activity in 
cell-free supernatant-based assays. Of the eleven sequenced isolates, only two, B. longum 
FI10917 and L. amylovorus Lac 20, did not contain predicted bacteriocin clusters using the 
BAGEL 3 software. B. longum FI10917 did not yield detectable antimicrobial activity, but L. 
amylovorus Lac 20 did, as described in Chapter VII. A total of 30 potential antimicrobials in 
24 operons were predicted by BAGEL 3. This included a number that were described 
previously (plantaricins N and K [241], three delta-lysins, gassericin T and four enterolysins 
A that were not the subject of further analysis. However, there were some potentially novel 
antimicrobials that had exhibited only a low percentage similarity to other annotated 
bacteriocins. Thus, two sactipeptides, two glycocins, one bovicin-like, five helveticin J-like 
and one lactococcin 972-like clusters had the potential to yield new antimicrobials. Further 
study of the L. gasseri LM19 genome showed that one of those clusters also apparently 
encoded new bacteriocins (Chapter IV).  
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One of the possible applications of this antimicrobial activity can be to the production of 
these bacteriocins in situ if their bacterial producers showed further probiotic activities. For 
this reason, some probiotic traits were also examined. Previously, isolates from the QIB 
culture collection were studied for probiotic activity [242], so additional information could 
improve our knowledge and the applicability of these isolates. Autoaggregation, 
antioxidant capability and BSH activity were measured. It has been noted in the literature 
that isolates from the human gut are very likely to have these feature [243]. However, one 
third of the tested isolates did not show a white precipitation. This is not indicative of 
absence of BSH activity, but only that these isolates were not able to precipitate sodium 
taurodeoxycholate hydrate in visible form. There are different BS [244] and different 
bacteria present different BSH [245].  Our work showed that although BSH activity and 
autoaggregation were relatively common our bacteria did not show notable antioxidant 
activity. 
Based on the different results summarised in this chapter, it was decided to further study 
L. gasseri LM19 for its multibacteriocinogenic characteristics and the presence of two novel 
bacteriocins in its genome. Additionally, nisin P was further studied because its activity was 
not reported previously, and it was only described by genome mining. L. amylovorus Lac 20 
was further investigated because the heat and protease tests suggested that its 
antimicrobial activity could have a peptidic origin, despite the absence of results using the 
predictive bioinformatics tools. L. crispatus 50 and L. crispatus 51 were studied for the same 
reason as L. amylovorus Lac 20. Finally, S. epidermidis 9c, F530B and 99, although not 
directly related to the thesis scope, were studied due to the nature of their isolation, since 
no human gut isolates of this species were reported in databases to date.   
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4.1. Introduction 
Lactobacillus gasseri is one of six closely related species which are collectively referred to 
as the Lactobacillus acidophilus complex [246, 247]. These species are considered 
ecologically and commercially important and have been extensively studied, revealing 
antimicrobial and other probiotic properties [248-252]. L. gasseri has been divided in two 
subgroups using the average nucleotide identity (ANI) [253]. Strains from this species have 
been isolated from the GI tract of animals and humans [254], the vaginal tract [253, 255], 
human milk [256] and oral cavity [257] and used for their probiotic properties, including 
antimicrobial and bacteriocin production [252].  
Many of the bacteriocins produced by L. gasseri, known as gassericins because of their 
origin, fall into different bacteriocin subgroups. Gassericin A is a cyclic peptide produced by 
L. gasseri LA39 isolated and purified from a human infant faecal sample [258-260]. 
Gassericins B1, B2, B3 and B4 were isolated from the vaginal isolate L. gasseri JCM 2124, 
with B1 and B3 being found to be identical to the α and β peptides of the two-component 
acidocin J1132 from L. acidophilus and B2 and B4 potentially representing modified forms 
of B3 [261]. Another bacteriocin, gassericin T, was found to be produced by L. gasseri SBT 
2055, an adult human faecal isolate [132]. Gassericin T is notable because its amino acid 
sequence showed high similarity to one of the peptides (LafA) of the two-component 
lactacin F family produced by L. johnsonii VPI11088 [132]. Along with the LafA peptide, L. 
johnsonii produces another hydrophobic peptide, LafX, which was highly similar to lactobin 
A and the putative product of gatX found in the operon of L. gasseri SBT 2055 [132]. Despite 
establishing the presence and activity of gassericin T, mature GatX could not be detected 
in the supernatant of SBT2055 during the characterisation process and the synergy of a 
possible two-peptide gassericin T could not be established. GatX was detected later by 
Mavric et al, in a different strain, L. gasseri K7 [262]. Acidocins LF221A and LF221B were 
isolated from the infant faecal isolate of L. acidophilus LF221, later renamed L. gasseri 
LF221, [263] but their classification as members of the two-peptide bacteriocin group has 
not been established experimentally [264]. Furthermore, the genome of L. gasseri K7, 
isolated from the faeces of a breast-fed baby, contains two putative two-peptide 
bacteriocin-encoding operons [265] that share a high level of homology to acidocins 
LF221A and LF221B and gassericin T [262]. More recently, the isolation and purification of 
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gassericin E from L. gasseri EV1461, isolated from the vagina of a healthy woman, has been 
reported [264].  Gassericin E exhibits high similarity to gassericin T, differing only by one 
amino acid residue in its mature form [264]. Interestingly, the gassericin E operon also 
contains a putative bacteriocin-like peptide-encoding gene, gaeX, the predicted product of 
which shares 100% identity to GatX of L. gasseri SBT 2055 and gassericin K7 B of L. gasseri 
K7 [264]. Finally, peptides encoding gassericin T (GatA and GatX) and novel gassericin S with 
similarity to acidocin LF221A (GasA and GasX) were all found in the genome of L. gasseri 
LA327, isolated from human large intestine tissue [266]. Kasuga et al demonstrated the 
synergistic activity between the two components of gassericin T, and those of gassericin S 
[266]. However, they could not demonstrate synergistic activity between gassericin S and 
gassericin T when they mixed the four peptides together. 
Here it is reported a new L. gasseri strain, LM19, isolated from breast milk, which possesses 
three bacteriocin clusters in its genome, including one encoding a novel gassericin, 
gassericin M. These studies reveal how different carbon sources influence the expression 
of the different bacteriocin clusters and the production of SCFA. Notably, LM19 survives, 
expresses bacteriocin genes and produces SCFA in detectable amounts in a complex faecal 
environment mimicking colonic conditions.  
4.2. Methods 
4.2.1. Isolation and analysis of L. gasseri LM19 
L. gasseri LM19 was originally isolated from breast milk on MRS agar at 37oC by Professor 
Juan Miguel Rodriguez from University Complutense of Madrid. Bioinformatic analysis was 
performed as described previously in sections 2.2.9.1. and 2.2.9.2.; alignments were 
performed using ClustalW [267] and visualised using Genedoc [268].  
4.2.2. Detection and purification of antimicrobial peptides 
This work was performed by Paula O’Connor at Teagasc Moorepark (Ireland). L. gasseri 
LM19 was grown anaerobically at 37oC in 2 l MRS broth for 24-48 h. The culture was 
centrifuged (8,000 x g, 20 min, 10oC) to separate cells from supernatant, and both samples 
were analysed independently. The cell pellet was resuspended in 400 ml 70% propan-2-ol, 
0.1% trifluoroacetic acid (TFA – ‘IPA’) using a stirrer for 3-4 h at room temperature, 
centrifuged again and the supernatant retained for further purification and activity testing 
by drop test using Lactobacillus bulgaricus LMG 6901 as an indicator strain. IPA was 
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removed from this extract by rotary evaporation until the sample volume was 120 ml, and 
it was applied to a 2 g 12 ml Strata® C18-E solid-phase extraction (C18-SPE) column 
(Phenomenex, UK), pre-equilibrated with methanol and water following manufacturer’s 
instructions. The column was washed with 20 ml 30% ethanol, 20 ml of 30% acetonitrile 
and the active fraction eluted with 30 ml of IPA. The IPA was removed from the C18 SPE 
IPA eluate and 4 ml aliquots of sample applied to a semi preparative Jupiter C5 Reversed 
Phase HPLC column (10 x 250 mm, 10 μm, 300Å) (Phenomenex, Cheshire, UK) (HPLC run I) 
running a 30-70% acetonitrile 0.1% formic acid (FA) gradient over 95 minutes where buffer 
A is 0.1% FA and buffer B is 100% acetonitrile 0.1% FA. Flow rate was 2.5 ml/min and 
fractions were collected at 1 min intervals. The fractions were further analysed by matrix 
assisted laser deionisation -time of flight-mass spectrometry (MALDI-TOF-MS; Axima TOF2 
MALDI-TOF mass spectrometer in positive-ion reflectron mode, Shimadzu Biotech, UK) to 
determine the masses of the potential peptides. For purification from the cell-free 
supernatant, the supernatant was applied to an Econo-column (BioRad, UK) containing 60 
g Amberlite XAD 16N. The column was washed with 400 ml 35% ethanol followed by 400 
ml 30% acetonitrile and antimicrobial activity eluted with 450 ml IPA. The IPA was removed 
from the XAD IPA eluate by rotary evaporation until the sample volume was 145 ml and it 
was then applied to a 5 g 20 ml C18-SPE column pre-equilibrated with methanol and water 
following manufacturer’s instructions. The column was washed with 30 ml 30% ethanol 
followed by 30 ml 30% acetonitrile and antimicrobial activity eluted with 30 ml IPA and 
fractionated by semi-preparative reversed phase HPLC as before. To increase purity, some 
HPLC fractions were reapplied to the C5 semi prep column, running shallower gradients. 
Specifically, 30-40% acetonitrile 0.1% FA gradient over 95 min for GamX and Bact_2, 30-
45% gradient for GamA, 35-65% gradient for Bact_1, GamM and GamY. Additionally, the 
six peptides were synthesised using microwave-assisted solid phase peptide synthesis 
(MW-SPPS) performed on a Liberty Blue microwave peptide synthesizer (CEM Corporation, 
USA). GamA and GamM were synthesised on a H-Lys(BOC)-HMPB)-ChemMatrix® resin, 
GamX was synthesised on H-Asn(Trt)-HMPB-ChemMatrix® resin, Bact_1 and Bact_2 on H-
Arg(PBF)-HMPB-ChemMatrix® resin and GamY on Fmoc-Phe-Wang (Novobiochem®, 
Germany) resin. Crude peptide was purified using RP-HPLC on a Semi Preparative Vydac C4 
(10 x 250 mm, 5 µ, 300 Å) column (Grace, USA) running acetonitrile-0.1% TFA gradients 
specific to the peptide of interest. Fractions containing the desired molecular mass were 
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identified using MALDI-TOF-MS on an Axima TOF2 MALDI TOF mass spectrometer and were 
pooled and lyophilised on a Genevac HT 4X lyophiliser (Genevac Ltd., UK). All peptides, from 
HPLC runs and synthetic ones, were assayed by well-diffusion assay using L. bulgaricus 
DPC6091 to compare activity and to assess synergistic activity among them.  
4.2.3. Transformation of L. gasseri 
Generation of electro-competent cells of L. gasseri LM19 was performed as described in 
sections 2.2.10.2. and 2.2.10.3.  
4.2.4. Fermentation studies 
L. gasseri was inoculated at 1% in 20 ml of MRS without glucose prepared in-house with 
different supplementation (Table 4.1) and incubated in anaerobic conditions at 37oC over 
48 h. 3 ml of each treatment were harvested at 24 and 48 h for further analysis of gene 
expression. Lower concentrations of glucose (0, 5, 1, 1.5%) were also tested in the same 
way. In addition to MRS, Batch model media was also prepared as described in section 
2.1.1. The pH was adjusted to 6.8 in both media and filter sterilised carbohydrate source 
supplementation (glucose, lactose, galactose, inulin, starch or pectin (Sigma, UK)) was 
added at 2% (w/v) after autoclaving. Fermentations were conducted in triplicate and 2 ml 
of each sample were collected at 24 h and 48 h. 1 ml was used for enumeration by plate 
count, pH measurement using a pH-000-85282 probe (Unisense, Denmark) and, once filter 
sterilized, antimicrobial activity using a well diffusion assay; the other was centrifuged at 
16,000 x g and the cell-free supernatant stored at -20oC for further analysis.  
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Table 4.1. Summary of supplements to MRS culture media  
Treatment Supplement 2% (w/v) 
1 - 
2 Glucose 
3 Lactose 
4 Sucrose 
5 Inulin 
6 Starch 
7 Pectin 
8 2% Glucose + 1% L. bulgaricus DPC 5383 
9 2% Glucose + 1% E. coli MC1022 
10 2% Glucose + 1% S. enterica LT2 
4.2.5. In vitro colon model 
Fermentations to simulate human colon conditions were performed, in 150 ml volumes, as 
described previously [269, 270]. Faecal inoculum was prepared as explained in section 
2.1.7. The temperature was maintained at 37 oC by a circulating water bath. Batch culture 
media was prepared as stated before, and 1% glucose was added as a carbohydrate source. 
Cultures were stirred, anaerobic conditions were maintained with oxygen-free nitrogen 
and pH maintained between 6.6 -7.0 by adding 1M NaOH or 1M HCl with automated pH 
controllers (Electrolab Ltd, UK) [269]. Overnight cultures of L. gasseri LM19 pUK200 and C. 
perfringens NCTC 3110 were added to the vessels at 1% (v/v). 6 ml samples were taken at 
4 h, 8 h, 24 h and 48 h for DNA and RNA extractions, SCFA analysis and enumeration of L. 
gasseri LM19 pUK200 by plate count on MRS supplemented with 7.5 μg/ml 
chloramphenicol. Experiments were carried out in triplicate using three different faecal 
donors. 
4.2.5.1. Detection of expressed bacteriocin genes from L. gasseri LM19 in faecal samples 
To test L. gasseri LM19 bacteriocin gene expression in faecal samples, 3 ml of each aliquot 
was treated for RNA extraction and cDNA synthesis as previously described in section 2.2.7. 
The presence or absence of L. gasseri LM19 bacteriocin genes was confirmed by PCR [271]. 
Thermal cycling was performed using a Verity 96 well Thermal Cycler (Applied Biosystems) 
using GoTaq G2 DNA polymerase (Promega) according to manufacturer´s instructions. 
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Primers used were summarized in table 2.5 and cycle conditions were the same as for RT-
qPCR.  
4.2.5.2. Quantification of C. perfringens NCTC 3110  
A standard curve for C. perfringens NCTC 3110 was constructed by extracting gDNA as 
described previously [272] at different concentrations (colony forming units (cfu)/ml) of C. 
perfringens NCTC 3110. Each DNA concentration was measured using qPCR to determine 
the cycle signal associated with each cell density. Colon model treatments were analysed 
by RT-qPCR and total cfu calculated for each treatment. 
4.2.5.3. DNA extraction, 16S sequencing and metagenomics analysis 
For DNA extraction, 16S rRNA amplification and sequencing and 16S-based metataxonomic 
analysis, 3 ml of each aliquot at different time points was treated for DNA extraction using 
the FastDNA Spin Kit for Soil (MP Biomedicals, USA) following manufacturer’s guidelines. 
Total DNA concentration was measured by Qubit 3 (Invitrogen, UK) and normalized. The V4 
region of the 16S rRNA gene was used for high throughput sequencing using the Illumina 
Miseq platform with primers 515F and 806R [273]. Data analysis were conducted using the 
Quantitative Insights into Microbial Ecology (QIIME2 version 2018.11) [226].  
4.2.5.4. Quantification of SCFA 
SCFA were measured using 1H-NMR as described in section 2.4.1.2. 
4.3. Results 
4.3.1. Antimicrobial activity 
L. gasseri LM19 showed antimicrobial activity against both Gram-positive and Gram-
negative pathogens (Table 4.2). The assay method affected the outcome, and it was noted 
that fewer strains were sensitive to the cell free supernatant than to cells grown on a plate.  
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Table 4.2. Summary of inhibitory activity of L. gasseri LM19 against different indicator 
strains. Different methods were tested.  
 Overlay Cross-
streak 
Drop 
test 
Filter 
disc 
Well-
diffusion 
S. enterica LT2 - - - - - 
E. coli ATCC 25922 - - - - - 
C. sakazakii NCTC 11467 - ++ - - - 
C. perfringens NCTC 
3110 
+ + - - - 
L. innocua NCTC 11288 - ++ - - - 
L. bulgaricus 5583 +++ +++ - ++ +++ 
C. jejuni NCTC 11168 np np np + np 
M. luteus FI10640 - ++ - + - 
 
-, No activity; +, 1 mm radius inhibition zone; ++, 1-5 mm radius inhibition zone; +++, >5 
mm inhibition zone; np, not performed 
4.3.2. Identification of bacteriocin gene clusters  
The sequenced genome of L. gasseri LM19 was assembled into contigs and analysed to 
identify putative bacteriocin clusters. The sequence has been submitted to the NCBI under 
accession number SHO00000000. RAST failed to reveal any clusters of interest; antiSMASH 
3.0 recognised a single Microcin M-like cluster, while BAGEL 4, which specifically targets 
regions with bacteriocin similarities, found three clusters predicted to encode a number of 
potential bacteriocins. Manual investigation confirmed the presence of two clusters, whose 
putative structural peptides showed a high similarity to previously identified antimicrobial 
peptides from Class IIb bacteriocins (clusters 1 and 3), and a helveticin-like protein. The 
latter contained no other bacteriocin-associated genes on the basis of Blastp analysis, 
consisting only of a single gene, the product of which showed 31.9 % identity and 43.1% 
amino acid consensus to helveticin J, which was originally characterised in Lactobacillus 
helveticus following heterologous expression [274]. Table 4.3 summarises current known 
gassericins. 
Cluster 1 (939 bp) is highly similar to the class IIb gassericin K7A cluster (EF392861) with 
99% nucleotide identity. The cluster was predicted to encode two short peptides with 
leader sequences (bact_1 and bact_2) and a putative immunity protein (Figure 4.1A). 
bact_1 and bact_2 show 100% similarity with the gassericin S structural genes gasA and 
gasX respectively [266], while the surrounding genes do not resemble any other genes 
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known to be associated with bacteriocin production. The putative immunity protein 
showed 97% amino acid homology to that of the acidocin LF221A cluster [275].  
Cluster 3 is 9736 bp in length and the associated open reading frames (orfs) 1-8 show a high 
nucleotide homology to the gassericin T cluster from L. gasseri LA158 (AB710328, 99% over 
100% coverage) and the gassericin E cluster from L. gasseri EV1461 (KR08485, 99% over 
95% coverage) (Figure 4.1B). There are two structural peptide-encoding genes, gamA and 
gamX, that are preceded by homologues of the gassericin E cluster as described previously 
[264]. It is likely that they perform the same functions, i.e., gamP, gamK, gamR for 
regulation, gamT and gamC for transport and, after the structural peptides, gamI for 
immunity, although a homologue to gaeX is missing. The predicted GamA peptide has the 
same sequence as GasT, Gas K7B cf and acidocin LF221B cf and has a single amino acid 
difference (W-L) from GasE (4.1). The second putative peptide, GamX, has the same 
sequence as GatX and GaeX, all of which differ by a single amino acid (G-A) from Gas K7 B 
and acidocin LF221B (Figure 4.1B). 
In cluster 3, there are two additional putative structural genes, designated as gamM and 
gamY, which appear to encode a two-component bacteriocin. These putative peptides also 
show some similarity to other two-peptide component gassericins, but to a lesser extent 
than those previously reported (Figure 4.1B). GamY shows similarity to GamM, with 25.4% 
identity and 47.6% consensus, and they both have similarity to K7 A cf (27.5% identity and 
38.8% consensus; 25.3% identity, 44.3% consensus, respectively) and to GamA (18.7% 
identity, 33.3% consensus with GamM). Surrounding gamY and gamM are genes encoding 
a short hypothetical protein with no matches (orf9), followed by a gene encoding a putative 
immunity protein, GamI2, with homology to an enterocin A immunity domain (pfam 08951, 
2.8e-7) and a putative transport accessory protein, GamC2, with some similarity to 
TIGR01295 bacteriocin transport accessory protein (1.18e-9), but also to a thioredoxin 
superfamily cd02947 (5.21e-7). After gamM, there is a further orf14 with no matches, 
followed by a third putative immunity gene with similarity again to pfam 08951 (1.1e-6). 
The genes on either side of the cluster resemble transporters involved in solute or cation 
transport, and so are not predicted to be part of the cluster.  
Chapter IV. Discovery of gassericin M produced by L. gasseri 
 
115 
 
 
Table 4.3. Bacteriocins described in L. gasseri. 
 
Gassericin Amino acid sequence  Molecular 
mass (Da) 
Reference 
A MIEKVSKNELSRIYGGNNVNWGSVAGSCGKGAVMGIYFGNPILGCANGAATSLVLQ
TASGIYKNYQKKR 
5652 [258, 259] 
B1 (N-terminal) NPKVAHCASQIGRSTAWGAVSGAATGTAVGQAVGA-X 6217 [261] 
B2 (N-terminal)  MISKPEKNTLRL-X 4400 [261] 
B3 (N-terminal)  GNPKVAHCASQIGRSTAW-X 6273 [261] 
B4 (N-terminal)  NPKVAHCASQIGRSTAW-X 5829 [261] 
GatX MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACGLG
GAAIGGYLGYKSN 
4763 [262] 
Acidocin 
LF221A α 
MIEKVSKNELSRIYGGNNVNWGSVAGSCGKGAVMEIYFGNPILGCANGAATSLVLQ
TASGIYKNYQKKR 
3393 [263] 
Acidocin 
LF221A 
β(cf) 
MKVLNECQLQTVVGGKNWSVAKCGGTIGTNIAIGAWRGARAGSFFGQPVSVGTG
ALIGASAGAIGGSVQCVGWLAGGGR 
5523 [263] 
Acidocin 
LF221B α 
MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACALG
GAAIGGYLGYKSN 
3393 [263] 
Acidocin 
LF221B β 
MKNFNTLSFETLANIVGGRNNWAANIGGVGGATVAGWALGNAVCGPACGFVGA
HYVPIAWAGVTAATGGFGKIRK 
5542 [263] 
K7 A MIEKVSKNELSRIYGGNNVNWGSVAGSCGKGAVMEIYFGNPILGCANGAATSLVLQ
TASGIYKNYQKKR 
5523 [265] 
K7 A (cf) MKVLNECQLQTVVGGKNWSVAKCGGTIGTNIAIGAWRGARAGSFFGQPVSVGTG
ALIGASAGAIGGSVQCVGWLAGGGR 
3393 [265] 
K7 B MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACALG
GAAIGGYLGYKSN 
4777 [265] 
K7 B (cf) MKNFNTLSFETLANIVGGRNNWAANIGGAGGATVAGWALGNAVCGPACGFVGA
HYVPIAWAGVTAATGGFGKIRK 
5542 [265] 
GasE MKNFNTLSFETLANIVGGRNNLAANIGGVGGATVAGWALGNAVCGPACGFVGAH
YVPIAWAGVTAATGGFGKIRK 
5469 [264] 
GamA 
(=GasT) 
MKNFNTLSFETLANIVGGRNNWAANIGGVGGATVAGWALGNAVCGPACGFVGA
HYVPIAWAGVTAATGGFGKIRK 
5542 This work, 
[132] 
GamX 
(=GaeX) 
MALKTLEKHELRNVMGGNKWGNAVIGAATGATRGVSWCRGFGPWGMTACGLG
GAAIGGYLGYKSN 
4763 This work 
Bact_1 
(=GasS) 
MKVLNECQLQTVVGGKNWSVAKCGGTIGTNIAIGAWRGARAGSFFGQPVSVGAG
ALIGASAGAIGGSVQCVGWLAGGGR 
6060 This work, 
[266]  
Bact_2 
(=GasX) 
MIEKVSKNELSRIYGGNNVNWGSVAGSCGKGAVMGIYFGNPILGCANGAATSLVLQ
TASGIYKNYQKKR 
5451 This work, 
[266] 
GamY MKTLNEQELTQIVGGKGNKGINWANVRCASAVTIGALGGGLAGPGGMVGGFLLGS
GACF 
4105 This work 
GamM MRKINKEELVEITGGFNAAKCAVGTAGGAFSIARGSAAFGVPGMVIGGILGGAAGAL
ASCK 
4124 This work 
X, sequence not available; cf, complemental factor; leader sequences are marked in bold 
where known.  
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Figure 4.1 (A) Cluster LM19 C1, encoding Bact_1 and Bact_2, and Cluster LM19 C3 encoding GamA, GamX, GamY and GamM. (B) Phylogenetic tree of the 
amino acid sequences of putative bacteriocins identified in L. gasseri LM19 in context with the other class IIb gassericins.
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4.3.3. Identification of antimicrobial peptides in culture 
This work was performed by Paula O’Connor at Teagasc Moorepark (Ireland). Cell and 
supernatant extracts from L. gasseri LM19 cultures were fractionated by HPLC and analysed 
by MS and their antimicrobial activity was assessed using L. bulgaricus 6901 as an indicator 
(Figures 4.2 and 4.3). Antimicrobial activity was present in both cells and supernatant 
(Figure 4.2A), with fractions containing the highest activity eluting in 50% and 75% IPA. MS 
shows that all peptide masses of interest are present.  
 
Figure 4.2 (A) Test for antimicrobial activity of cell (C) and supernatant (SN) fractions of L. 
gasseri LM19 culture against L. bulgaricus 6901. (B) MS chromatograms showing peptide 
masses of interest in the cell extracts.  
4.3.3.1. Purification of antimicrobials from cells 
MS analysis of HPLC fractions showed that many of them contained one or more peptide 
masses that were consistent with those predicted by in silico analysis of the genome (Table 
4.3, Figures 4.2 and 4.3). mV response was very low (40 mV compared to around 1000 mV 
from a good producer), suggesting that production and consequently yield was very low. 
Mass corresponding to GamX (4763 Da) was detected in fractions 32-36 (Figure 4.3A). 
Fractions 37-39 showed mass corresponding to GamA, 5541 Da (Figure 4.3B). Masses 
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corresponding to GamY and GamM co-eluted in fraction 49-55, equating with a 10 mV peak 
on the chromatogram suggesting extremely low yield (Figure 4.3C). Fractions 57-60 showed 
the expected mass from Bact_1, 6060 Da (Figure 4.3D). Fractions 85-97 showed putative 
GamM mass, 4126 Da (Figure 4.3E).   
4.3.3.2. Purification of antimicrobials from supernatant 
MS analysis of HPLC fractions 20-97 showed masses corresponding to Bact_1 and GamM. 
Masses corresponding to putative Bact_1 eluted in fractions 59-65, while putative GamM 
mass was detected in fractions 76-97. Masses corresponding to Bact_2 and GamA eluted 
also in the first HPLC fractionation and were fractionated again. GamX eluted in fractions 
86-90 (Figure 4.3E), and also in fractions 66-68, co-eluting with GamA. Putative Bact_1 
eluted in fractions 58-60. GamY eluted in fractions 69-72, and GamM appeared in fractions 
86-91.  
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Figure 4.3. MS chromatograms of fractions showing putative masses for A, GamX, 4763 
Da; B, GamA, 5541 Da; C, GamM, 4126 Da and GamY, 4107 Da; D, Bact_1, 6057 Da; E, 
GamM, 4126 Da; F, Bact_2, 5451 Da. 
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4.3.3.3. Synergy between peptides 
Three sets of fractions were compared, fractions from HPLC run I, fractions from from HPLC 
II run and synthetic peptides resuspended in milli Q water at 1 mg/ml (Figure 4.4A). All 
synthetic peptides except GamY showed antimicrobial activity, with the highest activity 
coming from GamA and Bact_2. Figures 4.4B and C show synergy assays between synthetic 
peptides. We observed clear synergy between Bact_1 and Bact_2 and a possible synergy 
between Bact_1 and GamA. No synergy was observed between GamM and GamY or 
between GamA and GamX.  
 
 
Figure 4.4 (A) Activity of GamX, (X); Bact_2, (2); GamA, (A); Bact_1, (1); GamY (Y); GamM, 
(M) from synthetic peptides and selected fractions from HPLC runs I and II containing 
similar masses; (B) Synergy between the different peptides; (C) Synergy between pairs of 
peptides. 
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4.3.4. Fermentations 
4.3.4.1. Carbon supplementation in media influences the expression levels of 
bacteriocin genes in L. gasseri LM19 
RT-qPCR was used to compare the expression of LM19 genes encoding bacteriocin 
structural peptides/proteins during growth with different carbon sources at 2% (v/v) or in 
the presence of competing microbes over 2 d, corrected on the basis of expression of the 
housekeeping gene encoding gyrase A. Ultimately, it was apparent that each bacteriocin 
gene was expressed at different levels depending on the carbon source that was used 
(Figure 4.5). Bact_1 and bact_2 exhibited a similar pattern across each treatment and time. 
There was very little expression during growth without a carbon supplement or with starch, 
and a tendency for higher expression of bact_1 and bact_2 with simple sugars rather than 
inulin or pectin. All genes were expressed during co-culture with other bacteria, but no 
significant changes were seen when compared to glucose alone. In contrast, the helveticin 
J-like gene showed increased expression in the absence of a carbon supplement and with 
the complex carbohydrates inulin, starch and pectin and, after 48 h, disaccharide lactose in 
comparison with the glucose control. Expression was not increased in co-culture. Indeed, 
the presence of E. coli caused a slight repression. The genes encoding GamA and GamX also 
showed similar behaviour to each other in that, although expression at 24 h without a 
carbon supplement was higher than that with glucose, this effect was lost at 48 h. 
Expression was lower with inulin and pectin at 24 h and at 48 h. Co-culture did not have a 
large effect, but expression after 48 h growth with S. enterica was slightly lower than in the 
absence of the pathogen. Genes encoding GamM and GamY differed from other putative 
bacteriocin-encoding genes in that an upregulation of their expression was observed at 48 
h in the absence of carbon supplementation. The same behaviour was observed with inulin 
supplementation, while starch expression was high at 24 h but lower at 48 h. As with gamA 
and gamX, 48 h co-culture with S. enterica LT2 lowered their expression levels.  
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Figure 4.5. Gene expression levels of bacteriocin genes present in L. gasseri LM19 genome 
when grown in home-made MRS supplemented with different carbohydrate sources. (N, 
no carbohydrate; Gl, glucose; L, lactose; G, galactose; I, inulin; S, starch; P, pectin; L.b. L. 
bulgaricus; S. e., S. enterica and E. c. E. coli). *, significant difference to glucose, p<0.05. 
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4.3.4.2. Different levels of available glucose affect the expression of bacteriocins in  
L. gasseri LM 19 in different ways 
Given the differences in the expression levels of the bacteriocin genes in L. gasseri LM19 in 
the absence of a carbon source supplement, the impact of growing in lower percentages of 
glucose was tested. The results confirmed previous observations, i.e., expression of bact_1 
and bact_2 genes was increased in line with increases in glucose availability, while 
expression of the helveticin J-like gene showed the opposite pattern. Expression levels of 
genes encoding GamA, GamX, GamM and GamY were increased in the absence of carbon 
supplementation at 48 h (Figure 4.6).  
4.3.4.3. Complex polymers increase viability of L. gasseri LM19  
L. gasseri LM19 was grown in colon model medium, simulating gut conditions, or home-
made MRS - alone or supplemented with simple sugars (glucose, lactose and galactose) or 
complex polymers (inulin, starch and pectin). In general, more viable cells were recovered 
from MRS; growth on simple sugars was highest at 24 h but, at 48 h, complex carbohydrates 
gave higher counts (Figure 4.7A). Interestingly, growth on no carbon source at 48 h was 
similar to that with simple sugars. On batch model medium, cell counts with glucose were 
lower than with all other treatments, and starch and pectin improved growth in at 48 h. 
Antimicrobial activity from batch model medium with glucose was almost as high as that 
from MRS despite a c. 3 log difference in cfu (Figure 4.7B). Glucose and galactose 
supplementation showed the highest antimicrobial activity at 24 h, however, after 48 h, 
complex carbohydrates produced the highest activity. At 48 h, higher levels of antimicrobial 
activity correlate with lower levels of pH and higher levels of cfu, suggesting that activity is 
related to bacterial numbers. The changes in activity with carbon supplementation over 
time suggest control of antimicrobial production in different nutritional environments.  
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Figure 4.6. Gene expression levels of bacteriocin genes present in L. gasseri LM19 genome when grown in home-made MRS supplemented with different 
glucose percentages. *, significant difference to glucose 2%, p<0.05. 
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Figure 4.7 (A) Cfu counts of L. gasseri LM19 recovered when grown in batch model media 
or home-made MRS supplemented with different carbon sources. (B) Antimicrobial activity 
of cultures in (A) measured by well diffusion assay (Figures above bars indicate mean pH) 
No S, no supplementation; G, glucose; L, lactose; Gal, galactose; I, inulin; S, starch and P, 
pectin. 
4.3.5. Colon model 
4.3.5.1. Survival of L. gasseri LM19 and C. perfringens in an in vitro colon model 
L. gasseri LM19 was transformed with a plasmid expressing chloramphenicol resistance to 
allow selection and enumeration of this strain from within a mixed microbial community. 
Transformation of electrocompetent cells gave an efficiency of 1.07x102 transformants/ng 
of DNA. Fermentations with three different faecal donors were performed with four vessels 
per fermentation inoculated with L. gasseri LM19-pUK200, C. perfringens NCTC 3110, L. 
gasseri with C. perfringens, or a media control. L. gasseri numbers recovered increased 
from 5.3, 5.22 and 5.22 Log10 cfu/ml in donors 1, 2 and 3, respectively at 4 h, to 6.12, 6.39 
and 6.36 Log10 cfu/ml at 8 h and 7.30, 7.31 and 7.47 Log10  cfu/ml at 24 h. However, after 
48 h, levels of recovery dropped to 3.66, 4 and 3.72 Log10 cfu/ml.  
C. perfringens levels were measured by qPCR, which detects DNA from both live and dead 
cells. Addition of L. gasseri LM19 did not have a negative effect on the C. perfringens 
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population in the fermentation with faecal sample from donor 1; there was a tendency to 
lower C. perfringens counts in co-culture at 24 h with donors 2 and 3, but the changes were 
not significant (Figure 4.8).  
 
Figure 4.8. C. perfringens NCTC 3110 population in the presence of L. gasseri LM19 in three 
different faecal fermentations measured by RT-qPCR. 
4.3.5.2. Bacteriocin gene expression 
PCR amplification of cDNA obtained from colon model samples using primers to detect the 
bacteriocin genes bact_1, bact_2, helveticin-J like, gamA, gamX, gamM and gamY, showed 
detectable levels of bacteriocin gene expression at 24 h (Figure 4.9). At 48 h, expression of 
only helveticin-J like, gamM and gamY was detected (data not shown).  
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Figure 4.9. Expression of bacteriocin genes in colon model at 24 h with donor 1. Lane 1, 
negative control; lane 2, bact_1; lane 3, bact_2; lane 4, gamA; lane 5, gamX; lane 6, helvJ; 
lane 7, gyrA; lane 8, cper; lane 9, molecular marker; lane 10, bact_1; lane 11, bact_2; lane 
12, gamA; lane 13, gamX; lane 14, helvJ; lane 15, gyrA; lane 16, gamI3; lane 17, cper; lane 
18, gamM; lane 19, gamY; lane 20, molecular marker; lane 21 gamM; lane 22, gamY. 
4.3.5.3. Impact of L. gasseri LM19 on gut microbiota composition 
Analysis of relative abundance at order, family and genus level was conducted using 16S 
rRNA metagenomics. The initial bacterial composition was, as expected, different between 
the three donors (Figure 4.10). Bacterial populations from donor 1 remained relatively 
stable over 24 h. The addition of L. gasseri LM19, C. perfringens or both did not result in a 
significant increase in proportions of Lactobacillales or Clostridiales, and all three 
treatments resulted in similar increases in Bifidobacteriales and Coriobacteriales relative 
to the control, with the L. gasseri LM19 with C. perfringens more similar to the L. gasseri 
LM19 alone.  
The initial population from donor 2 was constituted mainly of Clostridiales, with some 
Bacteroidales, Coriobacteriales and Bifidobacteriales. A change can be observed at 24 h in 
both the control and the samples where L. gasseri LM19 or L. gasseri LM19 with C. 
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perfringens were added, with an increase in Lactobacillales along with a small increase in 
Enterobacteriales. The decrease in relative abundance of Bifidobacteriales and 
Coriobacteriales in the control, L. gasseri and C. perfringens + L. gasseri treatments was 
statistically significant (p<0.05) and not observed in the C. perfringens sample. C. 
perfringens alone appeared to prevent the overgrowth of Lactobacillales, while 
Clostridiales were decreased, being replaced by Enterobacteriales, Bacteroidales, 
Coriobacteriales and Bifidobacteriales. It was noted that addition of L. gasseri LM19 with 
C. perfringens gave a profile with more similarity to the control or L. gasseri LM19 samples.  
In L. gasseri LM19 treatment of donor 3 samples, Bifidobacteriales and Enterobacteriales 
increased over time in a similar way to the control, but Clostridiales were almost 
completely replaced by Lactobacillales. This rise was not as large when the L. gasseri LM19 
was co-inoculated with C. perfringens, while addition of C. perfringens alone did not 
manage to maintain levels of Clostridales, with increases seen in Enterobacteriales, 
Bifidobacteriales and Lactobacillales. In this case, the L. gasseri LM19 + C. perfringens 
treatment at 24 h was more similar to the control, with the exception of the presence of 
Lactobacillales, suggesting that the C. perfringens effect on the microbial composition was 
changed by the inoculation with L. gasseri.  
4.3.5.4. SCFA analysis 
Increases in the production of formic, acetic, propionic and butyric acids were observed in 
the three faecal fermentations in colon model conditions inoculated with L. gasseri LM9. 
However, there was a high variability in SCFA production between the three donors (Figure 
4.11). In donor 1, production of SCFA, ethanol, succinate and, at 8 h only, lactate was 
increased compared to the control. In donor 2 there were notable increases in lactic acid 
from 4 h. Given the similar relative abundance of Lactobacillales (Figure 4.10) in control 
and L. gasseri treatment, this suggests an influence of L. gasseri LM19 on the native 
microbiota 
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Figure 4.10. Representation of relative abundance at order level in the faecal batch model 
fermentation for the three donors.  
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Figure 4.11. Production of SCFA in batch model faecal fermentation using inoculum from three different donors: blue, formate; orange, acetate; red, 
propionate; purple, butyrate; green, lactate.  
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4.4. Discussion 
This work reports the ability of L. gasseri LM19 isolated from human breast milk 
microbiome to exhibit antagonistic activity against different enteropathogens via the 
production of previously identified bacteriocins as well as one novel gassericin M. From 
these investigations, it became apparent that different media and carbon sources influence 
the expression of these bacteriocin genes. Furthermore, we have confirmed the ability of 
L. gasseri LM19 to survive and express these antimicrobial genes in a complex faecal 
environment under simulated colon conditions. Additionally, other characteristics that are 
considered desirable, such as the increase in SCFA production in a faecal fermentation, 
were studied. 
The presence of bacteria in human breast milk has been reported previously and the 
existence of a bacterial entero-mammary pathway has recently been proposed. [276]. 
These bacteria might have a gut origin and that could explain their ability to survive in GI 
tract conditions and exhibit antagonistic traits against other gut bacteria such as 
enteropathogens that might share the same environment. Gassericins are antimicrobial 
peptides that have been identified originally in L. gasseri. Several gassericins have been 
identified in sets of four, both two-peptide class II bacteriocins. K7 bacteriocins are a variant 
of acidocins LF221 and share similar sequences to GasT and its complementary peptide 
GatX, respectively, while GasE could be considered a variant of GasT. These two-
component bacteriocins also show similarities with other two-component bacteriocins 
isolated from species previously grouped with L. gasseri [129]. L. gasseri LM19 also 
presents two clusters of bacteriocins that show homology to acidocin LF221A and Gas K7A 
on one hand and acidocin LF221B and Gas K7B on the other hand. But additionally, it can 
be observed the presence of structural genes corresponding to a new two-component 
bacteriocin that show a greater variation in sequence to previously described gassericins.   
Partial purification of the products of these structural genes was conducted and it was 
observed the presence of masses matching the expected size in eluted fractions that 
exhibited antimicrobial activity. Particularly, masses predicted to match those of the new 
potential peptides GamM (4124 Da) and GamY (4105 Da) were associated with 
antimicrobial activity. Synthetic peptides confirmed the activity of GamM but GamY did not 
show activity or synergy with GamM. Synergistic activity was reported previously between 
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GasT and GatX and between the two components of gassericin S (here Bact_1 and Bact_2) 
respectively [266]. While Bact_1 and Bact_2 showed synergistic activity our GasT and GatX 
homologues, GamA and GamX, did not. However, it was observed a possible synergistic 
activity between GamA and Bact_1.  
It was demonstrated that L. gasseri LM19 is able to survive in simulated colon conditions 
within a complex faecal microbiota. Moreover, it is capable of expressing the bacteriocin 
genes in this context. In previous work it was demonstrated that another probiotic L. 
gasseri, strain K7, able to produce both two-component bacteriocins K7 A, K7 A (cf), K7 B 
and K7 B (cf), was able to survive in faecal samples. Its bacteriocins were also targeted by 
using conventional PCR and RT-qPCR [271]. The authors noted that bacteriocin genes were 
detected by PCR from other LAB species. However, in these controls and treatments where 
L. gasseri LM19 was not present, no PCR products were detected.  
L. gasseri LM19 showed mixed effects on a population of C. perfringens added to faecal 
fermentations of three different donors, causing a slight decrease in C. perfringens in only 
two out of three fermentations. This might indicate that the surrounding microbiota might 
play a synergistic or antagonistic role on the effect of L. gasseri LM19. However, it should 
be noted that in antimicrobial assays C. perfringens was only inhibited by L. gasseri LM19 
cells, not cell-free supernatant, which might suggest that they should be in close proximity 
for an antimicrobial effect. However, co-inoculation of L. gasseri LM19 with C. perfringens 
did seem to alter the effect of C. perfringens on the background microbiota in all three 
donors, the profiles seen after addition of L. gasseri LM19 with C. perfringens were more 
similar to L. gasseri alone or control samples than to samples containing only C. perfringens. 
Colon model fermentations also allowed to quantify production of formic, acetic, propionic 
and butyric acids using NMR. It was observed an increase in SCFA production in the faecal 
fermentation of the three donors. However, as with the microbial composition, the amount 
of each SCFA produced was very different from one donor to another, which might be 
related to production by other members of the microbiota that varied between the three 
donors. In a previous study of consumption of a beverage prepared with L. gasseri CP2305, 
the stools of the participants presented an increased level of SCFA too, while the microbiota 
experienced some alterations, including an increase in the presence of bacteria from 
Clostridium cluster IV, known for producing higher amounts of SCFA [277]. They could not 
conclude if the increase of SCFA was due to the effect of L. gasseri or due to the 
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proliferation of bacteria that produced more SCFA. SCFA production will also depend on 
diet and availability of nutrients in the gastrointestinal tract as well as the resident 
microbiota [278, 279].  
This work shows the ability of L. gasseri LM19, a multi-bacteriocin breast milk isolate, to 
survive in colon conditions. Its ability to express different bacteriocin genes, including a 
novel gassericin M, under these conditions, makes it a candidate for further application 
studies.  
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5.1. Introduction 
Nisin is a small peptide with antimicrobial activity against a wide range of pathogenic 
bacteria.  It was identified originally from a Lactococcus lactis subsp. lactis isolated from a 
dairy product [280] and classified as a class I bacteriocin because it is ribosomally 
synthesised and post-translationally modified [70]. Nisin has been studied extensively and 
its use has been extended to a wide range of applications in the food industry, biomedicine, 
veterinary and research fields [281-284]. It is approved as a food preservative by the Food 
and Agriculture Organisation and is Generally Recognized As Safe (GRAS) by the United 
States Food and Drug Administration [282].  
Structurally, nisin is considered a lantibiotic because it contains lanthionine (Lan), an 
unusual amino acid formed by two alanine residues linked by a sulphur atom through their 
β-carbon [282]. Other unusual amino acids present in nisin are dehydroalanine (Dha), 
dehydrobutyrine (Dhb) and β-methyl-lanthionine [282]. Nisin activity and stability are 
closely related to its structure and it can be altered by pH changes. When the pH rises, the 
activity decreases as a consequence of alterations in structure, and therefore, nisin is more 
stable at lower pHs. Nisin is heat-stable and also exhibits high stability at low temperatures, 
which makes it suitable for freeze-storage [285].   
Nisin has nine natural variants reported at the moment (Table 5.1, Figure 5.1). When nisin 
A was purified, four forms were isolated, named A, B, C and D [286], with A the most 
abundant. Another nisin form, named nisin E, was isolated some time later [287]. Nisin Z 
was described as the first natural variant of nisin A. They differ in the presence of an 
asparagine amino acid in position 27 instead of a histidine residue [288]. This variation has, 
in comparison, very little effect on most of the properties of the two molecules, such as 
antimicrobial activity, thermal and pH stability, but affects the solubility of the molecule, 
with nisin Z being more soluble at neutral pH [289] . A study of its distribution also revealed 
that the nisin Z variant was more widespread than the A variant [289]. Nisin Q was another 
variant that was identified in an environmental L. lactis and it was different from the 
original nisin A in the presence of a valine, leucine, asparagine and another valine in 
positions instead of alanine, methionine, histidine and isoleucine respectively [290]. Nisin 
F, produced by L. lactis isolated from fish gut, also has asparagine and valine in positions 
21 and 30 [291]. Nisin U and U2 were two new variants reported by Wirawan et al produced 
for the first time by a different species than L. lactis [292]; Streptococcus uberis strain 42 
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was isolated from bovine mammary secretions [293] and the nisin U and U2 variants that 
are produced were different to nisin A by nine and ten amino acids respectively. Nisin H, 
produced by S. hyointestinalis, was the first nisin variant isolated from a representative of 
a mammalian gastrointestinal (GI) tract (porcine) [61] and has five different amino acids in 
positions 1, 6, 18, 21 and 31. Recently, the nisin O operon has been reported, present in a 
Blautia obeum isolated from human gastrointestinal (GI) tract [92]. Unusually this operon 
has 4 structural genes, the first 3 being identical in the core peptide and have similarity to 
nisin U, and the fourth shows the highest variation compared to nisin A. Nisin P is predicted 
to be three amino acids shorter than nisin A in the C-terminus and differs to nisin A in ten 
amino acids (Figure 5.1). The Nisin P operon has been identified in the genomes of two 
Streptococcus species [294, 295] but its activity had not been reported before. 
Streptococcus agalactiae DPC 7040 was isolated and identified from human faeces by Dr. 
James Hegarty at Teagasc Moorepark. Its genome was sequenced and assembled by Dr. 
Catriona Guinane and using BAGEL3 identified a nisin P cluster, although it was not curated. 
Following their work, I curated the nisin P cluster and, after purification performed by Paula 
O’Connor at Teagasc Moorepark, I performed an in vitro characterisation of its activity, in 
comparison with the activities of nisin A and nisin H. The first approach was related to its 
inhibitory activity towards other nisin producers (cross-immunity assays) and testing its 
spectrum of action. After that, I performed minimum inhibitory concentration assays (MIC) 
to determine its potency as an antimicrobial in comparison with nisin A, and a faecal 
fermentation experiment was conducted to identify their effect on the faecal microbiota 
numbers. Additionally, a brief regulation experiment was carried out to determine its 
ability to induce the nisin A operon.  
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Table 5.1. Summary of nisin variants reported in the literature 
Nisin variant First reported in Reference 
A L. lactis subsp. lactis  [280] 
Z L. lactis strain NIZO 22186 (dairy product) [288] 
Q L. lactis 61-14 (Japanese river water) [290] 
F L. lactis F10 (freshwater catfish) [291] 
U and U2 S. uberis strain 42 (bovine mammary secretions) [292] 
P Streptococcus gallolyticus subsp. pasteurianus [294] 
H S. hyointestinalis DPC 6484 (porcine intestine) [61] 
O Blautia obeum A2-162 (human GI tract) [92] 
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Figure 5.1. Predicted ring structures of nisin natural variants. Residues highlighted in yellow 
depict amino acid changes when compared to nisin A. 
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5.2. Methods 
5.2.1. Optimisation of growth conditions for nisin P production 
S. agalactiae DPC 7040 was grown under different conditions and the activity of the 
supernatant was tested for antimicrobial activity. It was grown for 24, 48 and 72 h in BHI, 
MRS and TSB, both in aerobic and anaerobic conditions and in presence of 500 ng/ml of 
nisin A for induction purposes. 1 ml of each culture was tested each day by well-diffusion 
assay using L. bulgaricus 5583 as an indicator strain. Antimicrobial activity was measured 
in activity units per ml (AU*ml-1) [296, 297]. For this purpose, a serial 1:2 dilution was 
performed, and each fraction tested as stated. 
5.2.2. Extraction and purification of nisin A, H and P 
Nisin P, A and H were extracted and purified by Paula M. O’Connor at Teagasc Moorepark 
(Ireland). Nisin P production required initial induction with 500 ng/ml of nisin A which was 
included in all S. agalactiae DPC 7040 subcultures.  Nisin P was purified from 2 litres of S. 
agalactiae DPC 7040 grown anaerobically in BHI for 48 h, (2.0 x 108 cfu/ml). Cell-free 
supernatant was obtained by centrifuging the culture at 8,000 x g, 10 min. Culture 
supernatant was applied to a 30 ml SP Sepharose column pre-equilibrated with 20 mM 
sodium acetate pH 4.4. The column was washed with 100 ml of 20 mM sodium acetate pH 
4.4 and then eluted with 150 ml of 20 mM sodium phosphate buffer pH 7 containing 1M 
NaCl. The NaCl-containing eluate was applied to a 60 ml, 10 mg Strata–E C18 SPE column 
(Phenomenex, UK) pre-equilibrated with methanol and water. The column was washed 
with 60 ml 30% ethanol and antimicrobial activity eluted with 70% 2-propan-ol 0.1% TFA 
(IPA). The IPA sample was applied to a semi preparative Proteo Jupiter (10 x 250 mm, 90Å, 
4µ) RP-HPLC column (Phenomenex, Cheshire, UK) running a 30-37% acetonitrile 0.1% TFA 
gradient where buffer A was 0.1% TFA and buffer B was 100% acetonitrile, 0.1% TFA. The 
eluate was monitored at 214 nm and fractions were collected at intervals. Nisin P 
containing fractions deemed pure by MALDI TOF mass spectrometry were lyophilised using 
a a Genevac lyophiliser (Suffolk, UK). Nisin H was purified from 2 l of culture (1.2 x 108 
cfu/ml) grown overnight at 37 °C in TSB without induction and purified as per nisin P except 
a 25-40% acetonitrile 0.1%TFA gradient was used for HPLC purification.  Nisin A was purified 
from nisin A supplied by Handary SA (Belgium) by reversed phase HPLC using a 25-45% 
acetonitrile 0.1% TFA gradient as described above. 
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Nisin P, H and A HPLC fractions containing antimicrobial activity against L. bulgaricus were 
analysed via MALDI-TOF MS to determine the molecular mass of the peptides and to assess 
their purity. HPLC fractions deemed pure by MALDI-TOF MS were combined and were 
lyophilised in a Genevac lyophiliser. MALDI-TOF mass spectrometry was performed with an 
Axima TOF2 MALDI-TOF mass spectrometer in positive-ion reflectron mode (Shimadzu 
Biotech, UK).  
5.2.3. Nisin P structure  
Purified nisin P was analysed for mass and structure confirmation by Dr. Gerhard Saalbach 
at the John Innes Centre (JIC) in Norwich. The intact peptide was analysed by LC-MS on a 
Synapt G2-Si mass spectrometer coupled to an Acquity UPLC system (Waters, UK). Aliquots 
of the sample were injected onto an Acquity UPLC® BEH C18 column, 1.7 µm, 1x100 mm 
(Waters, UK) and eluted with a gradient of 1-50% acetonitrile in 0.1% formic acid in 9 min 
and then ramped to 100% acetonitrile in 1 min at a flow rate of 0.08 ml min-1 with a column 
temperature of 45°C. 
The LCMS was operated in positive MS-ToF resolution mode and with a capillary voltage of 
3 kV and a cone voltage of 40 V in the range of m/z 100–2000. Leu-enkephalin peptide 
(1 ng ml−1, Waters) was infused at 10 µl min−1 as a lock mass and measured every 20 s. 
Masslynx 4.1 software (Waters, UK) was used to generate the spectra by combining several 
scans. The peaks were centred, and the mass calculated from the monoisotopic peak. 
For structure confirmation, purified nisin P was digested with trypsin and analysed using 
nanoLC-MS/MS on an Orbitrap Fusion™ Tribrid™ Mass Spectrometer coupled to an 
UltiMate® 3000 RSLCnano LC system (Thermo Scientific, UK). The samples were loaded and 
trapped using a pre-column which was then switched in-line to the analytical column for 
separation. Peptides were separated on a nanoEase m/z column (HSS C18 T3, 100 Å, 1.8 
µm; Waters, UK) using a gradient of acetonitrile at a flow rate of 0.25 µl min-1 with the 
following solvent steps A (water, 0.1% formic acid) and B ( 80% acetonitrile, 0.15 formic 
acid): 0-4 min 3% B (trap only); 4-15 min increase to 13% B; 15-77 min increase to 38% B;77-
92 min increase to 55% B; followed by a ramp to 99% B and re-equilibration to 3% B. 
Data dependent analysis was performed using parallel CID and HCD fragmentation with the 
following parameters: positive ion mode, orbitrap MS resolution = 60k, mass range 
(quadrupole) = 300-1800 m/z, MS2 top20 in ion trap, threshold 1.9e4, isolation window 1.6 
Da, charge states 2-5, AGC target 1.9e4, max inject time 35 ms, dynamic exclusion 1 count, 
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15 s exclusion, exclusion mass window ±5 ppm. MS scans were saved in profile mode and 
MS2 scans were saved in centroid mode.  
MaxQuant 1.6.2.3 was used to generate recalibrated peak lists, and the database search 
was performed with the merged HCD and CID peak lists using Mascot 2.4.1 (Matrixscience, 
UK). The search was performed, with a precursor tolerance of 6 ppm and a fragment 
tolerance of 0.6 Da, on a S. agalactiae protein sequence database, which included the nisin 
P gene cluster (Uniprot, January 2018, 2,123 sequences) to which the nisin P peptide 
sequence had been added. The enzyme was set to trypsin/P with a maximum of 2 allowed 
missed cleavages. Dehydration (−18 Da) of serine and threonine, oxidation of methionine 
and carbamido-methylation (CAM) of cysteine were set as variable modifications. The 
Mascot search results were imported into Scaffold 4.4.1.1 (www.proteomsoftware.com) 
using identification probabilities of 99% for proteins and 95% or 0% for peptides, as 
discussed in the results. 
5.2.4. pH stability of nisin P compared to nisin H and A 
Nisin P, A and H were resuspended at 1 µg/ml of distilled water. Duplicate samples at pH 
3, 5, 6, 7 and 8 were prepared for each nisin.  Antimicrobial activity was tested at 24, 48 
and 72 h via well-diffusion assay by adding 50 µl of each solution to a well previously made 
in the agar containing L. bulgaricus 5583 as indicator and incubating the plates overnight 
at 37 oC anaerobically.  
5.2.5. Cross- immunity assays 
Cross immunity assays were conducted by well diffusion assay to test the activity of the 
purified nisin P and nisin A against natural nisin A, P, H and U producers. For that purpose, 
100 μl of an overnight inoculum of each indicator strain was added to 20 ml of melted agar 
media. 50 μl of pure peptides at 0.20 mg/ml were added to a well pre-formed in the agar 
and incubated overnight according to the growth requirements of the different nisin 
producers used as indicator strains. Growth of the indicator strain in the presence of 
peptide was taken as confirmation of immunity. Blastp analysis was performed on the 
proteins responsible of the immunity system, NisF, functioning as an ATPase, and NisE and 
NisG, the membrane spanning domain of the transporter, of natural producers of nisin A, 
P, H and U.  
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5.2.6. Spectrum of inhibitory activity 
Well diffusion assays were performed to determine the inhibitory targets of nisin P in 
comparison with nisin A. 50 µl of the purified peptides at a concentration of 0.2 mg/ml 
were added to wells preformed in agar inoculated with the different indicator strains. 
Inoculation consisted of adding 100 µl of an overnight culture of the indicator strain to 20 
ml of melted agar and incubating overnight under the requirements of the indicator strain. 
Inhibitory activity was determined by the absence of growth around the well.  
5.2.7. Activity induction 
Experiments were performed using L. lactis NZ9000 pNZ8150 gfp+, where gfp acts as a 
reporter of expression from a nisin inducible promoter [298]. An overnight culture of this 
strain was diluted 1:100 into fresh media and incubated until the OD600 reached 0.5. 
Purified nisin P, A and H were added to 1 ml of GM17 at a concentration of 1 mg/ml, 10 
μg/ml, 1 μg/ml, 500, 100, 20, 10, 5, 2 and 1 ng/ml and a further 20 µl of the L. lactis NZ9000 
pNZ8150 gfp+ were added to the mix. 200 µL were transferred to black 96-well plates 
(NuncTM, ThermoFischer, UK) and GFP was detected using a Synergy HT Microplate reader 
(BioTek, UK). The excitation filter was set at 485 nm and the emission filter at 528 nm.  
5.2.8. MicroMatrix fermentations 
5.2.8.1. Preparation of a faecal standard 
A faecal standard for fermentation in a micro-Matrix was prepared following methodology 
described by O’Donnell et al [299]. The samples of six healthy donors with no antibiotic 
treatment in the previous six months were collected and maintained at 4oC for 1-2 hours 
before being transferred to an anaerobic chamber (5% CO2, 10% H2 and 85% N2) for 
processing. 200 g of faeces in total were placed in a stomacher bag with 200 ml of 50 mM 
phosphate buffer containing 0.05% (w/v) cysteine hydrochloride. After filtering and 
homogenizing, the faecal slurry was centrifuged (4,000 x g, 25 min, Sorvall 3000 centrifuge) 
and re-suspended in 50 mM phosphate buffer. Sterile glycerol was added to the mix to a 
final concentration of 25% and aliquots were stored at -80oC until required.  
5.2.8.2. MicroMatrix fermentation 
Faecal standards were defrosted at 37oC before use and prepared at 10% concentration in 
faecal medium as described by Fooks and Gibson [300]. 2 ml of the mix were added to each 
well of a MicroMatrix 24-well cassette (Applikon ® Biotechnology, Netherlands). Purified 
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nisin A, P and H were added to the wells to a final concentration of 15 and 50 µM.  
Fermentations took place for 24 h at 37 °C, with pH of the medium adjusted and maintained 
to 6.8 in a MicroMatrix fermenter (Applikon ® Biotechnology). At time point 8 h, half of the 
wells received an additional dose of nisin A, P and H in the same concentration as at time 
0 h. 500 μl aliquots were withdrawn from each well at time points 0, 8, 24 h (T0, T8, T24) 
and kept frozen for further analysis.   
5.2.8.3. qPCR 
200 μL of aliquots from each Micro-Matrix fermentation were taken for DNA extraction 
using QIAmp Fast DNA Stool Mini Kit (Qiagen, Crawley, UK), following the manufacturer’s 
instructions. To compare total cell numbers with live cells, ethidium bromide monoazide 
(EMA) treatment was performed by adding EMA to the sample at a concentration of 10 
µg/ml, incubating the samples in darkness for 5 min and exposing them to 70-Watt HQI 
light for 10 min at 20 cm while keeping the samples on ice [301, 302]. Samples were then 
centrifuged at 12,000 g for 5 min and the supernatant discarded before proceeding with 
the standard DNA extraction with QIAmp Fast DNA Stool Mini Kit. Absolute quantification 
by qPCR was performed to determine bacterial numbers, using the Roche LightCycler 480 
II platform. To quantify 16S bacterial counts, a standard curve was created using 1010 to 
100 copies of 16S rDNA/μL. For amplification, 16S rRNA primers used were CO1 forward 
primer (5′-AGTTTGATCCTGGCTCAG-3′), and CO2 reverse primer (5′-TACCTTGTTACGACT-3′) 
[211] and KAPA Lightcycler 480 mix (KAPA Biosystems Ltd., UK) according to manufacturer’s 
instructions. All samples were run in triplicate. qPCR conditions are summarised in section 
2.2.8.3.  
5.3. Results  
5.3.1. Characterisation of the nisin P cluster from S. agalactiae DPC 7040 
The prototypical nisin A gene cluster consists of the structural gene nisA, followed by 
nisBCIPRKFEG [303]. In contrast the nisin P gene cluster in S. agalactiae DPC7040 has a 
similar gene order but nipPRKFEG genes have translocated to the front of the nipA 
structural, a phenomenon which also occurs in  nisin U [229] (Figure 5.2). This was observed 
when the nisin P gene cluster was first reported [295]. 
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Figure 5.2. Representation of the bacteriocin-encoding nisin P gene cluster compared to 
the nisin A operon. Figures indicate percentage of similarity with nisin A homologues. 
5.3.2. Extraction and purification of nisin P 
Nisin P and nisin H are produced by Streptococci that require complex media (BHI and MRS 
respectively) for growth and bacteriocin production. Nisin P production by S. agalactiae 
DPC7040 also required initial induction by nisin A, taking advantage of the inducing activity 
of nisin peptides [304]. The highest antimicrobial activity was achieved when S. agalactiae 
DPC7040 was cultured in BHI broth under anaerobic conditions for 48 h and induced with 
500 ng/ml of nisin A (Figure 5.3). Purification was achieved by a four-step process using 
Amberlite XAD16N, SP Sepharose, C18 SPE and Reversed phase HPLC. Overall yield was very 
low, i.e., 0.2-0.35 mg/l for nisin H and 0.1-0.2 mg/l for nisin P (Figure 5.4), while the yield 
for nisin A production was 3-4 mg/l. The lower yield obtained for nisin H and P could be 
partially due to less efficient purification, but it is most likely due to lower production of 
bacteriocin due to lower cell numbers, typically in the range of 108 for S. hyointestinalis and 
S. agalactiae compared to 109 cfu/ml for the nisin A producer, L. lactis NZ9000.  
 
 
Figure 5.3. Inhibitory areas of nisin A and nisin P against indicator strain L. bulgaricus 
DPC5583. 
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Figure 5.4. Purification of nisin P from S. agalactiae DPC7040 and nisin H from S. 
hyointestinalis DPC6484 cultures. For nisin P: (A) RP-HPLC chromatogram and (B) MALDI 
TOF MS of the active fraction number 24. Expected mass for nisin P is 2991 Da. For nisin H: 
(A) Fractionation of cell samples eluted from the Jupiter Proteo column; (B) MS detail of 
fraction 30 showing mass corresponding to the expected nisin H mass of 3453 Da.  
5.3.3. Prediction of nisin P structure 
5.3.3.1. Intact peptide 
The purified nisin P peptide was tested by Dr. Gerhard Salbaach (John Innes Centre) to 
confirm that the expected peptide was intact (Figure 5.5A). The extracted-ion 
chromatogram (XIC) shows the recovered nisin P at 9.56 min (Figure 5.5B). The base peak 
intensity chromatogram shows that some impurities were found (12.55 min), but presence 
of intact nisin P was confirmed (Figure 5.5C).  
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Figure 5.5. Spectra originated from LC-MS analysis of purified nisin P. (A) Elution gradient 
of 1-50% acetonitrile in 0.1% formic acid in 9 min and to 100% acetonitrile in 1 min (B) 
Extracted-ion chromatogram (XIC) of nisin P. (C) Base peak intensity chromatogram (BPI) 
for nisin P. 
 
Possible modifications were further assessed by the analysis of the eluted samples, that 
showed a series of charge states ranging from 5+ to 2+ (Figure 5.6A). The most abundant 
isotope was the one showing a charge state of 4+. A more detailed analysis of this isotope 
pattern showed a m/z value of 2987.3841, that matched the expected dehydrated mass of 
nisin P (m/z 2987.3922) (Figure 5.6B). The mass calculation is performed by multiplying per 
4 the 747.8533 ion mass and removing four charges of protons (747.8533*4) - (4*1.007276) 
= 2987.3841. Expected mass of dehydrated (-8 H2O) is 2987.3922 Da. Additional peaks have 
an addition of 4 m/z which is 16 Da = oxidation. Addition of 18 Da (H2O) (or multiples) 
cannot be seen, meaning that the major part of nisin P is completely dehydrated.  
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(A) 
 
(B) 
 
Figure 5.6 (A) Raw spectrum of series of charge states from 5+ to 2+. (B) Spectrum detail of 
charge state 4+, confirming expected mass of purified nisin P. The mass calculation is 
performed by multiplying per 4 the 747.8533 ion mass and removing four charges of 
protons (747.8533*4) - (4*1.007276) = 2987.3841. 
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5.3.3.2. Presence of lanthionine rings and final confirmation of structure 
After trypsin digestion, 7 exclusive unique peptides with 30 exclusive unique spectra, 
matching the sequence of Nisin P with 100% probability were detected (Table 5.2). Those 
spectra cover 31 of the 31 amino acid residues of Nisin P corresponding to 100% sequence 
coverage. The presence or absence of rings can be determined by the suppression of the 
MS2 fragmentation within the regions that correspond to those rings. Two types of 
modifications were observed: dehydrations and carbamido-methylation. Dehydrations (-
18) were present in S and T residues (Fig. 5.7). Dehydrations on the T residue have been 
reported only in some nisin variants [61, 93]. Carbamido-methylations (CAM, C+57) were 
observed in modified cysteine residues and are an indicator of the absence of a lanthionine 
ring, while unmodified cysteines indicate participation in ring formation. The N-terminal 
peptide VTSKSLCTPGCK and the C-terminal peptides TGILMTCAIKTATCGCHFG and 
TATCGCHF showed CAM modifications in approximately 50% of the 342, 144 and 91 
peptide spectra matches (PSMs) obtained by trypsin digestion with a probability of 100%. 
Another peptide, VTSKSLCTPGCKTGILMTCAIK and the full peptide, showed two 
modifications, with a low probability, in the same residues as VTSKSLCTPGCK. This indicates 
the absence of ring B in approximately 50% of the peptides. The presence of CAM 
modifications in the C-terminus in peptides TGILMTCAIKTATCGCHFG and TATCGCHFG 
indicates the absence of ring E in approximately 50% of the peptides. Based on this 
observation, the structure of nisin P was confirmed (Figure 5.8). 
Table 5.2. List of peptides obtained by digestion with trypsin and LC-MS/MS analysis. 
Domain Tryptic peptide m/z (1+) MC PSMs CAM  Highest 
probability 
(%) 
N-term VTSKSLCTPGCK 1,207.58 1 342 145 100 
N-term VTSKSLCTPGCKTGILMTCAIK 2,162.09 2 6 2 7 
Core TGILMTCAIK 1,029.54 0 37 0 - 
Core SLSLCTPGCKTGILMTCAIK 1,820.91 1 4 0 - 
Full  VTSKSLCTPGCKTGILMTCAIKTATCGCHFG 3,003.39 3 17 1 23 
C-term TGILMTCAIKTATCGCHFG 1,984.88 1 144 70 100 
C-term TATCGCHFG 916.3329 0 91 52 100 
MC: Missed cleavage. PSMs: Peptide Spectra Match.   
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Figure 5.7. MS/MS spectra for nisin P peptides obtained by trypsinisation and generated in 
Scaffold. b- ions are represented in red and y- ions in blue. (A) Spectrum of peptide showing 
presence of CAM modification (C+57) on one C residue indicating ring B is not present but 
ring A is. (B) Spectrum showing no CAM modification in ring B region. (C) detail of presence 
of ring C and hinge region, AIK (D) Presence of ring D and CAM modification indicating the 
absence of ring E. (E) Unmodified cysteine indicating ring E is present. 
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Figure 5.8. Location of the sites in nisin P cleaved by trypsin to form the different peptides 
summarised in table 5.2. * indicates that the ring is not always formed. 
5.3.4. Stability  
The antimicrobial activities of nisin A, P and H stored at pH 3, 5, 6, 7, and 8 for 24, 48 and 
72 h were compared by well-diffusion assay against L. bulgaricus 5583 (Figure 5.9). Overall, 
nisin A antimicrobial activity was more stable than both P and H to 72 h and at acidic pH. 
Nisin P was the least stable as it lost most inhibitory activity against L. bulgaricus 5583 after 
24 h and was inactive at 72 h at acidic pH though it retained some activity at pHs 7 and 8. 
While Nisin H activity was less stable than nisin A it was more stable than nisin P as it 
retained more activity at 24 h, showing an optimum at pH 5, also at 48 and 72 h, and it 
showed some activity at 72 h at pHs 5, 6, 7 and 8.  
Figure 5.9. Stability of nisin A, P and H stored at different pH for 24, 48 and 72 h measured 
by radius (mm) of inhibitory activity against L. bulgaricus 5583 using well-diffusion assay. 
Results are the mean of triplicate measurements +/- standard deviation.  
5.3.5. Cross- immunity assays 
Purified nisin P at 0.20 mg/ml had inhibitory activity against natural nisin A and U but not 
against S. hyointestinalis (nisin H producer, Table 5.3). S. agalactiae DPC 7040 required a 
lower concentration of nisin A to be inhibited (0.022 µM) than S. uberis strain 42 (0.4 µM) 
and  L. lactis NZ9800 (26µM). Nisin P inhibited L. lactis NZ9800 growth at 8.5 µM and S. 
uberis strain 42 at 4.25 µM. Nisin P inhibited nisin P producer S. agalactiae DPC7040 at 17 
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µM. Nisin clusters encoding nisin A, U and P have two systems involved in immunity, one 
through the immunity protein nisI and the other one through the ABC transporter system 
nisFEG. However, the cluster for nisin H does not have a nisI gene [61]. For this reason, a 
Blastp analysis was performed on the other system nisFEG. The analysis showed that, 
despite that these proteins are similar in nisin A, P and U, nisF and nisG from the nisin H 
cluster have very low percentage of similarity to them. Thus, nisF from nisin A, P and U only 
had 13.8%, 14.1% and 15.4% similarity to nisF from nisin H. NisG from nisin A, P and U had 
9%, 8.9% and 9.8% similarity to nisG from nisin H. NshE and NisE showed 48.3% and 43.8% 
identity to NipE, while NsuE shared 79.8% identity.  
 
Table 5.3. Summary of inhibitory activity of nisin P and A against different natural nisin 
producers 
Strain Activity nisin P Activity nisin A MIC nisin P MIC nisin A 
L. lactis  
NZ9800 (nisin A) 
++ + 8.5 μM 26 μM 
S. uberis  
strain 42 (nisin U) 
++ +++ 4.25 μM 0.4 μM 
S. hyointestinalis  
DPC6484 (nisin H) 
- - - - 
S. agalactiae  
DPC 7040 (nisin P) 
+ +++ 17 μM 0.022 μM 
 
5.3.6. Spectrum of inhibitory activity and MIC  
In general, purified nisin A was more potent and had wider spectrum of inhibition than nisin 
P (Table 5.4). Nisin P inhibited all lactobacilli and staphylococci strains assayed but 
inhibition was weaker compared to nisin A, which was able also to inhibit the growth of 
Listeria and enterococci.  This is consistent with the spectrum of action of other nisins, that 
have targeted lactobacilli and staphylococci and in general Gram positive [305].   
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Table 5.4. Summary of inhibitory activity of nisin P and A 
Strain Activity  
nisin P 
Activity  
nisin A 
MICs  
nisin P 
MICs  
nisin A 
S. enterica LT2 - - - - 
E. coli ATCC 25922 - - - - 
C. sakazakii NCTC 11467 - - - - 
C. perfringens NCTC 3110a - - - - 
L. innocua NCTC 11288 - - - - 
L. bulgaricus 5583 +++ +++ 0.01 μM 0.0005 μM 
L. monocytogenes (3564) - ++ - - 
E. faecium (4955) ++ +++ 0.265 μM 0.1 μM 
E. faecalis (LM1) - ++ - 6.5 μM 
E. faecalis (LM4) - ++ - 6.5 μM 
P. aeruginosa (2064 APC) - - - - 
S. aureus (7016) mastitis ++ +++ 0.531 μM 0.05 μM 
S. capitis (20G) ++ +++ 8.5 μM 0.812 μM 
S. simulans (2B10) ++ +++ 0.531 μM 0.325 μM 
S. epidermidis (99) + +++ 34 μM 0.812 μM 
L. gallinarum (43) + ++ 8.5 μM 0.812 μM 
L. frumenti (53) +++ +++ 1.06 μM 0.27 μM 
L. reuteri (54) + ++ 8.5 μM 0.812 μM 
L. paracasei (R1) ++ +++ 17 μM 1.62 μM 
L. plantarum (Lac 29) +++ +++ 1.06 μM 0.1 μM 
L. mucosae (28) +++ +++ 1.06 μM 0.54 μM 
L. reuteri (56) + ++ 69 μM 3.25 μM 
a C. perfringens NCTC 3110 has usually been reported to be sensitive to nisin A 
5.3.7. Activity induction 
Nisin P, A and H, have different concentration ranges for activating the nisin promotor 
(Table 5.5). The promoter was more sensitive to nisin A (1 ng/ml – 1 µg/ml) than nisin H 
(10 ng/ml – 1 µg/ml) and nisin P (100 ng/ml – 10 µg/ml). Higher concentrations of nisin P 
were required to activate the promotor, but its ability to induce gfp+ also worked at higher 
concentrations (10 µg/ml) than nisin A and H. The maximum concentration that nisin A and 
H were capable of inducing gfp+ was 1 µg/ml. The highest fluorescence using nisin A was 
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detected at a concentration of 500 ng/ml, after increasing with the concentration. 
However, at 1 µg/ml the fluorescence was lower than at 100 ng/ml. This weakening in 
fluorescence at high levels of concentration was not shown by nisin P nor nisin H induction.  
Table 5.5. Fluorescence levels of nisin induction of L. lactis NZ9000 pNZ8150 gfp+ by nisin 
P, A and H. 
 1 
mg/ml 
10 
ug/ml 
1 ug/ml 500 
ng/ml 
100 
ng/ml 
50 
ng/ml 
20 
ng/ml 
10 
ng/ml 
5 ng/ml 2 ng/ml 1 
ng/ml 
Nisin 
P 
- 1758.33 
± 41.66  
658.33 ± 
8.33  
316.66 ± 
33.33 
75 ± 
8.333 
- - - - - - 
Nisin 
A 
- - 1408.33 
± 25 
1916.5 ± 
83.5 
1458.33 
± 25 
1050 ± 
0 
549.99 
± 16.66 
358.33 
± 8.33 
224.99± 
8.33 
116.66 
± 16.66 
83.33± 
16.66 
Nisin 
H 
- - 1566.66 
± 33.33 
1133.33 
± 66.66 
608.33 
± 41.66  
358.33 
± 8.33  
208.33 
± 8.33 
108.33 
± 25 
- - - 
 
5.3.8. Nisin activity in faecal fermentation  
The analysis of total dead and live bacteria in faecal samples after fermentation in the 
presence of  two concentrations (15 µM and 50 µM) of the different nisins showed different 
profiles depending on nisin type and treatment at 8 and 24 h (Fig 5.10). There were 
significant differences in the total numbers of DNA from live cells between the control and 
the treatments with nisin A, P and H both at 8 and 24 h.  Nisin A treatments had the biggest 
effect on bacterial numbers. The effect of the 15 µM and 50 µM concentrations of nisin A, 
both with and without reinforcement dose, was also significant at 8 h and at 24 h. At 24 h, 
nisin A treatments that had received a reinforcement dose at 8 h showed the least amount 
of DNA copies of live cells. The nisin H treatment showed less inhibitory activity than nisin 
A, and there were significant differences between 15 µM and 50 µM concentrations at 8 h, 
but not at 24 h. All treatments showed cell numbers between Log10 6-7. Nisin P showed the 
least difference between total DNA and DNA from live cells and also showed the highest 
total DNA numbers, with all the treatments with cell numbers between Log10 7-8. The effect 
of the 15 µM and 50 µM concentrations of nisin P was not significant at 8 h nor at 24 h, and 
neither with the reinforcement doses. The 50 µM concentration showed significant higher 
numbers of DNA than the 15 µM concentration in nisin A treatment at 8 h and 24 h with 
the reinforcement dose, and in nisin H treatment at 8 h.   It is worth noting that the no nisin 
controls showed lower numbers of rDNA copies and a larger difference between live and 
dead cells than nisin P and H treatments.
Chapter V. Activity and structural characterisation of nisin P 
 
155 
 
 
Figure 5.10. Total bacteria after nisin A, P and H treatments measured by 16S rDNA qPCR after faecal fermentation at 8 and 24 h. Two concentrations of 
peptide were tested, 15 µM and 50 µM. Half of the wells received a reinforcement dose of the same concentration at 8 h. Results are the mean of duplicate 
measurements +/- standard deviation. Statistics was conducted with live cells data:  a, indicates significant difference between the treatment and the blank 
at 8 or 24 h; b, indicates significant difference between 15 µM and 50 µM concentrations; c, indicates significant difference between 8 and 24 h within the 
same nisin treatment. 
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5.4. Discussion 
This work is the first report of production and purification of nisin P, a natural variant of 
nisin, originally identified in the genomes of other two Streptococci species by genome 
mining [294, 295]. Genes related to nisin P were identified previously by phylogenetical 
categorization of LanB and LanC enzymes in Streptococcus pasteurianus and posterior 
analysis of its lanA gene suggested the ability of this strain to produce an analogue of nisin 
U that was designated nisin P [294]. The gene cluster was later reported on Streptococcus 
suis [295]. The faecal isolate S. agalactiae DPC 7040 produced nisin P after initial induction 
with nisin A.  
Nisin A has been considered the lantibiotic archetype for decades. It is the best known 
bacteriocin and it has been used extensively as a food preservative for more than half 
century. Its positive attributes and efficacy make it suitable scaffold for further 
antimicrobial development. Indeed, bioengineering has enabled the modification of the 
nisin A molecule to increase its bioactivity, specificity, stability and / or its range of action 
by targeted amino acid modifications for over 25 years [74, 90, 174, 285, 298, 306-309]. 
However, nature developed its own nisin variation system and new nisin variants are 
continuously being discovered. These variants have been found in a number of 
representatives from different environments, from dairy products (nisin A) to human (nisin 
O, P) animal (nisin H) and fish (nisin F) intestines and river water (nisin Q). We could 
hypothesize that the wide dissemination of the clusters encoding this molecule could be 
linked to its ability to provide a competitive advantage and increased fitness to the 
organisms that possess them, even among the different nisin variants.  
Cross-immunity assays indicated that nisin P was able to inhibit the growth of the nisin A 
and nisin U producers, suggesting that their immunity systems are different and cannot 
protect them from the effect of the nisin P. S. agalactiae DPC7040 was also very sensitive 
to nisin A effect. Nisin P and nisin A inhibited the growth of the nisin U producer, S. uberis 
strain 42. Although this has been reported previously [61], initially S. uberis strain 42 was 
reported as cross-resistant to nisin A effect, and it was hypothesised that this effect was 
due to the effect of the different nisin immunity systems, NisI and NisFEG [292]. Nisin A and 
nisin P were not able to inhibit the growth of S. hyalointestinalis DPC6484, the nisin H 
producer, something that was observed previously with nisin A [61]. S. hyalointestinalis 
DPC6484 does not have one of the two systems involved in lantibiotic immunity, nisI. NisI 
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has been reported to have a more crucial role in immunity than the NisFEG, the ABC 
transporter system, which was considered to provide around 20% of the wildtype immunity 
[310-312]. However, another study highlighted that nisI expression provided a very low 
level of immunity (1-4%) [313]. The low levels of similarity in NisFEG of S. hyalointestinalis 
DPC6484 to the ones from the nisin A, P and U producers, suggest that this system might 
have a more important role in lantibiotic immunity than previously suspected.  
When nisin P activity was compared to other nisin variants activities, A and H, a lower 
inhibitory effect was observed. Nisin P showed a higher MIC against a panel of food and 
gut isolates. It was expected that a bacteriocin produced by a human gut isolate would be 
more effective against other gut isolates due to potential environmental specificity. 
However, in this case, nisin A exhibited higher inhibitory activity than nisin P against these 
tested species. This was observed in the faecal fermentations too, where samples treated 
with nisin P showed a rise in total cell numbers and higher numbers of viable cells, while 
samples treated with nisin A and H showed lower numbers of live cells, with nisin A being 
the treatment that showed the lowest numbers of live cells.  
These differences in bioactivity might be explained by the structural differences between 
molecules. Thus, the nisin A molecule is characterised for having five rings containing 
lanthionine or methyl-lanthionine residues, in addition to three dehydro amino acid 
residues, Dhb2, Dha5 and Dha33. During the large number of studies conducted to assess 
the relationship between structure and activity, it was highlighted that some rings play a 
key role in the inhibitory activity of nisin A. Some examples include the observation that 
the hydrolytic cleavage of Dha33 had a very little biological effect, but the cleavage of Dha5 
led to a substantial loss of activity [314, 315]. However, it was not clear if the loss of activity 
was due to the loss of Dha5 or due to the conformational change of losing the ring A. For 
this reason, Dha5 was replaced with an alanine, resulting in no effect in inhibitory activity 
but substantially decreased its inhibitory activity of spore outgrowth [315]. Cleavage or 
removal of ring C abolished fully nisin activity, indicating its importance. However, the 
hydrolytic cleavage of the last five amino acids in the C-terminal part of the molecule only 
showed a 10 fold drop in growth inhibition activity against L. lactis, mainly attributed to the 
Val residue [314]. Nisin P is three amino acids shorter than nisin A in the C-term, which 
might me linked to a certain decrease in its antimicrobial activity. Further removal of amino 
acids in the C-terminal region, this time affecting rings D and E, showed a decrease of up to 
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100 fold of its inhibitory activity against L. lactis and 50 fold against M. luteus, suggesting 
that different residues or conformations might have a different outcome against different 
bacteria [314]. It was possible to establish a N-terminal part of the nisin A molecule, that 
includes rings A, B and C, responsible for the binding of nisin to the membrane surface and 
/ or its oligomerization. A more cationic C-terminal was thought initially to be involved in 
pore formation, but mode of action studies helped to rule out this idea, pointing that is was 
likely to work only by the interference with lipid II and cell wall biosynthesis [306, 316]. Ring 
B is known for being very sensitive in substitution studies and the replacement with large 
amino acids was highly detrimental for the activity, probably due to the inability of the 
cysteine thiol at position 11 to cyclize onto the Dhb present in position 8 [316]. In summary, 
the removal of the ring B constituted a loss of activity in the nisin mutants [316].  
Another important region involved in bioactivity in lantibiotics, and therefore, the nisin 
molecule, is the hinge region, in positions 21, 22 and 23 [317, 318]. The hinge region is 
constituted by the three amino acids (NMK in case of nisin A) that separate the N-terminal 
and C-terminal domains and are responsible of the reorientation after the binding with lipid 
II to penetrate into the target cell membrane [319]. The hinge region has also been linked 
to lantibiotic immunity and resistance. Thus, modifications to extend the hinge region 
showed that immunity and resistance proteins were not able to recognize it. However, the 
insertion into the cell membrane and its ability to form pores was malfunctioning [319]. Its 
importance in nisin antimicrobial activity has also been previously established through 
bioengineering studies [318-321]. These studies suggested a preference for small, chiral 
amino acids in that region  [320]. Nisin H has one change, an aromatic polar tyrosine (Y) 
instead of the non-polar methionine in the second position. Nisin P has two changes in the 
hinge region, in comparison with nisin A, in positions 21 and 22. In position 1 there is an 
exchange of a polar asparagine (N) for a non-polar alanine, with a small methyl side chain, 
and in position 22 there is an exchange of methinonine with an isoleucine (I), both non-
polar amino acids. The third position remains conserved in all known nisin variants, 
including the most recent nisin O, that along with nisin U, U2 and P, are the four natural 
nisin variants that have two substitutions in the hinge region, in positions 21 and 22. 
However, the introduction of serine (S) in position 21 and the naturally conserved position 
23 of the hinge region, has been proved to enhanced bioactivity [321]. In the same study, 
directed amino acid changes in positions 21 and 22 showed that presence of alanine in 
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position 21 reduced bioactivity against Methicillin resistant Staphylococcus aureus, ST528, 
S. aureus DPC5245 and S. agalactiae ATCC13813 to half of the reference bioactivity from 
nisin A. However, molecules carrying an isoleucine in position 21 showed an enhanced 
bioactivity against the three microorganisms in comparison with nisin A natural hinge 
region [321]. Despite this, no studies with positions 21 and 22 of the hinge region carrying 
alanine and isoleucine residues were performed previously. Hence, although small peptide 
substitution, like alanine, would appear to benefit bioactivity, and the presence of 
isoleucine in the second position was reported to increase bioactivity, the combination of 
both modifications does not seem to present an enhanced bioactivity, in comparison with 
nisin A, against our indicator strains.  
In the case of the structure of nisin P, analysis of trypsin digested and carbamidomethylated 
peptides established that, while the ring C was always present, rings B and E were only 
present partially, around 50 % in each case. This could explain the lower activity when it is 
compared with nisin A. On the other hand, nisin P might receive a benefit from the 
presence of a lysine residue in position 4 instead an isoleucine. Previous studies have 
shown that the presence of an additional positive charge in the ring A has a positive effect 
of its activity [316]. Further studies are required to determine if there are indeed instances 
where nisin P benefits by virtue of these changes.  
In addition to a lower activity, nisin A promoter seems to require higher concentrations of 
nisin P in comparison to nisin H and A to induce its production. However, this might be due 
to certain level of specificity of the molecule or the receptor. Given the structural 
differences between the two branches of nisin variants, Lactococci and Streptococci origin, 
it could be interesting to investigate if using nisin P or U as inducers and using cognate 
receptors would give the same levels of induction requirements.  
The effect of the three different nisin variants (P, A and H) over the microbiota in a 
fermentation of faecal material was studied using rDNA copy numbers of the 16S gene. 
Although bacteria can have multiple copies of rDNA [322], we have used the amplification 
of this gene as a reference to measure the effect of the different treatments. It is possible 
to observe a trend where the number of rDNA copies is bigger in nisin P than in nisin H 
treatments, and bigger in nisin H than in nisin A treatments, suggesting that the potency of 
each one individually correlates with the potency for general treatments in the faecal 
fermentation. 
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The study of both bioengineered and natural variants of nisin aids the understanding of 
structure-activity relationships of this molecule and that knowledge can be applied to other 
lantibiotics and to the further development of more efficient antimicrobials. Future 
investigation of nisin P modification and production in mixed communities might help to 
establish further knowledge on whether it would be a good candidate as antimicrobial 
agent in certain environments.
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6.1. Introduction 
S. epidermidis is a member of the coagulase-negative staphylococci (CoNS) and is 
considered a commensal, being frequently found as a component of the human 
microbiome. S. epidermidis has also been identified as a nosocomial pathogen responsible 
for antibiotic resistant infections, and has been isolated from catheters, bloodstream, 
prosthetic joints, ocular and mastitis infections [323]. This bacterium would appear to be 
highly adaptive, having also been associated with other hosts, including sheep, rodents and 
plants [324, 325]. Despite this, there is a pointed lack of comparative and evolutionary 
studies of ecologically diverse S. epidermidis isolates [324]. Within the human body, the GI 
tract is one of the primary locations where S. epidermidis can be found [323]. Furthermore, 
a recent study has identified a variety of gut pathogens, including S. epidermidis, in 
bloodstream infections, suggesting the GI tract as a source of those infections [326]. This 
highlights the importance of identifying traits that could reveal the origin S. epidermidis 
infection for accurate tracking and treatment of an infection, as well as potentially 
revealing opportunities for disease prevention. However, public databases do not contain 
complete genomes of S. epidermidis isolates of gut / stool origin and there is relatively little 
known about distinct features that S. epidermidis of this origin may possess.  
There are many factors which influence the composition and stability of microbes in the 
gut including pH, anaerobiosis, water activity, nutrients, and the presence and 
concentration of compounds such as bile acids (BA). It has been noted that bacteria 
adapted to live in the mammalian gut have developed strategies to overcome the 
antimicrobial activity of BAs, such as efflux systems, bile salt hydrolase (BSH) activity or 
remodelling of the cell wall [12]. Another important feature is the ability to resist other 
antimicrobial compounds of host and bacterial origin [327]. These compounds can have 
non-specific activity, like hydrogen peroxide or short chain fatty acids (SCFA), or target 
specific microbes in the ecosystem, such as some antimicrobial peptides (AMPs) [328]. In 
addition to needing to survive exposure to such antimicrobials, many gut microbes are 
producers of these compounds in order to gain a competitive advantage with respect to 
niche colonisation. Indeed, S. epidermidis is able to produce a delta lysin and an 
antimicrobial ᵟ-toxin called phenol-soluble modulin-γ [329].  
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Some lineages of S. epidermidis can cause infections, a phenomenon which has been 
associated with an increased density of antimicrobial resistance and virulence-related 
genes in the genomes of those disease-causing lineages [330]. Such S. epidermidis have 
been shown to cause pathological changes in the kidney and liver of rats and mice, among 
other organs [323]. Other features associated with the colonising ability of S. epidermidis 
include lipase activity, as this species is found mainly in lipid-rich regions (gut, skin, milk, 
etc) and biofilm formation. Indeed, biofilm formation is considered one of the most 
important traits in S. epidermidis colonisation, with a number of genes involved in the 
molecular mechanisms of the different stages of biofilm formation, such as adhesins 
involved in initial attachment, polysaccharide intercellular adhesin (PIA) matrix 
components involved in accumulation, teichoic acids in maturation and proteases and 
modulins in detachment [331, 332]. Taken together, there is evidence of traits that could 
reflect the ability of different strains of S. epidermidis to colonise different parts of the 
human body and suggest that pan-genome studies, such as that which highlighted formate 
dehydrogenase as a potential clinical biomarker of pathogenesis in S. epidermidis [333], 
have the potential to be of great value. 
Here it is described the study of the pan-genome of S. epidermidis, including three new 
isolates of gastrointestinal origin, with a view to identifying niche specific traits. The 
existence of traits associated with lifestyle adaptation to the human gut, such as growth in 
anaerobic conditions and the presence of bile acids (BA), antimicrobial relationships with 
representatives of the enterobacteria, and potential pathogenic traits, like biofilm 
formation, were also investigated.  
6.2. Methods 
6.2.1. Genomic analyses 
6.2.1.1. Genome Data Collection 
All available S. epidermidis genomes were downloaded from the RefSeq genome database 
on 04/07/18 and metadata was downloaded from PATRIC database on 05/02/2019. To 
have a consistent annotation, these genomes were annotated using Prokka (v. 1.11) and 
pan-genome-wide associations were performed using Roary [334] and Scoary [335] with 
default parameters. Probability was calculated using Benjamini and Hochberg with default 
parameters. The tree was built using PhyloPhlAn (v. 0.99) [336] and visualised using 
GraPhlAn [337]. PlasmidFinder 2.0 [338] was used to identify potential plasmids.  
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6.2.1.2. Genome-Phenotype association 
A pan-genome of the four strains for which both genome sequence and OmniLog® growth 
patterns were available was created using Roary and all identified genes were associated 
with growth on individual substrates using Scoary. An area under the curve (AUC) cutoff of 
500 was chosen to denote growth on a particular substrate. If the AUC in that well was less 
than 500, it was considered that the strain did not grow on that substrate. Only substrates 
on which at least one of the strains could grow are plotted. The list of remaining substrates 
was filtered to only those where there were differential growth patterns between strains 
(i.e., substrates on which either, none or all strains could grow were deemed uninformative 
and removed). MetaCyc was used for further confirmation of the results obtained [339]. 
6.2.2. Bile acids 
6.2.2.1. Sample preparation 
Skin isolates of S. epidermidis DSM 20042, DSM 28764 and faecal isolates 9c and F530B 
(Chapter III) were grown in 20 ml of suitable media supplemented with porcine bile (Sigma, 
UK) up to a final concentration of 0.3% v/v. Cultures were set in triplicate. 1 ml of each 
culture was collected at 24 and 48 h and kept at -20oC for further analysis. Solid phase 
extraction (SPE) clean-up was performed in the samples using Waters Oasis Prime HLB 1 30 
mg SPE cartridges in a SPE vacuum system and washed with 1 ml of 5% methanol. Elution 
was performed with 500 µl 100% methanol using the same procedure and 25 µl of internal 
standards for each bile acid (Steraloids, USA) were added. The final volume was transferred 
to low volume autosampler tubes for LC-MS analysis.  
6.2.2.2. LC-MS 
Clean extracts were analysed using HPLC – mass spectrometry operated in multiple 
reaction monitoring (MRM) mode by Dr. Mark Philo (QIB). Each sample (5 µl) was analysed 
using an Agilent 1260 binary HPLC coupled to an AB Sciex 4000 QTrap triple quadrupole 
mass spectrometer.  HPLC was achieved using a binary gradient of solvent A (water + 5mM 
ammonium acetate + 0.012% formic acid) and solvent B (methanol + 5mM ammonium 
acetate + 0.012% formic acid) at a constant flow rate of 600 µl/min. Separation was made 
using a Supelco Ascentis Express C18 150 x 4.6, 2.7 µm column maintained at 40°C. Injection 
was performed at 50% B and held for 2 min, ramped to 95% B at 20 min and held until 24 
min. The column equilibrated to initial conditions for 5 min. The mass spectrometer was 
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operated in electrospray negative mode with capillary voltage of -4500 V at 550°C. 
Instrument specific gas flow rates were 25 ml/min curtain gas, GS1: 40 ml/min and GS2: 50 
ml/min. Quantification was applied using Analyst 1.6.2 software to integrate detected peak 
areas relative to the deuterated internal standards. 
6.2.2.3. Growth curves 
Growth behaviour of S. epidermidis DSM 20042, DSM 28764, 9c and F530B was monitored 
aerobically and anaerobically. 20 ml of BHI was inoculated with 1% of each strain with or 
without 0.3% porcine bile and triplicate 300 μl aliquots were transferred to a honeycomb® 
sterile plate (Thermo Fisher Scientific) for Bioscreen C (Labsystems Oy) for measuring 
aerobic growth and to a 96 well plate for Infinite F50 (Tecan Group, Switzerland) for 
anaerobic conditions, using Bioscreener and Gen5 Data Analysis as software respectively. 
Growth rate (µ) was calculated using the formula µ = 2.303 (log OD2 – log OD1) / t2 – t1 [340] 
where OD2 is the value that doubles OD1, and t2 and t1 the time at those two measurements.  
6.2.4. Phenotypic analyses 
6.2.4.1. Antimicrobial activity 
Antimicrobial activity was measured as described in section 2.1.5.  
6.2.4.2. Adhesion and biofilm measurements 
Adhesion and biofilm formation abilities were conducted as described in section 2.2. 
6.2.4.3. Biolog analyses 
BIOLOG assays were performed as described in section 2.1.9. Additional strains used were 
bovine mastitis isolate S. epidermidis DPC6010 and cheese isolate DPC6293. 
6.3. Results 
6.3.1. S. epidermidis pan-genome  
The S. epidermidis pan-genome was constructed by Dr. Calum Walsh (Teagasc) and Dr. 
Lizbeth Sayavedra (QIB) and contained 16,399 total genes across 581 genomes: 1,036 core 
genes present in ≥ 99% of genomes, 419 soft core genes present in 95-99% of genomes, 
1,419 shell genes present in 15-95% of genomes, and 13,525 cloud genes present in less 
than 15% of genomes. To visualise results, two phylogenetic trees were constructed (Figure 
6.1 and B). The three stool isolates did not cluster together (Figure 6.1A). In the same way, 
cattle isolates did not cluster. However, rice and murine isolates did cluster (Figure 6.1B). 
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The genomes from the different body sites isolates did not cluster either, suggesting no 
specialisation.  
(A) 
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(B) 
 
 
Figure 6.1(A) Presence of S. epidermidis isolated from stool in the pan-genome. (B) 
Different origins of S. epidermidis in the pan-genome. Coloured inner circle shows different 
isolation sources. Coloured outer circle shows different isolation sites within the human 
body.  
Scoary identified 44 genes whose presence was significantly associated with being isolated 
from human stool (Table 6.1). 28 of these 44 ORFs (coloured in Table 6.1) were located on 
a 30 kb contiguous sequence which was identified as a probable plasmid by 
PlasmidFinder2.0, suggesting the likely acquisition of a horizontally transmitted genetic 
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element conferring the ability to survive in the human GI tract. Although not significantly 
associated, all three stool isolates contain a type V ACME gene cluster, a type of arginine 
catabolic module element (ACME). 
Table 6.1. Genes significantly correlated with gut-associated S. epidermidis isolates 
Gene Significance* Top Blastp match 
Blastp 
Identity 
group_464 0.01788 ISSag7, transposase OrfA [S.epidermidis VCU045] 100.00% 
sdrG 0.04113 MSCRAMM family cell wall-anchored protein SesJ [S. epidermidis] 93.19% 
group_439
1 0.01151 lipopolysaccharide biosynthesis protein [S. epidermidis] 100.00% 
group_120
34 0.01506 MULTISPECIES: hypothetical protein [Staphylococcus] 100.00% 
hsdR_1 0.01788 
MULTISPECIES: type I restriction endonuclease subunit R 
[Staphylococcus] 99.80% 
group_950
1 0.01151 MULTISPECIES: restriction endonuclease subunit S [Staphylococcus] 100.00% 
hsdM_1 0.01643 
MULTISPECIES: SAM-dependent DNA methyltransferase 
[Staphylococcus] 100.00% 
group_105
01 0.01329 hypothetical protein SEVCU037_0543 [S. epidermidis VCU037] 100.00% 
group_120
33 0.01506 DUF1643 domain-containing protein [S. epidermidis] 100.00% 
group_317 0.01643 tandem lipoprotein [S. epidermidis VCU045] 100.00% 
group_630
1 0.04732 
MULTISPECIES: type III-A CRISPR-associated RAMP protein Csm5 
[Staphylococcus] 100.00% 
cas6 0.04732 
MULTISPECIES: CRISPR-associated endoribonuclease Cas6 
[Staphylococcus] 100.00% 
group_107
20 0.01329 metal-dependent transcriptional regulator [S. epidermidis] 100.00% 
fecE_2 0.01329 
MULTISPECIES: metal ABC transporter ATP-binding protein 
[Staphylococcus] 99.59% 
mntB_2 0.01329 MULTISPECIES: metal ABC transporter permease [Staphylococcus] 100.00% 
mntA_2 0.01329 
MULTISPECIES: zinc ABC transporter substrate-binding protein 
[Staphylococcus] 100.00% 
group_124
47 0.01329 MULTISPECIES: recombinase family protein [Staphylococcus] 100.00% 
group_135
61 0.00155 MULTISPECIES: hypothetical protein [Staphylococcus] 99.85% 
group_135
60 0.00155 MULTISPECIES: hypothetical protein [Staphylococcus] 100.00% 
group_135
59 0.00110 MULTISPECIES: NERD domain-containing protein [Staphylococcus] 100.00% 
group_135
58 0.00110 
hypothetical protein HMPREF2913_01140 [Staphylococcus sp. 
HMSC065A08] 94.74% 
group_131
54 0.01329 
MULTISPECIES: poly(glycerol-phosphate) alpha-glucosyltransferase 
[Staphylococcus] 99.44% 
sdrI_1 0.04732 
YSIRK signal domain/LPXTG anchor domain surface protein [S. 
epidermidis] 97.94% 
sdrI_2 9.49E-05 YSIRK-type signal peptide-containing protein [S.  epidermidis] 87.93% 
group_982
6 0.01000 helix-turn-helix domain-containing protein [S. aureus] 85.71% 
group_166
36 9.49E-05 
hypothetical protein HMPREF2566_04185 [Staphylococcus sp. 
HMSC070A07] 100.00% 
group_166
37 9.49E-05 No significant similarity found  
group_166
38 9.49E-05 MULTISPECIES: hypothetical protein [Staphylococcus] 100.00% 
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group_166
39 9.49E-05 
MULTISPECIES: peptidase domain-containing ABC transporter 
[Staphylococcus] 100.00% 
group_166
40 9.49E-05 MULTISPECIES: DsbA family protein [Staphylococcus] 100.00% 
group_105
69 0.01643 hypothetical protein [S.  haemolyticus] 97.92% 
group_503 0.02693 MULTISPECIES: replication initiator protein A [Staphylococcus] 100.00% 
racA 9.49E-05 MULTISPECIES: DUF536 domain-containing protein [Staphylococcus] 100.00% 
group_588 0.00155 
RepB family plasmid replication initiator protein [Staphylococcus sp. 
HMSC070A07] 100.00% 
fas6 0.02047 
MULTISPECIES: TIGR00730 family Rossman fold protein 
[Staphylococcus] 100.00% 
group_110
17 0.00110 MULTISPECIES: hypothetical protein [Staphylococcus] 100.00% 
group_111
21 0.00033 hypothetical protein [Staphylococcus sp. HMSC068G11] 100.00% 
group_797
0 0.00232 hypothetical protein [Staphylococcus sp. HMSC070A07] 99.33% 
group_288
0 0.00812 MULTISPECIES: DUF3139 domain-containing protein [Bacteria] 100.00% 
group_437
4 0.04113 MULTISPECIES: hypothetical protein [Staphylococcus] 100.00% 
group_481 0.01788 MULTISPECIES: recombinase [Staphylococcus] 99.75% 
group_939
7 0.00110 MULTISPECIES: hypothetical protein [Bacilli] 100.00% 
group_875
5 0.00812 hypothetical protein B467_01449 [S. epidermidis M0881] 99.59% 
group_121
41 0.04732 MULTISPECIES: hypothetical protein [Bacilli] 100.00% 
* Benjamini and Hochberg 
6.3.2. Phenotype analysis using BIOLOG 
Phenotype experiments conducted using BIOLOG technology showed differences in the 
utilisation of carbon and nitrogen substrates and antibiotic sensitivity between strains 
(Figure 6.2). The mastitis isolate S. epidermidis DPC6010 showed an ability to grow in a 
broader range of carbon sources than the other isolates. All isolates were able to grow, to 
differing extents, on α-D-glucose, acetic acid, acetoacetic acid, D-alanine, D-fructose, D-
gluconic acid, D-psicose, D- xylose, glycerol, L-alanine, L-lactic acid, maltotriose, pyruvic 
acid, sucrose, butyric acid, pectin, Gly-Gln, and L-cysteine. The mastitis isolate was the only 
strain able to grow on α-hydroxybutyric acid, α-ketobutyric acid, D-mannitol, D-trehalose, 
fumaric acid, gly-pro, L-proline, L-threonine, tyramine, propionic acid, succinic acid and 
mannan. Skin isolates S. epidermidis DSM 20042 and DSM 28764 were the only isolates 
able to grow on gly-glu, and laminarin, and were the only strains not able to grow on 
dulcitol and D-glucosamine. The human stool isolates F530B and 9c did not show a 
distinctive substrate growth pattern from the other isolates. Looking at nitrogen sources, 
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no isolates were able to grow in ala-leu, inosine, L-glutamic acid, L-glutamine, L- ornithine, 
L- tryptophan nor N-acetyl-D-galactosamine.  
Antibiotic sensitivity only showed one differential pattern between skin and stool isolates 
in that the growth of the stool isolates was inhibited by lincomycin, but it did not fully 
inhibit the growth of skin isolates. The skin isolate DSM 28764 showed growth in the 
presence of all antibiotics tested. 
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Figure 6.2. Omnilog results for growth of S. epidermidis stool (9c and F530B), skin (DSM 
20042 and DSM 28764), cheese DPC6293 and mastitis DPC 6010. (A) Carbon sources (I) 
PM1; (B) Carbon sources (II) PM2A; (C) Nitrogen sources PM3B; (D) Antibiotic PM11C. 
Colour represent modified Omnilog units after the cut-off. 
6.3.3. Phenotype-genotype association 
A genome-wide association study to link genomes of S. epidermidis 9c, F530B, DSM 20042 
and DSM 28764 with the results obtained from BIOLOG-based phenotype analysis provided  
a list of 7697 genes related to the 78 substrates that yielded different growth patterns 
between the strains. Table 6.2 shortlists the genes significantly associated with stool 
isolates from table 6.1 that were involved in the metabolism of the BIOLOG substrates. It 
can be observed that several genes are linked to the metabolism of the same substrates, 
such as hsdR_1, hsdM_1, cas6, fecE_2, mntB_2, mntA_2, racA and fas6, which have all been 
associated with the metabolism of dulcitol, oxalomalic acid, 2,3-butanone, 2-deoxy-D-
ribose, 5-keto-D-Gluconic_acid, D-glucosamine and D-mannose. ISSag7 and the 
recombinase from group_481 have been linked with metabolism of the substrates 
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adenosine, D-melibiose, phenylethylamine, tyramine and uridine, but given the nature of 
these genes, it is likely that any such association is indirect. MetaCyc was used to establish 
a potential connection of the genes listed in table 6.3 with metabolic pathways, but none 
were found.  
Table 6.2. Genes significantly different in stool isolates of S. epidermidis and their 
connection to the metabolism of BIOLOG substrates 
Gene Name BIOLOG substrates 
Group_464 ISSag7, transposase OrfA  Adenosine, D-melibiose, phenylethylamine, 
tyramine, uridine. 
sdrG Fibrinogen-binding 
protein 
D-Glucose-6-Phosphate, D-Fructose-6-Phosphate 
hsdR_1 Type-1 restriction 
endonuclease subunit R 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Mannose  
hsdM_1 Type I restriction enzyme 
EcoKI M protein 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose 
cas6 CRISPR-associated 
endoribonuclease Cas6 
 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose 
fecE_2 Metal ABC transporter 
ATP-binding protein  
 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose  
mntB_2 Metal ABC transporter 
permease  
 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose 
mntA_2 Zinc ABC transporter 
substrate-binding protein  
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose 
racA 
 
Chromosome-anchoring 
protein RacA 
 
2,3-Butanone, Agmatine, 2-Deoxy-D-Ribose, 5-Keto-
D-Gluconic_acid, D-Cellobiose, D-Glucosamine, D-
Glucose-1-Phosphate, D-Glucuronic acid, D-Mannose, 
D-Sorbitol, Dulcitol, Histamine, L-Alanine_PM03, L-
Asparagine_PM01, L-Aspartic_acid_PM01, L-
Ornithine_PM03, L-Threonine_PM01, L-Tryptophan, 
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Mannan, Oxalomalic_acid, Propionic_acid, Uracil, 
Uric acid 
fas6 Cytokinin riboside 5'-
monophosphate 
phosphoribohydrolase 
Dulcitol, Oxalomalic acid, 2,3-Butanone, 2-Deoxy-D-
Ribose, 5-Keto-D-Gluconic_acid, D-Glucosamine, D-
Mannose 
Group_481 Recombinase Adenosine, D-melibiose, phenylethylamine, tyramine, 
uridine. 
 
6.3.4. Antimicrobial activity 
6.3.4.1. Putative antimicrobial and phage-related traits  
In addition to the antimicrobial-associated genomic traits identified by BAGEL3 in the stool 
isolates 9c, F530B and 99 (section 3.3.5), further genome analysis identified other elements 
associated with potential antimicrobial activity. Several antibacterial proteins, i.e., phenol 
soluble modulins, were identified in the genomes of S. epidermidis 9c, F530B, DSM 20042 
and DSM 28764. Additionally, different phage elements were identified in both stool and 
skin isolates. The elements identified by BAGEL3 in stool isolates, i.e., sactipeptide and 
delta-lysin, were also identified in the skin isolates (Table 6.3).  
Table 6.3. Putative antimicrobial traits in the genome of S. epidermidis isolates 
  9c F530B DSM  
20042 
DSM 
28764 
Phenol soluble modulin 
group_110 antibacterial protein (phenol soluble modulin) √ √ √ √ 
group_2324 antibacterial protein (phenol soluble modulin) √ √ √ √ 
group_2524 antibacterial protein (phenol soluble modulin) √ √ √ √ 
group_2453 antibacterial protein (phenol soluble modulin) √ √ 
 
√ 
group_1491 antibacterial protein (phenol soluble modulin) 
  
√ 
 
group_1492 antibacterial protein (phenol soluble modulin) 
  
√ 
 
group_2454 antibacterial protein (phenol soluble modulin) √ 
   
BAGEL 4 results 
 Delta-lysin √ √ √ √ 
 Sactipeptide √ √ √ √ 
Other potential antimicrobials in the genomes 
 Prophage phiRv2 integrase √   √ 
 Phage portal protein SPP1 Gp6-like √   √ 
 Phage Mu protein F like protein √ √   
 Phage gp6-like head-tail connector protein √  √  
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 Phage head-tail joining protein √   √ 
 Phage infection protein √ √ √ √ 
 Phage integrase √ √ √ √ 
 Phage protein  √ √ √ 
 Phage repressor    √ 
 Phage tail length tape-measure protein T √   √ 
 Phage tail fiber protein √   √ 
 Phage holin    √ 
 Phage N-acetylmuramoyl L-alanine amidase √ √ √ √ 
 Phage lysin, glycosyl hydrolase, family 25 √ √ √ √ 
 Phage capsid and scaffold √ √ √ √ 
 Phage terminase  √   √ 
 Prophage Clp protease-like protein √    
 Phage Rha protein √    
 DNA helicase phage-associated √    
 Single-stranded_DNA-specific exonuclease RecJ Bacteriophage 
SPBc2-type 
   √ 
 
6.3.4.2. Antimicrobial activity 
Antimicrobial assays showed different results for the tested isolates (Table 6.4). No 
inhibition zones were obtained from drop test, filter disc and well-diffusion assay for any 
isolate. However, overlay and cross streak assays, both involving direct cell contact 
between the indicator and the tested strain, showed different degrees of inhibitory activity. 
None of the strains inhibited C. perfringens NCTC 3110 or L. bulgaricus DPC 5583. On the 
other hand, all S. epidermidis strains inhibited the growth of E. coli ATCC 25922 by cross 
streak. S. enterica LT2 was inhibited, by cross streak assay, by all except isolate 99. 
According to BAGEL3 results in section 3.3.5 9c, F530B, DSM 20042 and DSM 28764 
contained a sactipeptide-like cluster that was absent from isolate 99, which may be 
responsible for this phenotypic difference. M. luteus was inhibited by all strains except by 
DSM 28764. L. innocua NCTC 112888 was inhibited by stool isolates 9c and F530B, using the 
cross streak technique, but only by 9c using the overlay assay. Only 9c and F530B inhibited 
M. luteus, as determined by overlay assays, while F530B was the only strain to inhibit C. 
sakazakii NCTC 11467, as determined by cross streak.  
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Table 6.4. Summary of inhibitory activity of S. epidermidis using different techniques 
 C. perfringens 
NCTC 3110 
S. enterica 
LT2 
E. coli 
ATCC 25922 
L. innocua 
NCTC 112888 
M. luteus 
MC8166 
C. sakazakii 
NCTC 11467 
L. bulgaricus 
DPC 5583 
Isolate O C O C O C O C O C O C O C 
9c - - - + - + + + + ++ - - - - 
F530B - - - ++ - ++ - + + + - + - - 
99 - - - - - + - - - + - - - - 
DSM 20042 - - - ++ - + - - - + - - - - 
DSM 28764 - - - + - + - - - - - - - - 
- -, No activity; +, 1 mm radius inhibition zone; ++, 1-5 mm radius inhibition zone; O, overlay assay; C, cross streak 
6.3.5.  S. epidermidis behaviour in presence of bile 
6.3.5.1. Growth curves 
Growth curves of stool and skin isolates were performed in the presence and absence of 
porcine bile and under aerobic and anaerobic conditions. When grown under aerobic 
conditions, F530B, 9c DSM 28764 and DSM 20042 behaved similarly and exhibit similar 
exponential growth rates (Figure 6.3). The four isolates showed the ability to grow in the 
presence of bile and their growth rate was not affected by it. Thus, the exponential growth 
rates of stool isolates 9c and F530B were 0.62 ± 0.01 and 0.59 ± 0.01 with BS and 0.62 ± 
0.01 and 0.60 ± 0.01 without BS respectively, while skin isolates DSM 20042 and DSM 28764 
presented 0.51 and 0.48 in presence of BS and 0.52 and 0.51 in absence of BS (Figure 6.3A). 
However, differences were observed when the four isolates were grown in the presence of 
BS under anaerobic conditions (Figure 6.3B). Differences in exponential growth rate were 
observed between stool and skin representatives: 9c and F530B showed 0.33 ± 0.01 and 
0.32 ± 0.01 in the presence of BS and 0.31 and 0.36 in absence of BS while DSM 20042 and 
DSM 28764 showed 0.15 ± 0.02 and 0.15 ± 0.06 with BS and 0.18 and 0.15 without BS in 
the media. The maximum exponential growth of 9c and F530B is reached at 9 h, with an 
OD600 of 1.0-1.1 and 1.2 respectively, and the OD600 starts to decrease progressively at 10 
h, arriving to 0.4-0.5 by 48 h. Both strains grow slightly better in the presence of BS. The 
skin isolates, DSM 28764 and DSM 20042 showed different growth behaviour: DSM 20042 
displayed slightly faster growth in the absence of BS in anaerobic conditions than in 
presence of BS. However, at 15 h this growth reaches its maximum, with an OD600 of 0.95 
nm, remaining at this level until 48 h. On the other hand, the DSM 20042 grown with BS in 
the medium reached a maximum OD600 of 1.18 at 25 h and remained at that level for the 
rest of the experiment. DSM 28764 growth was also slightly better in the absence of BS 
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until 22 h, when the DSM 28764 grown in the presence of BS improves and reaches 1.18 
OD600 by 48 h, while the DSM 28764 grown in absence of BS only reached an OD600 of 0.9 
OD. It is important to note that, in anaerobic conditions, while the stool isolates exhibit a 
fast growth at the beginning, this growth gets quickly exhausted and there is a depletion in 
OD, probably due to settling or lysis. On the other hand, although the skin isolates need 
more time to reach their maximum growth, they eventually achieved the same ODs as the 
stool isolates.  
 
Figure 6.3. A. Growth of skin and stool isolates in aerobic conditions and in presence or 
absence of bile. B. Growth of skin and stool isolates in anaerobic conditions and in presence 
or absence of bile. Results are the mean of three replicates ± standard deviation. 
6.3.5.2. Bile acids quantification 
The degradation of cholesterol yields the primary bile acids, cholic acid (CA) and 
chenodeoxycholic acid (CDCA) that are later transformed by intestinal bacteria into 
secondary bile acids by removing a hydroxyl group from the C7 of the primary bile acid 
molecule, giving deoxycholic acid (DCA) from CA and lithocholic acid (LCA) from CDCA. Bile 
also contains bile acids conjugated with glycine and taurine. Bile acids are commonly very 
stable and incubations in the absence of no bacteria had no effect on composition. 
However, when stool and skin isolates of S. epidermidis were grown in the presence of 
porcine bile, we detected a progressive increase of primary bile acids, CA and CDCA with 
time, as a result of the cholesterol degradation. However, we observed that concentrations 
of secondary bile acids, DCA and LCA, rose too. The concentrations of DCA in the culture of 
Chapter VI. Characterisation of S. epidermidis of gut origin 
 
177 
 
skin isolates were very variable, while the much lower levels of LCA varied widely in all 
isolates. It is worth noticing the absence of LCA in the culture of DSM 28764 until 48 h 
(Figure 6.4). There is a decrease of almost 100% at 24 h of glycine conjugated primary and 
secondary bile acids glycochenodeoxycholic acid (GCDCA), glycodeoxycholic acid (GDCA) 
and glycolithocholic acid (GLCA), which somewhat mirrored the rise in deconjugated acids 
for CDCA and DCA. The glycocholic acid (GCA) levels did not show as sharp decrease as the 
others. The levels of the taurine conjugated bile acids remained constant over time in S. 
epidermidis cultures of both skin and stool origins. 
6.3.6. Ability of S. epidermidis isolates to form biofilms 
6.3.6.1. Genomic comparison 
The comparison of the genes involved in biofilms development, previously described as 
virulence factors, in S. epidermidis 9c, F530B, DSM 20042 and DSM 28764 showed no major 
differences. Only two genes of potential relevance, sdrC_2, Ser-Asp rich fibrinogen/bone 
sialoprotein-binding protein SdrC and clfB, clumping factor B, were in the genomes of the 
stool isolates and absent in the genomes of skin isolates (Table 6.5). Both genes are related 
to the accumulation stage of biofilms, involved in cell-cell aggregation and matrix 
production. The SdrC protein has been highlighted as being a determinant of 
staphylococcal biofilm formation [341]. Ica genes, characteristic Staphylococcus genes 
involved in biofilm formation, were in the genome of all four isolates. Other genes involved 
in the biofilm maturation stage and related to thickness, such as teichoic acids, were also 
identified in the genomes of all the isolates.  
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Figure 6.4. Primary, secondary and conjugated bile acids in the media after fermentations with stool isolates 9c and F530B and skin DSM 20042 and DSM 
28764 isolates. Results (ng/ml) are the mean of duplicate measurements +/- standard deviation.
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Table 6.5. Presence of genes involved in biofilm formation in S. epidermidis stool isolates 
and skin type strains. 
Biofilm function 
Gene annotation 
9c F530B DSM  
20042 
DSM 
28764 
1. Initial attachment. Adhesion to material surface. 
atl bifunctional N-acetylmuramoyl-L-alanine amidase/endo-beta-N-
acetylglucosaminidase, Atl 
√ √ √ √ 
atl_2 bifunctional N-acetylmuramoyl-L-alanine amidase/endo-beta-N-
acetylglucosaminidase, Atl 
√ 
   
2. Accumulation. Cell-cell aggregation, matrix production. 
icaD intercellular adhesion protein IcaD √ √ √ √ 
icaC intercellular adhesion protein IcaC √ √ √ √ 
icaB intercellular adhesion deacetylase IcaB √ √ √ √ 
icaA intercellular adhesion protein IcaA √ √ √ √ 
group_28 extracellular matrix binding protein 
 
√ √ √ 
group_29 extracellular matrix binding protein 
  
√ 
 
group_30 extracellular matrix binding protein 
  
√ 
 
group_31 extracellular matrix binding protein √ 
   
sdrD Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrD √ √ √ √ 
sdrC Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrC √ √ √ 
 
sdrE_3 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE_1 √ 
 
√ √ 
sdrH Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrH √ √ √ 
 
sdrD_1 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE 
 
√ √ √ 
sdrE_1 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE_1 
 
√ 
 
√ 
group_20 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE √ 
 
√ 
 
group_61 cell-wall-anchored protein SasC √ 
 
√ 
 
sdrC_2 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrC √ √ 
  
clfB clumping factor B √ √ 
  
group_16 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE_1 √ 
   
group_1853 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrH 
   
√ 
group_21 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE 
  
√ 
 
group_22 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE 
   
√ 
group_23 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE √ 
   
sdrE_2 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE_1 
  
√ 
 
3. Maturation. Thickness increase, dependence of structural features. 
agrA autoinducer sensor protein response regulator protein √ √ √ √ 
agrB accessory gene regulator B √ √ √ 
 
agrD staphylococcal accessory gene regulator protein D √ √ √ 
 
agrB_1 accessory gene regulator B √ 
  
√ 
wecG teichoic acid biosynthesis protein √ √ √ √ 
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tagG teichoic acid ABC superfamily ATP binding cassette transporter, 
membrane protein 
√ √ √ √ 
group_2824 D-Ala-teichoic acid biosynthesis protein √ √ √ √ 
tagH Teichoic acid export ATP-binding protein, TagH √ √ √ √ 
tagB teichoic acid biosynthesis protein B √ √ √ √ 
tagX teichoic acid biosynthesis protein X √ √ √ √ 
group_3224 teichoic acid ABC superfamily ATP binding cassette transporter, 
membrane protein 
√ √ √ √ 
dltD D-alanine lipoteichoic acid and wall teichoic acid esterification secreted 
protein 
√ √ √ √ 
4. Regulation 
rsbU putative sigma factor sigB regulation protein √ √ v √ 
sarA staphylococcal accessory regulator family protein √ √ √ √ 
rsbW anti-sigma-B factor, serine-protein kinase √ √ √ √ 
sigB RNA polymerase sigma factor SigB √ √ √ √ 
rsbV anti-sigma-B factor, antagonist √ √ √ √ 
msa modulator of SarA, Msa √ √ 
 
√ 
sigB_2 RNA polymerase sigma factor SigB √ 
   
5. Other genes involved in biofilm formation 
group_2411 putative polysaccharide biosynthesis protein √ √ √ √ 
group_2526 lipopolysaccharide biosynthesis-related pr-like protein √ √ √ √ 
kdtB lipopolysaccharide core biosynthesis protein KdtB √ √ √ √ 
paaD putative metal-sulphur cluster biosynthetic enzyme, PaaD √ √ √ √ 
fmhB peptidoglycan pentaglycine interpeptide biosynthetic protein FmhB √ √ √ √ 
group_3157 SCP/PR1-like extracellular protein √ √ √ √ 
fmhA FemAB family peptidoglycan biosynthesis protein √ √ √ √ 
fmhB_2 peptidoglycan pentaglycine interpeptide biosynthetic protein FmhB √ 
   
 
6.3.6.2. Biofilm formation 
S. epidermidis strains F530B, 9c, DSM 20042 and DSM 28764 were equally able to form 
biofilms on abiotic surfaces, such PE and glass, at 1:100 and 1:1000 dilution (Table 6.6). S. 
epidermidis F530B was studied further to establish the ability of the cells to adhere to an 
abiotic gold electrode (RTCA) (Figure 6.5) and a biotic surface, the HT29 cell line. It showed 
good abiotic adhesion but a low percentage of adhesion to HT29 cells of 1.6 ± 0.4% (Figure 
6.6), however, a positive control, L. rhamnosus GG, only showed adhesion of 1.5 ± 0.5%.  
S. epidermidis F530B was also tested in competition with enteropathogens to assess if it 
could influence the adhesion levels of those pathogens to the biotic surface of the HT29 
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cell line, using both live and dead cells (Figure 6.7). Adhesion levels of E. coli LMG 2092 to 
HT29 were reduced significantly using both live and dead cells, while adhesion levels of S. 
enterica LT2 were reduced significantly only in the presence of live S. epidermidis F530B.  
  
Table 6.6. Biofilm formation measured by crystal violet staining on glass and PE 
 Glass PE 
Dilution 1:100 1:1000 1:100 1:1000 
S. epidermidis F530B 0.531 ± 0.027 0.026 ± 0.016 0.712 ± 0.027 0.032 ± 0.007 
S. epidermidis 9c 0.483 ± 0.104 0.011 ± 0. 009 0.698 ± 0.113 0.045 ± 011 
S. epidermidis DSM 20042 0.512 ± 0.085 0.012 ± 0.006 0.675 ± 0.051 0.012 ± 0.003 
S. epidermidis DSM 28764 0.611 ± 0.077 0.082 ± 0.032 0.669 ± 0.095 0.033 ± 0.008 
Media control 0.063 ± 0.001 0.057 ± 0.002 0.054 ± 0.002 0.059 ± 0.002 
 
 
Figure 6.5. Adhesion of S. epidermidis F530B to E-plates measured by RTCA. 
 
Figure 6.6. Percentage of adhesion of S. epidermidis F530B to HT29.  
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Figure 6.7. Percentage of adhesion of E. coli LMG 2092, S. enterica LT2 and C. sakazakii LMG 
5740 to HT29 with and without the presence of live or dead cells of S. epidermidis F530B.  
6.3.7. Microscopy 
TEM images show clustered cocci cells. It is possible to observe fibres that could be 
related to exopolysaccharides involved in biofilm matrix (Figure 6.8).   
 
Figure 6.8. TEM images from S. epidermidis 99 at different scales. 
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6.4. Discussion 
This work has investigated three S. epidermidis strains isolated from stool, a source which, 
to our knowledge, is not represented in online databases. These strains were placed in an 
updated S. epidermidis phylogenetic tree and further established genomic traits that 
differentiate these from S. epidermidis isolated from other sources, such as human body 
sites and other environmental niches. There were established phenotypic differences 
between these strains and other S. epidermidis isolated from human skin, cases of bovine 
mastitis and cheese, specifically in terms of utilisation of carbon and nitrogen sources and 
antibiotic sensitivity, and these differences with genomic information in strains of human 
origin were associated. Finally, the behaviour of these strains was compared in terms of 
traits that could influence their lifestyles, such as growth in the presence of bile and 
virulence traits such as biofilm formation.  
While there was no phylogenetic clustering of the three stool isolates of S. epidermidis, 
other strains with a common origin exhibited clustering, such as those isolated from rice 
and mice. However, the fact that these isolates were sourced from the same study may be 
significant [324]. S. epidermidis isolated from different sites in and on the human body 
appeared to be more heterogeneous than their non-human counterparts, a phenomenon 
that has been previously reported for S. epidermidis [342]. One pan-genome analysis 
conducted in 2012 examining skin commensal and hospital infection-associated S. 
epidermidis showed high levels of intra-site diversity and two clear phylogenetic groups 
which differentiated the commensal and the nosocomial isolates [333]. A second whole-
genome comparison study reported that rice endophytic strains are more related to rodent 
isolates than the majority of human isolates, an observation which is also reported using 
our approach [324]. These two studies were conducted on 99 and 93 genomes respectively, 
while this pan-genome approach used 581 genomes.  
While the three stool isolates described here do not form a distinct phylogenetic cluster, 
our pan-genome-wide association approach was able to identify 44 genes, in four clusters, 
significantly associated with stool isolates, including a predicted 30 kb plasmid. In addition, 
it is reported that all three stool isolates contain a type V ACME gene cluster, a recently 
described type of arginine catabolic module element (ACME) characterised by the presence 
of the arginine deaminase pathway-encoding arc operon, the oligopeptide permease ABC 
transporter-encoding opp3 operon, and the potassium transport system-encoding kdp 
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operon [343]. These ACME gene clusters play a role in colonisation of the host and evasion 
of the immune system [344, 345], have been previously described in S. epidermidis isolated 
from the human skin and oral cavity [343, 345], and are significantly enriched in infected 
subgingival oral implants compared to non-infected counterparts [346]. 
These results led to study possible phenotypic differences between stool and skin S. 
epidermidis isolates. Observations made from the simplified phylogenetic tree led to select 
strains isolated from bovine mastitis and cheese in addition to two of our stool isolates. It 
is shown that there were pronounced differences in the use of carbon sources between S. 
epidermidis of different origin, with the bovine mastitis-associated strain being the clear 
outlier. The cheese isolate showed a closer relationship with one of the stool isolates, 
F530B, while isolate 9c’s behaviour seemed to be closer to that of the skin isolates. There 
were identified common traits for both skin and stool isolates. Stool isolates showed 
significantly associated genes such as hsdR_1, hsdM_1, cas6, fecE_2, mntB_2, mntA_2, racA 
and fas6. These genes seemed to be involved in the ability to grow in dulcitol, oxalomalic 
acid, 2,3-butanone, 2-deoxy-D-ribose, 5-keto-D-gluconic acid, D-glucosamine and D-
mannose. However, further analysis indicated that this was a wrong association, 
highlighting the need of a careful analysis of bioinformatics data. Despite a small sample 
size, these carbon sources can be pointed to as an area for further research as a potential 
means for identifying the source of S. epidermidis isolates and designing better treatments 
for nosocomial infections. The nitrogen usage for the different S. epidermidis did not show 
major differences that could be associated to the isolate origin. However, many studies 
have been made on the nitrogen usage of S. epidermis [347, 348]. Staphylococcus spp have 
been proved extensively as being able to be trained to use different nitrogen sources by 
reorganising its metabolism to the extent of being able to use ammonia as a nitrogen 
source instead of amino acids [349, 350]. Despite the highly conserved core genome of 
Staphylococcus spp [351], they can show strain-specific metabolic adaptations [351-353].  
No known BSH genes were identified in the genomes of stool and skin isolates. However, it 
was observed that there was a change in the concentrations of bile acids in the culture 
media of both stool and skin isolates. With both stool and skin isolates, the glycine bond to 
the steroid nucleus of the bile was removed (deconjugation) in GCDCA, GDCA and GLCA, a 
process that increases bile tolerance and survival in the gut and is the pre-requisite for 
biotransformations in human colon, where DCA and LCA are the predominant BS in human 
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faeces [245]. When glycine and taurine are separated from the BS, they are used as sources 
of C and N [354]. The deconjugation is catalysed by the BSH and, despite the fact that no 
BSH were identified in the genomes, it is likely that these S. epidermidis genomes encode 
enzymes able to display that function when necessary. These results, in combination with 
the growth curves observed in anaerobic conditions, suggest that skin isolates are able to 
behave similarly to stool isolates but need some time to reorganise their metabolism in 
order to adapt to the surrounding environment. Interestingly, the growth displayed by the 
skin isolates in the presence of BS suggests that they used these BS as source of nutrients 
that help them increase their growth once their metabolism was adapted to the anaerobic 
conditions. The presence of BS not only did not cause growth inhibition, as it is often 
reported, but appeared beneficial for the growth of the S. epidermidis strains. However, 
this does not necessarily mean that they are using BS, as they could be using other 
compounds which are costly from a metabolic point of view, that led them to grow slowly 
anaerobically. The drop in glycine-conjugated bile acids raises the possibility that the 
glycine might have been used. Comparison of the growth of skin isolates and stool isolates 
revealed an initial faster growth of stool isolates in anaerobic conditions but followed by a 
growth drop. Growth was similar in the presence and absence of BS in the media. These 
suggests that their metabolic routes associated with anaerobic conditions and presence of 
BS were already active and there was no need to reorganise their metabolism. Taurine-
conjugated bile salts were not metabolised by any isolate, which is consistent with the fact 
that only one intestinal organism, Bilophila wadsworthia, is able to use taurine [355, 356]. 
Enzymes for biotransformations of CA into DCA and CDCA into LCA are not as wide spread 
in nature as enzymes for deconjugation, and only a few Clostridia are able to remove the 
hydroxyl from the position 7 [245, 357]. It has been reported, however, that some 
Clostridium and Bacteroides spp are able to use different metabolic routes that enhance 
bile salt degradation [354, 358, 359]. A significant rise in the concentration of DCA could be 
observed, and even with a high variability, it was observed too in the case of LCA. This 
suggests bile acid transformation of some type. Transcriptomics, proteomics and 
metabolomics might provide a route to identify the proteins and/or routes involved in this 
relationship between S. epidermidis and bile acids.    
Other traits considered to be associated with virulence, like biofilm formation, showed 
similar patterns in stool and skin isolates. Small differences were observed at genomic level, 
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in that only two genes of known relevance, sdrC (whose product showed some redundancy) 
and clfB, were present in the genome of stool isolates and were absent from the skin 
isolates. S.  epidermidis also showed some traits that could be interpreted as being 
desirable as, in addition to the production of antimicrobials active against Gram positive 
and negative pathogens, S. epidermidis F530B cells significantly reduced the adhesion of E. 
coli LMG 2092 and S. enterica LT2 to HT29 cells.  
Overall, these results suggest the absence of major specific genomic traits among S. 
epidermidis for adaptation to the different sites within the human body. Therefore, S. 
epidermidis adaptation to human body sites might rely on gene expression, and thus, 
transcriptomics, proteomics and metabolomics would be the next step to understand how 
the metabolism reorganises to adapt to these sites, with care to avoid laboratory 
domestication. Moreover, it is necessary to improve the genome annotations to learn 
which genes and metabolic pathways are associated to the successful adaptation to each 
body site.  
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7.1. Introduction 
The human microbiota associated with faeces includes several species of Lactobacillus. L. 
amylovorus and L. crispatus are two of these species, both of which are members of the L. 
acidophilus group [246, 247]. Despite being typical representatives of the human GIT, they 
have also been linked to other body sites, like the mouth and vaginal tract [360]. Strains of 
both L. amylovorus and L. crispatus have been identified as bacteriocin producers in the 
past. Several investigations have performed on the production of bacteriocin amylovorin 
L471, produced by L. amylovorus L471 [361-365]. Lactobin A is another bacteriocin 
produced by L. amylovorus LMG P-13139 [366]. Both strains were isolated from fresh corn 
steep liquor, and both bacteriocins share similar amino acid residues that show homology 
to the lafX gene product, part of the lactacin F operon. In both cases, the bacteriocins were 
classified as class IIb [366]. On the other hand, crispacin A, a 5393 Da bacteriocin, was 
purified from the supernatant and cells of L. crispatus JCM 2009, isolated from urine [367]. 
A few years later, further antimicrobial activity from a bacteriocin-like compound was 
reported from L. crispatus ATCC 33820, isolated from eye [368]. More recently, a class III 
helveticin-M has been reported to be produced by a chicken intestine-isolate, L. crispatus 
K313 [149]. The production of this bacteriocin was carried out by heterologous expression 
in E. coli and can be considered important because class III bacteriocins/bacteriolysins are 
not as extensively explored as other bacteriocins. Only four class III bacteriocins from 
lactobacilli have been characterised to date, including enterolysin A and helveticin J. The 
activity of enterolysin A has been well characterised [369], but helveticin’s mode of action 
remains unclear, although some evidence suggest that they cause impairment of cell wall 
and membrane in the target cells [149]. 
In addition to their antimicrobial activity, both L. amylovorus and L. crispatus have 
representatives that are considered probiotics. Assimilation and precipitation of 
cholesterol have been reported in both species [370-372]. Other probiotic-associated 
activities include production of phytase [373], alteration of body adiposity [374] and 
competitive exclusion of enteropathogens [375, 376]. Therefore, L. amylovorus and L. 
crispatus are lactobacilli species whose potential activity can be considered beneficial, not 
only in the human GIT, but also in animals [377] and the food industry [378]. 
Chapter VII. Antimicrobial activity of L. amylovorus and L. crispatus 
 
189 
 
Here, one strain of L. amylovorus isolated from human faeces, Lac 20, and two strains of L. 
crispatus isolated from the same source, Lac 50 and Lac 51, are studied, after showing 
antimicrobial activity associated with their respective supernatants and having had their 
genomes analysed by BAGEL (Chapter III). Different strategies to identify the antimicrobial 
compounds were followed, in order to isolate the putative peptide(s)/proteins responsible 
for antimicrobial activity.  The production of SCFA by L. amylovorus Lac 20 and L. crispatus 
Lac 50 and Lac 51 was measured after the supplementation with different carbon sources 
in fermentation conditions. Their adhesion and biofilm formation abilities were also 
studied. Given some behavioural differences that were observed between the two isolates 
of L. crispatus, some genotypic and phenotypic differences between them were studied.  
7.2. Methods 
7.2.1. Partial purification of bacteriocin of L. amylovorus Lac 20 
7.2.1.1. Initial characterisation 
L. amylovorus Lac 20 was grown overnight in 500 ml of culture according to previously 
specified conditions (Chapter II). The culture was centrifuged at 8,000 x g for 20 min and 
separated into pellet and supernatant fractions. The cell pellet was mixed with 50 ml 70% 
2-propan-ol 0.1% TFA (IPA) and stirred for 3 h at room temperature. The sample was 
centrifuged at 8,000 x g for 10 min and the supernatant assayed for activity against L. 
bulgaricus LMG6502 indicator. The culture supernatant was treated further: 5 ml of sample 
was passed through a Millipore centrifugal filter unit containing a 10 kDa cut off membrane. 
Heat stability was checked by heating aliquots of sample to 55, 70, 85 °C for 20 min. 50 μl 
aliquots were plated on an indicator plate. The solvent stability of the antimicrobial was 
assessed by mixing 300 µl of supernatant with 700 µl water, 0.1% TFA, acetonitrile and 
acetonitrile + 0.1% TFA. The mixtures were left at room temperature for approximately 2 h 
before plating on the indicator plate. 
7.2.1.2. Assessment of columns for peptide and protein purification 
The inhibitory activity was analysed by passing the active culture supernatant through 
different columns. The fractions that showed activity were analysed by MALDI-TOF MS to 
assess potential associated masses to the inhibitory activity. 3 ml of supernatant were 
applied to a 3 ml, 200 mg Strata–E C18 SPE column (Phenomenex, UK) pre-equilibrated 
with 15% methanol and 85% water. The column was eluted with 3 ml 30% ethanol and then 
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3 ml 70% 2-propanol 0.1 TFA (IPA).  3 ml of supernatant was applied to a 3 ml 200 mg Strata 
SCX column (Phenomenex, UK) pre-equilibrated with methanol and 50 mM sodium 
phosphate buffer pH 7.0 following manufacturer’s instructions. The column was eluted 
firstly with 3 ml 50 mM sodium phosphate buffer pH 7 and secondly with 3 ml 50 mM 
sodium phosphate buffer pH 7 containing 1M NaCl.  
10 ml of culture supernatant were applied to a column containing 500 mg of Amberlite XAD 
beads and the column was washed with 10 ml of 50 mM sodium phosphate buffer pH 7, 
30% ethanol and IPA. 20 ml of culture supernatant were applied to an Econo column 
containing 2 ml of SP sepharose. The sample was eluted with 10 ml of 50 mM sodium 
phosphate buffer pH 7, 10 ml of 50 mM sodium phosphate containing 1M NaCl pH 7, and 
10 ml of 20 mM potassium phosphate 25% acetonitrile pH 2.5 containing 2M NaCl. 
7.2.1.3. Cation-exchange 
Cation-exchange was performed and SP sepharose was used as a first step in purification. 
400 ml of sample were applied to an Econo column containing 20 ml of SP sepharose (GE 
Healthcare, UK). The column was eluted with 40 ml of 50 mM sodium phosphate buffer pH 
7, 40 ml of 50 mM sodium phosphate buffer pH 7 containing 200 mM NaCl, 40 ml of 50 mM 
sodium phosphate buffer pH 7 containing 500 mM NaCl and 40 ml of 50 mM sodium 
phosphate buffer pH 7 containing 1000 mM NaCl. The 3 ml of the 500 and 1000 mM NaCl 
eluates from the SP column were re-applied on a C18 SPE column following the steps 
described above for this column. 
7.2.2. Partial purification of bacteriocin of L. crispatus Lac 50 
7.2.2.1. Initial characterisation 
L. crispatus Lac 50 was grown overnight in 500 ml culture according to previously specified 
conditions (Chapter II). The culture was centrifuged at 8,000 x g for 20 min and separated 
into pellet and supernatant fractions. The cell pellet was mixed with 50 ml 70% 2-propan-
ol 0.1% TFA (IPA) and stirred for 3 h at room temperature. The sample was centrifuged at 
8,000 x g for 10 min and the supernatant assayed for activity against L. bulgaricus LMG6502 
indicator plates. The solvent stability of the antimicrobial in the culture supernatant was 
assessed by mixing 300 µl of supernatant with 700 µl water, 0.1% TFA, acetonitrile and 
acetonitrile + 0.1% TFA. The mixtures were left at room temperature for approximately 2 h 
before plating on an indicator plate. 
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7.2.2.2. Reversed phase 
Supernatant were applied to a 3 ml, 200 mg Strata–E C18 SPE column (Phenomenex, UK) 
pre-equilibrated with 15% methanol and 85% water. The column was eluted with 30% 
ethanol and 70% 2-propanol 0.1 TFA (IPA) later.  
7.2.2.3. Cation exchange 
Supernatant was applied to an Econo column containing 10 ml of SP sepharose. The column 
was washed with 50 mM sodium phosphate buffer, 20 mM sodium phosphate containing 
500 mM NaCl pH 7 and 20 mM sodium phosphate pH 7, containing 1M NaCl.  
7.2.2.4. Cation exchange with ÄKTA Fast Protein Liquid Chromatography (FPLC) 
Cation exchange was performed in an ÄKTA Fast Protein Liquid Chromatography (FPLC) 
system (GE Healthcare, UK) using a HiPrep SP HP 16/10 column (GE Healthcare, UK) and 
different buffers. Start buffers were 50 mM sodium acetate, 50 mM MES and 50 mM 
sodium phosphate at pHs 5, 6, 6.5 and 7. Elution buffers were 50 mM sodium acetate 1 M 
NaCl, 50 mM MES 1 M NaCl and 50 mM sodium phosphate 1 M NaCl at pHs 5, 6, 6.5 and 7. 
Samples were prepared by dilution in the start buffer. Bacterial supernatant was applied to 
a Millipore centrifugal filter unit containing a cut off membrane of different kDa sizes and 
centrifuged at 4,000 x g for 10 min. A 50 µl aliquot of the retained sample was tested to 
check its antimicrobial activity. The rest of the sample remaining in the cut off unit was 
equilibrated in the start buffer by performing washes, centrifuging each time at 4,000 x g 
for 10 min. The liquid retained was diluted in start buffer and then filter sterilised and 
injected on the AKTA FPLC system. Flow rate was set up at 3 ml/min, following 
manufacturer’s instructions. Fractions were collected for testing by well-diffusion assay.  
7.2.2.5. Cation exchange with ÄKTA Pure 
Cation exchange was performed in an ÄKTA Pure system (GE Healthcare, UK) using a HiPrep 
SP HP 16/10 column (GE Healthcare, UK) and different buffers. Start buffers were 50 mM 
sodium acetate and 50 mM MES at pHs 5 and 7. Elution buffers were 50 mM sodium acetate 
1 M NaCl, 50 mM MES 1 M NaCl and 50 mM at pHs 5 and 7. Samples were prepared by 
equilibrating 50 ml of bacterial supernatant previously tested for antimicrobial activity in 2 
l of start buffer. The equilibration was performed by dialysis (Snake skin 7000 MWCO, 
Thermo Scientific, USA) overnight at 4 oC in agitation. Flow rate was set up at 3 ml/min. 
Fractions were collected for testing by well-diffusion assay. 
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7.2.3. Protein gels 
SDS gels were performed as described in section 2.3.3. Gel slices were prepared for trypsin 
digestion as described in section 2.3.11. 
7.2.3.1. Native gels 
Native gels were used to analysed supernatant samples of L. crispatus Lac 50 and Lac 51. 
NativePAGE™ Novex ®Precast Bis-Tris gels of 3-12% Bis-Tris were used (Life technologies, 
UK) according to manufacturer’s instructions. 12.5 µl of sample were added to 2.5 µl of 
NativePAGE™ sample buffer (4x) and 10 µl of deionised water. The anode buffer was 
prepared by adding 50 ml of 20x NativePAGE™ running buffer to 950 ml of deionised water. 
Two cathode buffers were prepared, the dark blue by adding 50 ml of 20x NativePAGE™ 
running buffer and 50 ml of 20x NativePAGE™ cathode additive to 900 ml of deionised 
water, and the light blue by adding 50 ml of 20x NativePAGE™ running buffer and 5 ml of 
20X NativePAGE™ cathode additive to 945 ml of deionised water. Samples and standard 
were added to the wells and gels were run for 120 min at 150 V. For staining purposes, the 
gels were immersed in staining solution of 0.3% Coomassie, 45% methanol, 10% acetic acid 
and 45% deionised water, shaking horizontally for 30 min. Then they were added to a 
destaining solution of 20% methanol, 10% acetic acid and 70% deionised water, shaking for 
20-30 min. The destaining solution was replaced 3-5 times.  
7.2.4. Genomic analyses 
7.2.4.1. Sequencing and annotation 
L. amylovorus Lac 20, L. crispatus Lac 50 and Lac 51 genomes were sequenced, assembled 
and annotated as explained in section 2.2.9.1. However, L. amylovorus Lac 20 genome was 
re-assembled by Dr. Lizbeth Sayavedra (Quadram Institute Bioscience), in order to find if 
the absence of matches in BAGEL4 were due to assembly problems. The adapter sequences 
were trimmed, and reads were quality filtered (Q=2) using BBduck V37.02 (Bushnell B. - 
sourceforge.net/projects/bbmap/). Genomes were assembled with Spades V3.11.1 using 
the k-mers 21,33,55,77,99, and 127 [379]. The completeness and contamination of the 
genomes were assessed with CheckM v1.0.9 [380]. Assembly metrics were estimated with 
Quast V.4.6.1. L. amylovorus Lac 20, L. crispatus Lac 50 and Lac 51 genomes were re-
annotated using PATRIC V3.5.43 [381].  
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7.2.4.2. Genomic analyses 
L. amylovorus Lac 20, L. crispatus Lac 50 and Lac 51 genomes were analysed as described 
in section 2.2.9.2. Artemis was used to study the genomic environment of specific genes.  
7.2.4.3. Comparative genomics 
An initial comparison between L. crispatus Lac 50 and Lac 51 genomes was performed by 
Dr. Andrea Telatin. I conducted a new comparison using Mauve [382] and regions that 
showed differences were studied to identify affected genes. A final comparison was 
conducted using Roary [383] to identify the exact number of genes that were different.  
7.2.5. Analyses of probiotic traits 
Some probiotic traits were measured as explained in section 2.1.6 and included 
autoaggregation, antioxidant activity and BSH activity. Biofilm formation abilities were 
measured as described in section 2.2. Organic acid quantification was performed as 
described in section 2.4.1.1.  
7.2.6. Phenotypic comparison 
BIOLOG assays were performed as described in section 2.1.9.  
7.3. Results 
7.3.1. Partial purification of peptides 
7.3.1.1. Bacteriocin of L. amylovorus Lac 20 
Assays with partially purified L. amylovorus Lac 20 extracts showed that the cell extract was 
inactive, while the culture supernatant had inhibitory activity against L. bulgaricus 
LMG6502 (Figure 7.1). This antimicrobial activity was stable at 55, 70 and 85°C, suggesting 
it is a peptide rather than a protein. The activity was retained by the 10 kDa membrane 
retentate and no activity was associated with the permeate. The activity was stable at low 
pH (0.1% TFA), indicating that reversed phase should be an appropriate technique for 
purification. 
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Figure 7.1. Inhibition zones of L. amylovorus Lac 20 extracts against indicator strain L. 
bulgaricus LMG6502 after different treatments. Cell extract (C); supernatant (SN); heat 
treatments at 55, 70 and 85°C (55, 70 and 85); retentate in 10 kDa cut off membrane (G10); 
permeate from 10 kDa cut off membrane (L10); antimicrobial stability in water (W); 0.1% 
TFA (0.1%); acetonitrile (ACN); acetonitrile + 0.1% TFA (ACN 0.1%).   
The flow through and eluate obtained from the E C18 SPE column from both extracts 
showed a small zone and a very small zone was produced by the 70% 2-propanol 0.1% TFA 
(IPA) wash where antimicrobial activity was expected to elute (Figure 7.2). The flow 
through from the Strata SCX column showed a small zone of inhibition but no zone in the 
1M NaCl wash where antimicrobial activity was expected to elute. These results suggested 
that these columns were not suited for the purification of the antimicrobial in question. 
The results for the Amberlite XAD beads showed that some activity was lost in the flow 
through, a small inhibition zone with the sodium phosphate buffer and 30% ethanol washes 
and a larger inhibition zone for the IPA eluent were observed.  
The results for the Econo column containing 2 ml of SP sepharose showed that a little 
activity was lost in the flow through but that most eluted in the NaCl containing washes 
(Figure 7.2) and gave the highest final activity.  
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Figure 7.2. Inhibition zones of L. amylovorus Lac 20 extracts against indicator strain L. 
bulgaricus LMG6502 after different purification columns. C-18 row: flow through (FT); 30% 
ethanol (30E); IPA (70). SCX row: flow through (FT); 50 mM sodium phosphate buffer pH 
7.0 (W); 1M NaCl elution (1M). XDA row: flow through (FT); 3 ml 50 mM sodium phosphate 
buffer pH 7.0 elution h (B); 30% ethanol (30E); IPA (70). SP row: flow through (FT); 50 mM 
sodium phosphate buffer pH 7.0 (W); 50 mM sodium phosphate 1M NaCl (1M); 20 mM 
potassium phosphate 25% acetonitrile pH 2.5 2M NaCl (2M). 
The chromatograms obtained with the C18 SPE eluents did not show interesting results. 
However, the chromatograms obtained from the sepharose column 500 mM and 1000 mM 
NaCl fractions showed a 5265 Da mass that could be correlated with activity (Figure 7.3). 
That mass was more dominant in the 1000 mM NaCl sample but the 2000 mM NaCl sample 
is more active. The high salt content in the 2000 mM sample may prevent the mass from 
being detected, as salt content negatively impacts on MALDI TOF mass spectrometry. 
 
Figure 7.3. Chromatogram of fraction obtained from SP column washed with 10 ml of 50 
mM sodium phosphate buffer 1M NaCl.  
The cation-exchange showed that the majority of the activity eluted in the 500 and 1000 
mM NaCl eluates. The chromatogram for the 500 mM NaCl sample showed the 5265 Da 
mass but the chromatogram for the 1000 mM sample did not (Figure 7.4).  
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(A) 
 
(B) 
 
Figure 7.4. (A) Inhibition zones of L. amylovorus Lac 20 extracts against indicator strain L. 
bulgaricus LMG6502 after cation-exchange. Supernatant (SN); flow through (FT); 50 mM 
sodium phosphate buffer pH 7.0 (W); 50 mM sodium phosphate buffer pH 7.0 200mM NaCl 
(200); 50 mM sodium phosphate buffer pH 7.0 500mM NaCl (500); 50 mM sodium 
phosphate buffer pH 7.0 1000 mM NaCl (1000); Eluates from (500) re-applied to C18 SPE 
colum: flow through (FT); 30% ethanol (30E); IPA (70). Eluates from (1000) re-applied to 
C18 SPE colum: flow through (FT); 30% ethanol (30E); IPA (70). (B) Chromatogram of 
fraction (500) showing a mass of 5266 Da that might correspond to the potential peptide.  
7.3.1.2. Protein purification from L. crispatus Lac 50 
The supernatant and cell extract were assayed for activity on L. bulgaricus indicator plates 
and were both active, though there was little activity from the cells (Figure 7.5). The solvent 
stability showed that samples were stable at low pH as the 0.1% TFA sample results in the 
same size zone as the water sample. However, the supernatant diluted with both 
acetonitrile and acetonitrile 0.1% TFA lost activity, suggesting that the antimicrobial loses 
activity in the presence of acetonitrile. This suggests that the antimicrobial is not likely to 
be a peptide, but a protein.  
The fractions collected from reversed phase LC and tested on the indicator plate showed 
that the activity bound to the C18 column, that no activity was lost with the 30% ethanol 
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wash and no activity eluted with IPA. As the antimicrobial is inactive when mixed with 
acetonitrile it is likely to also lose activity when mixed with IPA. These results show that 
reversed phase techniques are not suitable for purification of this antimicrobial. The 
fractions collected from the cation exchange column and tested in the indicator plate 
showed that the antimicrobial activity was retained by the column and the activity eluted 
in the 500 and 1000 mM NaCl samples.  
Purification attempts performed by cation-exchange with ÄKTA FPLC and ÄKTA Pure were 
not able to separate the sample contents. Despite testing different buffers and different 
pH, the contents kept eluting in the unbound but with no separation. Fractions collecting 
the unbound molecules were tested and showed inhibitory activity by well diffusion assay 
against the indicator strain L. bulgaricus DPC5583.  
 
Figure 7.5. Inhibition zones of L. crispatus Lac 50 extracts against indicator strain L. 
bulgaricus LMG6502 after different treatments. Cells (C); supernatant (SN); antimicrobial 
stability in water (W); acetonitrile (A); 0.1% TFA (W 0.1); acetonitrile + 0.1% TFA (A 0.1%); 
C18 SPE separation: supernatant (SN); flow through (FT); 30% ethanol (30E); IPA (70). 
Cation exchange column: supernatant (SN); flow through (FT); 20 mM sodium phosphate 
buffer pH 7.0 (W); 20 mM sodium phosphate buffer pH 7.0 500 mM NaCl (500); 20 mM 
sodium phosphate buffer pH 7.0 1 M NaCl (1 M). 
7.3.2. Protein gels 
SDS gels allowed further confirmation of the molecular mass of the active antimicrobial 
peptides / proteins from L. amylovorus Lac 20 and L. crispatus Lac 50 and Lac 51. The size 
corresponding to the active bands of L. crispatus 50 and 51, that showed inhibitory activity 
against L. bulgaricus 5583, could encode a protein, which correlates with the data obtained 
by the heat and protease test and the partial purification information of L. crispatus Lac 50 
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(Figure 7.6). The L. amylovorus supernatant showed a clear inhibition zone around 5000 Da 
(Figure 7.6). No inhibition zones were obtained from overlays on the native gels.  
 
 
Figure 7.6. SDS gels A1 and B1 are overlaid by indicator strain L. bulgaricus DPC5583. A2 
and B2 show the band disposition. L. crispatus 50 and 51 supernatants are in lanes 1 and 2. 
L. amylovorus in lane 4. Lane 3, L. gasseri LM19 supernatant; lane 5, contents of the 1000 
mM NaCl eluate sample of L. amylovorus Lac 20. Standard BioRad Precision Plus protein 
Dual Extra Standards. 
7.3.2.1. Mass analysis of proteins from gel slices 
A total of 24 peptides and proteins were identified by mass spectrometry from bands 
excised from the region corresponding to antimicrobial activity (Appendix 4).  
The peptides and proteins were shortlisted for following study, based on the presence of 
potential trypsin cleavage sites. Molecular mass of potential peptides derived from that 
cleavage were compared for match with a potential antimicrobial peptide of 5 KDa. The 
gene environments of the 24 matches and the potential modified peptides studied in 
Artemis did not show genes related to described bacteriocin clusters.  
7.3.3. Study of some probiotic traits of L. amylovorus Lac 20 and L. crispatus Lac 50 and 
Lac 51 
7.3.3.1. Adhesion and biofilm formation on abiotic surfaces 
Adhesion to gold electrodes was measured in E-plates using RTCA using two concentrations 
of initial inoculum, 1:100 and 1:1000 dilutions. L. amylovorus Lac 20 showed the highest 
adhesion levels measured by cell index (CI), between 0.4-0.7 (Figure 7.7A). The levels of 
adhesion of L. crispatus Lac 50 in the E-plates were between 0.3-0.5. On the other hand, 
the CI of L. crispatus Lac 51 remained below the 0.2 level established as the medium 
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control, indicating that its adhesion levels at 24 h were at the same level as the medium 
alone (Figure 7.7A).  
To test biofilm capacity, crystal violet assays were performed (Figure 7.7B) on polystyrene 
(PE) and glass. Due to the nature of the assay and probably the nature of the adhesion and 
the manipulation process, high variability was found in crystal violet on E-plate. However, 
when bacteria were grown on PE and glass, less variability was observed. No significant 
differences were observed in the crystal violet assays between the two different inoculums 
for the different Lactobacilli. Lac 50 generally gave the highest levels of biofilm formation. 
(A) 
 
(B) 
 
Figure 7.7. (A) Adhesion levels of L. amylovorus Lac 20, L. crispatus Lac 50 and Lac 51 
measured in E-plates by RTCA. (B) Crystal violet assay to confirm biofilm formation on 
different abiotic surfaces (a) E-plate, (b) PE and (c) glass. Results are the mean of three 
samples ± SD. 
7.3.3.2. Biofilm formation on a biotic surface 
The HT29 cell line was used to establish the ability of the bacteria to adhere to a biotic 
surface. Unlike with abiotic surfaces, L. crispatus Lac 51 showed the highest levels of 
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adhesion to HT29, showing better adhesion than the positive control L. rhamnosus GG, 
while adhesion of L. amylovorus Lac 20 was negligible. (Figure 7.8).  
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Figure 7.8. Percentage of adhesion of lactobacilli strains to HT29 cell line. Results are the 
mean of three samples ± SD.  
7.3.3.3. Competitive exclusion of pathogens using live and dead Lactobacilli 
Investigations were carried out to determine if L. amylovorus Lac 20 and L. crispatus Lac 50 
and 51 could influence the adhesion levels of the enteropathogens E. coli LMG 2092, S. 
enterica LT2 and C. sakazakii LMG 5740 to HT29 cells. L. amylovorus Lac 20 had no 
significant effect on enteropathogen adhesion (Figure 7.9). However, L crispatus Lac 51 
significantly reduced the adhesion levels of S. enterica LT2 and C. sakazakii LMG5740 to 
HT29 both with live and dead cells. L. crispatus Lac 50 showed mixed results against S. 
enterica LT2, with dead cells giving a significant reduction in adhesion but live cells having 
less effect, and its presence did not produce significant differences in the adherence of the 
other two pathogens. Adhesion of C. sakazakii did appear to be promoted in the presence 
of live L. crispatus Lac 50, but variability between samples meant that this difference was 
not significant.  
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Figure 7.9. Adhesion of E. coli LMG 2092, S. enterica LT2 and C. sakazakii LMG 5740 to HT29 
cell line alone or in the presence of live cells (black) and dead cells (grey) of L. amylovorus 
Lac 20, L. crispatus Lac 50 and Lac 51. Results are the mean of two measurements ± SD.  
7.3.4. SCFA production 
L. amylovorus Lac 20 and L. crispatus Lac 50 and 51 were grown in three different media 
(batch model media, MRS and CFBM) supplemented with different carbon sources (no 
supplementation, glucose, lactose, galactose, inulin, starch and pectin) and the presence 
of lactic, formic, acetic, propionic and butyric acids were measured at 24 and 48 h (Figure 
7.10). For the three lactobacilli, the lowest levels of SCFA were found in the batch model 
media, while the highest levels were found in the MRS homemade media. Lactic acid was 
the SCFA most abundant in the three media and at the three timepoints. Overall, the media 
supplemented with simple sugars, more specifically glucose, lactose and galactose, showed 
the highest production of lactic acid. Additionally, acetic acid levels were higher, between 
20 and 30 nM, in MRS. Propionic acid also showed the highest levels in MRS, with levels of 
10 nM as a general rule. Butyric acid levels were very low in all combinations, between 0-2 
nM.  
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(C) 
 
 
Figure 7.10. SCFA levels for fermentations with (A) L. amylovorus Lac 20, (B) L. crispatus Lac 
50 and (C) L. crispatus Lac 51 in batch model media, MRS and CFBM supplemented with 
“no supplementation” (N), glucose (G), lactose (L), galactose (Gal), inulin (I), starch (S) and 
pectin (P) and measured at 24 and 48. Green bars represent lactic acid; blue, formic acid; 
orange, acetic acid; red, propionic acid; yellow, butyric acid.  
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7.3.5. Comparative genomics 
The genomes of the two strains of L. crispatus (Lac 50 and Lac 51) were compared. 2187 
genes were identified: 1658 genes (75.81 %) of them were classified as core genes with a 
probability of 99-100%; 529 genes (24.18 %) were identified as cloud genes, present in only 
one of the strains. Table 7.1 summarises selected genes that could explain the phenotypic 
differences, for example genes encoding for S-layer protein, fibronectin-binding protein 
and mucus-binding protein, which are commonly located on the outside of the cell, could 
explain the differences in behaviour and growth of these two strains.  
 
Table 7.1. List of genes affected by differences in L. crispatus genomic comparison. 
Gene L. crispatus  
Lac 50 
L. crispatus  
Lac 51 
Cadmium resistance transporter x √ 
Endoglucanase x √ 
Fibronectin-binding protein √ x 
Glutaminase √ x 
Glycosyl transferase 2C family 2 x √ 
GTP cyclohydrolase II x √ 
HAD superfamily hydrolase √ x 
Lactose permease √ x 
Lipopolysaccharide biosynthesis glycosyltransferase x √ 
Lipopolysaccharide synthesis sugar transferase x √ 
L-lactate permease √ x 
Major facilitator superfamily 2C Na-driven efflux pump √ x 
Mechanosensitive ion channel x √ 
Membrane alanine aminopeptidase √ x 
Mucus-binding protein √ x 
Nucleotidyltransferase 2FDNA polymerase for DNA repair x √ 
NUDIX family hydrolase x √ 
Permease of the major facilitator superfamily √ x 
Polysaccharide Transporter 2C PTS family x √ 
Potassium transport system protein kup √ x 
PTS system 2C cellobiose-specific IIC component x √ 
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Riboflavin biosynthesis protein ribD x √ 
Riboflavin synthase2C alpha and beta subunit √ x 
Serine protease √ x 
S-layer protein x √ 
S-ribosylhomocysteine lyase x √ 
UDP-galactopyranose mutase x √ 
UDP-glucose 4-epimerase x √ 
UDP-N-acetylmuramate--L-alanine ligase x √ 
 
7.3.6. Antimicrobial sensitivity using BIOLOG 
Based on the information obtained from the comparison and the observed behaviour of 
the two L. crispatus strains, it was hypothesised that differences on the cell surface might 
have an effect on other processes, such as the resistance to different antibiotics. For this 
reason, both L. crispatus Lac 50 and Lac 51 were tested for antimicrobial sensitivity using 
BIOLOG plates with antibiotics. Both strains grew and were inhibited by antibiotics 
targeting cell wall and membrane and elements inside the cell related to metabolism and 
cell processes (Tables 7.2 and 7.3). No patterns were observed and therefore, the results 
are not conclusive with respect to the influence that those differences on the cell surfaces 
might have on the behaviour against antibiotics. However, L. crispatus Lac 50 seemed to 
tolerate a larger number of antimicrobials, particularly those targeting the cell wall and 
protein synthesis and a number of toxic chemicals 
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Table 7.2. BIOLOG chemicals in the presence of which L. crispatus Lac 50 grows better than 
L. crispatus Lac 51.
 
Chemical Target 
Amikacin Cell wall 
Chlortetracycline Protein synthesis 30S 
Amoxicillin Cell wall 
Bleomycin DNA topoisomerase 
Colistin Cell wall 
Capreomycin Protein synthesis 
Demecloclycine Protein synthesis 30S 
Cefazolin Cell wall 
Chloramphenicol Protein synthesis 
Nalidixic acid DNA topoisomerase 
Neomycin Protein synthesis 30S 
Ceftriaxone Cell wall 
Gentamicin Protein synthesis 30S 
Cephalothin Cell wall 
Kanamycin Protein synthesis 30S 
Ofloxacin DNA topoisomerase 
Tetracycline Protein synthesis 30S 
Carbenicillin Cell wall 
Polymyxin B Membrane 
D,L-Serine hydroxamate tRNA synthetase 
5-Fluoroorotic acid Nucleic acid analog 
L-Aspartic-β-
hydroxamate 
tRNA synthetase 
Ampicillin DNA intercalator 
Dequalinium chloride Ion channel inhibitor, 
K+ 
Azlocillin Cell wall 
Oxolinic acid DNA topoisomerase 
6-Mercaptopurine Nucleic acid analog 
Doxycycline Protein synthesis 30S 
Potassium chromate Toxic anion 
Cefuroxime Cell wall 
5-Fluorouracil Nucleic acid analog 
Rolitetracycline Protein synthesis 30S 
Geneticin (G418) Protein synthesis 30S 
Ruthenium red Respiration, 
mitochondria 
Cesium chloride Toxic cation 
Glycine Cell wall 
Thallium (I) acetate Toxic cation 
Cobalt chloride Toxic cation 
Trifluoperazine  Anti-cholinergic 
Cupric chloride Toxic cation 
Moxalactam Cell wall 
Cefatoxamide Cell wall 
Phosphomycin Cell wall 
5-Chloro-7-iodo- 
8-hydroxy-quinoline 
Chelator 
Norfloxacin DNA topoisomerase 
Sulfanilamide Folate antagonist 
Trimethoprim Folate antagonist 
Dichlofluanid (Fungicide) 
Cetylpyridinium chloride Membrane 
1-Chloro-2,4-
dinitrobenzene 
Oxidises sulfhydryls 
Diamide Oxidises sulfhydryls 
Cinoxacin DNA topoisomerase 
Streptomycin Protein synthesis 30S 
Sodium selenite Toxic anion 
Ferric chloride Toxic cation 
Glycine hydroxamate tRNA synthetase 
Chloroxylenol (Fungicide) 
Sorbic acid Respiration, ionophore 
Ketoprofen Anti-capsule agent 
(biofilm) 
Sodium pyrophosphate  
decahydrate 
Chelator 
Trifluorothymidine Nucleic acid analog 
Pipemidic acid DNA topoisomerase 
Azathioprine Nucleic acid analog 
Sulfisoxazole Folate antagonist 
Pentachlorophenol Respiration, ionophore 
Sodium m-arsenite Toxic anion 
Sodium bromate Toxic anion 
Lidocaine Ion channel inhibitor, 
Na+ 
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Sodium metasilicate Toxic anion 
Sodium periodate Toxic anion 
Antimony (III) chloride Toxic anion 
Semicarbazide Amine oxidase 
inhibitor 
Tinidazole Oxidising agent 
Aztreonam Cell wall 
3, 5-Diamino-1,2,4-
triazole  
(Guanazole) 
Ribonucleotide 
reductase  
Inhibitor 
Myricetin DNA, RNA synthesis 
5-fluoro-5’-deoxyuridine Nucleic acid analog 
2-Phenylphenol DNA intercalator 
Plumbagin Oxidising agent 
Harmane Imidazoline binding 
sites 
Chlorhexidine Membrane 
Umbeliferone DNA intercalator 
Cinnamic acid Respiration, ionophore 
Phenyl-methyl-sulfonyl- 
fluoride (PMSF) 
Protease inhibitor 
D,L-Thioctic acid Oxidising agent 
Lawsone Oxidising agent 
Sodium caprilate Respiration, ionophore 
Hydroxylamine DNA damage, mutagen 
 
Table 7.3. BIOLOG chemicals in the presence of which L. crispatus Lac 51 grows better than 
L. crispatus Lac 50 
Chemical Target 
Lincomycin Protein synthesis 
50S 
Penicillin G Cell wall 
Oxacillin Cell wall 
Rifampicin RNA polymerase 
Protamine sulfate Membrane 
Thiamphenicol Protein synthesis 
Myricetin DNA, RNA 
synthesis 
2-Phenylphenol DNA intercalator 
Plumbagin Oxidising agent 
Josamycin Protein synthesis 
50S 
Gallic acid Respiration, 
ionophore 
Coumarin DNA intercalator 
Iodonitro tetrazolium violet Respiration 
Phenyl-methyl-sulfonyl-
fluoride (PMSF) 
Protease 
inhibitor 
Blasticidin S Protein synthesis 
Lauryl sulfobetaine Membrane 
Dihydrostreptomycin Protein synthesis 
30S 
Hexammine cobalt (III) 
chloride 
DNA synthesis 
Thioglycerol Reducing agent 
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7.3.7. Microscopy 
SEM was performed on cultures of L. amylovorus Lac 20, L. crispatus Lac 50 and Lac 51 
(Figure 7.11). Although all three strains presented occasional long chains these were seen 
to be more frequent in L. crispatus Lac 51. 
(A) 
 
(B) 
 
(C) 
 
Figure 7.11. SEM images at different scales for (A) L. amylovorus Lac 20, (B) L. crispatus Lac 
50 and (C) L. crispatus Lac 51. 
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7.4. Discussion 
In this chapter the antimicrobial activity from cultures of L. amylovorus Lac 20 and L. 
crispatus Lac 50 and Lac 51 was demonstrated. Different strategies were used with the aim 
of identifying the putative antimicrobial peptide produced by L. amylovorus Lac 20 and the 
putative antimicrobial protein produced by L. crispatus Lac 50, which could be the same as 
that produced by L. crispatus Lac 51. Additional characterisation of these isolates was 
performed to study potential probiotic traits. 
The antimicrobial activity of L. amylovorus Lac 20 is very likely to have a peptidic origin 
based on gel overlay assays and size exclusion. The absence of results obtained from the 
BAGEL4 analysis suggests either the presence of a totally new system or the absence of key 
data in the databases and algorithms that could potentially identify the gene or genes 
related to this potential peptide. The 24 proteins and peptides, or their modifications, 
obtained by trypsinisation of the SDS gel bands did not match the expected 5 kDa size 
expected from the results of the SDS gel overlayed with the indicator strain. The manual 
curation of the genomic environment of these 24 proteins and peptides did not show 
homologies to bacteriocin operons either. The search for homologies to lactacin X, 
amylovorin L471 and lactobin A also did not show any matches.  
It can be hypothesised, based on gel overlay assays, that the antimicrobial activity linked 
to L. crispatus Lac 50 is produced by a protein of an approximately 30 kDa. The loss of 
activity of the supernatant when heated and in the presence of acetonitrile also suggest a 
protein origin. In chapter III, section 3.3.5 summarised the five operons encoding putative 
antimicrobial proteins that were identified in the L. crispatus genomes of both Lac 50 and 
Lac 51 using BAGEL3. However, since the protein responsible for the observed antimicrobial 
activity has not been isolated yet, it has not been possible to link the activity to a structural 
gene and its operon. It has been reported that some bacteriocins can form aggregates of a 
molecular mass of around 30 kDa [384]. However, these aggregates were separated under 
reduced conditions by SDS gel [384]. The supernatants of L. crispatus Lac 50 and Lac 51 did 
not show these separations.  
It was notable that two closely related strains of L. crispatus isolated from the same 
environment showed such differences in behaviour with regard to biofilm formation and 
adhesion. The differences in behaviour observed between the two strains of L. crispatus 
Lac 50 and Lac 51 could be linked to some of their genomic differences. The surface S-layer 
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proteins in L. crispatus have been connected with its ability to adhere to the human 
intestinal cell line HT29 [385]. A putative lactocepin S-layer and a S- layer protein precursor 
were found in the genome of L. crispatus Lac 51 but were absent in L. crispatus Lac 50. This 
might explain the higher rate of bacterial adhesion of L. crispatus Lac 51 to HT29 and the 
lower rates of adhesion of E. coli LMG 2092, S. enterica LT2 and C. sakazakii LMG 5740 to 
HT29 in the presence of L. crispatus Lac 51; this could be considered competitive exclusion 
and has been reported previously [375]. This difference in the cell surface had the potential 
to result in a different response to antibiotics. Despite the fact that differences were 
observed, since L. crispatus Lac 50 grew better than L. crispatus Lac 51 in the presence of 
88 antimicrobials while L. crispatus Lac 51 grew better than L. crispatus Lac 50 in only 18, 
this might be due to a slower growth behaviour in Lac 51 that was observed throughout 
the study.  
It has been observed that aggregation can be mediated by an aggregation promoting factor 
(APF) similar to the S-layer protein [386]. Aggregation abilities have been proven to affect 
the adhesion to the mucosa of L. crispatus and its survival in the GIT [386].  Both L. crispatus 
Lac 50 and Lac 51 exhibited similar levels of auto-aggregation in vitro and both have in their 
genome the gene encoding the APF and the putative elongation factor Tu, which has also 
been associated with autoaggregation and adhesion [387]. The regulation of this factor has 
been linked to phenotypic changes between aggregative and non-aggregative isogenic 
mutants of L. crispatus [388], so there could be other factors important to cell surface 
quality than just the presence or absence of a gene. More phenotypic changes involve 
differences in growth rates that are related to enzymes associated with carbohydrate 
transport and metabolism, more specifically PTS system, GTP and aminopeptidase, among 
others [388]. These genetic elements have been identified in regions that show differences 
between L. crispatus Lac 50 and Lac 51. This could explain the differences observed in 
culture phenotype between both strains, including the adhesion to biotic and abiotic 
surfaces, where L. crispatus Lac 50 is able to adhere better than L. crispatus Lac 51. 
Autoaggregation and adhesion are desirable phenotypic traits that are considered 
probiotic because they confer the potential to colonise the gastrointestinal tract and avoid 
being washed out [389].   
Following results on section 3.3.6., L. amylovorus Lac 20 and L. crispatus Lac 50 and Lac 51 
exhibit bile salt hydrolase activity in presence of at least to one bile salt. Bile salt hydrolase 
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activity has been proven to interfere with bile recycling in the intestine, forcing the liver to 
move stored cholesterol [243]. This would help to lower cholesterol levels and it is a highly 
desirable characteristic that is already being exploited to design probiotic beverages [390] 
and has been observed in these species previously [251]. Further work would measure 
quantitatively the reduction rates of this BSH activity and compare it with the activity of 
other marketed probiotics. Antioxidant levels are a desirable trait. However, when the 
strains were cultured in appropriate conditions, the percentage of reduction of DPPH was 
very low, suggesting that further work would be needed to determine whether these 
strains have more antioxidant potential than that exhibited here and if it can be regulated 
or enhanced, as it has been observed with the SCFA, using different carbon sources. Simple 
sugars such as glucose, lactose and galactose, increased SCFA production, especially of 
lactic and acetic acids, although very little differences were observed in the production of 
propionic and butyric acids, which have been linked to the gut-brain axis as molecules that 
could be involved as regulators in a series of complex processes, like appetite and anxiety 
control, among others [391].  
In conclusion, L. amylovorus Lac 20 and L. crispatus Lac 50 and Lac 51 are isolates that show 
interesting capabilities in terms of antimicrobial and other probiotic characteristics and 
should be further studied to establish their full potential.  
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The work in this PhD thesis confirms our initial hypothesis that mining bacteria from the 
same niche as that occupied by target pathogens will identify novel antimicrobials that are 
uniquely suited to act in this niche. More specifically, gut and food isolates from culture 
collections in QIB and Teagasc, along with new strains isolated from the same sources, 
showed antimicrobial activity against gut and food pathogens. Those isolates with 
antimicrobial activity were investigated and the ones whose activity was potentially due to 
bacteriocin production were followed. Bacteriocin production was confirmed, and further 
characterisation was performed by the identification of their biosynthetic gene clusters and 
purification of the associated peptides or proteins for further characterisation. These 
analyses involved the examination of host range, the assessment of structure and/or the 
gene expression response to environmental conditions. Additionally, the stability and 
activity of these peptides were tested in faecal fermentations in complex environments to 
study their effect on the native microbiota.  
The initial stages of the PhD project involved the identification of bacteria that exhibited 
antagonistic activity against a range of pathogens that were selected based on their 
importance as agents of food spoilage or gut infection. 313 isolates, 17% of 2100 isolates, 
showed antimicrobial activity against at least one indicator strain, a percentage that was 
similar to those reported previously [63, 392]. The isolation of bacteria with antagonistic 
activity from faecal samples presented three main challenges: the bacteria were only 
selected because they were able to grow in the specific media, what is known as plate count 
anomaly. In some cases bacteria were able to exhibit antimicrobial activity, but either lost 
it in the later experiments or were not able to be subcultured again. The last two situations 
are very likely to happen due to the loss of specific factors from the faecal material that are 
not available when subcultured. These factors might include nutritional requirements for 
growth and inducers to trigger antimicrobial activity, either molecules or other bacteria. 
Alternative approaches developed by other groups for antimicrobial discovery include 
genome mining and the development of Hidden Markov Models to analyse metagenomes 
[393] or using heterologous gene expression to be able to express previously identified 
antimicrobial genes [394, 395]. The food screenings also presented difficulties related to 
the variety of species that were recovered. All fermented foods tested (kefir, gherkins, 
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yogurt and miso) were not produced by natural starter cultures, but manufactured 
commercially, which might decrease their bacterial diversity.  
The type of bioassay was a factor that seemed to be critical for the identification of 
antimicrobial-producing strains. Bioassays that required contact with the indicator strain, 
such as the overlay and cross-streak assays, most frequently yielded antimicrobial activity, 
in contrast with assays using cell-free supernatant, such as the drop test, filter disc and 
well-diffusion assays. Only cell-free supernatant of four isolates, L. gasseri LM19, L. 
amylovorus Lac 20, L. crispatus Lac 50 and L. crispatus Lac 51, exhibited antimicrobial 
activity against at least one indicator strain. This suggests that in many instances the inter-
strain contact is required to trigger antagonistic mechanisms not required in a non-
competition environment. However, the lack of activity in supernatants might also be due 
to a low concentration of the antimicrobial [396]. Bacterial colonies are also more densely 
populated than liquid culture, and therefore, quorum sensing might be another mechanism 
underlying antimicrobial production [397]. Colony MS was performed on bacterial colonies, 
revealing potential peptide masses that were further studied, although this information 
should be considered as supportive and not as definitive with respect to antimicrobial 
identification.   
Some of the isolates that showed interesting characteristics were the subject of genome 
sequencing, and the analysis of their genomes allowed us to make decisions for further 
work, based on the identification of putative bacteriocin gene clusters within these 
genomes. A total of 30 potential antimicrobials in 24 operons were predicted by BAGEL 3. 
However, BAGEL 3 was not able to identify bacteriocin clusters in all genomes, as was the 
case for L. amylovorus Lac 20. For other organisms, it identified operons of potential 
interest but which only contained some genes that represented those typically associated 
with bacteriocin operons. Thus, manual curation of BAGEL results is recommended to avoid 
false positives and, when possible, linking with experimental data. The presence of these 
putative bacteriocin operons and the predicted masses of their potential structural genes 
was correlated with the mass information obtained by colony MS, allowing a targeted 
selection of isolates for further study. Therefore, this combination of techniques can be 
used as part of a strong pipeline to identify new antimicrobials for further characterisation.  
L. gasseri LM19 was selected for deeper study following those criteria. It is a breast milk-
derived bacterium whose genome encodes four bacteriocins, one of them being a novel 
Chapter VIII. Conclusions and future work 
 
216 
 
class IIb bacteriocin, which was named gassericin M. The work performed proved both its 
ability to show antagonist activity against enteropathogens and to survive in a colon 
environment. L. gasseri is a species for which several class IIb bacteriocins have been 
described in the past. However, many of them are similar, being variants that have received 
different names. A revision of the known gassericin names would be useful to improve 
clarity for future work. L. gasseri LM19 carries genes that encode bacteriocins homologous 
to gassericin T and gassericin S. Peptides with masses matching the expected size of the 
class IIb peptides encoded in the genome of L. gasseri LM19 were partially purified, and 
due to the low yield, they were also synthesised, for testing purposes. Both the fractions 
with the predicted masses and the synthesised peptides exhibited antimicrobial activity.  
These bacteriocin genes showed a differential expression response to different carbon 
sources and different growth media. This line of work can be further developed to optimise 
the conditions for bacteriocin production. However, scale up of bacteriocin production can 
be a challenging process, since many elements can interfere with production, such as the 
presence of NaCl. Bacteriocins can also be adsorbed to the producer cells after a long 
fermentation process, and so specific strategies may need to be employed for different 
bacteriocins [364]. 
This work also demonstrates that L. gasseri LM19 is able to survive in simulated colon 
conditions, a characteristic that is desirable in an organism that aims to be used to control 
gut pathogens in situ. L. gasseri LM19 was able to express the putative bacteriocin genes 
in that environment and its addition showed mixed effects controlling a population of C. 
perfringens added to faecal fermentations. However, the metataxonomics profiles in the 
C. perfringens treatments where L. gasseri was added showed that bacterial composition 
changes were less acute than in the presence of C. perfringens alone. SCFA production 
measured by NMR also showed variability between the three donors, but it was increased 
in the L. gasseri LM19 treatments. The pre-established microbial communities might 
explain the different effects that probiotic intake has in different people [398, 399].  
However, further studies would be needed in this front since, despite the suitability of 
colon models to assess certain characteristics like survival in colon conditions, the model 
does not integrate other aspects, like dietary and inflammatory factors [400]. 
Future work with L. gasseri LM19 might involve combination with prebiotics to form 
synbiotics. As shown here, a suitable prebiotic, like inulin or starch might increase the 
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production of butyrate and the gene expression of putative bacteriocins. This could 
increase the potential beneficial effects of L. gasseri LM19. Another possibility is 
microencapsulation, to ensure higher numbers of L. gasseri LM19 are able to arrive to the 
colon.  
Lactobacilli are often found to be producers of antimicrobial activity and have been 
extensively studied as potential probiotics [401]. L. amylovorus Lac 20 and L. crispatus Lac 
50 and Lac 51 are three isolates which were able to show antimicrobial activity and were 
studied further for probiotic traits. The antimicrobial activity is believed to be displayed by 
a peptide in the case of L. amylovorus Lac 20 and by a protein in the case of L. crispatus Lac 
50 and Lac 51. However, although a number of methods were attempted for purification, 
further work is needed to confirm this hypothesis. The next steps could involve the use of 
N terminal sequencing once the peptide and proteins are separated and concentrated. 
With this information it would be possible to identify the structural genes in the genome. 
Knocking out those potential genes and correlating this with the loss of antimicrobial 
activity would give us confirmation that they are the correct genes. The absence of 
potential identities by in silico searches suggests that, in the case of L. amylovorus Lac 20, 
the antimicrobial molecule and machinery might be completely novel.  
The phenotypic differences observed between the two L. crispatus strains Lac 50 and Lac 
51 could also be explored further. It is likely that they are not only due to genomic 
differences, but also due to different responses to the environmental conditions, that could 
be addressed with transcriptomics and proteomics. 
Nisin P, a natural nisin variant, was previously identified by genome mining in two other 
streptococcal species, but this work is the first report of its activity and its structure 
confirmation. The study of its cluster in S. agalactiae DPC7040 showed that the nipPRKFEG 
genes were translocated to the front of the structural gene, something that was observed 
previously in the nisin U operon. The study of the NisFEG proteins involved in immunity 
also showed that this system might have a more important role in lantibiotic immunity than 
previously suspected. Nisin P was purified, and its antimicrobial activity was characterised 
in comparison to nisin A and H. Overall, nisin P exhibited less potent antimicrobial activity 
than nisin A against the tested strains and in a complex environment such as a faecal 
fermentation. Nisin P structure was confirmed by nanoLC-MS, showing that the rings B and 
E were only present partially, which might explain some differences in bioactivity, based on 
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bioengineering studies performed in the past. Other nisin P structural features which might 
be related to the lower activity involve the two different amino acids in the hinge region in 
positions 21 and 22, or the three amino acids shorter at the C-terminal region of the 
molecule, when compared with nisin A. This structure seems to be specific also for the 
receptor, based on the higher levels of nisin P that were required to activate the nisin A 
promotor. Further work would include the use of nisin P and /or U as inducers with cognate 
receptors. The understanding of structure-activity relationships of nisin P can be applied to 
other lantibiotics and to the further development of more efficient antimicrobials [90].  
In addition to the study of bacteriocin producers, this work provides the first genomic 
reference of S. epidermidis isolates of human stool origin. Three stool-isolated S. 
epidermidis strains were sequenced and localised in a phylogenomic tree constructed with 
the rest of the available S. epidermidis genomes from different isolation origin. Although 
the three genomes did not cluster in the phylogenomic tree, 44 genes were significantly 
associated with the stool isolates. All three stool isolates also contained a type V ACME 
gene cluster, linked to colonisation and evasion of the immune system, previously reported 
in mouth isolates. Study at the genomic level did not show major differences between stool 
isolates and the rest of the genome-wide S. epidermidis pangenome. However, phenotype 
comparison between stool and skin isolates showed metabolic behaviour that could 
indicate some level of plasticity to adapt to the different conditions within the human body. 
A phenotype-genotype association between the BIOLOG results on utilisation of carbon 
and nitrogen sources showed that some of those genes that were significantly associated 
with stool isolates were involved in metabolism. 
Both skin and stool S. epidermidis isolates showed very similar growth curves when grown 
in the presence and absence of bile in aerobic conditions. However, stool isolates were able 
to grow faster in anaerobic conditions, at similar rates in the presence and absence of bile, 
while the growth of skin isolates was slower. In the first hours, the absence of bile was 
beneficial for the growth but, after that, the skin isolates grown in the presence of bile 
showed higher growth levels. This correlates with the depletion in the glycine-conjugated 
forms of the bile acids, a phenomenon that might indicate the use of these glycine 
molecules as nutrients. Nonetheless, no bile salt hydrolase genes were discovered through 
genome analysis. This indicates either the need to improve annotation of bile hydrolysing 
genes or that the hydrolase activity is being carried out by other enzymes or metabolic 
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mechanisms. The increase of secondary bile acids also suggests some kind of bile acid 
transformation. Further work would involve the use of transcriptomics, proteomics and 
metabolomics to identify the proteins and/or routes involved in this relationship between 
S. epidermidis and bile acids.  
The work on S. epidermidis and L. crispatus strains shows the importance of not only 
thinking in terms of genomic information to understand the behaviour of human-
associated bacteria, but also how their ability to adapt might rely on gene expression. 
Transcriptomics, proteomics and metabolomics would be the next steps to unveil and 
understand how S. epidermidis reorganises its metabolism to adapt to the environment. 
However, this raises the challenge of avoiding laboratory domestication. Understanding 
these adaptations to the different body sites might allow the discovery of new therapeutic 
targets and the development of effective treatments that could prevent the development 
of antibiotic resistance.  
Overall, this work reinforces the idea that food and gut microbes are a rich source of both 
novel antimicrobials and new strains whose study can further our knowledge of bacterial 
adaptation to environment. Understanding and exploiting this adaptation would be the key 
for a rational design and application of antimicrobials that would help against the 
development of antimicrobial resistance. 
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Appendix 1 
Table S1. Class I bacteriocins 
 
Bacteriocin Produced by Isolated from Doi / reference 
Anacyclamide 
(AcyE) 
Anabaena sp. SYKE763A Lake 10.1128/AEM.01061-09 
Astexin Asticcacaulis excentricus Fresh water 10.1039/c2np20085f. 
Avermipeptin Streptomyces avermitilis DSM 46492 Soil 10.1002/cbic.201200118 
https://www.dsmz.de/catalogues/details/c
ulture/DSM-46492.html 
BLD 1648 Bifidobacterium longum (strain DJO10A) Human intestine  10.1186/1471-2164-9-247 
Bottromycin A2 Streptomyces sp Soil 10.1093/oxfordjournals.jbchem.a128451 
25;251(8):2299-306. 
Bottromycin D Streptomyces scabiei 87.22 Soil 10.1111/j.1364-3703.2009.00561.x. 
Bovicin HJ50 Streptococcus bovis Raw milk doi.org/10.1099/mic.0.26437-0 
BsaA2 Staphylococcus aureus (strain MW2) Septicemia  MMWR Morb Mortal Wkly Rep. 1999 
20;48(32):707-10.  
Butyrivibriocin Butyrivibrio fibrisolvens AR10 Rumen Appl Environ Microbiol. 1997 63(2): 394–
402. 
Butyrivibriocin 
OR79 
B.  fibrisolvens OR79A Rumen Appl Environ Microbiol. 1999 65(5):2128-35 
Catenulipeptin Catenulispora acidiphila DSM 44928 Forest soil 10.1021/cb3002446  
https://www.dsmz.de/catalogues/details/c
ulture/DSM-44928.html 
Cinnamycin 
(Ro09-0198) 
Streptoverticillium griseoverticillatum 
MAR 164CMY6, synonym of 
Streptomyces cinnamoneus 
Soil 199(2):411-5. 
https://www.lgcstandards-
atcc.org/products/all/19769.aspx?geo_cou
ntry=ie#generalinformation 
https://www.dsmz.de/catalogues/details/c
ulture/DSM-40114.html  
Cypemycin Streptomyces sp. OH-4156 Soil  10.7164/antibiotics.46.1666 
Cytolysin  ClyLl 
and ClyLs 
Enterococcus faecalis Gut Cell Microbiol. 2003 5(10):661-9 
10.1038/415084a 
Duramycin 
(Leucopeptin)  
S. griseoverticillatum, synonym of S. 
cinnamoneus 
Soil 10.1021/ja01548a029 
https://www.lgcstandards-
atcc.org/products/all/19769.aspx?geo_cou
ntry=ie#generalinformation 
https://www.dsmz.de/catalogues/details/c
ulture/DSM-40114.html  
Duramycin B Streptoverticillium sp (strain R2075) Soil 10.7164/antibiotics.43.1403 
Duramycin C Streptomyces griseoluteus R2107 Soil 10.7164/antibiotics.43.1403 
Enterocin_W  E. faecalis NKR-4-1 Pla-ra,  Thai 
fermented fish 
10.1128/AEM.06497-11 
Entianin Bacillus subtilis subsp. spizizenii Desert 10.1128/AEM.01962-10 
https://www.dsmz.de/catalogues/details/c
ulture/DSM-15029.html 
Epidermin Staphylococcus epidermidis TÜ 3298 Skin 10.1007/BF00256208 
https://patents.google.com/patent/EP0431
350A1/fi 
10.1128/genomeA.00112-16 
Epilancin 15X S.epidermidis 15X154 Wound infection 10.1016/j.febslet.2005.01.083 
Ericin A B. subtilis Soil 10.1111/j.1365-2958.2005.04587.x 
Ericin S B. subtilis Soil  10.1111/j.1365-2958.2005.04587.x 
Erythreapeptin Saccharopolyspora erythraea NRRL 
2338 
Soil 10.1002/cbic.201200118 
https://www.lgcstandards-
atcc.org/products/all/11635.aspx?geo_cou
ntry=ie 
FrEUN1f 0188 
putative 
linardin 
Frankia sp. EUN1f Root  10.1007/978-94-011-5232-7_38 
10.1073/pnas.1008608107 
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Gallidermin Staphylococcus gallinarum Tü 3928 Chicken skin 10.1023/A:1005667406165 
Gardimycin 
(actagardine) 
Actinoplanes liguriae ATCC 31048 Soil  10.7164/antibiotics.52.730 
https://www.lgcstandards-
atcc.org/products/all/31048.aspx?geo_cou
ntry=ie 
Geobacillin I Geobacillus thermodenitrificans NG80-2 Subsurface oil 
reservoir 
10.1073/pnas.0609650104 
10.1073/pnas.1116815109 
Geobacillin I 
like 
Geobacillus kaustophilus HTA426 Sea mud Mariana 
Trench 
10.1128/AEM.01669-12  
Geobacillin II G. thermodenitrificans NG80-2 Subsurface oil 
reservoir 
10.1073/pnas.1116815109  
Glycocin F Lactobacillus plantarum KW30 Fermented corn 10.1111/j.1365-2672.1996.tb03561.x  
10.1002/chem.201405692  
Grisemycin Streptomyces griseus NBRC 13350 Soil 10.1128/JB.00204-08 
10.1128/JB.00171-11  
Griseopeptin S. griseus DSM 40236 Soil  10.1002/cbic.201200118 
https://www.dsmz.de/catalogues/details/c
ulture/dsm-40236.html 
Haloduracin  Bacillus halodurans C-125 Soil 10.1073/pnas.0606088103  
https://www.lgcstandards-
atcc.org/products/all/BAA-
125.aspx?geo_country=ie 
Htur 3018 
putative 
linardin 
Haloterrigena turkmenica DSM 5511 Soil https://www.dsmz.de/catalogues/details/c
ulture/DSM-5511.html 
Labyrinthopept
in A1/A3 
Actinomadura namibiensis Soil  10.1099/ijs.0.02286-0  
10.1002/anie.200905773  
Labyrinthopept
in A2 
A. namibiensis Soil  10.1099/ijs.0.02286-0  
10.1021/bi200526q 
Lacticin 3147 Lactococcus lactis subsp. lactis Irish kefir grain Appl Environ Microbiol. 1996 62(2):612-9. 
Lacticin 481 
(Lactococcin 
DR) 
L. lactis subsp lactis CNRZ 481 Dairy isolate https://patents.google.com/patent/CA2695
487A1/no 
10.1007/978-1-4615-2668-1_7 
Lactocin S Lactobacillus sakei L45 Dry fermented 
sausage 
Appl Environ Microbiol. 1991 57(6):1829-
34. 
Lantibiotic 
107891 
Microbispora sp. 107891 Environment https://patents.google.com/patent/CA2695
487A1/no 
Lariatin A Rhodococcus sp. K01-B0171 Soil 10.1021/ja056780z 
10.1038/ja.2007.48 
Lariatin B Rhodococcus sp. K01-B0171 Soil 10.1021/ja056780z 
10.1038/ja.2007.48 
Lichenicidin 
VK21 
Bacillus licheniformis VK21 Thermal springs  10.1021/bi100871b 
10.1023/A:1015463122840 
Lxx19440 
putative_linard
in 
Leifsonia xyli CTCB07 Plant pathogen 10.1094/MPMI.2004.17.8.827  
Lxx19470 
putative 
linardin 
L. xyli CTCB07 Plant pathogen 10.1094/MPMI.2004.17.8.827 
Macedocin Streptococcus macedonicus ACA-DC 198 Greek cheese 10.1128/aem.68.12.5891-5903.2002 
Macedovicin S. macedonicus ACA-DC 198 Greek cheese 10.1016/j.fm.2012.09.008 
McdA1 S. macedonicus ACA-DC 198 Greek cheese 10.1016/j.idairyj.2007.10.006 
Mersacidin Bacillus sp (strainHIL-Y85/54728) Soil 10.7164/antibiotics.45.832 
Michiganin A Clavibacter michiganensis subsp. 
michiganensis 
Tomato pathogen 10.1128/AEM.00639-06 
Microbisporicin 
NAI-107 
Microbispora corallina Environment  10.1073/pnas.1008285107 
10.1016/j.chembiol.2007.11.009 
10.1021/bi700131x 
Microcin B17 
(MccB17) 
Escherichia coli LR05 Human gut baby 10.1099/mic.0.26396-0 
10.1002/prot.340010305 
Microcin E492 Klebsiella pneumoniae RYC492 Human faeces 10.1007/BF00692715 
10(1):74-85. 
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Microcin H47 
(MccH47) 
E. coli H47 Human faeces 10.1128/jb.172.11.6585-6588.1990 
Microcin L E. coli LR05 Human faeces 10.1111/j.1574-6968.2000.tb09408.x 
Microcin M E. coli K12 MC4100 Human faeces 10.1099/mic.0.26396-0 
Microcin V 
(ColicinV) 
E. coli human faeces 10.1128/MMBR.00036-06 
Microcyclamide Microcystis aeruginosa 
NIES-298 
Freshwater  10.1021/np000159p 
10.1016/S0040-4039(00)76848-1 
Mutacin 1140 
(MutacinIII) 
Streptococcus mutans JH1140 Spontaneous 
mutant of JH1000 
(oral cavity) 
66(6): 2743–2749 
https://www.lgcstandards-
atcc.org/products/all/55677.aspx?geo_cou
ntry=ie 
Mutacin B 
Ny266 
S. mutans Human mouth 10.1016/s0014-5793(97)00425-0 
10.1139/m89-056 
Mutacin II 
(Mutacin H-
29B) 
S. mutans Human mouth 10.1139/m89-056 
10.1186/1471-2180-6-36 
Mvan 2782 
putative 
linardin 
Mycobacterium vanbaalenii PYR-1 Oil contaminated 
sediment 
10.1128/JB.00215-11 
10.1007/s10532-008-9189-z 
NAI-802  Actinoplanes sp. DSM 24057  Environment 10.1038/ja.2012.92 
https://patents.google.com/patent/US2014
0094402A1/en 
Nisin A L. lactis Milk 10.1111/j.1751-7915.2010.00207.x 
Nisin F L. lactis F10 Freshwater catfish 10.1128/AEM.01862-07 
Nisin Q L. lactis 61-14 River water  10.1271/bbb.67.1616 
Nisin U Streptococcus uberis Bovine mastitis 10.1128/AEM.72.2.1148-1156.2006 
Nisin Z L. lactis NIZO 221 86 Dairy isolate 10.1111/j.1432-1033.1991.tb16317.x 
Nmul A1818 
putative 
linardin 
Nitrosospira multiformis ATCC 25196 Soil 10.1073/pnas.1008608107 
https://www.lgcstandards-
atcc.org/products/all/25196.aspx?geo_cou
ntry=ie 
Nosiheptide Streptomyces actuosus ATCC 25421 Soil 10.1007/BF01575585 
https://patents.google.com/patent/US3057
779 
https://www.lgcstandards-
atcc.org/Products/All/25421.aspx?geo_cou
ntry=ie#generalinformation 
Nukacin A 
(NukacinISK-1) 
Staphylococcus warneri ISK-1 Nukadoko, 
fermented rice bran 
10.1271/bbb.64.2420 
Paenibacillin Paenibacillus polymyxa OSY-DF Kimchee 10.1128/AEM.02023-06 
Patellamide A Prochloron sp. Cyanobacterial 
symbiont  
10.1073/pnas.0501424102 
Pep5 S. epidermidis Diagnostic material 
in laboratory 
10.1007/BF00447005 
Plantaricin W L. plantarum LMG 2379 Fermented wine 10.1099/00221287-147-3-643 
Plantazolicin Bacillus amyloliquefaciens FZB42 Soil 10.1128/JB.00784-10 
Prenylagaramid
e B 
Planktothrixa gardhii NIES-596 Cyanobacteria  10.3390/md13116910 
Prenylagaramid
e C 
P. gardhii NIES-596 Cyanobacteria  10.3390/md13116910 
Putative  
lantibiotic 
Streptococcus pyogenes M1GAS Human wound 
infection 
10.1073/pnas.071559398 
Putative 
lantibiotic 
S. pyogenes SSI-1 Human septic shock  10.1101/gr.1096703 
Putative 
lantibiotic 
S. aureus subsp. aureus MSSA 476 Osteomyelitis  10.1073/pnas.0402521101 
Putative 
lantibiotic 
precursor 
Bacillus cereus ATCC 14579 Gelatine-dish 
exposed to the air in 
a cow-shed 
10.1038/nature01582 
10.1098/rstb.1887.0011 
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https://www.lgcstandards-
atcc.org/products/all/14579.aspx?geo_cou
ntry=ie#generalinformation 
Rp 71.955 Streptomyces sp AA3891 Soil 10.1007/BF00211754 
https://patents.google.com/patent/EP0603
030A3/en 
Ruminococcin 
A 
Ruminococcus gnavus Human faeces 10.1128/aem.67.9.4111-4118.2001 
Salivaricin 9 Streptococcus salivarius M18 Human saliva 10.1099/mic.0.044719-0 
Salivaricin A S. salivarius 20P3   Human saliva Appl Environ Microbiol. 1993 59(7):2014-21 
Salivaricin B S. salivarius K12 Human saliva 10.1371/journal.pone.0077751 
10.1128/AEM.02265-06 
Salivaricin A2 S. salivarius K12 Human saliva 10.1128/AEM.02265-06 
Salivaricin A3 S. salivarius Human saliva 10.1128/AEM.72.2.1459-1466.2006 
Salivaricin A4 S. salivarius Human saliva 10.1128/AEM.72.2.1459-1466.2006 
Salivaricin  A5 S. salivarius Human saliva 10.1128/AEM.72.2.1459-1466.2006 
Salivaricin D S. salivarius 5M6c Human faeces 10.1128/AEM.06588-11 
Salivaricin G32 S. salivarius G32 Human saliva 10.1155/2012/738503 
Salivaricin A S. pyogenes MGAS 10394 Human throat https://www.lgcstandards-
atcc.org/Products/All/BAA-
946.aspx?geo_country=ie  
Sap B Streptomyces coelicolor Potato 10.1016/0092-8674(91)90096-H 
78:528-38 
SCAB 84151 
putative 
linardin 
S. scabiei 87.22 Potato 10.1111/mpp.12296 
http://webcat.warwick.ac.uk/record=b2340
081~S15 
SCAB 
84201putative 
linardin 
S. scabiei 87.22 Potato http://webcat.warwick.ac.uk/record=b2340
081~S15 
SGR 1511 
putative 
linardin 
S. griseus IFO 13350 Soil 10.1128/JB.00171-11 
SGR 1512 
putative 
linardin 
S. griseus IFO 13350 Soil 10.1128/JB.00171-11 
SGR 1513 
putative 
linardin 
S. griseus IFO 13350 Soil 10.1128/JB.00171-11 
SGR 1514 
putative 
linardin 
S. griseus IFO 13350 Soil 10.1128/JB.00171-11 
SiamycinI 
(BMY-29304) 
Streptomyces sp. AA6532 Soil 10.1007/BF00211754 
SiamycinII 
(BMY-29303) 
Streptomyces sp. AA3891 Soil 10.1007/BF00211754 
Smb S. mutans GS5    Human caries 10.1128/AAC.49.2.541-548.2005 
10.1128/JB.01106-12 
Sporulation-
killingfactor 
skfA 
B. subtilis (strain168) Chemically induced 
from Marburg strain 
10.1128/JB.00722-08 
Staphylococcin 
C55 Saca A 
S. aureus C55 Skin J Bacteriol. 1969 97(3):985-91 
Streptococcin 
A-FF22 
S. pyogenes Human throat  10.1128/aac.4.3.214 
Streptococcin 
A-M49 
S. pyogenes Nephritis J Clin Microbiol. 1976  4(3): 232–238 
Sublancin 168 B. subtilis (strain168) Chemically induced 
from Marburg strain 
10.1128/JB.00722-08 
Subtilin B. subtilis Soil 10.3181/00379727-61-15216 
SvirD4 22614 
putative 
linardin 
Streptomyces viridochromogenes Unknown (possibly 
soil) 
10.1073/pnas.1008608107 
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Thermophilin 
1277 
Streptococcus thermophilus SBT1277 Raw milk 10.1111/j.1365-2672.2006.03159.x 
Thiocillin  B. cereus (strain ATCC 14579/DSM31) Soil  10.1073/pnas.0900008106 
http://www.bacdive.dsmz.de/resultpdf.php
?resultid=607 
Thiocillin GE 
37468 
Streptomyces sp. Waksman and Henrici 
(ATCC® 55365) 
Soil  10.7164/antibiotics.44.693 
Thiomuracin A Nonomurae sp. Soil 10.1021/jm300783c 
Thiostrepton A Streptomyces azureus Soil 10.1007/978-3-642-46403-4_18 
Thuricin CD Bacillus thuringiensis DPC 6431 Human faeces 10.1073/pnas.0913554107  
Thuricin H 
(thuricin 17) 
B. thuringiensis SF361 Honey 10.1111/j.1574-6968.2009.01749.x 
Trichamide Trichodes miumerythraeum ISM101   Bloom-forming 
marine 
cyanobacterium 
0.1128/AEM.00380-06 
Trunkamide A Lissoclinum sp Great Barrier Reef 10.1021/jo9914566 
Ulithiacyclamid
e 
Lissoclinum patella Western Caroline 
Islands 
10.1021/ja00537a053 
Variacin Kocuria varians Salami 10.1046/j.1365-2672.2001.01222.x 
Venezuelin Streptomyces venezuelae Soil 10.1371/journal.pbio.1000339 
Thiocillin 
GE2270 
Planobispora rosea Soil 10.7164/antibiotics.44.693 
10.7164/antibiotics.44.702 
https://www.lgcstandards-
atcc.org/Products/All/53773.aspx?geo_cou
ntry=ie 
Subtilosin A B. subtilis (strain 168) Chemically induced 
from Marburg strain 
10.1128/JB.00722-08 
10.1093/oxfordjournals.jbchem.a135315 
Capistruin Burkholderia thailandensis E264 Soil 10.1021/ja802966g 
https://www.lgcstandards-
atcc.org/products/all/700388.aspx?geo_co
untry=gb 
Circularin A Clostridium beijerinckii ATCC 25752 Soil 10.1128/aem.69.3.1589-1597.2003 
https://www.dsmz.de/catalogues/details/c
ulture/DSM-791.html 
Carnocyclin A Carnobacterium maltaromaticum 
UAL307 
Fresh pork 10.1128/AEM.00817-08 
Butyrivibriocin 
AR10 
Butyrivibriofibri solvens AR10 Rumen Appl Environ Microbiol. 1997 63(2): 394–
402. 
Enterocin AS-48 E. faecalis AS-48 Human faeces 10.1139/m86-141 
Enterocin AS-
48RJ 
E. faecalis RJ16 Goat cheese 10.1016/j.syapm.2005.01.007 
Garvicin ML Lactococcus garvieae DCC43 Mallard ducks 10.1128/AEM.01173-10 
Gassericin A Lactobacillus gasseri LA39 Human faeces 10.1271/bbb.62.2438 
Lactocyclicin Q Lactococcus sp. QU12 Cheese 10.1128/AEM.02299-08 
Leucocyclicin Q Leuconostoc mesenteroides TK41401 Japanese pickles 10.1128/AEM.06348-11 
Microcin 
J25(MccJ25) 
E. coli AY25 Human faeces 10.1128/jb.174.22.7428-7435.1992 
Uberolysin S. uberis 42 Mastitis 10.1099/mic.0.2006/005967-0 
Carnolysins A1 Carnobacterium maltaromaticum C2 Brazilian smoked 
fish 
10.1016/j.ijfoodmicro.2013.12.019 
Carnolysins A2 C. maltaromaticum C2 Brazilian smoked 
fish 
10.1016/j.ijfoodmicro.2013.12.019 
Ticin A1 B. thuringiensis BMB3201 Soil China 10.1128/AEM.01851-15 
Ticin A2 B. thuringiensis BMB3201 Soil China 10.1128/AEM.01851-15 
Ticin A3 B. thuringiensis BMB3201 Soil China 10.1128/AEM.01851-15 
Formicin Bacillus paralicheniformis APC 1576 Mackerel intestine 10.1099/mic.0.000340 
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Appendix 2 
Table S2. Class II bacteriocins  
 
Bacteriocin Produced by Isolated from Doi / reference 
Abp118 L. salivarius UCC-118 Human gut 10.1099/00221287-148-4-973 
AcdB acidocin  Lactobacillus acidophilus M46 Unknown (reference omitted) 10.1099/13500872-141-7-
1629 
10.1111/j.1574-
6968.1994.tb06724.x 
Acidocin 8912 L. acidophilus Dairy product 10.1080/00021369.1991.1087
0929 
Acidocin J1132 L. acidophilus JCM1132 Human faeces Appl Environ Microbiol. 1996 
62(3):892-7 
Acidocin LF221B (Gassericin 
K7B) 
L. gasseri LF221B Human faeces 10.1007/s002530051221 
Acidocin A L. acidophilus TK9201 Starter fermented milk Appl Environ Microbiol. 1995  
61(3): 1061–1067 
AdDLP Anaeromyxobacter 
dehalogenans 
Soil 10.1371/journal.pone.000210
3 
10.1016/j.bbrc.2009.07.043 
AFP-1 Streptomyces tendae Tü901 Soil J Bacteriol. 1999 181(24): 
7421–7429 
Amylovorin Lactobacillus amylovorus DCE 
471 
Corn liquor 10.1016/S0723-
2020(96)80003-8 
Aureocin A53 S. aureus A53 Pasteurised commercial milk 10.1128/aem.68.11.5274-
5280.2002 
Bac32 Enterococcus faecium VRE 
200 
Human faeces 10.1128/AAC.50.4.1202-
1212.2006 
Bac43 E. faecium VRE 82 Human faeces 10.1128/aem.68.11.5274-
5280.2002 
Bacteriocin 31 E. faecalis YI717 Clinical isolate 10.1128/jb.178.12.3585-
3593.1996 
Bacteriocin J46 L. lactis subsp. cremoris J46 Fermented milk 10.1006/anae.1996.0018 
Bacteriocin like peptide 
associated 
S. pyogenes M1GAS Wound infection 10.1073/pnas.071559398 
Bacteriocin like peptide 
associated 
S. pyogenes SSI-1 Human septic shock 10.1101/gr.1096703 
Bacteriocin LS2 L. salivarius BGH01 Human mouth 10.1016/j.ijantimicag.2012.04
.011 
Bacteriocin T8 E. faecium T8 Human vaginal secretions  10.1128/AEM.00436-06 
Bavaricin A L. sakei MI401 Sour doughs 10.1111/j.1365-
2672.1993.tb02755.x 
Bavaricin MN Lactobacillus sake MN Meat 62(12): 4529–4535 
57(6): 1683–1688 
BlpI Streptococcus pneumoniae 
TIGR4 (previously JNR.7/87) 
Human blood 10.1126/science.1061217 
BlpJ S. pneumoniae TIGR4 
(previously JNR.7/87) 
Human blood  10.1126/science.1061217 
BlpM S. pneumoniae TIGR4 
(previously JNR.7/87) 
Human blood 10.1126/science.1061217 
10.1128/IAI.01775-05 
BlpN S. pneumoniae TIGR4 
(previously JNR.7/87) 
Human blood 10.1126/science.1061217 
10.1128/IAI.01775-05 
BlpO S. pneumoniae TIGR4 
(previously JNR.7/87) 
Human blood 10.1126/science.1061217 
10.1128/IAI.01775-05 
BlpU S. thermophilus 18311 Yogurt 10.1038/nbt1034 
Bovicin 255 peptide Streptococcus sp. LRC0255 Rumen 10.1128/AEM.67.2.569-
574.2001 
Brochocin C Brochothrix campestris ATCC 
43754 
Soil 59(7): 2326–2328 
 https://www.lgcstandards-
atcc.org/products/all/43754.a
spx?geo_country=ie 
Appendices 
 
251 
 
BTL B. subtilis B-TL2 Tobacco stems 10.1016/j.peptides.2007.11.0
24 
Carnobacteriocin A (Piscicolin 
61) 
Carnobacterium piscicola 
LV61 
Meat  Current Microbiology 
August 199429(2):63-8 
Carnobacteriocin B2 C. piscicola LV17 Vacuum-packed meat Appl Environ Microbiol. 1996 
62(11):4095-9 
Appl Environ Microbiol. 1990 
56(8):2503-10 
Carnobacteriocin BM1 
(CarnobacteriocinB1) 
C. piscicola LV17B Vacuum-packed meat 10.1128/MMBR.00016-05 
Carnocin CP52 C. piscicola CP5 Ripened cheese Curr Microbiol. 1997 
35(6):319-26 
Cerein 7B B. cereus Bc7 Soil 10.1111/j.1574-
6968.2005.00009.x 
10.1111/j.1574-
6968.1999.tb08696.x 
Coagulin A Bacillus coagulans I4 Cattle faeces 10.1046/j.1365-
2672.1998.00466.x 
Colicin V Xylella fastidiosa 9a5c Infected twigs of orange tree 10.1089/omi.2005.9.43 
https://www.ncbi.nlm.nih.gov
/bioproject?cmd=ShowDetail
View&TermToSearch=271 
Curvacin A Lactobacillus curvatus 
LTH1174 
Dry sausages 10.1016/S0723-
2020(11)80223-7 
Curvaticin FS47 L. curvatus FS47 Retail meat 10.1016/0168-
1605(93)90017-b  
Appl Environ Microbiol. 1994 
60(6):2191-5 
Curvaticin L442 L. curvatus L442 Fermented sausage 10.1007/s10482-005-9004-3 
Delta-lysin I S. warneri RK Environment 10.1016/j.peptides.2008.01.0
17 
10.1016/j.femsle.2005.03.046 
Divercin RV41 Carnobacterium divergens 
V41 
Construction 10.1159/000104756 
Divercin V41 C. divergens V41 Fish viscera 10.1099/00221287-144-10-
2837 
Divergicin 750 C. divergens 750 Laboratory stock, 
Bundesanstalt fur 
Fleischforschung, Kulmbach. 
Germany, 
10.1111/j.1574-
6968.1996.tb08043.x 
Divergicin A C. divergens LV13 Fish 62(11):4095-9 
10.1128/jb.177.11.3143-
3149.1995 
Divergicin M35 C. divergens M35 Smoked mussels 10.1016/j.ijfoodmicro.2004.0
4.013 
Durancin TW-49M Enterococcus durans QU49 Carrot 10.1111/j.1365-
2672.2008.03798.x 
E50-52 E. faecium commercial broilers 10.1021/jf073284g 
Enterocin P-like E. faecium P 13 Dry fermented sausage Appl Environ Microbiol. 1997 
63(11):4321-30 
EJ97enterocin E. faecalis EJ97 Waste water 10.1007/s002030050678 
EntA E. faecium PLBC21 T136 Wood pigeons  10.1007/s00253-007-1044-3 
Enterocin 1071 E. faecalis BFE 1071 Minipig faeces 10.1128/aem.66.4.1298-
1304.2000 
Enterocin A E. faecium CTC492 Dry fermented sausage Appl Environ Microbiol. 1996 
62(5):1676-82 
Enterocin B E. faecium T136 Dry fermented sausage 10.1099/00221287-143-7-
2287 
Enterocin CRL35 Enterococcus mundtii CRL35 Cheese 10.1128/AAC.48.7.2778-
2781.2004 
Enterocin E-760 Enterococcus sp. NRRL B-
30745 
Chicken ceca 10.1128/AAC.01569-06 
Enterocin L50  E. faecium L50  Dry fermented sausage Appl Environ Microbiol. 1995 
61(7): 2643–2648 
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Enterocin NKR-5-3A E. faecium NRK-5-3 Fermented fish 10.1271/bbb.110972 
Enterocin NKR-5-3D E. faecium NRK-5-3 Fermented fish 10.1271/bbb.110972 
Enterocin NKR-5-3Z E. faecium NRK-5-3 Fermented fish 10.1271/bbb.110972 
Enterocin P E. faecium P13 Dry sausages Appl Environ Microbiol. 1997 
63(11):4321-30 
Enterocin Q E. faecium L50 Fermented sausage 10.1128/jb.182.23.6806-
6814.2000 
Enterocin RJ-11 E. faecalis RJ-11 Rice bran 10.1128/aem.69.10.5546-
5553.2003 
Enterocin SE-K4 E. faecalis K4 Grass silage 10.1128/MMBR.00016-05 
Enterocin X E. faecium KU-B5 Sugar apples 10.1128/AEM.02264-09 
Enterocin-HF E. faecium M3K31 Griffon vultures faeces 10.1021/acs.jafc.5b03882 
Enterocin M E. faecium AL-41 Environment 10.17221/21/2016-CJAS 
EP-20 Xenorhabdus budapestensis 
NMC-10 
Entomopathogenic bacteria  10.1016/j.peptides.2012.03.0
27 
Fulvocin C Myxococcus fulvus Mx f16 Soil   10.1007/bf00405407 
Garvieacin Q  L. garvieae BCC 43578 Nham (fermented pork 
sausage) 
10.1128/AEM.06891-11 
Gassericin T L. gasseri SBT 2055 Human faeces 10.1271/bbb.64.2201 
GP-19 X. budapestensis NMC-10 Entomopathogenic bacteria 10.1016/j.peptides.2012.03.0
27 
Halocin C8 Halobacterium sp AS7092 Great Chaidan Salt Lake 10.1007/s00792-003-0335-6 
Hiracin JM79 Enterococcus hirae DCH5 Mallard duck 10.1128/AEM.02559-07 
10.1016/j.ijfoodmicro.2007.0
4.012 
Hominicin Staphylococcus hominins 
MBBL2-9 
Vagina  10.1016/j.bbrc.2010.07.024 
10.1111/j.1365-
2672.2009.04485.x 
Enterocin 96 E. faecalis WHE 96 Munster cheese 10.1128/AEM.02772-08 
Ipomicin Streptomyces ipomoeae 91-03 Sweet potato pathogen 10.1128/AEM.01598-08 
Lactacin F Lactobacillus johnsonii  Human faeces 10.1007/978-1-4615-2668-
1_14 
60(3):1006-13 
Lacticin Q L. lactis QU5 Fresh corn 10.1128/AEM.02286-06 
Lacticin Z L. lactis Q14 Horse intestine 10.1271/bbb.70169 
Lactocin 705 Lactobacillus casei CRL 705 Dry fermented sausage 10.1016/S0944-
5013(99)80015-9 
Lactococcin 972 L. lactis subsp. lactis IPLA 972 Cheese 10.1099/00221287-142-9-
2393 
Lactococcin A Clostridium perfringens strain 
SM101/TypeA  
Derivative of NCTC 8798 
isolated from meat  
J Bacteriol. 1998 180(1):136-
42 
Lactococcin A L. lactis subsp. cremoris LMG 
2130 
Milk 173(12): 3879–3887 
10.1099/ijs.0.023945-0 
Lactococcin B L. lactis subsp. cremoris 9B4 Milk 10.1099/ijs.0.023945-0 
59(4):1041-8 
Lactococcin G L. lactis LMG2081 Pear 174(17): 5686–5692 
10.1128/AEM.03988-15 
Lactococcin MMFII L. lactis MMFII Dairy  product 10.1111/j.1574-
6968.2001.tb10924.x 
Lactococcin Q L. lactis QU4 Corn 10.1128/AEM.72.5.3383-
3389.2006 
Laterosporulin Brevibacillus sp. GI-9 Soil 10.1371/journal.pone.003149
8 
Leucocin A (LeucocinA-
UAL187) 
Leuconostoc gelidum UAL 187 Vacuum-packaged meat. J Bacteriol. 1991 173(23): 
7491–7500 
Leucocin B (LeucocinB Ta11a) Leuconostoc carnosum Ta11a Vacuum-packaged meat 10.1007/BF01570155 
Leucocin_C L. mesenteroides TA33a Processed meat 10.1099/00221287-144-5-
1343 
Leucocin K7 L. mesenteroides K7  Fermented pickle 10.1007/s10529-016-2127-y 
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Lichenin B. licheniformis 26 L-10/3RA Buffalo rumen 10.1046/j.1365-
2672.2001.01429.x 
LSEI 2163 L. casei ATCC 334 Dairy products, emmental 
cheese 
10.1007/s00253-012-4149-2 
https://www.lgcstandards-
atcc.org/products/all/334.asp
x?geo_country=ie 
LSEI 2386 L. casei ATCC 334 Dairy products, emmental 
cheese 
10.1007/s00253-012-4149-2 
https://www.lgcstandards-
atcc.org/products/all/334.asp
x?geo_country=ie 
Mesentericin B105 L. mesenteroides Y105 Goat milk  10.1099/00221287-138-12-
2725 
Mesentericin Y105 (anti-
Listeria) 
L. mesenteroides Y105 Goat milk  10.1099/00221287-138-12-
2725 
Microcin C7 E. coli RYC25 Newborn  faeces 10.1128/aac.27.5.791 
Microcin I47 E. coli H47 Human faeces 10.1099/mic.0.26396-0 
Microcin PDI E. coli 25 Cattle  10.1038/srep42529 
Microcin S E. coli G3/10 DSM 17252 Symbioflor human  10.1155/2016/3535621 
10.1371/journal.pone.003335
1 
MR10 E. faecalis MRR10-3 Uropygial gland of the 
hoopoe (Upupa epops). 
10.1128/AEM.02940-05 
Mundticin L E. mundtii CUGF08 Alfalfa sprouts 10.1128/AEM.00752-09 
Mundticin ATO6 E. mundtii ATO 6 Chicory endive 10.1016/s0005-
2736(98)00086-8 
Mundticin KS E. mundtii NFRI 7393 Grass silage  10.1128/aem.68.8.3830-
3840.2002 
Mutacin IV S. mutans UA140 Human caries 10.1128/AEM.67.1.15-
21.2001 
Penocin A Pediococcus pentosaceus 
ATCC 25745 
Plant 10.1099/mic.0.28794-0 
https://www.lgcstandards-
atcc.org/Products/All/25745.a
spx?geo_country=ie 
Piscicolin 126 C. piscicola JG126  Spoiled ham Appl Environ Microbiol. 1996 
62(8):2897-903 
Plantaricin 1.25β L. plantarum TMW 1.25 Sausage fermentation 10.1016/S0167-
4781(00)00003-8 
Plantaricin 423 L. plantarum 423 Sorghum beer 10.1046/j.1365-
2672.1998.00451.x 
Plantaricin A L. plantarum C-11 Cucumber fermentation 10.1590/S1517-
83822009000200001 
Plantaricin ASM1 L. plantarum A-1 Mexican tortilla 10.1016/j.ijfoodmicro.2009.1
0.021 
Plantaricin C19 L. plantarum C-19 Fermented cucumber 10.1016/s0168-
1605(01)00482-2 
Plantaricin E/F L. plantarum C-11 Fermented cucumber 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin F L. plantarum BF001 Catfish fillets 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin J/K L. plantarum C-11 Fermented cucumber 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin K L. plantarum DK9 Fufu, cassava product 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin N L. plantarum C-11 Fermented cucumber 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin NC8 L. plantarum NC8 Grass silage 10.1016/0963-
9969(92)90121-K 
Plantaricin S L. plantarum LPCO10 Green olive fermentations 10.1128/aem.68.8.3830-
3840.2002 
Plantaricin SA6 L. plantarum SA6 Fermented sausages 10.1111/j.1365-
2672.1995.tb03417.x 
PlnK (putative) L. plantarum WCFS1 Human saliva 10.1073/pnas.0337704100 
Propionicin SM1 Propionibacterium jensenii 
DF1 
Swiss raw milk 10.1016/S0723-
2020(00)80002-8 
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Propionicin T1 Propionibacterium thoenii Dairy product 10.1128/aem.66.10.4230-
4236.2000 
Propionicin F Propionibacterium 
freudenreichii subsp. 
freudenreichii LMGT2946 
Cheese starter 10.1128/AEM.70.12.7303-
7310.2004 
Protease-activated 
antimicrobial protein (PAMP) 
P. jensenii Dental plaque  Appl Environ Microbiol. 1992 
58(1): 215–220 
Putative bacteriocin Streptococcus gordonii ATCC 
35105 (previously classified as 
Streptococcus sanguis White 
in White and Niven) 
Isolated from endocarditis 
patients 
10.1128/JB.01023-07 
 
Putative bacteriocin S. pyogenes MGAS 10394 Human throat https://www.lgcstandards-
atcc.org/Products/All/BAA-
946.aspx?geo_country=ie  
Putative bacteriocin S. pyogenes MGAS 5005 Human cerebroespinal fluid  https://www.lgcstandards-
atcc.org/Products/All/BAA-
947.aspx?geo_country=ie 
Putative bacteriocin S. pyogenes MGAS 315 Streptococcal toxic shock https://www.lgcstandards-
atcc.org/products/all/BAA-
595.aspx?geo_country=ie  
Putative bacteriocin S. mutans UA159 Human caries 10.1073/pnas.172501299 
Putative bacteriocin S. pyogenes MGAS 6180 Human blood https://www.lgcstandards-
atcc.org/products/all/BAA-
1064.aspx?geo_country=ie  
Putative bacteriocin L. sakei subsp. sakei 23K French sausage 10.1038/nbt1160 
Rhamnosin A Lactobacillus rhamnosus 
strain 68 
Human faeces  10.1111/j.1365-
2672.2009.04539.x 
Sakacin 5XSakX L. sakei 5  Malted barley 10.1128/aem.69.12.7194-7203.2003 
Sakacin A L. sake Lb706 Meat product 10.1007/978-1-4615-2668-
1_16 
Sakacin G L. sake 2512 Dry fermented sausages 10.1128/AEM.68.12.6416-
6420.2002 
10.1111/j.1365-
2672.1994.tb01105.x 
Sakacin P L. curvatus strain CRL705 Fermented sausages 10.1128/JB.06416-11 
Sakacin P L. sakei I151 Fermented sausages 10.1007/s00253-005-0172-x 
Sakacin Q L. curvatus ACU-1  Dry sausages 10.1016/j.meatsci.2014.03.00
3 
SakT L. sakei 5 malted barley 10.1016/j.femsle.2004.05.011 
Salivaricin P  L. salivarius DPC6,005 porcine intestine 10.1128/AEM.00666-06 
Serracin P Serratia plymuthica A30 Rotten potato tissue 10.1128/JB.01699-12 
Subpeptin JM4-B B. subtilis JM4 Soil  10.1007/s00284-005-0004-3 
Subtilosin (SboX) Bacillus amyloliquefaciens   Dairy Yogu FarmTM 10.1111/j.1365-
2672.2007.03626.x 
Thermophilin 13 S. thermophilus SFi13 Nestle strain collection 10.1371/journal.pone.005923
9 
Thermophilin A S. thermophilus ST134 In-house culture collection 10.1007/bf00172834 
Thuricin S B. thuringiensis subsp. 
entomocidus HD198 strain 
Bacillus Genetic Stock Center 
collection (Columbus, Ohio). 
10.1139/w06-116 
Trifolitoxin Rhizobium leguminosarum bv. 
trifolii Strain T24 
Soil 10.1104/pp.85.2.335 
Ubericin A S. uberis Bovine mastitis 10.1128/AEM.01818-07 
UviB B. thuringiensis serovar 
israelensis ATCC35 
Sewage 10.1016/j.femsle.2005.07.008 
https://www.lgcstandards-
atcc.org/products/all/35646.a
spx?geo_country=ie 
Warnericin RC S. warneri RK Environment 10.1016/j.femsle.2005.03.046 
Weisselin A Weissella paramesenteroides 
DX 
Fermented sausages 10.1016/j.enzmictec.2013.04.
003 
Weissellicin M Weissella hellenica QU13 Barrel for pickles 10.1111/j.1365-
2672.2011.05180.x 
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Weissellicin Y W. hellenica QU13 Barrel for pickles 10.1111/j.1365-
2672.2011.05180.x 
Pentocin KCA1 Lactobacillus pentosus KCA1 Vagina 10.1371/journal.pone.005923
9 
BlpD / Thermophilin 9 S. thermophilus LMD-9 Dairy product 10.1038/nbt1034 
10.1073/pnas.0607117103 
10.1128/JB.00966-07  
https://www.lgcstandards-
atcc.org/products/all/BAA-
491.aspx?geo_country=ie#ge
neralinformation 
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Appendix 3 
Table S3. Class III bacteriocins 
 
Bacteriocin Produced by Isolated from Doi / reference 
Alveicin A Hafnia alvei Enteric bacteria from 
wild Australian 
mammals 
10.1128/jb.186.6.1598-1605.2004 
Alveicin B H. alvei Enteric bacteria from 
wild Australian 
mammals 
10.1128/jb.186.6.1598-1605.2004 
Bacteriocin Thermotoga maritima MSB8 Geothermally-heated 
sea floors 
10.1080/09593330.2010.484076 
Bacteriocin 28b Serratia marcescens enterobacteria 10.1016/0923-2508(96)80293-2 
Albusin B Ruminococcus albus 7. Rumen 10.1128/aem.70.5.3167-3170.2004 
Carocin D Pectobacterium 
carotovorum subsp. 
carotovorum Pcc21 
Phytopathogen isolated 
from host plant 
10.1128/AEM.03103-09 
19(1):42-50 
Closticin 574 Clostridium tyrobutyricum 
ADRIAT 932 
NIZO food research 
(Ede, The Netherlands) 
10.1128/aem.69.3.1589-1597.2003 
Colicin Erwinia carotovora subsp. 
atroseptica SCRI1043 
Phytopathogen 10.1111/j.1365-2672.2009.04462.x 
Colicin B E. coli K12/5K Human faeces 10.1128/MMBR.00036-06 
Colicin-A Citrobacter freundii CA 31 enterobacteria 10.1128/MMBR.00036-06 
10.1111/j.1432-1033.1981.tb05380.x 
Colicin M E. coli K-12 32T 19F/T1 K-12 faecal 10.1128/MMBR.00036-06 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC
429005/pdf/aac00335-0086.pdf 
Halocin H4 H. mediterranei R4 (ATCC 
33500) 
Salt ponds 179(2): 548–551 https://www.lgcstandards-
atcc.org/products/all/33500.aspx?geo_country=i
e  
Halocin S8 Haloarchaeon sp S8a Great Salt Lake 10.1128/JB.182.17.4951-4958.2000 
Lin M18 Bordetella bronchiseptica 
RB50 
Rabbit 10.1038/ng1227 
Linocin M18 Wolinella succinogenes Rumen  10.1007/s10482-007-9151-9  
 https://www.lgcstandards-
atcc.org/products/all/29543.aspx?geo_country=
gb  
Linocin M18 Brevibacterium linens M18 Cheese  10.1038/ng1227 
Putative 
Bacteriocin family 
protein 
Nocardia farcinica IFM 10152 Human bronchus 10.1073/pnas.0406410101 
Putidacin L1 Pseudomonas sp. strain 
BW11M1 
Rizhosphere 10.1128/jb.185.3.897-908.2003 
Zoocin A Streptococcus zooepidemicus 
strain 4881 
Animal origin 10.1017/s0022172400063774 
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Appendix 4  
Table S4. Peptides and proteins shortlisted from the trypsin digestion of the band with 
antimicrobial activity extracted from SDS gel from L. amylovorus lac 20 supernatant. GG 
motifs common to bacteriocin leader cleavage sites are highlighted; alternative masses are 
calculated with the removal of this potential leader 
 
Peptide / protein Annotated as Mass 
(Da) 
Alternative  
Masses 
(Da) 
MKSKHAIYWLICLIVIVLGGWYMYGHLNRSSATSSMVSTTAKSKATAKD 
SSSEDSNMRTPIDWQKSSETIPYPDRSKVKDLWVKVSLKGNRTYLYDGS 
KIIYTMYSSGGVYQKDDKTGKMKSATPTGTFYVQAERGDSFFNQELGE 
GANYYVSWLNHGEYLFHSVPTKADGSYNLKEAAKLGKSTGSHGCIRLSV 
PDAKWMEQNLPEGTKVVIADN 
Alanine 
carboxypeptidase 
24073 21834 
MIMDLQFFSHHKGGGSTANGRNSAGRRLGTKAADGSVVTAGSIIYRQ 
RGTHIHPGENVGRGGDDTLFAKIDGVVKFERMGRNNRKVSVYPVAE   
LSU ribosomal 
protein L27p 
9985 8298, 
4647, 6334 
MAFDKDAIIASLKEASISDLNDLVKAIEEEFDVSAAAPVAVAGAAGGDA 
AAKDSFTVELTSAGSAKVKVIKAVKDITGLGLKDAKDLVDNAPSAVKED 
VKEDEANDIKEKLEAAGATVTLK 
LSU ribosomal 
Protein L7/L12 
12330 4578, 7656 
MALDLYKYVASIPDYPEKGIIFRDILPLMADGEAFKQATDEITAFARERN 
VDMVVGPEARGFIVGCPVAYELGVGFAPARKKGKLPRATVSASYQLEY 
GEATLQMENDSVKPGQRVLVVDDLLATGGTIGATIDMVEQMGGKVV 
GAAFLIELKELEGRKHLRDIDIKTLMEF  
Alanine 
phosphoribosyl_ 
transferase 
18784 5017, 3613 
MNSTKYKRFLMVLIFMVSLWLVPQAQAAVANNAAEFTIDPVYPSEQQ 
ADNTGYFSLAVHPASTVPVKVKITNTNQHQAITYRLKVGNATTNPDGSI 
NYANFKAKKDPTAQYQLTDFIDHAKRGQKITVPANSDRTVTVNLRLPAH 
AFSGIVAGGVYVERLTNGANQQSGNFQTQNHFAMTLPILVTEHPHAKR 
IAKMQLAQVKVQKGQIAARLHNVRPVLFGKLTIHARITKAHQTKALVKK 
TVTNYQVAPNSAFDFVVTDPKQPLNTGHYTLTMNLQSGKRQWYFSRA 
FTVTASQAAPLTKRTGWLGLPLLLWLIGGGLILIILALVGVILKQRKKLSQQ 
Cell surface 
protein precursor 
37714 16737, 
20880 
MIQTIDLKKGMVFERGGKLLKVLQINHHKPGKGNTLMQMDIQDVRTGS 
IVHTTMRPSEKVEQVNVDKKNAQYLYDEGNTAVFMDMETYEQYEISDE 
QLTEEKKYLVENMQVQMDFVGSELVGIELPTTVVLTVEHTEPMIKGATID 
GGGKPATMSTGLVVNVPAFIKNGDQIVVNTMDGSYKSRA 
Translation 
elongation factor 
20629 3867 
MISKPDKNKIRQRRHMRVRGKISGTAERPRLSVYRSNKNIYAQLIDDVKG 
VTLASASTLDSEVSGNTKTEQAAGVGALIAKRGVEKNISGVVFDRGGYLY 
HGRVQALAEAARENGLQF 
LSU ribosomal 
protein L18p 
12914 2406, 
10411 
MKLNELKPAAGSRFKRLRKGRGLSSGHGFTSGRGTKGQKAHGKTRLGFE 
GGQMPLYRQMPKRGFSNINRKEYAIVNLTTLNRFDDGAEVTPAVLLENG 
VIKNVKSGVKILGNGKLTKKLTVKANKFSASAVKAIEAAGGKTEVM 
LSU ribosomal 
protein L15p 
15486 5298 
MASQSYIDPSKLDLEDQVVSINRVTKVVKGGRRLRFAALVIVGDKKGHVGF 
GTGKAQEVPEAIRKASAAAQKNLIEVPIVGTTIPHEVIGTYGGGKIMLKPAV 
EGSGVAAGGAVRNVMELAGVADVTSKRLGSNTPINVVRATFEGLKALKSA 
EEVSQLRGVSVDHLAE 
SSU ribosomal 
protein S5p 
17595 3263, 
9840, 
6034, 7061 
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Appendix 5 
Table S5. BIOLOG chemicals that inhibit growth of L. crispatus Lac 50 and Lac 51 
Chemical Target 
Cloxacillin Cell wall 
Erythromycin Protein synthesis 50S 
ribosomal 
Vancomycin Cell wall 
Novobiocin (3c) DNA topoisomerase 
Spyramycin Protein synthesis 50S 
Cetylpyridinium 
chloride 
Membrane 
Diamide (1c) Oxidises sulfhydryls 
Poly-L-lysine (2c) Membrane 
Sodium bromate (2c) Toxic anion 
Sodium periodate (2c) Toxic anion 
Harmane (2c) Imidazoline binding sites 
FCCP Respiration, ionophore 
D,L-Thioctic acid (2c) Oxidising agent 
Phenethicillin Cell wall 
 
Table S6. BIOLOG chemicals that have no influence on the growth of L. crispatus Lac 50 and 
Lac 51 
Chemical Target 
Potassium tellurite Toxic anion 
Demecocycline Protein synthesis 30S 
Enoxacin DNA topoisomerase 
Neomycin Protein synthesis 30S 
Kanamycin Protein synthesis 30S 
Ofloxacin DNA topoisomerase 
Penimepicycline Protein synthesis 30S 
Sulfamethazine Folate antagonist 
Sulfadiazine Folate antagonist 
Sulfathiazole Folate antagonist 
Sulfamethoxazole Folate antagonist 
Nickel chloride Toxic cation 
2,2’-Dipyridyl Chelator, lipophilic 
Dequalinium chloride Ion channel inhibitor, K+ 
Geneticin (G418) Protein synthesis 30S 
Glycine Membrane 
Moxalactam Cell wall 
Sulfanilamide Folate antagonist 
5-Azacytidine DNA methylation 
Sulfisoxazole (only 51) Folate antagonist 
Semicarbazide Amine oxidase inhibitor 
Tinidazole Oxidising agent 
Coumarin (3C) DNA intercalator 
 
Table S.7. BIOLOG chemicals in which presence L. crispatus Lac 50 and Lac 51 behaved 
similarly 
Chemical Target 
Amoxicillin  Cell wall 
Cloxacillin Cell wall 
Lomefloxacin DNA topoisomerase 
Mynocycline Protein synthesis, 
30S 
Nafcillin Cell wall 
Erythromycin Protein synthesis 
50S 
Potassium tellurite Toxic anion 
Penimepicycline Protein synthesis 
30S 
Sisomicin Protein synthesis 
30S 
Vancomycin Cell wall 
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Paromomycin Protein synthesis 
30S 
Sulfamethazine Folate antagonist 
Sulfadiazine Folate antagonist 
Sulfathiazole Folate antagonist 
Sulfamethoxazole Folate antagonist 
Novobiocin DNA topoisomerase 
2,4-Diamino-6,7-
diisopropyl-pteridine 
Folate antagonist 
Tobramycin Protein synthesis 
30S 
Spectinomycin Protein synthesis 
30S 
Spiramycin Protein synthesis 
50S 
Rifampicin RNA polymerase 
Dodecyltrimethyl 
ammonium bromide 
Membrane, 
detergent 
Cytosine-1-beta-D-arabino-
furanoside 
Nucleic acid analog 
Manganese chloride Toxic cation 
Trifluoperanize Anti-cholinergic 
Tylosin Protein synthesis 
50S 
Cinoxacin (3c) DNA topoisomerase 
5-Azacytidine DNA methylation 
Rifamycin SV RNA polymerase 
Aluminium sulfate Toxic cation 
Chromium chloride Toxic cation 
L-Glutamic-g-hydroxamate tRNA synthetase 
Ketoprofen  Anti-capsule agent 
(biofilm) 
Poly-L-lysine Membrane 
Sodium bromate Toxic anion 
Lidocaine Ion channel 
inhibitor 
Sodium metasilicate Toxic anion 
Sodium periodate Toxic anion 
Antimony (III) chloride Toxic cation 
Triclosan Lipid synthesis, fatty 
acid inhibitor 
Coumarin DNA intercalator 
Methyltrioctylamonium 
chloride 
Membrane 
Harmane Imidazoline binding 
sites 
Chlorhexidine Membrane, 
electron transport 
Cinnamic acid Respiration, 
ionophore 
Disulphiram Nucleic acid 
inhibitor 
FCCP Respiration, 
ionophore 
D,L-Thioctic acid Oxidising agent 
Phenethicillin Cell wall 
Blasticidin S Protein synthesis 
Hexammine cobalt (III) 
chloride 
DNA synthesis 
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